» 2019 International Congress

Date: Thursday, January 1, 1970

Time: 12:00am-12:00am

Meeting:

1:45pm-3:15pm: A case of donepezil-induced multifocal myoclonus

C. Amlang, P. Kim, A. Padalia, B. Roy, S. Schaefer (New Haven, CT, USA)

1:45pm-3:15pm: A Case of Pregabalin induced Parkinsonism

BC. Ari, F. Mayda Domac, G. Ozgen Kenangil (Istanbul, Turkey)

1:45pm-3:15pm: A hot, cold case of Parkinson’s disease: Charcot and Bachère: was this case misdiagnosed?

R. Kikuchi, T. Okamoto, S. Akaike, M. Miller, M. Kawamura (Tsurumi-Ku, Yokohama, Kanagawa, Japan)

1:45pm-3:15pm: Acceptability and Effectiveness of an Online Curriculum in Movement Disorders for Neurology Housestaff: A pilot study

S. Schaefer, L. Vadlamani, P. Juthani, J. Moeller (New Haven, CT, USA)

1:45pm-3:15pm: Adaptor Protein Complex 4-associated Hereditary Spastic Paraplegia (AP-4-HSP): A Paradigm of Childhood-Onset Hereditary Spastic Paraplegia Caused By Defective Protein Trafficking

R. Behne, J. Teinert, M. Wimmer, S. Dwyer, A. Davies, J. Hirst, G. Borner, M. Robinson, L. Barrett, I. Chen, E. Buttermore, M. Sahin, D. Ebrahimi-Fakhari (Boston, MA, USA)

1:45pm-3:15pm: An unusual cause of rhabdomyolysis in the patients with Parkinson’s disease: A report of two cases

J. Srikajon, P. Srivanitchapoom, Y. Pitakpatapee, T. Sangpeamsook, C. Satukijchai, A. Suengtaworn (Bangkok, Thailand)

1:45pm-3:15pm: Assessment of a Movement Disorders Video Curriculum for Neurology Clerkships

S. Bette, D. Shpiner, J. Margolesky, C. Luca, H. Moore, C. Singer, Y. Reyes-Iglesias (Miami, FL, USA)

1:45pm-3:15pm: Assessment, identification and classification of movement disorders in 22q11.2 deletion syndrome

W. Fung, A. Cunningham, T. Massey, J. Hall, M. Owen, M. Van-Den-Bree, K. Peall (Newport, United Kingdom)

1:45pm-3:15pm: Association between coffee and chimarrão (yerba mate) ingestion and risk of Parkinson’s disease

MS. Medeiros, AF. Schumacher-Schuh, V. Altmann, CRM. Rieder (Porto Alegre, Brazil)

1:45pm-3:15pm: Brain neurotransmitters and neuropeptides alternations in Parkinson’s induced mouse models

N. Kumar, R. Khanna (Jaipur, India)

1:45pm-3:15pm: Camillo Negro and his contributions to Neurology

A. Meira, B. Betini, F. Germiniani, H. Teive (Curitiba, Brazil)

1:45pm-3:15pm: Chlorogenic acid and Trianthema portulacastrum combinational therapy mitigates rotenone induced Parkinsonism in wistar rats

E. Yadav (Prayagraj, India)

1:45pm-3:15pm: Clinically Relevant Changes in AIMS Based on Clinical and Patient Global Impression of Change in Patients With Tardive Dyskinesia Treated with Deutetrabenazine

H. Barkay, A. Wilhelm, M. Wieman, M. Gordon, R. Hauser, JM. Savola (Netanya, Israel)

1:45pm-3:15pm: Clonazepam as a cure or a cause? : Withdrawal Emergent Syndrome

S. Raju, K. Vyas (Bangalore, India)

1:45pm-3:15pm: Combination Antiretroviral therapy (cART)-induced cerebellar and prefrontal cortex disorders: A Study on the impact of Naringenin and Quercetin

E. Akang, O. Dosumu, A. Fagaroye, I. Usman, A. Oremosu, A. Akanmu (Lagos, Nigeria)

1:45pm-3:15pm: Deep brain stimulation in children: analysis of indication, outcome and complications

DR. Maiti (Cleveland, OH, USA)

1:45pm-3:15pm: Dietary Vitamin E as a protective factor for Parkinson’s Disease: a clinical and experimental study

T. Schirinzi, G. Martella, P. Imbriani, G. Di Lazzaro, M. Alwardat, M. Pierantozzi, N. Mercuri, A. Pisani (Rome, Italy)

1:45pm-3:15pm: Drug-induced Negative Myoclonus: A Case Report

L. Lerjefors, M. Mainardi, A. Antonini, M. Carecchio (Padova, Italy)

1:45pm-3:15pm: Drug-Induced Parkinsonism May Persist Beyond Two Years After Discontinuation of Dopamine Transmission Blocking Agents

J. Randhawa, R. Mehanna (Houston, TX, USA)

1:45pm-3:15pm: Environmental toxicants and Parkinson’s disease in south of Morocco

Y. Naji, N. Kissani (Marrakech, Morocco)

1:45pm-3:15pm: Etiology and Clinical Study of Basal Ganglionic Lesions in a Sample of Egyptian Children

H. Zehry, S. Darwish, H. Gad, S. El Zayat, M. Tharwat, H. Emam (Dakahlyia, Egypt)

1:45pm-3:15pm: Exposed-Only Analysis of Gene-Pesticide Interaction in Parkinson’s Disease (PD)

J. Kaye, L. Lima, C. Tanner, S. Finkbeiner, R. Swanson, S. Goldman (San Francisco, CA, USA)

1:45pm-3:15pm: Frequency of PD Non-Motor symptoms in healthy factory workers

C. Guerra-Galicia, C. Tenorio (San Luis Potosí, Mexico)

1:45pm-3:15pm: Geste antagoniste in Catalan art – Santiago Rusiñol’s Laughing Girl

F. Germiniani, P. Marques, L. Pinheiro, G. Franklin, G. Ribas, H. Teive (Curitiba, Brazil)

1:45pm-3:15pm: Heavy metals implicated in a geographical cluster of progressive supranuclear palsy induce tau accumulation and apoptotic cell death in cultured neurons

C. Alquezar, J. Felix, E. Mccandlish, B. Buckley, D. Caparros-Lefebvre, C. Karch, L. Golbe, A. Kao (San Francisco, CA, USA)

1:45pm-3:15pm: High dose amantadine therapy may cause increased falling in Parkinson’s patients

L. Verhagen Metman (Chicago, IL, USA)

1:45pm-3:15pm: Impact of the Home Environment on Falls Risk: A Cross-Sectional Study of Patients with Parkinson’s Disease

Y. Thongchuam, S. Phumphid, O. Phokaewvarangkul, R. Bhidayasiri (Bangkok, Thailand)

1:45pm-3:15pm: Impairment of Neurological Ontogenesis in Children with Austism Spectrum Disorders

V. Kozyavkin, T. Voloshyn (Truskavets, Ukraine)

1:45pm-3:15pm: Implementation of a Peer-to-Peer Mentoring Intervention for Center of Excellence Coordinators

C. Hunter, K. Arney, J. Fleisher, P. Palmentera, J. Shurer, F. Cubillos (Houston, TX, USA)

1:45pm-3:15pm: Inspiring Neurology Residents to Select Movement Disorders Fellowship Training

K. Harper, T. Davis, F. Phibbs, PD. Charles (Nashville, TN, USA)

1:45pm-3:15pm: Ixcellence Network®, an International Innovative Educational Programme To Improve Cervical Dystonia And Spastic Paresis Management: Feedback survey from 839 attendees

C. Colosimo, TM. Chung, LJ. Jacinto, K. Bhatia, A. Fulford-Smith, R. Bhidayasiri (Roma, Italy)

1:45pm-3:15pm: Jane Avril: Toulouse-Lautrec’s favourite courtisan and Moulin Rouge’s choreic dancer

F. Germiniani, C. Camargo, G. Franklin, G. Ribas, L. Pinheiro, P. Marques, H. Teive (Curitiba, Brazil)

1:45pm-3:15pm: Knowledge and attitude towards movement disorders among final year medical students in a Nigerian university

E. Nwazor, C. Okeafor (Owerri, Nigeria)

1:45pm-3:15pm: Levodopa-responsive tremor in a young child as a delayed complication of osmotic demyelination from severe hypernatremia

L. Tochen, M. Cameron, C. Brady, M. Fleming (Washington, DC, USA)

1:45pm-3:15pm: Long-Term Outcomes in Patients with Tardive Dyskinesia who Were Early Responders with Valbenazine

S. Factor, C. Comella, S. Marder, J. Burke, K. Farahmand, S. Siegert (Atlanta, GA, USA)

1:45pm-3:15pm: Long-Term Outcomes with Valbenazine 40 mg/day in Adults with Tardive Dyskinesia

S. Marder, C. Comella, C. Singer, C. Chepke, J. Burke, K. Farahmand, S. Siegert (Los Angeles, CA, USA)

1:45pm-3:15pm: Long-Term Treatment With Deutetrabenazine Is Associated With Continued Improvement in Tardive Dyskinesia: Results From an Open-Label Extension Study

R. Hauser, H. Barkay, H. Fernandez, S. Factor, J. Jimenez-Shahed, N. Gross, M. Gordon, JM. Savola, K. Anderson (Tampa, FL, USA)

1:45pm-3:15pm: Management of life threatening dyskinesias in GNAO1 related movement disorder: two new cases and review of the literature

M. Hull, M. Parnes (Houston, TX, USA)

1:45pm-3:15pm: Memantine induced dyskinesia in Alzheimer’s disease

M. Kaiserova, L. Hvizdošova, K. Mensikova, P. Kanovsky (Olomouc, Czech Republic)

1:45pm-3:15pm: MOVEMENT DISORDERS FEATURES ASSOCIATED WITH WEST SYNDROME

FS. Ngoungoure Halima, AM. Magnerou, CV. Hotcho Nganhou, M. Ndiaye, AG. Diop (Douala, Cameroon)

1:45pm-3:15pm: Moving ear syndrome secondary to bromopride and response to botulinum toxin

F. Sekeff-Sallem, J. Pedroso, O. Barsottini (Sao Paulo, Brazil)

1:45pm-3:15pm: Neuroart: A Hummingbird in the Cage of the Brain

A. Kleinert (Tuxtla Gutierrez, Mexico)

1:45pm-3:15pm: Neurological complications secondary to metronidazole: Case Report

M. Teran, P. Salles (Santiago, Chile)

1:45pm-3:15pm: Neurology Residents Versus a Mobile Medical Application in deducing differential diagnoses in Movement Disorders: A multi-center, cross-sectional, observational study

V. Vishnu, P. Vinny, R. Rajan, V. Goyal, P. Srivastava, V. Lal, P. Sylaja, L. Narasimhan, S. Dwivedi, P. Nair, D. Ramachandran, A. Gupta (New Delhi, India)

1:45pm-3:15pm: Novel compound heterozygous mutations in the TSFM gene causes childhood-onset chorea

CH. van Riesen, K. von Au, S. Biskup, A. Kühn, A. Kaindl, A. van Riesen (Berlin, Germany)

1:45pm-3:15pm: Opsoclonus-Myoclonus-Ataxia Syndrome – Ljubljana University Children’s Hospital clinical series

J. Orazem Mrak, D. Osredkar, D. Neubauer (Ljubljana, Slovenia)

1:45pm-3:15pm: Optimal treatment of geniospasm: a case report and review of the literature

M. Hull, M. Parnes (Houston, TX, USA)

1:45pm-3:15pm: Pantothenate kinase-associated neurodegeneration in Tunisian families

H. Benrhouma, I. Kraoua, H. Klaa, A. Rouissi, EM. Valente, I. Benyoussef Turki (Tunis, Tunisia)

1:45pm-3:15pm: Patient-centered approach to elicit and compare the treatment goals of patients with tardive dyskinesia, their care partners, and healthcare providers

C. Kutz (Colorado Springs, CO, USA)

1:45pm-3:15pm: Pediatric anti-N-methyl-D-aspartate receptor encephalitis associated with Coat’s-like retinal telangiectasia

N. Kumar, D. Radhakrishnana, R. Shree, G. Madhaw, R. Samanta, S. Kumari (Rishikesh, India)

1:45pm-3:15pm: Pre-status and status dystonicus in children and adolescents

G. Garone, F. Graziola, F. Nicita, F. Frascarelli, F. Randi, M. Zazza, L. Cantonetti, F. Vigevano, CE. Marras, A. Capuano (Rome, Italy)

1:45pm-3:15pm: Protective and therapeutic activity of Cinnamaldehyde in the mouse model of Parkinson’s disease

S. Rajput, S. Sinha (New Delhi, India)

1:45pm-3:15pm: Public awareness and education of Parkinson’s Disease among Nepalese Population

R. Ojha, R. Karn (Kathmandu, Nepal)

1:45pm-3:15pm: Quercetin administration abrogates the Parkinson’s disease (PD)-like motor and non-motor symptoms and attenuates the behavioral, neurochemical and biochemical deficits induced by rotenone toxicity in rats

S. Madiha, S. Haider (Karachi, Pakistan)

1:45pm-3:15pm: Re-emerging Neuroleptic Malignant Syndrome (NMS) without Re-introduced Neuroleptic in a Schizophrenia Patient: a Case Report

D. Tunjungsari, A. Tiksnadi (Jakarta, Indonesia)

1:45pm-3:15pm: Reconstructing the history of Machado-Joseph disease

A. Meira, J. Pedroso, F. Germiniani, O. Barsottini, H. Teive (São Paulo, Brazil)

1:45pm-3:15pm: Regardless of impaired renal function, negative myoclonus can be induced by gabapetin and pregabalin

DY. Kwon, MH. Park (Gyenggi-Do, Republic of Korea)

1:45pm-3:15pm: Smartphone-based gait assessment of psychiatric patients on neuroleptics

S. Hassin-Baer, T. Fay-Karmon, V. Livneh, S. Israeli-Korn, Y. Rubel, K. Tchelet, Z. Yekutieli, M. Linder, H. Yahalom, G. Yahalom (Ramat-Gan, Israel)

1:45pm-3:15pm: Spectrum of Movement disorders in pediatric immune-mediated diseases

A. Saan, K. Linn, A. Minaye, C. Hlaing, K. Ko, H. Wintaung, N. Lin, Y. Wintaung (Yangon, Myanmar)

1:45pm-3:15pm: Steroid-responsive myoclonus in the context of pembrolizumab treatment: a novel neurological phenotype.

M. Murphy, S. O'Dowd, M. Alexander (Dublin, Ireland)

1:45pm-3:15pm: Subchronic copper exposure induces parkinsonism in rats: Neuromodulatory potential of curcumin

A. Abbaoui, H. Gamrani (Marrakech, Morocco)

1:45pm-3:15pm: Subthalamic Nucleus of Luys: A review. What has evolved since 1865?

G. Froehner, A. Meira, F. Germiniani, M. Meneses, R. Munhoz, H. Teive (Curitiba, Brazil)

1:45pm-3:15pm: The Clinical, Molecular and Radiographic Spectrum of Adaptor Protein Complex 4-associated Hereditary Spastic Paraplegia (AP-4-HSP): Results from the AP-4-HSP International Registry

J. Teinert, R. Behne, M. Wimmer, A. Diplock, E. Carmody, K. Dies, D. Jensen, J. Bennett, M. Sahin, D. Ebrahimi-Fakhari (Boston, MA, USA)

1:45pm-3:15pm: The development of a patient education and treatment programme for people with Parkinson’s disease

P. Sloan, J. Farrell, J. Mchattie, L. Ebenezer, H. Evans (Bridgend, United Kingdom)

1:45pm-3:15pm: The dopamine receptor antagonist haloperidol enhances beta and gamma oscillations and bursts in the motor cortex

M. Alam, T. Doll, J. Krauss, K. Schwabe (Hannover, Germany)

1:45pm-3:15pm: The legacy of Charles David Marsden: A role model in the field of movement disorders

G. Froehner, L. Zubko, M. Pedro Franco, A. Meira, F. Germinani, H. Teive (Curitiba, Brazil)

1:45pm-3:15pm: The Role of Environmental Toxins (Rotenone) in Parkinson’s Disease

Z. Akbarkhodjaeva, DJ. Tursunov (Tashkent, Uzbekistan)

1:45pm-3:15pm: Toning down SPNs to improve motor responses to dopaminergic stimulation in Parkinson’s disease

G. Beck, H. Mochizuki, S. Papa (Atlanta, GA, USA)

1:45pm-3:15pm: Training and Usage of Botulinum Neurotoxin-A Guided Injection in Cervical Dystonia & Spastic Paresis: results from the INPUT survey

R. Bhidayasiri, K. Bhatia, LJ. Jacinto, TM. Chung, A. Fulford-Smith, C. Colosimo (Roma, Italy)

1:45pm-3:15pm: TUBB4A mutation: Expansion of H-ABC phenotype with apparent iron accumulation in the basal ganglia – case report and literature review

C. Gorodetsky, I. Tein (Toronto, ON, Canada)

1:45pm-3:15pm: Waiting and waiting on Dopamine transporter imaging in drug induced parkinsonism

JY. Yun, CY. Lee, MY. Chun, B. Jeon (Seoul, Republic of Korea)

1:45pm-3:15pm: “So much easier”; patient’s perceptions of Virtual Clinics for Parkinson’s Disease

L. Evans, B. Mohamed, EC. Thomas (Cardiff, United Kingdom)

1:45pm-3:15pm: 3 Year QoL Results for PD Patients Receiving DBS: Product Surveillance Registry

M. Schiess, S. Palfi, J. Azulay, A. Lopez Rios, H. Xiong, K. Sandberg, JK. Krauss (Houston, TX, USA)

1:45pm-3:15pm: 5 cases Static Encephalopathy of childhood with NeuroDegeneration in Adulthood (OMIM 300894) in children

M. Bobylova, N. Perumova, T. Prygunova, K. Mukhin (Moscow, Russian Federation)

1:45pm-3:15pm: 7,8- Dihydroxyflavone prevents 3-NitropropionicAcid (3-NP)-induced Striatal Toxicity by Modulating the TrkB receptor and Microglial Activation Pathway

S. Ahmed, M. Kwatra, VGM. Naidu (Kamrup, India)

1:45pm-3:15pm: A case of Aceruloplasminemia with vertical saccadic eye movement abnormalities

O. Dogu, N. öksüz, H. Kaleagasi (Mersin, Turkey)

1:45pm-3:15pm: A case of cerebellar ataxia caused by Pembrolizumab for Non-small cell lung cancer

T. Moto, H. Nagayama, K. Kimura (Tokyo, Japan)

1:45pm-3:15pm: A Case of Diurnally Variable Gut Discomfort in a Patient with RLS

J. Coleman, A. Amara (Birmingham, AL, USA)

1:45pm-3:15pm: A case of hemimasticatory spasm with well therapeutic response to serial injections of botulinum toxin

SK. Yang, JJ. Lin (Changhua County, Taiwan)

1:45pm-3:15pm: A Case of Secondary Myoclonic Hyperkinesia

H. Amirjanyan, K. Harutyunyan (Nor Hach, Armenia)

1:45pm-3:15pm: A Case Presentation of Wilson’s Disease

D. Al Elwany, S. Ahmed, H. Deraz, C. Ragaey (Cairo, Egypt)

1:45pm-3:15pm: A case report of two siblings Aicardi-Goutières Syndrome type 2

C. Fujiwara Murakami, E. Nakagawa, A. Meira, F. Germiniani, E. Pereira, H. Ghizoni Teive (Curitiba, Brazil)

1:45pm-3:15pm: A case report of Wilson Disease in a Kyrgyz teenager

A. Jusupova (Bishkek, Kyrgyzstan)

1:45pm-3:15pm: A coding VPS13C haplotype is associated with reduced risk for Parkinson disease

U. Rudakou, J. Ruskey, L. Krohn, S. Laurent, D. Spiegelman, L. Greenbaum, G. Yahalom, A. Desautels, J. Montplaisir, S. Fahn, C. Waters, L. Levy, C. Kehoe, S. Narayan, Y. Dauvilliers, N. Dupré, S. Hassin-Baer, R. Alcalay, G. Rouleau, E. Fon, Z. Gan-Or (Montreal, QC, Canada)

1:45pm-3:15pm: A descriptive study with molecular and cytogenetic analysis in patients of ataxia telangiectasia(AT) from the Indian subcontinent

S. Das, S. Danda, M. Thomas, S. Yoganathan, V. Srivastava, S. Cleave A, A. Barney (Vellore, India)

1:45pm-3:15pm: A detailed delineation of the clinical phenotype, natural history and quality of life in patients with North Sea Progressive Myoclonus Epilepsy

S. Polet, L. Koens, M. van Egmond, D. Sival, E. Brusse, M. Willemsen, R. Lambrechts, O. Brouwer, G. Drost, H. Kremer, J. de Vries, M. de Koning-Tijssen, T. de Koning (Groningen, Netherlands)

1:45pm-3:15pm: A family of Phospholipase A2-associated neurodegeneration presented as complicated hereditary spastic paraplegia

MC. Wu, MY. Lan, JW. Li, YF. Chen, YY. Chang (Kaohsiung, Taiwan)

1:45pm-3:15pm: A genome-wide genetic pleiotropy approach identified shared loci between multiple system atrophy and inflammatory bowel/Crohn’s disease

A. Shadrin, A. Sreelatha, S. Mucha, C. Blauwendraat, O. Frei, D. Ellinghaus, A. Franke, G. Wenning, A. Singleton, T. Gasser, H. Houlden, S. Scholz, O. Andreassen, M. Sharma (Oslo, Norway)

1:45pm-3:15pm: A global survey on speech language therapists’ awareness to Huntington’s disease

A. Nuzzi, S. Naor, N. Inbar, T. Gurevich, Y. Manor (Santeramo In Colle, Italy)

1:45pm-3:15pm: A homozygous pentanucleotide repeat expansion in cerebellar ataxia, neuropathy and vestibular areflexia syndrome (CANVAS)

M. Gisatulin, V. Dobricic, Y. Hellenbroich, V. Tadic, A. Münchau, C. Zühlke, M. Bahlo, P. Lockhart, K. Lohmann, C. Helmchen, N. Brüggemann (Lübeck, Germany)

1:45pm-3:15pm: A Human Factors Study of the DopaFuse® Delivery System

J. Harmon, S. Japp, C. Long, J. Spiridigliozzi, A. Heller, B. Heller, C. King, P. Plante, R. Draper, T. Lau, E. Heller (Bala Cynwyd, PA, USA)

1:45pm-3:15pm: A Korean case of Fragile X-associated mild ataxia without tremor

WW. Lee, BK. Kim, O. Kwon, JM. Park, JJ. Lee, K. Kang (Seoul, Republic of Korea)

1:45pm-3:15pm: A life-threatening case of Anti-IgLON5 disease

M. Filidei, N. Tambasco, F. Paolini Paoletti, S. Simoni, E. Brahimi, G. Cappelletti, P. Nigro, P. Calabresi (Perugia, Italy)

1:45pm-3:15pm: A Multiple Ascending-Dose Study of LY3154207, A Dopamine D1 Receptor Positive Allosteric Modulator (D1PAM)

K. Biglan, D. Wilbraham, K. Svensson, M. Tsai, W. Kielbasa (Indianapolis, IN, USA)

1:45pm-3:15pm: A novel intronic pentanucleotide TTTGA repeat insertion in SAMD12 causes familial cortical myoclonic tremor with epilepsy type 1

ZD. Cen, Y. Chen, S. Chen, XH. Chen, B. Wang, F. Xie, OY. Zhiyuan, ZW. Jiang, AS. Fu, B. Hu, HM. Yin, X. Qiu, F. Yu, XP. Du, WC. Has, YX. Liu, HT. Wang, DH. Yang, LB. Wang, CY. Liu, JF. Xiao, BR. Zhang, W. Luo (Hangzhou, China)

1:45pm-3:15pm: A novel intronic variant in MAPT causes FTLD-parkinsonism: Implications for regulatory mechanism of MAPT pre-mRNA splicing

P. Gonzalez-Latapi, B. Bustos, D. Larson, L. Kinsley, N. Siddique, T. Siddique, T. Simuni, E. Bigio, S. Lubbe, R. de Silva, D. Krainc, N. Mencacci (Chicago, IL, USA)

1:45pm-3:15pm: A novel p.Trp42Arg REEP1 mutation associated with autosomal recessive Distal spinal muscular atrophy with vocal cord and diaphragmatic paralysis

R. Kaiyrzhanov, R. Maroofian, M. Behnam, M. Salehi, V. Salpietro, H. Houlden (London, United Kingdom)

1:45pm-3:15pm: A novel TGM6 heterozygous mutation in a patient with cerebellar ataxia

A. Manini, T. Bocci, E. Monfrini, D. Ronchi, M. Vizziello, G. Franco, A. de Rosa, F. Sartucci, A. Di Fonzo (Milan, Italy)

1:45pm-3:15pm: A Phase 2 Dose Escalation Study of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-Daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies

H. Kaufmann, I. Biaggioni, K. Chatamra, A. Panneerselvam, B. Haumann, R. Vickery (New York, NY, USA)

1:45pm-3:15pm: A Phase 2 Study of the Efficacy, Durability and Safety of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies

H. Kaufmann, I. Biaggioni, K. Chatamra, A. Panneerselvam, B. Haumann, R. Vickery (New York, NY, USA)

1:45pm-3:15pm: A Phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): Final study results

T. Simuni (Chicago, IL, USA)

1:45pm-3:15pm: A phase IIa trial studying the safety and tolerability of IRL752 in patients with Parkinson’s disease dementia

P. Svenningsson, P. Odin, N. Dizdar, F. Bergquist, A. Johansson, D. Nyholm, K. Wictorin, J. Tedroff (Uppsala, Sweden)

1:45pm-3:15pm: A pilot study of the feasibility and effects of table tennis training in Parkinson’s Disease

K. Olsson, A. Johansson, E. Franzén (Stockholm, Sweden)

1:45pm-3:15pm: A Protocol to Test the Effects of TDCS on Consolidation of Writing Practice in Parkinson’s Disease

S. Broeder, T. Kramer, R. Meesen, G. Verheyden, JJ. Orban Dexivry, A. Nieuwboer (Leuven, Belgium)

1:45pm-3:15pm: A randomized clinical trial of multimodal balance training with rhythmical cues: effects on freezing of gait in Parkinson’s disease

T. Capato, N. de Vries, J. Inthout, J. Ramjith, E. Barbosa, J. Nonnekes, B. Bloem (Nijmegen, Netherlands)

1:45pm-3:15pm: A randomized, placebo-controlled, double-blind clinical study in Japan of Opicapone treatment for Parkinson’s Disease -Comfort-PD Study part 1

A. Takeda, R. Takahashi, Y. Tsuboi, M. Nomoto, T. Maeda, A. Nishimura, N. Hattori (Sendai, Japan)

1:45pm-3:15pm: A recessive repeat expansion causes CANVAS and is a common cause of Late-Onset Ataxia

H. Houlden, M. Reilly, S. Zuchner, W. Marques, P. Fratta, A. Bronstein, A. Rossor, A. Rebelo, E. Buglo, N. Andrade, N. Wood, D. Kaski, S. Efthymiou, V. Salpietro, M. Versino, I. Callegari, D. Devigili, P. Tomaselli, E. Tribollet, M. Ilyas, J. Polke, P. Sivakumar, Z. Jaunmuktane, J. Humphrey, Y. Yan, H. Tariq, J. Vandrovcova, R. Sullivan, R. Simone, A. Cortese (London, United Kingdom)

1:45pm-3:15pm: A retrospective analysis of clinical and electrophysiological characteristics of patients with myoclonus

A. Gunduz, M. E. Kızıltan, H. Ser, N. Yeni, C. Ozkara, V. Demirbilek, C. Yalçınkaya, G. Kızıltan (Istanbul, Turkey)

1:45pm-3:15pm: A review of interactive voice response systems in Parkinson’s Disease

J. Domingues, T. Guerreiro, D. Branco, A. Rodrigues, R. Bouça-Machado, J. Ferreira (Aveiro, Portugal)

1:45pm-3:15pm: A Robust and Rapid Method of PCR amplification To Confirm Triplet Repeat Disorders: Single-Step Blood Direct PCR

I. Singh, V. Swarup, S. Shakya, V. Goyal, A. Srivastava (New Delhi, India)

1:45pm-3:15pm: A safety, tolerability and biomarker update from an ongoing open-label extension study of RG6042 in adults with early manifest Huntington’s disease

S. Tabrizi, B. Leavitt, P. Sanwald Ducray, E. Wild, V. Schlegel, G. Hooper, A. Nicotra, J. Chevure, A. Smith, R. Lane, F. Bennett, L. Boak, R. Doody, S. Schobel (London, United Kingdom)

1:45pm-3:15pm: A single nigral injection of human ENGRAILED-1 induces long-lasting behavior benefit in an experimental primate model of Parkinson Disease

A. Prochiantz, E. Pioli, C. Friedel, K. Moya, E. Bézard, A. Bousseau (Paris, France)

1:45pm-3:15pm: A Smart Device System (Wearable technology band) to Identify New Phenotypical Characteristics in Parkinson‘s disease patients

V. Sharma, S. Sharma (Delhi, India)

1:45pm-3:15pm: A study for expanding application sites of rotigotine transdermal patch

S. Itaya, Y. Choh, M. Takahashi, A. Inaba, K. Orimo, Y. Ono, H. Kujirai, S. Orimo (Tokyo, Japan)

1:45pm-3:15pm: A Study of Microglial Metabolism in Neuroinflammation

T. Domenick, B. Cyr, R. Yost, M. Okun, V. Vedam-Mai (Gainesville, FL, USA)

1:45pm-3:15pm: A study of Mutation in ATP7B gene and its correlation with clinical phenotype and radiological features in patients of Wilson Disease-a population based study in a tertiary care institute in eastern India

J. Chaudhuri, T. Biswas, A. Biswas, S. Biswas, G. Gangopadhyay, A. Dutta (Kolkata, India)

1:45pm-3:15pm: A Systems Approach Model for Pantothenate Kinase-Associated Neurodegeneration (PKAN)- Assessment and Treatment

S. Baser, C. Muniz, F. Middleton, R. Ericson, C. Bass (Pittsburgh, PA, USA)

1:45pm-3:15pm: A Unified Staging System for Prodromal and Manifest Huntington’s disease

A. Mohan, Z. Sun, S. Ghosh, Y. Li, Y. Cheng, J. Hu, C. Sampaio (Yorktown Heights, NY, USA)

1:45pm-3:15pm: Abnormal Gait in Cerebrotendenious Xanthomatosis a case report

H. Amer, S. Ali, S. Sherif, S. El-Jaafary (Cairo, Egypt)

1:45pm-3:15pm: Abnormal posture during treatment of restless legs syndrome in an old woman: A case report

K. Hirata, K. Suzuki, M. Saito, T. Shiina, H. Sakuramoto, M. Hamaguchi, T. Kadowaki (Mibu, Japan)

1:45pm-3:15pm: Acquired (non-Wilsonian) hepatocerebral degeneration: case report

E. Gracheva, I. Miliukhina, A. Sokolov, YU. Seliverstov (St.petersburg, Russian Federation)

1:45pm-3:15pm: Acquired hepatocerebral degeneration treated with calcium disodium edetate chelation

Z. Voysey, L. Azzopardi, B. Fiddes, S. Bradberry (Romford, United Kingdom)

1:45pm-3:15pm: Acute chorea secondary to cephalosporin

BED. Ines, BRA. Zeineb, MAN. Malek, ZAO. Jamel, MRI. Ridha (Tunis, Tunisia)

1:45pm-3:15pm: Acute hemichorea in patient of uncontrolled type 2 diabetes mellitus; a case report with characteristic imaging

M. Salem, A. Helmy, E. Abdeldayem, A. Shalash (Cairo, Egypt)

1:45pm-3:15pm: Acute hypertensive crisis with myoclonic movements induced by withdrawal of intrathecal combined clonidine and morphine administration

A. Saryyeva, J. Krauss, L. Cassini Ascencao (Hannover, Germany)

1:45pm-3:15pm: Acute, contact-dependent behavioral changes in Parkinson disease (PD) patients during monopolar contact review of subthalamic deep brain stimulation (DBS) using directional leads

CHR. Vander Linden, C. Bogaert, D. Colle, H. Colle (Ghent, Belgium)

1:45pm-3:15pm: Addition of Opicapone to Safinamide in Parkinson’s Disease patients

M. Russo, C. Carrarini, F. Dono, M. Di Pietro, M. Rispoli, L. Ferri, M. Onofrj (Chieti, Italy)

1:45pm-3:15pm: Advanced Care Planning in complex Parkinson’s disease

L. Richardson, N. Butt, M. Khwaja, H. Avery, G. Alg, A. Chatterjee (Reading, United Kingdom)

1:45pm-3:15pm: Agreement Between the GAITRite® Walkway System and the Wearable Inertial Sensor BTS G-Walk® for Measurement of Gait Parameters

H. Horáková, K. Poláková, E. Růžička, H. Brožová (Prague, Czech Republic)

1:45pm-3:15pm: Alcohol- Induced Cerebellar Ataxia

B. Zeigelboim, H. Teive, C. Santos Junior, J. Malisky, M. da Rosa, R. Sampaio, M. José (Curitiba, Brazil)

1:45pm-3:15pm: Alexander Technique Group Classes Are a Feasible and Promising Intervention for Care Partners of People living with Parkinson’s disease

M. Gross, R. Ravichandra, B. Mello, R. Cohen (Candler, NC, USA)

1:45pm-3:15pm: Alignment of objective markers of speech with listener based judgements and disease severity in Friedreich ataxia

A. Vogel, A. Tsanas, H. Reece, L. Corben, G. Tai, M. Delatycki (Melbourne, Australia)

1:45pm-3:15pm: Alleviation of Parkinson’s and Associated Depression using Silymarin in Rotenone induced Mice Model of Parkinson’s Disease

D. Khatri (Pune, India)

1:45pm-3:15pm: Alpha-synuclein promoter (SNCA-Rep1) polymorphism is associated with non-motor symptoms in early Parkinson’s disease

ASL. Ng, YJ. Tan, Y. Zhao, ZH. Lu, EYL. Ng, SYE. Ng, NSY. Chia, F. Setiawan, ZY. Xu, KY. Tay, WL. Au, EK. Tan, LCS. Tan (Singapore, Singapore)

1:45pm-3:15pm: Altered intrinsic power spectral density of the precuneus in patients with hyperkinetic functional movement disorders

R. Marapin, H. Horn, J. Gelauff, B. de Jong, Y. Dreissen, J. Koelman, R. Renken, J. Marsman, M. Tijssen (Groningen, Netherlands)

1:45pm-3:15pm: Amplification of α-synuclein aggregates in cerebrospinal fluid by rapid ultrasonication-based assay

K. Kakuda, K. Ikenaka, K. Araki, Y. Kajiyama, M. So, T. Ohmichi, Y. Nagai, T. Tokuda, Y. Goto, H. Mochizuki (Suita, Japan)

1:45pm-3:15pm: An adult type Niemann-Pick disease type C family: Huntington’s disease-like expression

I. Toyoshima, F. Takeda, C. Wada (Yurihonjo, Japan)

1:45pm-3:15pm: An Experimental Study to Assess the Professional and Social Consequences of Tardive Dyskinesia

R. Ayyagari, D. Goldschmidt, F. Mu, S. Caroff, B. Carroll (Boston, MA, USA)

1:45pm-3:15pm: An open-label, 1-year extension clinical study in Japan of Opicapone treatment for Parkinson’s disease -Comfort-PD study part 2

A. Takeda, R. Takahashi, Y. Tsuboi, M. Nomoto, T. Maeda, A. Nishimura, N. Hattori (Sendai, Japan)

1:45pm-3:15pm: An updated flow chart for the evaluation of chorea

R. Walker (Bronx, NY, USA)

1:45pm-3:15pm: Analysis of Levodopa Content in Commercial Formulations of Mucuna pruriens Seeds Used in Integrative Treatment of Parkinson’s Disease

T. Denne (Kenmore, WA, USA)

1:45pm-3:15pm: Analysis of the Shape of the Gocovri Steady-state PK Profile: Implications for an Extended Release Product

R. Hauser, S. Isaacson, A. Mittur, A. Formella, R. Patni (Tampa, FL, USA)

1:45pm-3:15pm: Ancillary Service Utilization and Impact in Huntington’s Disease

J. Yomtoob, C. Yeh, D. Bega (Chicago, IL, USA)

1:45pm-3:15pm: Another mitochondrial disease mimic: Two Case reports of adult riboflavin transporter deficiency (RTD) type 2 with muscle adenosine monophosphate (AMP) deaminase deficiency

L. Zhang, D. Thyagarajan (Melbourne, Australia)

1:45pm-3:15pm: Anthropometric Profile and Vitamin D Status in the Functional Performance of a Brazilian Elderly Parkinsonian Population

L. Leandro, S. Kusma, H. Teive, C. Moreira (Curitiba, Brazil)

1:45pm-3:15pm: Apathy : Clinical Correlates in Parkinson’s disease Psychosis

YM. Wan, D. van Wamelen, V. Leta, D. Trivedi, A. Podlewska, TS. Lee, EK. Tan, D. Aarsland, K. Chaudhuri (London, United Kingdom)

1:45pm-3:15pm: Apomorphine induced hemolytic anemia: A case report and literature review

F. Hajiakhoundi, M. Motamed, M. Rohani, G. Shahidi (Tehran, Islamic Republic of Iran)

1:45pm-3:15pm: Application of the “5-2-1” Screening Criteria in Advanced Parkinson’s Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel: Interim Analysis from the DUOGLOBE Study

A. Antonini, J. Aldred, L. Bergmann, N. Kovács, P. Kukreja, W. Robieson, D. Standaert, KR. Chaudhuri (Padova, Italy)

1:45pm-3:15pm: Are Cognitive Changes in Hereditary Spastic Paraplegias Restricted to Complicated Forms?

L. Jacinto-Scudeiro, G. Machado, A. Ayres, D. Burguêz, M. Polese-Bonatto, C. González-Salazar, M. Siebert, M. França Jr, M. Olchik, J. Saute (Porto Alegre, Brazil)

1:45pm-3:15pm: Assessing the response to Levodopa/carbidopa intestinal gel infusion based on genetic status

A. Thaler, V. Livneh, A. Hillel, H. Strauss, G. Yahalom, H. Shabtai, A. Migirov Senderovich, S. Israeli-Korn, T. Fay-Carmon, N. Giladi, S. Hassin Baer, T. Gurevich (Ramat Gan, Israel)

1:45pm-3:15pm: Assessment of Caregiver Burden in Huntington’s disease

M. Yu, K. Tan, K. Koloms, D. Bega (Chicago, IL, USA)

1:45pm-3:15pm: Assessment of Gait in Huntington’s disease patients using EncephaLog smartphone’s application

NI. Inbar, N. Omer, A. Bar David, N. Geva, I. Dabakarov, L. Barsky, Z. Yekutieli, N. Giladi, T. Gurevich (Tel Aviv, Israel)

1:45pm-3:15pm: Assessment of Neuropsychological Outcomes Using a New Multiple Source, Constant- Current Rechargeable Deep Brain Stimulation System for the Treatment of Parkinson’s Disease – INTREPID Study

A. Tröster, R. Jain, L. Chen, I. Study Group, M. Okun (Phoenix, AZ, USA)

1:45pm-3:15pm: Assessment of RADIAL, a tool for the diagnostic of autosomal recessive cerebellar ataxia: a prospective study

O. Gebus, M. Renaud, M. Koenig, J. Chelly, C. Tranchant, M. Anheim (Strasbourg, France)

1:45pm-3:15pm: Assessment of the risk of falls in patients with Parkinson’s disease using Time Up and Go

F. Sattolo, L. Rodrigues, L. Lima, M. Diogo, R. Guimarães (Campinas, Brazil)

1:45pm-3:15pm: Association analysis between SCNN1A rs10849446, SPTLC3 rs6041636 and rs627354 and Parkinson’s disease and multiple system atrophy in a large Chinese population

XJ. Gu, YP. Chen, RW. Ou, B. Cao, HF. Shang (Chengdu, China)

1:45pm-3:15pm: Association between Gait during Daily Life and Clinical Measures: Effects of Bout Length

V. Shah, J. Mcnames, C. Curtze, M. Mancini, P. Carlson-Kuhta, J. Nutt, M. El Gohary, F. Horak (Portland, OR, USA)

1:45pm-3:15pm: Association of genetic polymophisms with pharmacokinetics of levodopa in South indian PD patients

R. Borgohain, T. Sd, T. Syed, V. Kutala, R. Kandadai, S. Meka, S. Tandra (Hyderabad, India)

1:45pm-3:15pm: Associations of Genetic, Epigenetic and Phenotypic Measures in the Dominican Republic PKAN Cohort

F. Middleton, A. Espinoza, D. Larocca, R. Ericson, M. Santana Jimenez, K. Wagner, P. Stoeter, C. Bass, C. Muniz, S. Baser (Pittsburgh, PA, USA)

1:45pm-3:15pm: Associations of microtubule associated protein tau (MAPT) H1 subhaplotypes and the MAPT H2 haplotype with demographic and clinical features in Parkinson`s disease

A. Deutschlander, M. Heckman, T. Konno, M. Ossi, N. Diehl, A. Soto, A. Strongosky, R. Uitti, J. van Gerpen, O. Ross, W. Zbigniew (Jacksonville, FL, USA)

1:45pm-3:15pm: Asymmetry of motor symptoms in patients with Parkinson’s Disease

Y. Trufanov, N. Svyrydova, V. Svistun, I. Harkava, H. Bondarenko, N. Zhhilova (Kyiv, Ukraine)

1:45pm-3:15pm: Ataxia by Mutation in CACNA1A Gene – Case Series

P. Almeida, J. Pedroso, I. Brandi (Salvador, Brazil)

1:45pm-3:15pm: Ataxia with(out) oculomotor apraxia: A unique SETX mutation in 3 siblings

P. Khemani, A. Kuhlman, B. Bulica, N. Patel (Seattle, WA, USA)

1:45pm-3:15pm: Ataxin-2 gene in the Cuban population: Mutagenesis and epigenetic DNA methylation disease influencing phenotype

J. Laffita-Mesa, L. Velazquez Perez (Stockholm, Sweden)

1:45pm-3:15pm: Atropine as Alternate Therapy for Treatment of Sialorrhea in Parksinson’s Disease

K. Papesh, J. Nguyen (Las Vegas, NV, USA)

1:45pm-3:15pm: Auditory-Perceptual Voice and Speech Evaluation in ATP1A3-positive Patients

M. Finger, L. Madden, K. Ruckart, K. Downes, J. Cook, B. Snively, A. Brashear, I. Haq (Winston-Salem, NC, USA)

1:45pm-3:15pm: Augmented Brain Wave Synchronicity in Sleep in Parkinson’s Disease Patients

A. Hohler, O. Vaou, X. Zhang, J. Wang, A. Quaicoe, F. Lombardi, R. Endelapour, J. Holsapple, P. Ivanov (Boston, MA, USA)

1:45pm-3:15pm: Automated Immunohistochemical Detection of Skin Depositions of Pathological alpha-Synuclein in Idiopathic REM Sleep Behavior Disorder and Parkinsonism

T-S. Tsao, A. Al-Qassabi, A. Racolta, KI. Taylor, W. Zago, RB. Postuma, S. Dziadek (Basel, Switzerland)

1:45pm-3:15pm: Automatic quantification of micro-sleep stability in isolated REM sleep behavior disorder and Parkinson’s disease

M-L. Muntean, M. Cesari, F. Sixel-Döring, B. Mollenhauer, JAE. Christensen, HBD. Sorensen, PJJ. Jennum, C. Trenkwalder (Kassel, Germany)

1:45pm-3:15pm: Availability of Parkinson’s disease medicines in Ghana: a national survey

M. Cham, I. Sefah, K. Oppon, R. Odikro, C. Amenorvi, A. Malik, J. Duah, G. Pezzoli, F. Baiden, R. Cilia (Sogakope, Ghana)

1:45pm-3:15pm: Balance training modulates the concentration of pro- and anti-inflammatory cytokines in the plasma of elder people and PD patients. A pilot study

J. Szymura, J. Kubica, M. Więcek, J. Pera (Krakow, Poland)

1:45pm-3:15pm: BeaT-PD, An Industry-Academic Collaboration to Understand PD Progression in Ashkenazi Jews

N. Giladi, A. Orr-Urtreger, M. Gana-Weisz, A. Thaler, O. Goldstein, M. Lalioti, K. Evans, M. Hutchison, O. Mabrouk, A. Dowling, T. Fox, M. Yang, K. Parekh, E. Even Sapir, D. Ben Baast, M. Artzi, H. Lerman, L. Yachimovich, B. Cohen, S. John, A. Mirelman, J. Cederbaum (Tel Aviv, Israel)

1:45pm-3:15pm: Behavioural aspect of transgenic Drosophila melanogaster as a model of Parkinson’s disease treated by Ropinirole alginate nanocomposite

F. Naz, R. X, YHS. Siddique (Aligarh, India)

1:45pm-3:15pm: Beliefs, Knowledge and Attitudes Towards Parkinson’s Disease: Turkey Experience from a Global Perspective

Y. Degirmenci, P. Limousin, GM. Hariz, N. Cakar (Duzce, Turkey)

1:45pm-3:15pm: Benefit and Weakness with botulinum toxin: time course and relationship.

P. Kassavetis, K. Alter, C. Lungu, B. Karp (Bathesda, MD, USA)

1:45pm-3:15pm: Benign hereditary chorea: A Tunisian family case presentation

M. Akkari, H. Ben Rhouma, H. Klaa, A. Rouissi, I. Kraoua, I. Turki (Tunis, Tunisia)

1:45pm-3:15pm: Bilateral Putaminal AAV2-GDNF Delivery the Treatment of Advanced Parkinson’s Disease

K. Bankiewicz, C. Lungu, D. Hammoud, P. Herscovitch, D. Ehrlich, D. Argersinger, S. Sinharay, G. Scott, T. Wu, W. San Sebastian, V. Suhakar, M. Fiandaca, K. Zaghloul, M. Hallett, R. Lonser, J. Heiss (San Francisco, CA, USA)

1:45pm-3:15pm: Biomarkers of idiopathic REM sleep behavior disorder versus RBD within narcolepsy

E. Antelmi, F. Pizza, Y. Sosero, V. Donadio, A. Incensi, R. Liguori, G. Plazzi (Bologna, Italy)

1:45pm-3:15pm: Biphasic Dyskinesias in Parkinson’s disease Patients treated with Levodopa/Carbidopa Intestinal Gel: Insights from a Multicenter Retrospective Analysis

M. Marano, T. Naranian, L. Di Biase, A. Di Santo, R. Arca, G. Cossu, P. Marano, V. Di Lazzaro, A. Fasano (Rome, Italy)

1:45pm-3:15pm: Botulinum Neurotoxin (BoNT) treatment in functional movement disorders: an extended follow up

J. Dijk, M. Tijssen, J. Koelman, Y. Dreissen, F. Lambert (Groningen, Netherlands)

1:45pm-3:15pm: Botulinum toxin treatment of muscle spasms in a case of Satoyoshi syndrome

I. Bledsoe (San Francisco, CA, USA)

1:45pm-3:15pm: Botulinum toxin type A therapy in a movement disorders unit: a 23-year experience.

M. Velez, C. Cosentino, L. Torres (Lima, Peru)

1:45pm-3:15pm: BouNDless: An active-controlled randomized, double-blind double-dummy study of continuous ND0612 infusion in patients with fluctuating Parkinson’s disease

W. Poewe, K. Kieburtz, F. Stocchi, S. Oren, T. Yardeni, L. Adar, O. Rosenfeld, C. Olanow (Innsbruck, Austria)

1:45pm-3:15pm: Brain and spinal cord structural alterations in non-ataxic and ataxic SCA3 mutation carriers

J. Faber, I. Giordano, B. Koyak, R. Wolz, S. Romanzetti, MC. Franca Jr, H. Jiang, A. Durr, B. Bender, J. Diedrichsen, T. Klockgether (Bonn, Germany)

1:45pm-3:15pm: Brain MRI Volume Changes after 12 months laquinimod treatment of Huntington disease (LEGATO-HD)

R. Reilmann, M. Gordon, A. Feigin, K. Anderson, S. Tabrizi, B. Leavitt, J. Stout, P. Piccini, N. Hobbs, R. Manber, B. Borowsky, G. Rynkowski, R. Volkinshtein, J. Savola, M. Hayden (Victoria, Australia)

1:45pm-3:15pm: Brain MRI-based discrimination between multiple system atrophy type cerebellar from other late onset sporadic cerebellar ataxias: a prospective study with implications for diagnosis criteria

G. Carré, JL. Dietemann, O. Gebus, S. Montaut, O. Lagha-Boukbiza, T. Wirth, S. Kremer, IJ. Namer, M. Anheim, C. Tranchant (Strasbourg, France)

1:45pm-3:15pm: Burden of Huntington’s disease in the US: Analysis of an insured population

K. Raimundo, J. Luo, R. Tan, T. To, R. Fuller, J. Warner (South San Francisco, CA, USA)

1:45pm-3:15pm: Can a smartphone accelerometer differentiate between functional and organic tremor ?

M. Khider Ahmed, T. Mouton, J. Ackerman, N. Brey, C. Albertyn, F. Henning, J. Carr (Cape Town, South Africa)

1:45pm-3:15pm: Can people with Parkinson’s disease rely on their coping capacity over time? A longitudinal study using the Sense of Coherence (SOC) scale

J. Andersson, G-M. Hariz, L. Forsgren (Umeå, Sweden)

1:45pm-3:15pm: Can we hear pathology in premanifest Huntington’s disease? Acoustic and listener-based analysis of speech

J. Chan, C. Shirbin, J. Stout, A. Vogel (Melbourne, Australia)

1:45pm-3:15pm: Cardiac involvement in AVED

S. Lucas-Delpozo, D. Moreno-Martínez, M. Tejero-Ambrosio, J. Hernández-Vara (Barcelona, Spain)

1:45pm-3:15pm: Caregiver burden does not improve in the long-term after deep brain stimulation for Parkinson disease

E. Jackowiak, A. Maher, C. Persad, P. Patil, K. Chou (Ann Arbor, MI, USA)

1:45pm-3:15pm: Caregiver support and its association with advanced Parkinson’s disease and clinical outcomes

A. Fasano, L. Bergmann, V. Fung, Y. Jalundhwala, K. Onuk, Z. Pirtosek, W. Robieson, K. Seppi, A. Takáts, P. Martinez-Martin (Totronto, ON, Canada)

1:45pm-3:15pm: Case report: Chorea-acynthocytosis with two compoud heterozygous VPS13A large deletions

D. Spieler, A. Mühlbäck, A. Velayos-Baeza, F. Castrop, C. Maegerlein, J. Slotta-Hispenina, B. Bader, B. Haslinger, J. Klempir, A. Danek (Freiburg, Germany)

1:45pm-3:15pm: Case Series of 3 Individuals of African Descent with Dentatorubral-Pallidoluysian Atrophy

C. Kutz, C. Bundukamara (Colorado Springs, CO, USA)

1:45pm-3:15pm: Cerebellar ataxia and cutaneous lesions: a clinical case

L. Azevedo Kauppila, P. Dias, C. Silva, A. Sousa, M. Rosa, L. Correia Guedes (Lisboa, Portugal)

1:45pm-3:15pm: Cerebellar Ataxia in Patients with Huntington’s Disease, an underestimated symptom?

GLF. Franklin, HAT. Teive, FBG. Germiniani, SR. Raskin, GMP. Pavanelli, SSM. Milano, NSL. Lima, OPB. Barsottini, JLP. Pedroso, FAM. Maggi, VT. Tumas, PMC. Carvalho, PCA. Azevedo, ILC. Lopes-Cendes (Curitiba, Brazil)

1:45pm-3:15pm: Cerebral cavernous malformations and movement disorders

M. Polemikos, E. Hermann, J. Krauss (Hannover, Germany)

1:45pm-3:15pm: Cerebral palsy masqueraders in an adult movement disorder tertiary centre: when to investigate an alternative diagnosis?

S. Duarte, R. Martins, M. Magalhães (Porto, Portugal)

1:45pm-3:15pm: Cerebrotendinous Xanthomatosis presenting Parkinsonism with bilateral iron accumulation in the basal ganglia

J. Li, S. Liu, E. Xu, H. Qiao, W. Mao, P. Chan (Beijing, China)

1:45pm-3:15pm: Certification of cause of death in patients with Parkinson’s Disease (PD)

M. Khwaja, A. Chatterjee (Reading, United Kingdom)

1:45pm-3:15pm: Changes in close relationships among patients with Parkinson’s disease and their partners following initiation of device-aided treatment

J. Timpka, M. Scharfenort, T. Sahlström, V. Hernström, T. Henriksen, D. Nyholm, P. Odin (Lund, Sweden)

1:45pm-3:15pm: Changes in GABAergic transmission of striatal neurons in presymptomatic Huntington’s Disease

M. Treven, F. Zirpel, I. Mody (Vienna, Austria)

1:45pm-3:15pm: Changes in Supine Blood Pressure with Long Term Use of Droxidopa

S. Gorny, L. Hewitt, A. Lindsten, M. Karnik-Henry, S. Kymes, A. Favit (Deerfield, IL, USA)

1:45pm-3:15pm: Changes to Speech Production after SpeechVive Treatment in Individuals with Parkinson’s Disease

J. Huber, E. Stathopoulos, J. Sussman, K. Richardson, D. Matheron, S. Snyder (West Lafayette, IN, USA)

1:45pm-3:15pm: Characterization of cerebrospinal fluid profile in hereditary spastic paraparesis 10

M. Andréasson, K. Lagerstedt-Robinson, K. Samuelsson, G. Solders, K. Blennow, M. Paucar, P. Svenningsson (Stockholm, Sweden)

1:45pm-3:15pm: Characterization of impulsivity in Colombian patients with Huntington’s disease

L. Colmenares, C. Rodriguez, W. Fernandez (Bogotá, Colombia)

1:45pm-3:15pm: Chlorogenic acid attenuates the MPTP induced apoptosis in Parkinson’s disease mouse model through pAkt signaling pathway

S. Singh, S. Singh (Varanasi, India)

1:45pm-3:15pm: Chorea-acanthocytosis: Challenges in early diagnosis and excellent treatment response to Deep Brain Stimulation (DBS) – a case report

J. Walch, F. Brugger, D. Brogle, R. Bauer, S. Haegele-Link, G. Kägi (St. Gallen, Switzerland)

1:45pm-3:15pm: Classification of Neurorehabilitation treatments: Preliminary results of a Multicentre Italian Study

T. Bowman, F. Mestanza Mattos, R. Russo, M. Boninsegna, F. Marazzini, A. Marianelli, E. Pelosin, M. Putzolu, C. Cosentino, M. Petrarca, F. Tirinelli, M. Tondinelli, F. Trecate, M. Budel, A. Turolla, M. Agostini, D. Munari, P. Pillastrini, M. Branchini, D. Lunedei, G. Sgubin, D. Cattaneo, S. Mezzarobba (Milano, Italy)

1:45pm-3:15pm: Classification of spinocerebellar degeneration based on ratio of brainstem white matter to cerebellar gray matter by voxel-based morphometry

T. Taguchi, K. Nanri, H. Kato, H. Terashi, H. Aizawa (Tokyo, Japan)

1:45pm-3:15pm: Clinical and cognitive features of anxiety in Parkinson’s disease

G. Carey, L. Defebvre, A. Moonen, A. Leentjens, K. Dujardin (Lille, France)

1:45pm-3:15pm: Clinical and fMRI effects of Action Observation and Motor Imagery Training on dual-task performances in Parkinson’s disease patients with postural instability and gait disorders

E. Sarasso, F. Agosta, N. Piramide, E. Canu, M. Chiesi, I. Ravani, S. Galantucci, A. Tettamanti, MA. Volontè, M. Filippi (Milan, Italy)

1:45pm-3:15pm: Clinical and genetic features of paroxysmal kinesigenic dyskinesia (PKD) studied with whole exome sequencing (WES)

Z. Xu, Z. Lu, CK. Lim, SC. Low, E. Ng, AH. Tan, SY. Lim, EK. Tan, LCS. Tan (Singapore, Singapore)

1:45pm-3:15pm: Clinical and genetic heterogeneity in Indian subcontinent patients with Autosomal Dominant Spinocerebellar Ataxia 42

A. Mehta, M. Javali, P. R, K. Haskar, D. Gupta, P. Acharya, S. Srinivasa (Bengaluru, India)

1:45pm-3:15pm: Clinical and molecular features of a Chinese family with spinocerebellar ataxia type 6

H. Luan, A. Liu (Yantai, China)

1:45pm-3:15pm: Clinical Audit of Hospital Admissions for Parkinson Disease

HL. Lan, LW. Wei, ST. Shu Ting, KY. Kay Yaw, WL. Wing Lok, LT. Louis Cs (Singapore, Singapore)

1:45pm-3:15pm: Clinical Correlates of Genetic and Biomarker Profiles in Patients with Progressive Supranuclear Palsy: Data from the ARISE Study

H. Soares, Z. Jin, N. Fisseha, M. Gold, C. Locke, B. Rendenbach-Mueller, E. Smith, I. Suridjan, A. Vasanthakumar, N. Mendonca (Ludwigshafen, Germany)

1:45pm-3:15pm: Clinical hypnosis in functional movement disorders: a potential therapeutic strategy

C. Buiza-Aguado, C. Ordas-Bandera, M. Guillan-Rodriguez, J. Del Val, PJ. Garcia Ruiz-Espiga, JC. Martinez-Castrillo, I. Parees-Moreno, A. Alonso-Canovas (Madrid, Spain)

1:45pm-3:15pm: Clinical outcome in early-treated Sepiapterine Reductase Deficiency (SRD): A case report

F. Nardecchia, S. Galosi, F. Manti, MT. Giannini, C. Carducci, M. Tolve, V. Leuzzi (Rome, Italy)

1:45pm-3:15pm: Clinical spectrum of Functional Movement Disorders: A clinic based study from a developing country

D. Dash, M. Tripathi, R. Singh (Delhi, India)

1:45pm-3:15pm: Clinico-genetic correlation in 102 Spinocerebellar Ataxia Type 12 (SCA 12) patients

AK. Srivastava, A. Takkar, V. Goyal, F. Mohammad, R. Rajan, A. Garg (New Delhi, India)

1:45pm-3:15pm: Clinico-pathological Findings In Autopsy Cases With Non-Specific Glial Tauopathy

E. Zamrini, CH. Adler, GE. Serrano, N. Zhang, DR. Shprecher, SH. Mehta, MN. Sabbagh, E. Driver-Dunckley, HA. Shill, LI. Sue, TG. Beach (Sun City, AZ, USA)

1:45pm-3:15pm: Clinicopathologic Characterization and Abnormal Autophagy of HDLS

W. Tian, L. Cao, S. Chen (Shanghai, China)

1:45pm-3:15pm: Cockayne Syndrome manifesting as late adult onset cerebellar ataxia: expanding the phenotype

R. Chuang (Seattle, WA, USA)

1:45pm-3:15pm: Comorbidities and medications in Huntington’s disease, Parkinson’s disease and the general population in a US claims database

L. Ishihara, E. Wild, D. Oliveri (Welwyn Garden City, United Kingdom)

1:45pm-3:15pm: Comparison of Gene Expression in Parkinson’s Disease and Bipolar Disorder

FV. Delos Reyes (Quezon City, Philippines)

1:45pm-3:15pm: Complex disease burden in Parkinson’s and Advance Care Planning

M. Khwaja, A. Chatterjee, G. Alg, A. Cotton, L. Richardson, H. Avery (Reading, United Kingdom)

1:45pm-3:15pm: Complex Training of Balance in Parkinson’s Disease

ANN. Istomina, IR. Milyukhina (Saint-Petersburg, Russian Federation)

1:45pm-3:15pm: Considerations before initiating therapy in Parkinsonism: basing on the health-related quality of life.

FT. Liu, J. Wang (Shanghai, China)

1:45pm-3:15pm: Continuous circadian intracerebroventricular administration of anaerobic dopamine: A new therapeutic concept for Parkinson’s disease?

C. Moreau, C. Laloux, C. Lachaud, E. Pioli, Q. Li, P. Pascal, L. Defebvre, R. Bordet, E. Bezard, M. Fisichella, D. Devos (Lille, France)

1:45pm-3:15pm: Convalescent Chorea in West Nile Virus Encephalitis

A. Kirby, M. Afshari (Chicago, IL, USA)

1:45pm-3:15pm: Correlation between degree of dysarthria, motor severity and quality of life in patients with Parkinson’s disease

M. Olchik, C. Rieder, L. Scudeiro, R. Rech, R. Millette, A. Ayres (Porto Alegre, Brazil)

1:45pm-3:15pm: Correlation Between Drooling and Quality of Life in Parkinson’s Disease

O. Criciotoiu, D. Stanca, R. Latea, L. Giurgiulescu, A. Mita, V. Gheorman, D. Gheonea (Craiova, Romania)

1:45pm-3:15pm: Correlation between structural neuroimaging and clinical outcomes in a small sample of patients with early Huntington’s disease

C. Estevez Fraga, E. Johnson, F. Rodrigues, P. Zeun, N. Hobbs, E. Rees, R. Roos, B. Landwehrmeyer, A. Durr, S. Gregory, R. Scahill, G. Rees, S. Tabrizi (London, United Kingdom)

1:45pm-3:15pm: Correlations between genetics and cortical dysfunction of paroxysmal kinesgenic dyskinesia

Y. Liu, Y. Chen, Y. Wu (Taipei, Taiwan)

1:45pm-3:15pm: Creutzfeld Jacob disease presenting with functional-appearing, bizarre movements without significant cognitive impairment

M. Mcgraw, Z. Grujic, P. Vittal, J. Pallone (Winfield, IL, USA)

1:45pm-3:15pm: Creutzfeldt-Jakob disease with a M232R substitution (CJD232) masquerading as parkinson look-alike syndrome

KO. Jung, H. Kim, JH. Park (Bucheon-Si, Republic of Korea)

1:45pm-3:15pm: CSF levels of NFL (neurofilament light chain) in Parkinsons’ disease patients

E. Papuć, K. Rejdak (Lublin, Poland)

1:45pm-3:15pm: Cultural bias in performance of motor tasks? Comparison between Japanese and German healthy adults

K. Otte, M. Suzuki, H. Röhling, R. Kuroiwa, S. Mansow-Model, M. Mori, H. Zimmermann, AU. Brandt, F. Paul, S. Hirano, S. Kuwabara, T. Schmitz-Hübsch (Berlin, Germany)

1:45pm-3:15pm: Dancing larynx syndrome associated with trigeminal neuralgia secondary to multiple sclerosis

D. Shpiner, M. Ortega, H. Moore (Miami, FL, USA)

1:45pm-3:15pm: Daytime sleepiness in Parkinson’s disease: an indicator of impaired activities of daily living

T. Canento, J. Tan, B. Cruse, C. Wools, M. Ghaly, M. Beckley, F. Leen, AH. Evans (Melbourne, Australia)

1:45pm-3:15pm: Decreased serum alpha-synuclein in patients with Restless Legs Syndrome and association with SNCA-Rep1 polymorphism

YC. Wu, XY. Zhu, TT. Wu, T. Liu, HM. Wang, YJ. Chen, X. Li, XX. Cui (Shanghai, China)

1:45pm-3:15pm: Deep Brain Stimulation in Early-Stage Parkinson’s Disease Provides Long-Term Rest Tremor Benefit Through Five Years

M. Hacker, M. Turchan, T. Davis, F. Phibbs, P. Hedera, P. Konrad, D. Charles (Nashville, TN, USA)

1:45pm-3:15pm: Defence Mechanism of Ego and Coping Strategy Style of the Patient with Parkinson’s Disease

M. Kulsum, S. Choudhury, A. Ghosh, P. Ghosh (Kolkata, India)

1:45pm-3:15pm: Dementia with Lewy bodies: GBA1 mutations are associated with cerebrospinal fluid alpha-synuclein profile

S. Lerche, G. Machetanz, I. Wurster, B. Roeben, M. Zimmermann, A. Pilotto, A-K. Hauser, C. Schulte, I. Lachmann, T. Gasser, D. Berg, W. Maetzler, K. Brockmann (Tübingn, Germany)

1:45pm-3:15pm: Dentatorubral-Pallidoluysian Atrophy outside of Asia: A case report of the first Austrian family harbouring this rare mutation

M. Amprosi, W. Nachbauer, E. Indelicato, A. Eigentler, G. Puttinger, J. Gusenleitner, T. von Oertzen, S. Boesch (Innsbruck, Austria)

1:45pm-3:15pm: Depression in Parkinson’s diseaese: Experience of the neurology department in Mohammed VI third level university hospital

H. El Yachkouri, M. Chraa, N. Kissani (Marrakesh, Morocco)

1:45pm-3:15pm: Design and Baseline Characteristics of an Open-Label, Randomized, 26-Week Study Comparing Levodopa-Carbidopa Intestinal Gel to Optimized Medical Treatment on Non-Motor Symptoms in Patients with Advanced Parkinson’s Disease – INSIGHTS Study

S. Chung, M. Garriga, M. Ceravolo, N. Tambasco, W. Robieson, M. Facheris, O. Sánchez-Soliño, L. Barbato (Seoul, Republic of Korea)

1:45pm-3:15pm: Design, characterization and In vivo evaluation of intranasal delivery of levodopa loaded microspere for Parkinsonism

S. Jain, A. Jain, SB. Bhargav (Sagar, India)

1:45pm-3:15pm: Detecting unsuspected mitochondrial disease: an algorithmic approach

N. Pulley, C. Condon, I. Haq (Winston-Salem, NC, USA)

1:45pm-3:15pm: Detection of genetic modifiers in PRKN

K. Ogaki, H. Nakaoka, K. Daida, A. Hayashida, A. Ikeda, Y. Li, H. Yoshino, M. Funayama, K. Nishioka, I. Inoue, N. Hattori (Tokyo, Japan)

1:45pm-3:15pm: Determining Outcome of Deep Brain Stimulation Surgery in Parkinson’s Disease Patients

E. Yoon, S. Ahmed, S. Bandres-Ciga, S. Scholz, C. Lungu, D. Hernandez, A. Singleton, D. Ehrlich (Bethesda, MD, USA)

1:45pm-3:15pm: Development of a web-based tool for systematic collection of phenotypes of hereditary movement disorders from medical literature

J. Lee, S. Fujioka, S. Hong, N. Kim, Y. Kim, H. Ma, Y. Tsuboi, Y. Kim (Anyang, Republic of Korea)

1:45pm-3:15pm: Development Of Anti-Parkinsonism Poly Herbal Sustained Release Formulation Composed Of Potential Traditional Plant Extracts

S. Jain, A. Jain, S. Bhargav (Sagar, India)

1:45pm-3:15pm: Development of Mucoadhesive Sustained Release Floating Tablets of Silymarin using Natural Polymer for Improved Anti-Parkinson Efficacy

D. Gugulothu, R. Nagapuri, DK. Khatri (Pune, India)

1:45pm-3:15pm: Diagnosis and management strategies used in series of Parkinson’s disease patients who experienced subthalamic nucleus deep brain stimulation induced mood elevation

L. Spiegel, J. Weinstein, J. Ostrem, A. Seritan (San Francisco, CA, USA)

1:45pm-3:15pm: Diagnostic journeys of people with Parkinson’s disease in Kenya, sub-Saharan Africa

N. Fothergill Misbah, K. Hampshire, S. Moffatt, J. Kwasa, J. Hooker, R. Walker (Newcastle Upon Tyne, United Kingdom)

1:45pm-3:15pm: Difference in perception of the wearing-off between patients and physicians in Parkinson’s disease

Y. Tsuboi, R. Nakagawa, M. Ishido, Y. Yoshinaga, T. Hashimoto, T. Mishima, S. Fujioka (Fukuoka, Japan)

1:45pm-3:15pm: Differences in correlation with cardiac sympathetic denervation between depression and anhedonia in drug naïve Parkinson disease patients

H. Murakami, T. Shiraishi, T. Umehara, S. Omoto, H. Motegi, R. Nakada, T. Sato, A. Onda, H. Matsuno, T. Komatsu, K. Bono, K. Sakai, H. Mitsumura, Y. Iguchi (Tokyo, Japan)

1:45pm-3:15pm: Different clinical entities of Segawa syndrome within a family

J. Sarangerel (Ulaanbaatar, Mongolia)

1:45pm-3:15pm: Differential effects of stem cell therapy in adult and middle-aged Parkinsonian mice

A. Nelke, S. García-López, A. Martínez-Serrano, M. Pérez Pereira (Madrid, Spain)

1:45pm-3:15pm: Differential enhancement of ERK, PKA and Ca2+ signaling in direct and indirect striatal neurons of Parkinsonian mice

LL. Mariani, S. Longueville, JA. Girault, D. Hervé, N. Gervasi (Paris, France)

1:45pm-3:15pm: Differential Gait Progression in idiopathic Parkinson’s disease with and without freezing of gait

A. Glover, L. Pillai, S. Doerhoff, T. Virmani (Little Rock, AR, USA)

1:45pm-3:15pm: Differential Gene Expression in Parkinson Disease and Chronic Traumatic Encephalopathy

FV. Delos Reyes (Quezon City, Philippines)

1:45pm-3:15pm: Digenic inheritance of WARS2 and CHRNA6 mutations in infantile parkinsonism

S. Galosi, S. Martinelli, V. Cordeddu, S. Fucile, C. Limatola, R. Carrozzo, M. Tartaglia, V. Leuzzi (Rome, Italy)

1:45pm-3:15pm: Digital biomarker sensor feature data reflect quality of life judgements (PDQ39) in recently diagnosed Parkinson’s disease patients

F. Lipsmeier, K. Taylor, E. Volkova-Volkmar, H. Staunton, R. Postuma, T. Kilchenmann, D. Wolf, Y. Zhang, WY. Cheng, A. Scotland, J. Schjodt-Eriksen, F. Boess, D. Ness, C. Gossens, A. Post, M. Lindemann (Basel, Switzerland)

1:45pm-3:15pm: Digital monitoring of Huntington’s disease with smartphone and smartwatch wearable technology: The Digital-HD study

R. Tortelli, T. Kilchenmann, F. Rodrigues, L. Byrne, A. Bamdadian, F. Lipsmeier, S. Schobel, M. Lindemann, E. Wild (London, United Kingdom)

1:45pm-3:15pm: Directional versus omnidirectional Deep Brain Stimulation for Parkinson’s disease: Results of a prospective, blinded, multi‑center, single-arm crossover study

AS. Schnitzler, PM. Mir, MB. Brodsky, LV. Verhagen, SG. Groppa, BC. Cheeran, EK. Karst, FD. Defresne, JV. Vesper (Mainz, Germany)

1:45pm-3:15pm: Disease-in-a-dish: drug discovery using patient-derived stem cells in Hereditary Spastic Paraplegia

Y. Fan, G. Wali, R. Sutharsan, C. Sue, A. Mackay-Sim (Sydney, Australia)

1:45pm-3:15pm: Dissecting the genetic complexity of Parkinson’s disease: a Parkin-GBA study

Z. Hanss, I. Boussaad, F. Massart, J. Jarazo, R. Krüger (Belvaux, Luxembourg)

1:45pm-3:15pm: Distinct phenotypic expression in a large PKAN cohort in the Dominican Republic

S. Baser, C. Muniz, F. Middleton, R. Ericson, M. Santana Jimenez, C. Bass (Pittsburgh, PA, USA)

1:45pm-3:15pm: Distribution Characteristics of Limbs Discomfort in Restless Legs Syndrome

X. Li, YC. Wu, XY. Zhu (Shanghai, China)

1:45pm-3:15pm: Does cognitive-motor training improve the balance in Parkinson’s disease? Randomized clinical trial

M. Terra, N. Barboza, I. de Almeida, M. Bueno, S. Smaili (Londrina, Brazil)

1:45pm-3:15pm: Does Gait in Real Life differ between People with Parkinson’s Disease and Healthy Controls?

V. Shah, J. Mcnames, C. Curtze, M. Mancini, P. Carlson-Kuhta, J. Nutt, M. El Gohary, F. Horak (Portland, OR, USA)

1:45pm-3:15pm: Does information from the Personal KinetiGraph™ (PKG) influence neurologists´ treatment decisions?

M. Sundgren, P. Rousu, A. Johansson (Stockholm, Sweden)

1:45pm-3:15pm: Does REM Sleep Behavior Disorder Change in the Progression of Parkinson’s Disease?

M. Figorilli, A. Marques, M. Meloni, B. Pereira, M. Puligheddu, F. Durif, ML. Fantini (Clermont-Ferrand, France)

1:45pm-3:15pm: Does socio-economic status have impact on quality of life in persons with Parkinson’s disease?

R. Aggarwal, V. Goyal, A. Srivastava, M. Behari (Delhi, India)

1:45pm-3:15pm: Does Team-based Outpatient Palliative Care Improve Patient or Care Partner-Centered Outcomes in Parkinson’s Disease and Related Disorders?

B. Kluger, M. Katz, N. Galifianakis, K. Hall, S. Pantilat, R. Khan, C. Friedman, W. Cernik, J. Long, J. Kutner, S. Sillau, J. Miyasaki (San Francisco, CA, USA)

1:45pm-3:15pm: Dopamine agonist withdrawal syndrome in Sardinian patients affected by Parkinson’s disease

P. Paolo, R. Pau, G. Orofino, T. Ercoli, F. Marrosu, G. Defazio (Monserrato, Italy)

1:45pm-3:15pm: Dopamine receptor variants alter outcomes with levodopa in early-stage Parkinson’s disease

D. Fischer, P. Auinger, J. Goudreau, A. Cole-Strauss, K. Kieburtz, J. Elm, M. Hacker, P. Charles, J. Lipton, B. Pickut, C. Sortwell (Grand Rapids, MI, USA)

1:45pm-3:15pm: Dopaminergic Neuroregeneration in the Diencephalon of 6-OHDA-Lesioned Adult Zebrafish-Based Parkinson’s Disease Model

Y. Vijayanathan, SM. Lim, MP. Tan, FT. Lim, AB. Abdul Majeed, K. Ramasamy (Kuala Lumpur, Malaysia)

1:45pm-3:15pm: Duloxetine for pain in Parkinsons disease; A single center double blind randomised placebo controlled trial.

S. Azmin, T. Canento, B. Cruse, S. Sung, M. Farrell, A. Evans (Kuala Lumpur, Malaysia)

1:45pm-3:15pm: Duration of rimabotulinumtoxinB action in the treatment of adult sialorrhea

S. Isaacson, M. Lew, F. Pagan, R. Pahwa, D. Chary, T. Clinch (Boca Raton, FL, USA)

1:45pm-3:15pm: Dyadic analysis of the Parkinson’s disease impact on the patient-spouse couple

E. Constant, E. Brugallé, E. Wawrziczny, B. Flinois, K. Dujardin, P. Antoine (Villeneuve D'Ascq, France)

1:45pm-3:15pm: Dynamics of Device-based Treatments for Parkinson´s Disease in Germany from 2010 – 2017

L. Tönges, D. Bartig, C. Krogias, D. Richter (Bochum, Germany)

1:45pm-3:15pm: Dysphagia in Adults with Niemann-Pick Disease Type C

C. Lewis, M. Walterfang, A. Vogel (Melbourne, Australia)

1:45pm-3:15pm: Dystonia as a main clinical feature of AAMR with a novel GMPPA mutation:A case report

SL. Li, H. Wang, L. Wang, Y. Guo, XH. Wan, HP. Li, JY. Shi (Peking, China)

1:45pm-3:15pm: Early onset parkinsonism and optic atrophy due to SLC25A46 mutations

G. Bitetto, MC. Malaguti, E. Monfrini, A. Di Fonzo (Milan, Italy)

1:45pm-3:15pm: Effect of 8-Weeks Treadmill Training on Selected Gait Parameters and Quality of Life of Patients with Parkinson’s Disease

A. Ogundele, M. Olaogun, M. Komolafe (Ile Ife, Nigeria)

1:45pm-3:15pm: Effect of an Increase in Dose of Istradefylline, an A2A Receptor Antagonist, in Levodopa (LD)-Treated Patients with Parkinson’s Disease (PD)

N. Hattori, T. Nomura, P. Salzman, H. Kitabayashi, M. Ishiuchi, K. Toyama, A. Mori (Tokyo, Japan)

1:45pm-3:15pm: Effect of Balanced Based Torso Weighting on gait in parkinsonism

D. Safarpour, M. Mancini, C. Murchison, S. Wood, A. Lesher, J. Duda, J. Morley (Philadelphia, PA, USA)

1:45pm-3:15pm: Effect of dopamine D2-receptor antagonist and basal ganglia neuromodulation on neuronal activity in the cerebral motor area and cerebellar dentate nucleus

K. Schwabe, A. Abdulbaki, S. Helgers, J. Krauss, M. Alam (Hannover, Germany)

1:45pm-3:15pm: Effect of gastrointestinal surgery on the pharmacokinetics of levodopa in Parkinson’s disease

N. Miyaue, M. Nomoto, H. Yabe, Y. Yamanishi, S. Tada, R. Ando, M. Kubo, M. Nagai (Ehime, Japan)

1:45pm-3:15pm: Effect of Medication Review on Reported Symptoms in Parkinson’s disease Patients

C. Stuijt, T. Laar (Groningen, Netherlands)

1:45pm-3:15pm: Effect of Once-Daily Opicapone on the Pharmacokinetics of Repaglinide

G. Loewen, G. Liang, R. Jimenez, K. Olson, E. Smith, H. Bozigian (San Diego, CA, USA)

1:45pm-3:15pm: Effect of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: Parkinson’s Disease Questionnaire (PDQ-39) analysis from the BIPARK-I double-blind experience

J. Rocha, E. Tolosa, J. Ferreira, A. Lees, O. Rascol, W. Poewe, A. Santos, D. Magalhães, P. Soares-da-Silva (Coronado, Portugal)

1:45pm-3:15pm: Effect of pill box organizers with alarm on improvement of adherence to pharmacotherapy in patients with Parkinson’s disease: a pilot study

I. Straka, M. Minár, M. škorvánek, M. Grofik, J. Benetin, P. Valkovič (Bratislava, Slovakia)

1:45pm-3:15pm: Effect of polygenic load on striatal dopaminergic deterioration in Parkinson’s disease

KJ. Pak, MJ. Lee (Busan, Republic of Korea)

1:45pm-3:15pm: Effect of Rehabilitation on Freezing of Gait in Parkinson’s disease: A meta-analysis

M. Gilat, P. Ginis, N. D'Cruz, A. Nieuwboer (Leuven, Belgium)

1:45pm-3:15pm: Effect of Speech therapy in the sleep of patients with Machado-Joseph disease (MJD) or spinocerebellar ataxia type 3 (SCA3)

G. Diaféria, JL. Pedroso, S. Park, F. Haddad, L. Haddad, L. Prado, G. Prado, O. Barsottini (São Paulo, Brazil)

1:45pm-3:15pm: Effectiveness and safety of a herbal medication, HH368, for clinical symptoms of idiopathic Parkinson’s disease: a randomized controlled, pilot trial protocol

KH. Cho, SW. Kwon, C. Jin, WS. Jung, SK. Moon, SH. Lee (Seoul, Republic of Korea)

1:45pm-3:15pm: Effectiveness on the balance and the walking of a program of home-rehabilitation by digital support versus paper book on Parkinson’s patients: a randomized controlled trial.

M. Moreau, B. Fraudet, P. Gallien, B. Nicolas, E. Leblong (Rennes, France)

1:45pm-3:15pm: Effects of Cognitively Challenging Agility Exercise Program on Clinical and Objective Measures in People with Parkinson’s Disease

P. Carlson-Kuhta, N. Hasegawa, SH. Jung, V. Shah, A. Ragothaman, D. Peterson, K. Smulders, L. King, M. Mancini, J. Lapidus, J. Nutt, F. Horak (Portland, OR, USA)

1:45pm-3:15pm: Effects of gender on caregiving in Parkinson’s disease

S. Horn, S. Wu, Y. Dai, F. Cubillos, N. Dahodwala (Miami, FL, USA)

1:45pm-3:15pm: Effects of safinamide and rasagiline on in vivo glutamate release in 6-OHDA hemilesioned rats

CA. Pisanò, A. Brugnoli, S. Novello, C. Caccia, C. Keywood, E. Melloni, G. Padoani, S. Vailati, M. Morari (Ferrara, Italy)

1:45pm-3:15pm: Effects of Virtual Reality Exercise Program using the Sony PlayStation 2 gaming platform on Balance, Emotion and Quality of Life in Patients with Parkinson’s Disease

G-H. Lee (Cheonan, Republic of Korea)

1:45pm-3:15pm: Effects of zonisamide on parkinsonism in patients with dementia with Lewy bodies by severity of cognitive dysfunction and BPSD: subgroup analysis of pooled data from two trials

K. Hasegawa, J. Goldman, T. Odawara, K. Kochi, O. Konishi, H. Maruyama, S. Toya, K. Kosaka, M. Murata, I. Mckeith (Kanagawa, Japan)

1:45pm-3:15pm: Efficacy and safety of the 5-Hydroxytryptophan on Depression and Apathy in Idiopathic Parkinson’s disease.

M. Meloni, M. Puligheddu, M. Carta, M. Figorilli, G. Defazio (Cagliari, Italy)

1:45pm-3:15pm: Efficacy and safety of the 5-Hydroxytryptophan on Levodopa-Induced Motor Complications in Parkinson’s disease.

M. Meloni, M. Puligheddu, A. Cannas, M. Figorilli, G. Defazio, M. Carta (Cagliari, Italy)

1:45pm-3:15pm: Efficacy and Safety of the 5-Hydroxytryptophan on REM Sleep Behavior Disorder in Parkinson’s Disease.

M. Meloni, M. Figorilli, M. Carta, L. Tamburrino, A. Cannas, M. Fantini, G. Defazio, M. Puligheddu (Cagliari, Italy)

1:45pm-3:15pm: Efficacy and safety of zonisamide in patients with dementia with Lewy bodies with parkinsonism: pooled analysis of phase 2 and 3 trials

J. Goldman, K. Hasegawa, T. Odawara, K. Kochi, H. Maruyama, O. Konishi, S. Toya, K. Kosaka, M. Murata, I. Mckeith (Chicago, IL, USA)

1:45pm-3:15pm: Efficacy of carbidopa/levodopa enteral suspension (CLES) in advanced Parkinson’s disease patients previously treated with deep brain stimulation (DBS) – A subgroup analysis from PROviDE study

S. Isaacson, R. Pahwa, S. Thakkar, P. Kandukuri, Y. Jalundhwala, P. Kukreja, Y. Bao, N. Gupta, I. Pan, J. Aldred (Boca Raton, FL, USA)

1:45pm-3:15pm: Efficacy of Istradefylline, an A2A Receptor Antagonist, When Added to Levodopa (LD) and Other Medications for Parkinson’s Disease (PD)

P. Lewitt, N. Hattori, A. Mori, K. Toyama, E. Ohta, P. Salzman, S. Isaacson (West Bloomfield, MI, USA)

1:45pm-3:15pm: Efficacy of Motor Imagery Questionnaire-RS as a Diagnostic Tool in Rehabilitation of Movement Disorders

D. Kaur, N. Bhardwaj, S. Kumari, S. Kumari, A. Gupta, G. Kumar (Patna, India)

1:45pm-3:15pm: Efficacy of opicapone in Parkinson’s disease patients according to baseline pramipexole use: a post-hoc analysis from combined BIPARK-I and II.

A. Lees, J. Ferreira, O. Rascol, W. Poewe, F. Stocchi, A. Santos, D. Magalhães, J. Rocha, P. Soares-da-Silva (London, United Kingdom)

1:45pm-3:15pm: Efficacy of opicapone in Parkinson’s disease patients according to baseline presence of dyskinesia: a post-hoc analysis from combined BIPARK-I and II

A. Lees, J. Ferreira, A. Antonini, H. Reichmann, R. Costa, D. Magalhães, J. Rocha, P. Soares-da-Silva (London, United Kingdom)

1:45pm-3:15pm: Efficacy of opicapone in Parkinson’s disease patients according to baseline rasagiline use: a post-hoc analysis from combined BIPARK-I and II

A. Lees, J. Ferreira, O. Rascol, W. Poewe, E. Tolosa, H. Gama, D. Magalhães, J. Rocha, P. Soares-da-Silva (London, United Kingdom)

1:45pm-3:15pm: Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: Patient and Clinical Global Impression of Change from the BIPARK-I double-blind experience

J. Rocha, F. Stocchi, A. Lees, J. Ferreira, W. Poewe, O. Rascol, A. Santos, D. Magalhães, P. Soares-da-Silva (Coronado, Portugal)

1:45pm-3:15pm: Efficacy, Safety and Tolerability of Tavapadon in Subjects With Early Stage Parkinson’s Disease

D. Gray, R. Riesenberg, J. Werth, Y. Zhang, M. Versavel, S. Duvvuri (Boston, MA, USA)

1:45pm-3:15pm: Electroconvulsive Therapy (ECT): An Effective Option for the Treatment of Medication-Resistant Psychiatric Symptoms in Huntington’s Disease: A Case Series and Review of the Literature

J. Adrissi, N. Nadkarni, E. Gausche, D. Bega (Chicago, IL, USA)

1:45pm-3:15pm: Enabling efficient use of digital health technologies to support Parkinson’s disease drug development through precompetitive collaboration

J. Cedarbaum, K. Taylor, D. Hill, R. Alexander, Y. Luo, R. Rubens, N. Zach, J. Cosman, A. Dowling, K. Fisher, L. Oliva, J. Hitchcock, M. Lawton, D. Conrado, K. Romero, M. Minchik, D. Meulien, B. Yang, M. Forman, L. Bataille, D. Dexter, J. Gallagher, M. Braxenthaler, M. Lindemann, B. Boroojerdi, G. Stebbins, B. Bloem, M. Hu, E. Dorsey, D. Stephenson (Cambridge, MA, USA)

1:45pm-3:15pm: Encephalomyelopathy Due to Cerebrotendinous Xanthomatosis

ACO. Oliveira, LFV. Vasconcellos, BXC. Cordeiro, LLN. Najar (Rio de Janeiro, Brazil)

1:45pm-3:15pm: Entity of excessive daytime sleepiness in Parkinson’s disease

O. Iakovleva, O. Levin, M. Poluektov (Moscow, Russian Federation)

1:45pm-3:15pm: Epidemiological study of multiple system atrophy: data from HoRC-MSA Project 2014-2019

M. Matsushima, I. Yabe, K. Sakushima, I. Iwata, Y. Kanatani, N. Nishimoto, T. Matsuoka, T. Katayama, H. Uesugi, K. Sako, A. Takei, A. Tamakoshi, S. Shimohama, N. Sato, S. Kikuchi, H. Sasaki (Sapporo, Japan)

1:45pm-3:15pm: Evaluating IL6 and mitochondrial DNA levels as a potential biomarker in carriers of Parkin and PINK1 mutations

M. Borsche, I. König, S. Delcambre, S. Petrucci, A. Balck, T. Gasser, N. Brüggemann, S. Pereira, K. Badanjak, K. Brockmann, E M. Valente, R. Youle, A. Grünewald, C. Klein (Lübeck, Germany)

1:45pm-3:15pm: Evaluating Implementation of an Evidence-based Physical and Occupational Therapy (LSVT BIG®) for Parkinson’s Disease: Germany, France and Japan

C. Fox, L. Guse, L. Ramig (Tucson, AZ, USA)

1:45pm-3:15pm: Evaluating the Inappropriate Use of Antipsychotics in Parkinson’s Disease Psychosis Patients Within Large National US Healthcare Databases

A. Shim, V. Abler, N. Rashid (San Diego, CA, USA)

1:45pm-3:15pm: Evaluating the real-world effectiveness of carbidopa/levodopa enteral suspension (CLES) on patients with advanced Parkinson’s disease in USA: Interim-evidence from the PROviDE study

R. Pahwa, S. Isaacson, P. Kandukuri, Y. Jalundhwala, P. Kukreja, Y. Bao, N. Gupta, I. Pan, J. Aldred (Kansas City, KS, USA)

1:45pm-3:15pm: Evaluating the real-world impact of levodopa/carbidopa intestinal gel (LCIG) on motor symptoms using wearable sensors: Evidence from PROviDE study

R. Pahwa, R. Dorsey, S. Isaacson, P. Kandukuri, Y. Jalundhwala, P. Kukreja, N. Gupta, I. Pan, Y. Bao, D. Heldman (Kansas City, KS, USA)

1:45pm-3:15pm: Evaluation and Intervention of Aquatic Physiotherapy in People with Parkinson’s Disease: Repercussions on Balance

V. Israel, D. Iucksch, J. Siega, A. Silva, B. Yamaguchi, M. Ferreira (Curitiba, Brazil)

1:45pm-3:15pm: Evaluation of corneal parameters in patients with idiopathic REM Sleep Behavior Disorder

S. You, KT. Kim, J. Jun, YW. Cho (Daegu, Republic of Korea)

1:45pm-3:15pm: Evaluation of neuroprotection by human ENGRAILED-1 in a chronic AAV-hα-synuclein-A53T (AAV-A53T) rat model of Parkinson Disease

A. Prochiantz, G. Porras, A. Simonnet, E. Pioli, C. Friedel, E. Bézard, A. Bousseau (Paris, France)

1:45pm-3:15pm: Evaluation of Retinal Layers in Restless Legs Syndrome

N. Ongun, G. Ongun (Burdur, Turkey)

1:45pm-3:15pm: Evaluation of swallowing function by video-fluorography in patients with parkinsonism

S. Nogawa, Y. Chin, H. Kanke, R. Kawamura, T. Nakayama, K. Tokuoka, T. Furukawa (Tokyo, Japan)

1:45pm-3:15pm: Evidence of survival and integration of implanted autologous peripheral nerve graft in substantia nigra in a patient with Parkinson’s disease

DR. Ginjupally, G. Quintero, Z. Guduru, J. Gurwell, J. Slevin, A. Granholm, G. Gerhardt, C. van Horne (Denver, CO, USA)

1:45pm-3:15pm: Evolution of anti-parkinsonian drug prescribing patterns in Parkinson’s disease

S. Neo, A. Wong, HL. Ng, W. Li, KY. Tay, WL. Au, L. Tan (Singapore, Singapore)

1:45pm-3:15pm: Evolution of ataxia in risk persons for spinocerebellar ataxia (SCA)

H. Jacobi, S. Tezenas Dumontcel, T. Klockgether, O. The-Risca-Investigators (Bonn, Germany)

1:45pm-3:15pm: Exergame training in Early Onset Ataxia patients

R. Brandsma, I. Ganzevoort, M. Berg, ZT. Dominguez Vega, LD. Jelsma, MM. Schoemaker, NM. Maurits, CJC. Lamoth, DA. Sival (Groningen, Netherlands)

1:45pm-3:15pm: Expanding the Phenotype of KCNA2 Mutation: Tics and Stereotypies

J. Legacy, M. Burns, A. Elkouzi, W. Deeb, I. Malaty (Gainesville, FL, USA)

1:45pm-3:15pm: Exploring anti-hypertensives as possible disease modifying agents in Parkinson’s disease using artificial intelligence and epidemiology

N. Visanji, S. Hensley Alford, A. Lacoste, P. Madan, I. Buleje, Y. Han, S. Spangler, L. Kalia, C. Marras (Toronto, ON, Canada)

1:45pm-3:15pm: Exploring the effects of intrastriatal AAV5-miHTT therapy on MRS signal and mutant huntingtin levels in the Q175FDN mouse model of HD

B. Leavitt, A. Vallès, A. Stam, C. Brouwers, V. Fodale, A. Bresciani, A. Hill, A. Yung, B. Russell-Schulz, P. Kozlowski, A. Mackay, D. Ma, F. Beg, J. Higgins, S. van Deventer, M. Evers, P. Konstantinova (Vancouver, BC, Canada)

1:45pm-3:15pm: Exploring the experience and challenges for PD STAT clinical trial participants: a qualitative study

T. North, J. Grose, V. Eyre, D. Webb, R. Chapman, A. Foggo, M. Webber, C. Carroll (Plymouth, United Kingdom)

1:45pm-3:15pm: Expression profiles from CD14+ monocytes in PD patients with GBA mutations

G. Riboldi, E. Udine, E. Navarro, M. Parks, B. Henderson, K. Sharma, T. Sikder, M. Zhuang, J. Crary, S. Frucht, T. Raj (New York, NY, USA)

1:45pm-3:15pm: Factitious Disorder Imposed on Another mimicking a Dopamine Dysregulation Syndrome

DRC. Carneiro, MS. Sousa, ASM. Morgadinho, CJ. Januário (Coimbra, Portugal)

1:45pm-3:15pm: Factors Influencing Decision-Making About End of Life Care in Patients With Parkinson’s Disease and Their Family Members

R. Bužgová, R. Kozáková, M. Bar, M. škutová, P. Ressner, P. Bártová (Ostrava, Czech Republic)

1:45pm-3:15pm: Factors that interfere in the functionality according to Functional Independence Measure in people with Parkinson’s Disease.

E. Libardi, M. Piemonte, E. Guelfi, E. Okamoto (São Paulo, Brazil)

1:45pm-3:15pm: Factors underlying reduced aerobic capacity in Huntington disease

A. Rao, S. Norris, J. Montes, P. Wasserman, K. Marder (New York, NY, USA)

1:45pm-3:15pm: Familial Creutzfeldt-Jakob disease with D178N and Met129Val

N. Omer, E. Kahana, S. Simchoni, A. Bar-Shira, T. Naiman, A. Orr-Urtreger, B. Aminov, D. Klepikov, N. Giladi, N. Bregman (Tel Aviv, Israel)

1:45pm-3:15pm: Fatal evolution of cutaneous necrosis in a patient treated with subcutaneous apomorphine infusions

C. Marse, J. Benoit, F. Rocher, C. Giordana (Nice, France)

1:45pm-3:15pm: Feasibility and acceptability of a therapist-delivered physical activity coaching intervention for people with premanifest and early stage Huntington’s Disease and Parkinson’s Disease

K. Long Ms, M. Caciula Phd, C. Friel Edd, L. Quinn Edd (New York City, NY, USA)

1:45pm-3:15pm: Ferroptosis, a recently identified cell death, as a therapeutic target for Parkinson’s disease.

H. Bouchaoui, L. Mahoney-Sanchez, A. Jonneaux, F. Gouel, M. Dutheil, JC. Devedjian, G. Garçon, D. Devos (Lille, France)

1:45pm-3:15pm: Fine-mapping of SNCA variants in REM sleep behavior disorder identifies distinct associations

L. Krohn, R. Wu, J. Ruskey, S. Laurent, L. Philstrom, I. Arnulf, M. Hu, Y. Dauvilliers, B. Hogl, A. Stefani, E. Holzknecht, C. Monaca, A. Beatriz, G. Plazzi, E. Antelmi, L. Ferini-Strambi, A. Heidbreder, V. Cochen, B. Mollenhauer, K. Sonka, M. Figorilli, F. Dijkstra, M. Viaene, W. Oertel, J. Gagnon, M. Nalls, C. Blauwendraat, A. Singleton, A. Desautels, J. Montplaisir, O. Ross, B. Boeve, N. Dupre, E. Fon, R. Postuma, G. Rouleau, Z. Gan-Or (Montreal, QC, Canada)

1:45pm-3:15pm: First year of Opicapone for Advanced Parkinson Disease: real-life experience in a single Movement Disorders Unit

JB. Paredes, J. Poles, V. Hristova, S. Madrona, S. Argos, P. Torre, JL. Moreno, I. Moreno, JC. Castrillo, A. Canovas (Madrid, Spain)

1:45pm-3:15pm: First-In-Human Study of LY3154207, a Dopamine D1 Receptor Positive Allosteric Modulator (D1PAM)

K. Biglan, K. Svensson, W. Kielbasa (Indianapolis, IN, USA)

1:45pm-3:15pm: Formulations and evaluations of Intranasal Nose to Brain Delivery of Curcumin with resveratrol Nanoparticle for treatment of Parkisonism

A. Jain, S. Jain (Sagar, India)

1:45pm-3:15pm: Four-Week Trunk-Specific Exercise Program decreases Forward Trunk Flexion in Parkinson’s disease: a single- blinded, randomized controlled trial

M. Gandolfi, M. Tinazzi, F. Magrinelli, G. Buselli, E. Dimitrova, N. Polo, P. Manganotti, A. Fasano, N. Smania, C. Geroin (Verona, Italy)

1:45pm-3:15pm: Fragile X Gray Zone Alleles in Men are associated with Parkinsonism

D. Hall, S. Nag, E. Berry-Kravis, A. Ali, B. Ouyang, Y. Liu, A. Buchman, D. Bennett (Chicago, IL, USA)

1:45pm-3:15pm: Fragile X syndrome presenting with levodopa unresponsive parkinsonism

J. Mayer, J. Panicker, S. Alusi (Liverpool, United Kingdom)

1:45pm-3:15pm: Frequency of neuropsychiatric symptoms in non-demented early and late-onset Parkinson’s disease patients

A. Seubert-Ravelo, MG. Yáñez-Téllez, G. Neri-Nani, X. Ortiz-Jiménez, C. Guerra-Galicia (Estado de México, Mexico)

1:45pm-3:15pm: Functional exam findings in Lewy Body Disease

J. Nguyen, K. Papesh (Las Vegas, NV, USA)

1:45pm-3:15pm: FUNCTIONAL MOTOR SYMPTOMS IN PARKINSON’S DISEASE, AND FUNCTIONAL PARKINSONISM: A SYSTEMATIC REVIEW

M. Ambar Akkaoui, P. Geoffroy, E. Roze, B. Degos, B. Garcin (Bobigny, France)

1:45pm-3:15pm: Functional stiff person like disorders: clinical features and red flags

B. Balint, A. Jha, M. Edwards, HM. Meinck, K. Bhatia (London, United Kingdom)

1:45pm-3:15pm: GABA-A Receptor Positive Allosteric Modulators: Phase 2 Proof of Concept Studies of Brexanolone Injection and SAGE-217 in Essential Tremor

J. Paskavitz, A. Bullock, D. Nguyen, A. Smith, B. Farley, M. Quirk, I. Kaul, S. Li, A. Ellenbogen, C. Silber, J. Doherty, H. Colquhoun, S. Kanes (Cambridge, MA, USA)

1:45pm-3:15pm: Gait in Spinocerebellar Ataxia Type12 (SCA-12)

M. Narang, A. Srivastava, R. Aggarwal, R. Rajan, M. Faruq, M. Srivastava (Delhi, India)

1:45pm-3:15pm: GBA and ATP13A mutation and PD: clinical phenotype, eye movements and pathogenic implications

GM. Riboldi, J. Martone, J. Rucker, JR. Rizzo, T. Hudson, W. Dauer, S. Frucht (New York, NY, USA)

1:45pm-3:15pm: GBA mutation: Linking Parkinson’s and Gaucher’s Diseases

C. Sarabia-Tapia, S. Lopez-Alamillo, N. Monroy-Jaramillo, D. Davila-Ortiz, M. Rodriguez-Violante, A. Cervantes-Arriaga (Mexico City, Mexico)

1:45pm-3:15pm: GBA p.Glu326Lys substitution increases the risk to develop Parkinson’s disease; is it enough to affect disease phenotype?

O. Goldstein, M. Gana- Weisz, D. Cohen-Avinoam, A. Bar-Shira, A. Thaler, T. Shiner, A. Mirelman, N. Giladi, A. Orr-Urtreger (Tel Aviv, Israel)

1:45pm-3:15pm: GBA1 biomarkers in longitudinal CSF: GCase, Sphingolipids and alpha-synuclein

S. Lerche, C. Schulte, G. Machetanz, I. Wurster, B. Röben, M. Zimmermann, C. Deuschle, A. Hauser, I. Liepelt-Scarfone, J. Böhringer, I. Krägeloh-Mann, I. Lachmann, W. Maetzler, T. Gasser, M. Mielke, D. Berg, K. Brockmann (Tuebingen, Germany)

1:45pm-3:15pm: Gender gap in scientific granting competitions in movement disorders – insights from a national Canadian funding agency

S. Appel-Cresswell, P. Blanchet, J. Wysocki, R. Postuma (Vancouver, BC, Canada)

1:45pm-3:15pm: Gene Expression Profiling of depression in Huntington’s disease

G. Colpo, N. Rocha, E. Furr Stimming, A. Lucio (Houston, TX, USA)

1:45pm-3:15pm: Gene panel testing in movement disorders: an efficient approach highlighting overlaps and heterogeneity

S. Montaut, C. Tranchant, N. Drouot, G. Rudolf, C. Guissart, J. Tarabeux, T. Stemmelen, A. Velt, C. Fourrage, P. Nitschke, B. Gerard, JL. Mandel, M. Koenig, J. Chelly, M. Anheim (Paris, France)

1:45pm-3:15pm: Generalised Polymyoclonus In a Patient With Central Nervous System Tuberculosis

K. Shahedah, MS. Mohamad Salmi (Pahang, Malaysia)

1:45pm-3:15pm: Genetic analysis of DNA methylation and hydroxymethylation genes in Parkinson’s disease

L. Qin, L. Shu, B. Tang, Q. Xu (Changsha, China)

1:45pm-3:15pm: Genetic diagnosis of Chorea-acanthocytosis using whole exome sequencing revealed novel VPS13A Gene mutation

H. Ryu, C. Hong, J. Lee (Daegu, Republic of Korea)

1:45pm-3:15pm: Genetic markers revealed in dysregulated pathways in ischemic stroke may lead to Parkinson’s disease

H. Singh, V. Swarup, A. Srivastava (Marseille, France)

1:45pm-3:15pm: Genetic panel testing in Parkinson’s disease

T. Toomsoo, I. Rubanovich, I. Kalju, S. Ott, A. Lindmäe, M. Mällo, K. Jaakson, K. Joost, K. Vender (Tallinn, Estonia)

1:45pm-3:15pm: Genetic polymorphism (rs6971) in translocator protein (TSPO) and its clinical relevance in Parkinson’s disease

P. Surathi, M. Matarazzo, A. Sethi, J. Mckenzie, N. Neilson, R. Ross, M. Schulzer, M. Farrer, S. Booromand, J. Stoessl (Vancouver, BC, Canada)

1:45pm-3:15pm: Genetic study of patients with Parkinson’s disease subjected to second line therapies

F. Carrillo, S. Jesus, T. Periñan, R. Escuela, D. Buiza, MA. Labrador, M. Carrión, A. Adarmes, D. Macias, P. Gomez-Garre, P. Mir (Seville, Spain)

1:45pm-3:15pm: Genetics of Parkinson’s in India – Young Onset Parkinson’s Disease (GOPI-YOPD) – A Preliminary Demographic profile

P. Kukkle, V. Goyal, R. Kandadai, R. Borgohain, H. Kumar, A. Mukherjee, A. Biswas, S. Das, U. Muthane, S. Desai, P. Wadia, P. Pal, R. Yadav, V. Ramprasad (Bangalore, India)

1:45pm-3:15pm: Genotype-Phenotype correlations of Episodic Ataxia (EA). MDSGene Systematic Review

A. Shetty, K. Nabieva, F. Zeldenrust, A. Rasheed, J. Huang, S. Petkovic, K. Lohmann, C. Klein, C. Marras, O. Waln (Lübeck, Germany)

1:45pm-3:15pm: GLYCOPAR – A randomized, placebo-controlled, 2-arm parallel-group superiority phase II study of glycopyrrolate for moderate-to-severe sialorrhea in Parkinson’s disease

T. Mestre, E. Freitas, M. Lopez, A. Basndwah, L. de Oliveira, D. Al-Shorafat, Z. Alarfaz, H. Shinawi, S. Reddie, D. Mancini, J. Lui, D. Grimes, S. Fox (Ottawa, ON, Canada)

1:45pm-3:15pm: Gocovri Dose Adjustment in Elderly Parkinson’s Patients at Risk for Renal Impairment: Implications from an Exposure Simulation Model

I. Isaacson, A. Mittur, R. Patni (Boca Raton, FL, USA)

1:45pm-3:15pm: Grey-matter volume changes underpinning irritability and aggression in early manifest Huntington’s disease

S. Martinez-Horta, F. Sampedro, J. Perez-Perez, A. Horta-Barba, J. Pagonabarraga, J. Kulisevsky (Barcelona, Spain)

1:45pm-3:15pm: Gut Feelings about Parkinson’s Disease: The Influence of the Gut Microbiota in a Rodent Model

A. Gorecki, L. Preskey, M. Bakeberg, J. Kenna, C. Gildenhuys, S. Dunlop, F. Koengten, R. Anderton (Nedlands, Australia)

1:45pm-3:15pm: Gut problems in Huntington’s disease? Evidence for a leaky gut in the R6/2 mouse model of HD

TL. Stan, N. Franke, M. Sjögren, M. Björkqvist (Lund, Sweden)

1:45pm-3:15pm: Healthcare Resource Utilization and Costs of Parkinson’s Disease Dementia With Psychosis in the US Medicare Population

J. Wetmore, H. Yan, M. Irfan, Y. Peng, D. Gilbertson, S. Li, N. Rashid, A. Shim (Minneapolis, MN, USA)

1:45pm-3:15pm: Healthcare utilization and emergency department/inpatient costs in adult and pediatric functional neurological disorders

C. Stephen, C. Lungu, A. Espay (Boston, MA, USA)

1:45pm-3:15pm: Hemi masticatory spasm (HMS) : Series of 7 cases

D. Radhakrishnan, V. Goyal, G. Shukla, M. Singh (New Delhi, India)

1:45pm-3:15pm: Hemiballismus-hemichorea due to ischemic stroke

AM. Magnerou, PE. Sounga Bandzouzi (Douala, Cameroon)

1:45pm-3:15pm: Hemichorea revealing a putaminal cavernous angioma

Y. Mecheri, F. Serradj, BS. Fekraoui, A. Hamri (Constantine, Algeria)

1:45pm-3:15pm: Hemifacial spasm management: 26-year experience

Y. Herrero-Infante, A. Rodriguez-Sanz, J. Mañez-Miró, F. Vivancos-Matellano (Madrid, Spain)

1:45pm-3:15pm: Hereditary and geneological aspects of Parkinson’s disease and essential tremor in people of Uzbek nationality

R. Matmurodov, K. Khalimova (Tashkent, Uzbekistan)

1:45pm-3:15pm: Heterozygous DCC mutations, more than congenital mirror movements

S. Thams, M. Islam, M. Lindefeldt, A. Nordgren, T. Granberg, D. Nilsson, M. Paucar (Stockholm, Sweden)

1:45pm-3:15pm: HGprt deficiency affects early brain development in vivo in a mouse model of Lesch-Nyhan disease

J. Witteveen, S. Loopstok, L. Luque Ballesteros, A. Boonstra, N. van Bakel, W. van Boekel, G. Martens, J. Visser, S. Kolk (Nijmegen, Netherlands)

1:45pm-3:15pm: HGprt deficient brain RNA expression patterns reveal specific abnormalities related to neuronal function in a mouse model of Lesch-Nyhan disease.

J. Visser, C. Klemann, G. Martens (Nijmegen, Netherlands)

1:45pm-3:15pm: High Content Screening of synucleinopathy in primary cortical neurons : dissecting out the interplay between the basic synuclein pools

F. de Giorgi, E. Bezard, F. Ichas (Bordeaux, France)

1:45pm-3:15pm: High Dose Botulinum Toxin Therapy: Safety, Benefit and Endurance of Efficacy

S. Chiu, B. Patel, M. Burns, J. Legacy, A. Shukla, A. Ramirez-Zamora, W. Deeb, I. Malaty (Gainesville, FL, USA)

1:45pm-3:15pm: High dose off-label Safinamide treatment in Young Onset Parkinson’s Disease patients

C. Carrarini, M. Russo, F. Barbone, F. Dono, M. Rispoli, M. Onofrj, A. Thomas (Chieti, Italy)

1:45pm-3:15pm: High rate of mutations in complex dystonia revealed by exome sequencing

T. Wirth, C. Tranchant, N. Drouot, B. Keren, L. Cif, C. Mignot, R. Lefaucheur, L. Lion-François, A. Méneret, D. Gras, E. Flamand-Roze, C. Laroche, P. Burbaud, S. Bannier, O. Boukbiza, MA. Spitz, V. Laugel, M. Bereau, D. Doummar, G. Rudolf, M. Anheim, J. Chelly (Illkirch-Graffenstaden, France)

1:45pm-3:15pm: Hippotherapy for axial symptoms, gait and posture in people with Parkinson disease: A case report

T. Mcisaac, J. Hayes, J. Goodman, O. Harpham, N. Erickson (Mesa, AZ, USA)

1:45pm-3:15pm: Homozygous BZRAP1 mutations cause autosomal recessive dystonia

NE. Mencacci, MM. Brockmann, S. Pajusalu, B. Atasu, P. Gonzalez-Latapi, M. Schwake, B. Balint, A. Papandreou, A. Pittman, J. Simon-Sanchez, S. Wiethoff, TT. Warner, T. Gasser, M. Kurian, E. Lohmann, K. õunap, KP. Bhatia, C. Rosenmund, T. Sudhof, NW. Wood, D. Krainc, C. Acuna Goycolea (Chicago, IL, USA)

1:45pm-3:15pm: Homozygous Huntington’s disease with two reduced penetrance alleles: A Case Report

K. Grimm, C. Zühlke, C. Gerloff, S. Zittel (Hamburg, Germany)

1:45pm-3:15pm: Huntington Disease-Like 2: A Case Presentation and Review of the Literature

J. Pleen, V. Saini, N. Doher, R. Walker, V. Singh (Kansas City, KS, USA)

1:45pm-3:15pm: Huntington’s Disease Protein Huntingtin Associates with its own mRNA

M. Rakhimova, M. Daropova (Tashkent, Uzbekistan)

1:45pm-3:15pm: Huntington’s Disease presenting as sporadic cerebellar ataxia

GLF. Franklin, FAN. Nascimento, GMP. Pavanelli, SSM. Milano, HAT. Teive, NSL. Lima, SR. Raskin (Curitiba, Brazil)

1:45pm-3:15pm: Huntington’s disease: A case review of Sub-Saharan Africans with diverse origins

M. Muthinja, J. Hooker (Nairobi, Kenya)

1:45pm-3:15pm: Hydralazine protects nigrostriatal dopaminergic neurons from MPP+ and MPTP induced neurotoxicity: Roles of Nrf2-ARE signaling pathway

XF. Guo, T. Wang, J. Huang, N. Xiong, C. Han, K. Ma, Y. Xia, F. Wan, JJ. Hu, SJ. Yin, L. Kou, YD. Sun, JW. Wu (Wuhan, China)

1:45pm-3:15pm: Hyperammonemic Encephalopathy as Primary Cause of Movement Disorders: Report of Two Cases

G. Fabiani, FMB. Germiniani, S. Raskin, HAG. Teive (Curitiba, Brazil)

1:45pm-3:15pm: Hyperkinetic Movement Disorders in Congenital Disorders of Glycosylation

G. Mostile, R. Barone, A. Nicoletti, R. Rizzo, D. Martinelli, L. Sturiale, A. Fiumara, J. Jankovic, M. Zappia (Catania, Italy)

1:45pm-3:15pm: Hypophosphatasia presenting as parkinsonism with compound heterozygous mutations in ALPL gene

WF. Yu, ZX. Zhao, LW. Liu, JL. Hu, FF. Wang, YM. Liu (Jinan, China)

1:45pm-3:15pm: Identification of aberrant circulating miRNAs in Parkinson’s disease plasma samples

L. Chen, J. Yang (Tianjin, China)

1:45pm-3:15pm: Identification of candidates for device-assisted therapy in Parkinson’s disease using Artificial Neural Networks

C. Valderrama Martín, L. Triguero Cueva, MJ. Pérez Navarro, CJ. Madrid Navarro, R. Calle Calle, I. Rego García, A. Mínguez Castellanos, IM. Galván León, F. Escamilla Sevilla (Granada, Spain)

1:45pm-3:15pm: Identification of genetic alterations and SNCA mutation in Parkinson’s disease patients of Coimbatore Population, India

D. Venkatesan, B. Vellingiri (Coimbatore, India)

1:45pm-3:15pm: Identification of modifier genes related to G proteins pathways on the motor capacity of a Drosophila melanogaster model of Friedreich’s ataxia

EG. Zucchet, J. Gonzalez, P. Calap, P. Gonzalez Cabo, MD. Moltó Ruiz (Valencia, Spain)

1:45pm-3:15pm: Identifying In-Clinic Wearable Sensor Features that Predict Parkinson’s Disease Severity

A. Dowling, A. Mirelman, J. Hausdorff, M. Sela, O. Assais, N. Giladi, J. Cedarbaum (Cambridge, MA, USA)

1:45pm-3:15pm: Identifying the association of depression and distress in Pakistani patients diagnosed with Parkinsonism syndrome

A. Fatima (Lahore, Pakistan)

1:45pm-3:15pm: Imaging Parkinson’s disease pathology: A comparison between neuromelanin-sensitive MRI, susceptibility weighted imaging and [11C]PE2I DAT PET

A. Chandra, G. Pagano, T. Yousaf, H. Wilson, M. Politis (London, United Kingdom)

1:45pm-3:15pm: Immediate effect of the virtual and augmented reality and neurofunctional physiotherapy on postural control and cognition in patients with Parkinson’s disease: a randomized clinical trial

S. Smaili, H. Araújo, R. de Souza, T. da Silva, T. Nascimento, M. Terra (Londrina, Brazil)

1:45pm-3:15pm: Immediate Effects of Non-Motorized Treadmill Training for One Session on Gait and Fall Risk In Parkinson’s Disease

A. Boddy, K. Mitchell, W. Brewer, J. Ellison (St. Augustine, FL, USA)

1:45pm-3:15pm: Impact of caring for patients with Huntington’s disease on work status

K. Raimundo, R. Tan, T. To, J. de Courcy, U. Ondhia, H. Rickards, M. Nance (San Francisco, CA, USA)

1:45pm-3:15pm: Impact of cathine and carthinone use among Parkinson’s disease Patients

S. Zewde (Addis Ababa, Ethiopia)

1:45pm-3:15pm: Impact of cathine and cathinone use among Parkinson’s disease Patients

S. Zewde (Addis Ababa, Ethiopia)

1:45pm-3:15pm: Impact of ND0612 on patient reported outcomes: A blinded rater study of 2 dosing regimens

F. Stocchi, W. Poewe, S. Oren, R. Case, K. Kieburtz, C. Olanow (Rome, Italy)

1:45pm-3:15pm: Impact of Offering Genetic Testing and Counseling to People with Parkinson’s Disease in a Clinical Setting

A. Naito, J. Beck, C. Casaceli, A. Hall, K. Marder, M. Nance, M. Schwarzschild, T. Simuni, R. Alcalay (Miami, FL, USA)

1:45pm-3:15pm: Impact of oral COMT-inhibitors on gut microbiota and biologically active microbial metabolites in patients with Parkinson’s Disease

D. Grün, V. Zimmer, J. Kauffmann, M. Unger, J. Spiegel, KU. Dillmann, A. Schwiertz, K. Faßbender, M. Fousse (Homburg, Germany)

1:45pm-3:15pm: Impact of repeated oral administration of Opicapone on the plasma pharmacokinetics of levodopa

M. Nomoto, A. Takeda, K. Iwai, A. Nishimura, N. Hattori (Ehime, Japan)

1:45pm-3:15pm: Impact of subthalamic deep brain stimulation on sensorimotor and motor cortical oscillatory activity in free-moving hemiparkinsonian rats

A. Abdulbaki, T. Doll, J. Krauss, M. Alam, K. Schwabe (Hannover, Germany)

1:45pm-3:15pm: Improvements in gait deficits with peripheral nerve grafts implanted into the substantia nigra in patients with Parkinson’s disease during deep brain stimulation surgery: 2-year follow-up study

G. Gera, K. Rickard, C. Crumpton, A. Borgsmiller, Z. Guduru, C. Horne, G. Qunitero (Lexington, KY, USA)

1:45pm-3:15pm: Impulse Control Disorder (ICD) in the Patient with Parkinson’s Disease (PD)

M. Kulsum, S. Choudhury, A. Ghosh, P. Ghosh (Kolkata, India)

1:45pm-3:15pm: In the shadow of Parkinson disease: what to tell patients with REM sleep behavior disorder?

D. Barone, A. Lee, N. Hellmers, S. Lakhani, H. Sarva, C. Henchcliffe (New York, NY, USA)

1:45pm-3:15pm: In vivo and In vitro study of 17β estradiol against amyloid beta neurotoxicity in synaptosomes of aging female rats : A therapeutic potential drug for Alzheimer’s disease

P. Kumar, N. Baquer (New Delhi, India)

1:45pm-3:15pm: Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline body mass index: post-hoc analysis from double-blind combined BIPARK-I and II data.

F. Ikedo, J. Ferreira, A. Lees, E. Tolosa, W. Poewe, R. Costa, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

1:45pm-3:15pm: Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline disease severity: post-hoc analysis from double-blind combined BIPARK-I and II data

R. Costa, A. Lees, J. Ferreira, O. Rascol, F. Stocchi, H. Gama, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

1:45pm-3:15pm: Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline dopamine agonist use: post-hoc analysis from double-blind combined BIPARK-I and II data

F. Ikedo, A. Lees, J. Ferreira, O. Rascol, F. Stocchi, R. Costa, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

1:45pm-3:15pm: Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline MAO-B inhibitors use: post-hoc analysis from double-blind combined BIPARK-I and II data

R. Costa, J. Ferreira, A. Lees, E. Tolosa, W. Poewe, H. Gama, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

1:45pm-3:15pm: Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to gender: post-hoc analysis from double-blind combined BIPARK-I and II data

F. Ikedo, J. Ferreira, A. Lees, E. Tolosa, W. Poewe, R. Costa, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

1:45pm-3:15pm: Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to race: post-hoc analysis from double-blind combined BIPARK-I and II data.

R. Costa, A. Lees, J. Ferreira, O. Rascol, F. Stocchi, H. Gama, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

1:45pm-3:15pm: IncobotulinumtoxinA is effective, long lasting and well tolerated treatment of hemifacial spasm

S. Ochudlo, A. Krzak-Kubica, J. Gawryluk (Katowice, Poland)

1:45pm-3:15pm: Incongruity of Functional Tremor Predicts Better Response to Transcranial Magnetic Stimulation Treatment

N. Prezelj, K. Vogelnik, Z. Pirtošek, M. Kojović (Ljubljana, Slovenia)

1:45pm-3:15pm: Increased level of a lysosomal phospholipid, BMP, in urine of LRRK2 G2019S mutation carriers with or without Parkinson’s disease: implications for therapeutic development

R. Alcalay, F. Hsieh, S. Padmanabhan, M. Baptista, C. Kehow, S. Narayan, A. Boehme, K. Merchant (Cambridge, MA, USA)

1:45pm-3:15pm: Increasing chances of detecting a neuroprotective signal in PhI/II PD clinical trials?

S. Palfi, C. Denot, A. Bousseau, JC. Corvol (Paris, France)

1:45pm-3:15pm: Inflammatory cytokines in Saudi Parkinson cohort

N. Alsomali, E. Al-Ofi, M. Obaid, A. Alrafiah (Riyadh, Saudi Arabia)

1:45pm-3:15pm: Influence of baseline OFF-time in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II

A. Santos, J. Ferreira, A. Lees, H. Reichmann, W. Poewe, F. Ikedo, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

1:45pm-3:15pm: Influence of demographic characteristics in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II.

A. Santos, J. Ferreira, A. Lees, H. Reichmann, W. Poewe, F. Ikedo, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

1:45pm-3:15pm: Influence of disease duration in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II

H. Gama, J. Ferreira, A. Lees, A. Antonini, O. Rascol, A. Santos, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

1:45pm-3:15pm: Influence of disease severity in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II

H. Gama, A. Lees, J. Ferreira, O. Rascol, A. Antonini, A. Santos, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

1:45pm-3:15pm: Influence of motor fluctuations duration, levodopa dose and duration of use in efficacy responses of Parkinson’s disease patients: post-hoc analysis from combined BIPARK-I and II.

A. Santos, A. Lees, J. Ferreira, O. Rascol, A. Antonini, F. Ikedo, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

1:45pm-3:15pm: Inhibition of mitochondrial complexes induces unique transcriptomic and epigenetic profiles: implications to neurodegeneration induced movement disorders

R. Sathyanarayanan, S. Bharath (Bangalore, India)

1:45pm-3:15pm: Inpatient vs outpatient workup of patients with ataxia and suspected paraneoplastic cerebellar degeneration: Does work-up location matter?

N. Witek, M. Afshari, Y. Liu, B. Ouyang, D. Hall (Chicago, IL, USA)

1:45pm-3:15pm: Insomnia as clinical onset symptom in Juvenile Huntington’s Disease: Evaluation of a Family

M. Gultekin (Kayseri, Turkey)

1:45pm-3:15pm: Integrated therapy for Functional Movement Disorders: results from a pilot clinic

S. Lidstone, L. Macgillivray, C. Marras, M. Josef, L. Muc, A. Lang (Toronto, ON, Canada)

1:45pm-3:15pm: Intermediate CAG repeat length in the HTT gene and comorbidity – The SHAPE Study (Swedish-Huntingtin-Alleles-and-PhenotypE)

M. Ghazarian, E. Stattin, J. Sundblom, V. Niemelä (Uppsala, Sweden)

1:45pm-3:15pm: Internal pallidum stimulation reduces mobile generalized dystonia in Wilson’s disease

S. Paschen, A. Helmers, J. Volkmann, G. Deuschl, D. Berg, KE. Zeuner (Kiel, Germany)

1:45pm-3:15pm: Intestinal Levodopa/Carbidopa Infusion as a Therapeutic Option for Freezing of Gait After Deep Brain Stimulation in Parkinson’s Disease

B. González, S. Jauma, R. Gomez, C. Marzal, M. Calopa (Hospitalet de Llobregat, Spain)

1:45pm-3:15pm: INTREPID: A 2-Year Follow-Up of a Prospective, Double Blinded, Multi-Center Randomized Controlled Trial Evaluating Deep Brain Stimulation with a New Multiple Source, Constant-Current Rechargeable System for Treatment of Parkinson’s Disease

J. Vitek, R. Jain, L. Chen, I. Study Group, P. Starr (Minneapolis, MN, USA)

1:45pm-3:15pm: Intronic pentanucleotide TTTCA repeat insertions do not cause familial and sporadic cortical myoclonic tremor with epilepsy in the UK

WY. Yau, H. Houlden (London, United Kingdom)

1:45pm-3:15pm: Investigating the impact of a-synuclein pathology on human embryonic stem cell derived dopaminergic neurons transplanted in an accelerated a-synuclein rat model of Parkinson’s disease

D. Hoban, S. Shrigley, L. Breger, J. Nelander Wahlestedt, T. Cardoso, B. Mattsson, K. Luk, M. Parmar, A. Björklund (Lund, Sweden)

1:45pm-3:15pm: Investigation into the causes of reduced caffeine levels in Parkinson’s disease

MI. de Bartolo, G. Leodori, A. Fabbrini, M. Costanzo, D. Belvisi, A. Conte, S. Manetto, A. Ciogli, C. Villani, A. Berardelli, G. Fabbrini (Rome, Italy)

1:45pm-3:15pm: Investigation of the protective efficacy of alpha-synuclein-specific antibodies in a novel neuronal cell model for synucleinopathies

A. Peukert, M. Höllerhage, W. Zago, G. Höglinger (Munich, Germany)

1:45pm-3:15pm: Involuntary movements with abnormal brain imaging: A Case Report

W. Webb, P. Chapman, V. Sung, M. Dean (Birmingham, AL, USA)

1:45pm-3:15pm: Iron Supplementation for the Treatment of Restless Legs Syndrome – A Systematic Review and Meta-Analysis

M. Kestenbaum, N. Lev (Kfar Saba, Israel)

1:45pm-3:15pm: Is Restless Legs Syndrome Usual in Patients with Sickle Cell Disease and Beta Thalassemia?

E. Okuyucu, M. Guntel, E. Ucar, G. Oktay (Hatay, Turkey)

1:45pm-3:15pm: Is sprint running exercise feasible, safe and enjoyable to subjects with mild-to-moderate Parkinson’s disease?

E. Monteiro, L. Peyré-Tartaruga, E. da Silva, A. Zanardi, P. Jimenez-Reyes, J. Morin, A. Pagnussat (Porto Alegre, Brazil)

1:45pm-3:15pm: Is the activation ratio of transversus abdominis associated with mobility and core endurance in patients with Idiopathic Parkinson’s Disease?: A Preliminary study

B. Aktar, S. Ozyurek, E. Goz, B. Donmez Colakoglu, B. Balci (Izmir, Turkey)

1:45pm-3:15pm: Is the gene expression of TAF1 modified by the X-linked dystonia-parkinsonism-associated hexanucleotide repeat?

K. Grütz, S. Schaake, B. Laabs, CJ. Reyes, U. Walter, D. Dressler, RD. Jamora, RL. Rosales, N. Brüggemann, K. Lohmann, IR. König, C. Klein, A. Westenberger (Lübeck, Germany)

1:45pm-3:15pm: Isolated delusion in idiopathic Parkinson’s disease: particularities in a subgroup of patients

A. Gonçalves, A. Delgado, J. Velosa, R. Simões, J. Vale (Loures, Portugal)

1:45pm-3:15pm: Isolated unilateral tensor veli palatini myoclonus causing objective tinnitus without palatal elevation

C. Selvadurai, S. Schaefer (New Haven, CT, USA)

1:45pm-3:15pm: Kinematic Gait Analysis in patients with ataxic disorders

D. Batra, A. Bhattacharya, A. Stezin, N. Kamble, P. Pal (Bengaluru, India)

1:45pm-3:15pm: Laboratory Performance of the DopaFuse® Delivery System

R. Draper, J. Harmon, A. Heller, B. Heller, E. Heller, C. King, T. Lau, P. Plante, J. Spiridigliozzi (Austin, TX, USA)

1:45pm-3:15pm: Lack of Notable Skin Reactions from a Novel Levodopa/Carbidopa Prodrug after 10 Days of Repeated 24-Hour Continuous Subcutaneous Infusion at the Same Administration Site

M. Facheris, X. Qi, C. Locke, M. Rosebraugh, J. Benesh (North Chicago, IL, USA)

1:45pm-3:15pm: Language characteristics of picture description task by Hebrew speaking patients with Parkinson’s disease

D. Shpunt, S. Naor, N. Diamant, A. Faust-Socher, H. Shabtai, R. Peled, A. Migirov, T. Gurevich, Y. Manor (Tel Aviv, Israel)

1:45pm-3:15pm: Long Term Follow Up Following Multidisciplinary Inpatient Rehabilitation for Functional Movement Disorders

A. Kompoliti, C. Hebert, J. Behel, G. Pal, R. Kasi (Chicago, IL, USA)

1:45pm-3:15pm: Long-term apomorphine infusion (APO) users versus short-term APO users: What is the reason to discontinue therapy? A multi-centre study

R. Bhidayasiri, O. Phokaewvarangkul, K. Boonpang, Y. Thongchuam, T. Boonmongkol, P. Garcia Ruiz (Bangkok, Thailand)

1:45pm-3:15pm: Long-term impact of Levodopa Carbidopa Intestinal Gel (LCIG) on reducing “Off” time: Results from a systematic review of studies with ≥ 12 months of follow-up

A. Antonini, P. Odin, R. Pahwa, J. Aldred, A. Alobaidi, Y. Jalundhwala, P. Kukreja, L. Bergmann, S. Inguva, Y. Bao, K. Chaudhuri (North Chicago, IL, USA)

1:45pm-3:15pm: Long-term levodopa-carbidopa intestinal infusion in Parkinson’s disease: survival and mortality

CA. Artusi, R. Balestrino, G. Imbalzano, S. Bortolani, S. Tuttobene, E. Montanaro, M. Zibetti, L. Lopiano (Torino, Italy)

1:45pm-3:15pm: Long-term safety and efficacy of apomorphine infusion in Parkinson’s disease (PD) patients with persistent motor fluctuations: results of the 1-year open-label phase of the TOLEDO study

R. Katzenschlager, W. Poewe, O. Rascol, C. Trenkwalder, G. Deuschl, K. Chaudhuri, T. Henriksen, T. van Laar, D. Lockhart, A. Lees (London, United Kingdom)

1:45pm-3:15pm: Long-term safety and efficacy of rimabotulinumtoxinB in the treatment of adult sialorrhea

K. Dashtipour, S. Isaacson, M. Lew, D. Chary, T. Clinch, R. Pahwa (Boca Raton, FL, USA)

1:45pm-3:15pm: Longitudinal analysis of disease progression in a large PKAN cohort in the Dominican Republic

C. Muniz, S. Baser, R. Ericson, M. Santana Jimenez, C. Bass, F. Middleton (Santo Domingo, Dominican Republic)

1:45pm-3:15pm: Longitudinal analysis of the modified Hoehn and Yahr disease stage in PD-1101, a Phase 1b clinical study of VY-AADC01

A. van Laar, R. Richardson, A. Sedkov, E. Fine, K. Bankiewicz, B. Ravina, P. Larson, C. Christine (Pittsburgh, PA, USA)

1:45pm-3:15pm: Longitudinal CSF-profile and brain pathology mirrors clinical course of LRRK2-Related Parkinson’s Disease

I. Wurster, S. Lerche, I. Lachmann, M. Neumann, T. Gasser, K. Brockmann (Tübingen, Germany)

1:45pm-3:15pm: Longitudinal digital observation of the holistic quality of the life of patients with Parkinson’s disease

F. Thieken, A. Greuel, L. Timmermann, K. Sohrabi, C. Woopen, B. Schmitz-Luhn, A. Janhsen, C. Eggers (Marburg, Germany)

1:45pm-3:15pm: Longitudinal DNA methylation changes, in blood, associated with Parkinson’s disease progression

A. Henderson, K. Fisch, J. Hua, E. Driver-Dunckley, C. Sherzer, P. Desplats, T. Dunckley (Tempe, AZ, USA)

1:45pm-3:15pm: Looking “cherry red spot myoclonus” in the eyes

GM. Riboldi, J. Martone, JR. Rizzo, T. Hudson, S. Frucht, J. Rucker (New York, NY, USA)

1:45pm-3:15pm: Lower urinary tract symptoms and urodynamic findings in SCAs

M. Jang, H. Kim, B. Jeon, A. Kim (Jeonju, Republic of Korea)

1:45pm-3:15pm: LRP10 variants and Parkinson’s disease in the Chinese population

JN. Foo, E. Chew, M. Lian, M. Tandiono, EK. Tan (Singapore, Singapore)

1:45pm-3:15pm: LY-341,495, an mGlu2/3 antagonist, abolishes the anti-dyskinetic and anti-psychotic effects of the mGlu2/3 orthosteric agonist LY-354,740 in the MPTP-lesioned marmoset

A. Hamadjida, S. Nuara, J. Gourdon, P. Huot (Montreal, QC, Canada)

1:45pm-3:15pm: Magnetic Resonance Spectroscopy Evaluation of Neuronal Integrity and Astrocytosis in a Phase 2 Study of Laquinimod as a Treatment for Huntington Disease (LEGATO-HD)

B. Leavitt, R. Reilmann, M. Gordon, K. Anderson, A. Feigin, S. Tabrizi, J. Stout, P. Piccini, B. Russell-Schulz, A. Mackay, B. Borowsky, G. Rynkowski, R. Volkinshtein, J. Savola, M. Hayden (Vancouver, BC, Canada)

1:45pm-3:15pm: Management of Akinesia in Parkinson’s Disease with Apomorphine Subcutaneous Injection

F. Rakhimov, B. Sultanov (Tashkent, Uzbekistan)

1:45pm-3:15pm: Management of Patients with Functional Movement Disorders: A Transcultural Perspective

C. Maurer, D. Anderson, A. Asadi-Pooya, J. Baizabal, M. Damianova, C. Ganos, R. Kanaan, M. Tijssen, J. Kwasa, I. Moreno, S. Pandey, JE. Park, D. Saylor, M. Stamelou, C. Stephen, T. Teodoro, M. Tinazzi, K. Lafaver (Stony Brook, NY, USA)

1:45pm-3:15pm: MDS Rare Movement Disorders Study Group Global Genetic Testing Survey: exploring the unmet needs

R. Walker, H. Jinnah, M. Rodriguez Violante, C. Gonzalez, E. Gatto (New York, NY, USA)

1:45pm-3:15pm: Mechanism-based classification in PD cohorts

B. Labrador, F. Danjou, S. Bekadar, FX. Lejeune, H. Froehlich, M. Hofmann-Apitius, JC. Corvol (Paris, France)

1:45pm-3:15pm: Mechanisms underlying therapeutic group singing in persons with Parkinson’s disease

E. Stegemoller, A. Zaman, K. Diaz, E. Shirtcliff, M. Kohut (Ames, IA, USA)

1:45pm-3:15pm: Medical management of primary hemifacial spasm

G. Kumar, D. Kaur, A. Singh (Patna, India)

1:45pm-3:15pm: Metabolomic Analysis of Fecal Matter from Parkinsonian Mice

V. Vedam-Mai, E. Gill, J. Koelmel, R. Yost, T. Garrett, M. Okun (Gainesville, FL, USA)

1:45pm-3:15pm: Methylation status of SNCA gene in patients with Parkinson disease in Russian population

E. Iakovenko, N. Abramycheva, S. Illarioshkin, E. Fedotova (Moscow, Russian Federation)

1:45pm-3:15pm: MicroRNA Expression in the Diagnosis of Parkinson’s Disease

J. Roy, D. Guévremont, A. Garvey, N. Cutfield, J. Williams (Dunedin, New Zealand)

1:45pm-3:15pm: Mobility Impairments in Huntington’s Disease due to Cognitive Dysfunction

M. Rakhimova, N. Yusupova (Tashkent, Uzbekistan)

1:45pm-3:15pm: Modeling of Parkinson’s disease by damaging dopaminergic neurons

L. Toshpulatova, M. Kulmanova (Tashkent, Uzbekistan)

1:45pm-3:15pm: Modern aspects of genetics of child cerebral palsy with symptomatic epilepsy

D. Aminova (Tashkent, Uzbekistan)

1:45pm-3:15pm: Modulation of Na+/K+ ATPase activity of rat brain synaptosome by norepinepherine and serotonin

S. Sinha (Prayagraj, India)

1:45pm-3:15pm: Modulation of the Startle Response in REM Sleep Behavior Disorder

M. Puligheddu, M. Figorilli, ML. Fantini, M. Carta, F. Traccis, R. Frau, P. Devoto, D. Pani, M. Bortolato (Salt Lake City, UT, USA)

1:45pm-3:15pm: Molecular Integration in Neurological Diagnosis (MIND): A Center-Wide Approach to Improve Molecular and Genetic Characterization of Parkinson’s Disease

T. Tropea, J. Rick, N. Han, S. Rudovsky, A. Siderowf, V. van Deerlin, A. Chen-Plotkin (Philadelphia, PA, USA)

1:45pm-3:15pm: Motor and non-motor symptoms burden, autonomy, quality of life and principal caregiver status is worse in patients with 5-2-1 positive criteria: a simple screening tool for identifying PD patients who need an optimization of Parkinson´s treatment.

D. Santos, T. de Deus, E. Suárez Castro, A. Aneiros (A Coruña, Spain)

1:45pm-3:15pm: Motor assessments in HD clinical trials: Q-Motor versus the UHDRS-TMS – what did we learn from recent studies?

R. Reilmann, R. Schubert, P. Barallon, P. Pracht, B. Habbel (Muenster, Germany)

1:45pm-3:15pm: Motor Training Based on Video Games Reduces Freezing of Gait Regardless of Games Combination: A Parallel, Prospective, Double-Blind, Randomized Clinical Trial

P. Barbosa, A. Lopes, A. Falconi, M. D’Alencar, M. Piemonte (Sao Paulo, Brazil)

1:45pm-3:15pm: Movement disorders as a clinical feature of Subacute Sclerosing Pan Encephalitis: Expansion of phenotypic spectrum

D. Dash, M. Tripathi, R. Singh (Delhi, India)

1:45pm-3:15pm: Movement disorders associated with autoimmune encephalitis

A. Chouksey, S. Pandey (New Delhi, India)

1:45pm-3:15pm: Movement disorders in late-onset inborn errors of metabolism – a new diagnostic algorithm

L.. Koens, M. Tijssen, T. de Koning (Groningen, Netherlands)

1:45pm-3:15pm: Movement Disorders in Post Stroke Patients: A Retrospective Analysis

M. Christie, V. Laticevschi, R. Mehanna (Houston, TX, USA)

1:45pm-3:15pm: Movement Disorders Patients in Long-Term Care: Protecting Access to Appropriate Treatment

B. Kennedy, J. Peterson, D. Charles (Washington, DC, USA)

1:45pm-3:15pm: MRI based Volumetric analysis of the sub-thalamic and red nuclei in Advanced Parkinson’s disease- an institutional study

V. Shah, R. Alugolu, R. Kandadai, A. Arora (Hyderabad, India)

1:45pm-3:15pm: MRI, Clinical, and Neuropathological Findings after Bilateral Intra-striatal Administration of rAAV5-miHTT in Non-human Primates

J. Higgins, B. Blits, L. Spronck, A. Valles-Sanchez, M. Evers, S. van Deventer, P. Konstantinova, M. de Haan (Lexington, MA, USA)

1:45pm-3:15pm: Mu opioid receptor agonism, not antagonism, for the treatment of L-DOPA-induced dyskinesia in Parkinson’s disease

E. Bezard, Q. Li, E. Pioli, A. Crossman (Bordeaux, France)

1:45pm-3:15pm: Multi-kinase Abelson (c-Abl) and Discoidin Domain Receptors (DDR1/2) inhibitors, Nilotinib, alters CSF soluble TREM2 (sTREM2) in individuals with Parkinson’s Disease

F. Pagan, M. Hebron, B. Wilmarth, Y. Torres-Yaghi, E. Mundel, N. Yusuf, C. Moussa (Washington, DC, USA)

1:45pm-3:15pm: Multimodal characterization of the visual network in Huntington’s disease

O. Odish, S. Gregory, I. Mayer, J.. Mills, E. Johnson, R. Scahill, J. Rothwell, G. Rees, J. Long, S. Tabrizi, R. Roos, M. Orth (Leiden, Netherlands)

1:45pm-3:15pm: Muscle Ultrasound Comparison between Early, Intermediate and Late Onset Friedreich’s Ataxia

R. Verbeek, A. Waalkens, M. Kuiper, C. Verschuuren-Bemelmans, J. Vd Hoeven, J. de Vries, J. van Gaalen, M. Willemsen, H. Kremer, K. Bürk, D. Sival (Groningen, Netherlands)

1:45pm-3:15pm: MYORG is associated with recessive primary familial brain calcification

D. Arkadir, A. Lossos, D. Rahat, M. Abu Snineh, V. Meiner (Jerusalem, Israel)

1:45pm-3:15pm: NBIA-like MRI findings in a patient with Huntington’s disease

T. Shimizu, T. Matsukawa, Y. Abe, H. Suga, N. Tominaga, M. Nagai, T. Iizuka, H. Ishiura, J. Mitsui, S. Tsuji, R. Hanajima, K. Nishiyama (Yonago, Japan)

1:45pm-3:15pm: Need of next generation sequencing technology to de-convolute autosomal recessive cerebellar ataxias in India

S. Shakya, R. Kumari, A. Garg, A. Srivastava, M. Faruq (New Delhi, India)

1:45pm-3:15pm: Neuritic pathology in Parkinson’s Disease results from loss of anti-oxidant response activity

S. Ryan, M. Stykel, C. Coackley, T. Ryan (Guelph, ON, Canada)

1:45pm-3:15pm: Neurofascin is a novel gene associated with autosomal recessive spastic and polyneuropathy

L. Straniero, E. Monfrini, S. Bonato, G. Monzio Compagnoni, A. Bordoni, R. Dilena, R. Silipigni, D. Ronchi, S. Duga, A. Di Fonzo (Pieve Emanuele, Milan, Italy)

1:45pm-3:15pm: Neurological Wilson Disease: Clinical Aspects and Evolution in 10 Cases

Y. Mecheri, F. Serradj, A. Boulefkhad, H. Semra, A. Mzahem, A. Hamri, Y. Sifi (Constantine, Algeria)

1:45pm-3:15pm: Neuromelanin MRI detects monoaminergic cell loss in Huntington Disease Expansion Gene Carriers.

ER. de Natale, H. Wilson, G. Dervenoulas, F. Niccolini, SJ. Tabrizi, M. Politis (London, United Kingdom)

1:45pm-3:15pm: Neuropathological findings in a SPG4 gene mutation carrier

S. Forcén, I. Aldecoa, AM. Crespo, O. Ramos, L. Ispierto, R. álvarez, D. Vilas (Badalona, Spain)

1:45pm-3:15pm: Neuropathology in a case of HD-like syndrome caused by mutations in RNF216

P. Santens, A. Sieben, B. Dermaut (Ghent, Belgium)

1:45pm-3:15pm: Neuroprotective and neurotrophic efficacy of Ginkgo biloba extracts against 3-nitropropionic acid-induced oxidative stress in a rat model of Huntington’s disease

P. Kashyap, S. Gupta (Darbhanga, India)

1:45pm-3:15pm: Neuropsychiatric clusters in patients with Parkinson’s disease and their clinical and demographic correlates

M. Sommerauer, C. Schedlich-Teufer, P. Reker, E. Kalbe, J. Kessler, M. Barbe (Köln, Germany)

1:45pm-3:15pm: Neuropsychiatric manifestations in Parkinson’s disease

O. Cherkaoui Rhazouani, N. Jalami, M. Chraa, N. Kissani (Marrakech, Morocco)

1:45pm-3:15pm: Neuropsychological and behavioral profile of patients with isolated REM sleep behaviour disorders (iRBD) and patients with RBD associated with Parkinson’s Disease (PDRBD)

M. Figorilli, P. Pisanu, MG. Mascia, M. Meloni, RM. Lecca, G. Gioi, P. Congiu, L. Tamburrino, G. Defazio, M. Fantini, M. Puligheddu (Monserrato, Italy)

1:45pm-3:15pm: Neuropsychological profile of patients with functional movement disorders

G. Vechetova, T. Nikolai, M. Slovak, Z. Hanzlikova, M. Vranka, E. Bolcekova, T. Teodoro, E. Ruzicka, M. Edwards, T. Serranova (Prague, Czech Republic)

1:45pm-3:15pm: NILO-PD: A Phase 2A Study of Nilotinib in Patients with Advanced Parkinson’s Disease: Study Design and Status Update

T. Simuni, B. Fiske, K. Merchant, C. Coffey, H. Matthews, R. Wyse, P. Brundin, D. Simon, M. Schwarzschild, D. Weiner, J. Adams, C. Venuto, L. Trusso, L. Baker, M. Kostrzebski, T. Ward, G. Rafaloff (Boston, MA, USA)

1:45pm-3:15pm: NKX2-1-Related Disorder with Cerebral Folate Deficiency

J. Maclean, Q. Luc, L. Ramos-Platt, S. Saitta, C. Quindipan (Los Angeles, CA, USA)

1:45pm-3:15pm: Non-CpG methylation in the FXN gene in patients with Friedreich’s ataxia

E. Nuzhnyi, N. Abramycheva, M. Ershova, S. Klyushnikov, N. Nikolaeva, S. Illarioshkin, E. Fedotova (Moscow, Russian Federation)

1:45pm-3:15pm: Non-Medical Switching: Impact on Movement Disorders Patients’ Access and Care

B. Kennedy, J. Peterson, D. Charles (Washington, DC, USA)

1:45pm-3:15pm: Normative Curves for Selected Unified Huntington Disease Rating Scale Measures

J. Mills, J. Long, A. Mohan, J. Ware, C. Sampaio (Iowa City, IA, USA)

1:45pm-3:15pm: Normative Reference for Timed Up and Go Test (TUG) in Young Indian Adults- Preliminary Results

D. Kaur, K. Umakant, T. Aziz, P. Jaiswal, M. Kumari, A. Gupta, G. Kumar (Patna, India)

1:45pm-3:15pm: Novel exploratory outcome assessments in GENERATION HD1

D. Trundell, S. Schobel, R. Roos, K. Anderson, A. Thobhani, G. Hooper, M. Nguyen, S. Tabrizi (Welwyn Garden City, United Kingdom)

1:45pm-3:15pm: Novel Mutation of NUS1 Gene Presenting With Developmental And Epileptic Encephalopathy and Movement Disorders

N. Prakash, N. Mencacci, C. Zadikoff, L. Kinsley, T. Simuni, S. Lubbe, D. Krainc (Chicago, IL, USA)

1:45pm-3:15pm: Novel p.Pro193Arg missense mutation in ABCD1-gene associated with phenotype of ALD/AMN: a case report

K. Steidel, J. Waldthaler, C. Eggers, D. Pedrosa (Marburg, Germany)

1:45pm-3:15pm: Objective quantifiable assessment of nocturnal movements in patients with Parkinson’s disease using a wearable sensor

A. Mirelman, I. Hillel, L. Rochester, A. Nieuwboer, B. Bloem, L. Avanzino, S. Shema-Shiratzki, I. Maidan, T. Herman, J. Cederbaum, N. Giladi, J. Hausdorff (Tel Aviv, Israel)

1:45pm-3:15pm: Ocular Motor Findings in Spinocerebellar Ataxia Type 17

SU. Lee, JY. Choi, JM. Kim, JS. Kim (Seoul, Republic of Korea)

1:45pm-3:15pm: Olfactory Hallucinations Induced by Pramipexole Treatment in Parkinson’s Disease

G. Hatipoglu, S. Ozkaynak (Antalya, Turkey)

1:45pm-3:15pm: Oligomeric Alpha-synuclein in Erythrocyte Membrane in Early Parkinson’s Disease

GL. Liu, C. Tian, T. Feng (Beijing, China)

1:45pm-3:15pm: Onset of action for rimabotulinumtoxinB in the treatment of adult sialorrhea

L. Bahroo, S. Isaacson, R. Pahwa, D. Chary, T. Clinch, M. Lew (Washington, DC, USA)

1:45pm-3:15pm: Onset symptoms and time to diagnosis in Friedreich´s Ataxia

E. Indelicato, W. Nachbauer, A. Eigentler, M. Amprosi, P. Giunti, C. Mariotti, J. Arpa, A. Dürr, T. Klopstock, L. Schöls, T. Klockgether, K. Bürk, M. Pandolfo, J. Schulz, S. Boesch (Innsbruck, Austria)

1:45pm-3:15pm: Open-label safety and tolerability of L-Dihydroxyphenylserine (L-DOPS) and high dose carbidopa therapy in Parkinson’s disease patients

K. Hay, K. Mcdonell, P. Trujillo, M. Donahue, N. van Wouwe, D. Claassen (Nashville, TN, USA)

1:45pm-3:15pm: Open-Label Study of Pimavanserin Patients With Comorbid Parkinson’s Disease and Depression

J. Norton, D. Fredericks, G. Alva, J. Aldred, B. Coate, D. Dekarske, M. Cantillon, R. Owen (San Deigo, CA, USA)

1:45pm-3:15pm: Opicapone added to safinamide in patients affected by Parkinson’s disease for better controlling motor fluctuations

C. Liguori, M. Pierantozzi, R. Cerroni, NB. Mercuri, A. Stefani (Rome, Italy)

1:45pm-3:15pm: Opicapone and levodopa-carbidopa intestinal gel infusion: a cost saving analysis in the United Kingdom

V. Leta, D. van Wamelen, A. Sauerbier, S. Jones, A. Podlewska, D. Trivedi, M. Parry, P. Odin, A. Storch, Z. Pirtošek, A. Antonini, K. Ray Chaudhuri (London, United Kingdom)

1:45pm-3:15pm: Opicapone as a levodopa sparing agent: pooled analysis of BIPARK-I and II double-blind trials

R. Hauser, O. Rascol, W. Poewe, J. Ferreira, A. Lees, O. Klepitskaya, G. Liang, A. Santos, D. Magalhães, J. Rocha, P. Soares-da-Silva (Tampa, FL, USA)

1:45pm-3:15pm: Opicapone improves motor and non-motor wearing off symptoms in Parkinson’s disease: an observational real-world study

C. Oehlwein, K. Mittmann, D. Sarkisjan, J. Baron, M. Oehlwein, K. Witt (Gera, Germany)

1:45pm-3:15pm: Opicapone odds ratio in relative OFF-time reduction: a post-hoc analysis from combined BIPARK-I and II data

J. Rocha, W. Poewe, O. Rascol, A. Lees, J. Ferreira, A. Santos, D. Magalhães, P. Soares-da-Silva (Coronado, Portugal)

1:45pm-3:15pm: OPICAPONE: REAL WORLD EVIDENCE IN TOLEDO´S MOVEMENT DISORDERS UNIT

JC. Segundo-Rodríguez, N. López-Ariztegui, MI. Morales-Casado, N. García-Alvarado, A. Avila-Fernández, J. Pérez-Matos (Toledo, Spain)

1:45pm-3:15pm: Opinions and clinical practices related to diagnosing and managing patients with functional (psychogenic) movement disorders: from 2009 to 2019

K. Lafaver, D. Bega, M. Hallett, A. Lang, S. Lidstone, C. Maurer, F. Morgante, D. Perez, C. Stephen, J. Stone, T. Teodoro, A. Wu, A. Dwivedi, A. Espay (Louisville, KY, USA)

1:45pm-3:15pm: Opsoclonus and ataxia in the setting of synchronous primary malignancies

H. Leal Bailey, S. Wijemanne Sarathkumara, R. Knightstep (San Antonio, TX, USA)

1:45pm-3:15pm: Opsoclonus-myoclonus-ataxia syndrome associated to rubella

BED. Ines, BRA. Zeineb, HAM. Salma, ZAO. Jamel, MRI. Ridha (Tunis, Tunisia)

1:45pm-3:15pm: Outcomes After Weighted Lumbosacral Orthosis (LSO) and Exercises in Patients with Progressive Cerebellar Ataxia

S. Mele (Philadelphia, PA, USA)

1:45pm-3:15pm: Outcomes of the first-in-human study with a recombinant botulinum toxin E (rBoNT-E): safety and pharmacodynamic profile of rBoNT-E compared with abobotulinumtoxinA

L. Pons, C. Vilain, P. Picaut (Cambridge, MA, USA)

1:45pm-3:15pm: Pallidal surgery and physiological mechanism in choreic movements

T. Hashimoto, T. Goto, K. Yoshida, L. Johnson, J. Vitek (Minneapolis, MN, USA)

1:45pm-3:15pm: Paraneoplastic Cerebellar Degeneration As Initial Symptom Of Renal Cell Carcinoma

S. Souza, B. Oliveira, I. Sodré, A L. Oliveira, R. Oliveira, D. Terrana, M. Spitz (Rio de Janeiro, Brazil)

1:45pm-3:15pm: Parkinson Kinetigraph – does it change the management of PD patients?

F. Bergquist, A. Cvejtkovic, AC. Sjöström, S. Wallerstedt (Gothenburg, Sweden)

1:45pm-3:15pm: Parkinson´s Disease, respiratory capacity and functionality: a Physical Therapy perspective

V. Israel, B. Yamaguchi, A. Silva, D. Iucksch, J. Siega (Curitiba, Brazil)

1:45pm-3:15pm: Parkinson’s disease patients with both GBA and LRRK2 mutations are phenotypically similar to LRRK2 – a possible protective effect?

N. Omer, A. Thaler, L. Goldstein, A. Orr-Urtreger, M. Gana Weisz, O. Goldstein, D. Cohen Avinoam, M. Kestenbaum, M. Lioti, S. John, J. Cederbaum, A. Mirelman, N. Giladi (Tel Aviv, Israel)

1:45pm-3:15pm: Parkinson’s disease and intermittent hypoxia training: beneficial or harmful?

M. Sharifi-Bonab, J. Sesink, B. Bloem, D. Devos, J. Deguil, C. Moreau (Nijmegen, Netherlands)

1:45pm-3:15pm: Parkinson’s disease in Middle East, North Africa and South Asia: Consensus from the MDS Task Force on the Middle East

H. Khalil, L. Chahine, J. Junaid Siddiqui, M. Salari, S. El-Jaafary, Z. Aldaajani, M. Abu Al-Melh, T. Mohammad, M. Abu Snineh, N. Syed, M. Bhatt, M. Habib, M. Habahbeh, S. Tabbal, B. Jeon, J. Bajwa (Irbid, Jordan)

1:45pm-3:15pm: Parkinson’s disease Polygenic Risk Factor Scores in Patients with Inflammatory Bowel Disease

H. Maghzi, D. Li, E. Hogg, A. Garland-Becerra, E. Tan, A. Maghzi, D. Mcgovern, M. Tagliati (Los Angeles, CA, USA)

1:45pm-3:15pm: Parkinson’s Disease Treatments and Outcomes: US v Non-US Patients

TL. Davis, M. Rafferty, K. Lyons, A. Ramirez-Zamora, H. Gao, S. Wu, F. Cubilllos, EC. Nelson (Lebanon, NH, USA)

1:45pm-3:15pm: Parkinsonism and other motor features in familial frontotemporal dementia with mutations in the MAPT, GRN, or C9orf72 gene (LEFFTDS cohort)

A. Deutschlander, R. Savica, M. Heckman, D. Brushaber, J. Syrjanen, H. Rosen, A. Boxer, B. Boeve, Z. Wszolek (Jacksonville, FL, USA)

1:45pm-3:15pm: Parotitis as Adverse Event Following BoNT Injections for Sialorrhea

K. Papesh, J. Nguyen (Las Vegas, NV, USA)

1:45pm-3:15pm: Paroxysmal asymmetric dystonic arm posturing – a less recognised but characteristic manifestation of ATP1A3-related disease

B. Balint, C. Stephen, V. Udani, C. Sankhla, N. Barad, A. Lang, K. Bhatia (Boston, MA, USA)

1:45pm-3:15pm: Path to Prevention (P2P) – Developing a Prodromal PD Progression Biomarker Program

K. Marek, A. Siderowf, C. Coffey, T. Foroud, V. Arnedo, E. Flagg, S. Chowdhury, K. Kieburtz, L. Chahine, J. Seibyl (New Haven, CT, USA)

1:45pm-3:15pm: Patient and physician perspectives on the care and assistance needs in Huntington’s disease

K. Raimundo, R. Tan, T. To, J. de Courcy, U. Ondhia, H. Rickards, M. Nance (South San Francisco, CA, USA)

1:45pm-3:15pm: Patient insights into the burden of OFF-episodes in Parkinson’s disease: Qualitative Interviews

C. Ervin, J. Sutphin, A. Thach, A. Lee, C. Mansfield, J. Coulter (Research Triangle Park, NC, USA)

1:45pm-3:15pm: Patient organisation collaboration to advance patient engagement in Parkinson’s research

N. Ratcliffe, K. Schroeder (New York, NY, USA)

1:45pm-3:15pm: People with Parkinson’s Disease (PPD): disease, stigma and the others

M. Bacigalupe (La Plata, Argentina)

1:45pm-3:15pm: Permanent chorea in 76-years-old female with poorly controlled diabetes

F. Abu Ahmad, A. Socher, A. Gadoth, O. Aizenstein, A. Hilel, R. Hurvitz-Alon, N. Giladi, T. Gurevich (Tel Aviv, Israel)

1:45pm-3:15pm: PEX 16: EXPANDING THE CLINICAL SPECTRUM OF PEROXISOMAL BIOGENESIS DISORDERS

D. N, J. Agadi (Bangalore, India)

1:45pm-3:15pm: Pharmacokinetics of Opicapone and Effect on COMT and Levodopa Pharmacokinetics in Patients with Parkinson’s Disease

G. Loewen, P. Lewitt, C. Olanow, K. Kieburtz, G. Liang, R. Jimenez, K. Olson, E. Roberts (San Diego, CA, USA)

1:45pm-3:15pm: Pharmacological effect of adenosine A2A receptor antagonist for levodopa-induced dyskinesia associated with cellular energy homeostasis

NAO. Kanzato (Okinawa, Japan)

1:45pm-3:15pm: Phosphodiesterase inhibitors as a treatment for Friedreich’s ataxia

J. González-Fernández, E. Zucchet, P. Calap-Quintana, P. González Cabo, MD. Moltó Ruiz (València, Spain)

1:45pm-3:15pm: Pilot Study Comparing Home Sleep Profiler to In-laboratory Polysomnogram for REM Sleep Behavior Disorder Diagnosis

D. Shprecher, D. Levendowski, C. Guevarra, J. Lee-Iannotti, G. Lazarz (Sun City, AZ, USA)

1:45pm-3:15pm: Pilot testing of the Integrated Parkinson’s Disease Care Network: feasibility, efficacy outcomes and cost description analysis

T. Mestre, D. Kessler, J. Shen, A. Basndwah, H. Shinawi, C. Nussey, A. Ohman, S. Kumar, D. Côté, C. Liddy, K. Thavorn, M. Taljaard, D. Grimes (Ottawa, ON, Canada)

1:45pm-3:15pm: Plasma membrane Ca2+ Atpase 1 as a candidate to mediate the degeneration of dopaminergic neurons by inflammation in Parkinson’s disease

B. Erhardt, MS. Marcora, A. Delella Ezcurra, J. Casabona, R. Tarelli, L. Frenkel, P. Bochicchio, D. Bodin, B. Silva, V. Cavaliere Candedo, MI. Farías, C. Ferrari, M. Allo, C. Höcht, A. Chernomoretz, E. Castaño, MC. Leal, F. Pitossi (Capital Federal, Argentina)

1:45pm-3:15pm: PNKP deficiency mimicking a benign hereditary chorea: the misleading presentation of a neurodegenerative disorder

C. Caputi, M. Tolve, S. Galosi, M. Inghilleri, C. Carducci, A. Angeloni, V. Leuzzi (Roma, Italy)

1:45pm-3:15pm: POLR3A-related spastic ataxia: new mutations and a look into the clinical and MRI phenotype

J. Infante, KM. Serrano, E. Marco-de Lucas, A. Sánchez-Rodríguez, J. Berciano, M. Corral, X. Farré, A. Matilla (Santander, Spain)

1:45pm-3:15pm: Polyneuropathy in patients with continuous levodopa/carbidopa intestinal gel (LCIG) infusion

KAM. Pauls, J. Toppila, M. Koivu, J. Eerola-Rautio, M. Udd, E. Pekkonen (Helsinki, Finland)

1:45pm-3:15pm: Polysomnographic features of Spinocerebellar Ataxia type 3 – a case report

DRC. Carneiro, IL. Luzeiro, ASM. Morgadinho (Coimbra, Portugal)

1:45pm-3:15pm: Population Pharmacokinetics and Pharmacodynamics of Ampreloxetine (TD-9855) in Patients with Neurogenic Orthostatic Hypotension (nOH)

A. Lo, J. Kanodia, R. Vickery, D. Bourdet (South San Francisco, CA, USA)

1:45pm-3:15pm: Post-pump chorea and progressive supranuclear palsy like syndrome following major cardiac surgery: A case series

GW. Kim, KW. Park, NR. Choi, HS. Ryu, HJ. Kim, CS. Lee, SJ. Chung (Daegu, Republic of Korea)

1:45pm-3:15pm: Post-stroke movement disorders: an analysis of 24 cases

M. Burzhunova, N. Garabova, L. Geraskina (Moscow, Russian Federation)

1:45pm-3:15pm: Potential treatment considerations for refractory REM behavior disorder

J. Nguyen, K. Papesh (Las Vegas, NV, USA)

1:45pm-3:15pm: Practice Patterns with Onabotulinum Toxin-A for Movement disorders: South Asian Neurologist Survey

G. Kumar, P. Wadia, H. Kumar, P. K, S. Gupta, V. Goyal, A. Raza, A. Zuzek, A. Patel (Bengaluru, India)

1:45pm-3:15pm: Pre-diagnosis physical activity habits are associated with age of diagnosis and postural instability in Parkinson’s disease

M. Landers, K. Johnson, S. Johnson, J. Lyle, T. Ormsby, D. Salgo, J. Zorn, A. Murtishaw, A. Salazar, J. Kinney (Las Vegas, NV, USA)

1:45pm-3:15pm: Pre-Dopa DBS: is early deep brain stimulation able to modify the natural course of Parkinson’s disease?

M. Porta, D. Servello, AR. Bona, E. Zekaj, G. Gonzalez-Escamilla, G. Groppa (Milan, Italy)

1:45pm-3:15pm: PRECISE-PD: From pathophysiology to precision medicine for Parkinson’s disease

JC. Corvol, S. Durrleman, S. Lehericy, D. Devos, W. Meissner, E. Bezard, D. Grosset, H. Morris, O. Monchy, EA. Fon, F. Durif, F. Tubach, Y. de Rycke, O. Rascol (Paris, France)

1:45pm-3:15pm: Preclinical Development of a Novel Carbidopa/Levodopa Precision Olfactory Delivery (POD®) Drug-Device Combination Product for the Treatment of OFF Episodes in Parkinson’s Disease

K. Satterly, G. Davies, B. Gajera, J. Wright, H. Lin, S. Muppaneni, K. To, S. Shrewsbury, J. Hoekman (Seattle, WA, USA)

1:45pm-3:15pm: Preclinical efficacy of drugs identified by IBM-Watson for repurposing to treat L-DOPA-induced dyskinesia

N. Visanji, A. Lacoste, P. Ravenscroft, S. Spangler, S. Fox, A. Lang, J. Brotchie, T. Johnston (Toronto, ON, Canada)

1:45pm-3:15pm: Preclinical profile of dopamine D1PAM: A novel mechanism in clinical development for Lewy Body dementia

K. Svensson, J. Beck, J. Hao, J. Schaus, X. Wang, B. Heinz, S. Mitchell, K. Wafford, C. Yang, L. Zhang, S. Castner, G. Williams, H. Marston, R. Bruns (Indianapolis, IN, USA)

1:45pm-3:15pm: Predicting Impulse Control Disorders in Parkinson’s Disease: A Challenging Task

J. Faouzi, S. Bekadar, O. Colliot, JC. Corvol (Paris, France)

1:45pm-3:15pm: Predictive Factors for Depression in a Multicentric Parkinson’s Disease Mexican Cohort

A. Banegas-Lagos, A. Cervantes-Arriaga, D. Garza-Brambila, E. Garcia-Berlanga, K. Salinas-Barboza, S. Isais-Millan, A. Anaya-Escamilla, E. Velazquez-Avila, G. Parra, A. Gonzalez-Cantú, M. Rodriguez-Violante, D. Martinez-Ramirez (Monterrey, Mexico)

1:45pm-3:15pm: Predictors of Health-Related Quality of Life in Patients with Cervical Dystonia

SA. Reijneveld, Z. Gdovinova, MAJ. Tijssen, JP. van Dijk, T. Hoekstra, M. Turcanova Koprusakova, M. Smit, M. Skorvanek, V. Han (Martin, Slovakia)

1:45pm-3:15pm: Preliminary validation of a novel, comprehensive digital biomarker smartphone application to assess motor symptoms in de-novo diagnosed Parkinson patients

F. Lipsmeier, K. Taylor, E. Volkova-Volkmar, R. Postuma, T. Kilchenmann, D. Wolf, Y. Zhang, W. Cheng, A. Scotland, J. Schjodt-Eriksen, F. Boess, D. Ness, C. Gossens, A. Post, M. Lindemann (Basel, Switzerland)

1:45pm-3:15pm: Preoperative quantitative evaluation of psychological determinants in abnormal head postures

E. Sanrey, C. Labate, L. Cif, V. Gonzalez, E. Borgeais, E. Chan Seng, P. Coubes (Montpellier, France)

1:45pm-3:15pm: Prevalence and risk factors for impulsive compulsive behaviors in a cohort of Parkinson’s disease patients

S. Simoni, N. Tambasco, P. Eusebi, P. Nigro, E. Brahimi, F. Paolini Paoletti, M. Filidei, G. Cappelletti, P. Calabresi (Perugia, Italy)

1:45pm-3:15pm: Prevalence of chronic kidney disease in patients with idiopathic Parkinson’s disease in a tertiary care hospital in Mexico City

S. Isais-Millan, CA. Rojas-Guerrero, A. Arriaga, M. Rodriguez-Violante, D. Zuñiga-Garcia, RO. Millan-Guerrero, V. Campos-Gasga, V. Garcia-Barrera, R. Santos-Montero (Colima, Mexico)

1:45pm-3:15pm: Prevalence of Fabry disease among patients with Parkinson’s disease

A. Mosejova, S. Oppermann, V. Han, P. Dosekova, J. Cobejova, M. Cobej, P. Levicka, S. Liesenerova, T. Lorincova, M. Ostrozovicova, D. Sendekova, V. Sukovska, Z. Gdovinova, P. Bauer, M. Skorvanek (Kosice, Slovakia)

1:45pm-3:15pm: Prevalence of Huntington’s Disease in Sardinia, Italy

A. Muroni, MR. Murru, T. Ercoli, V. Melas, E. Casaglia, M. Melis, E. Cocco, G. Defazio (Cagliari, Italy)

1:45pm-3:15pm: Prevalence of Oropharyngeal Dysphagia in Hereditary Spastic Paraplegias

L. Jacinto-Scudeiro, G. Machado, A. Ayres, D. Burguêz, M. Polese-Bonatto, C. González-Salazar, M. Siebert, M. França Jr, M. Olchik, J. SAUTE. (Porto Alegre, Brazil)

1:45pm-3:15pm: Prevalence of Rem Behavior Disorder (RBD) in different motor subtypes of Parkinson`s Disease corroborated by Polisomnography

O. Cardenas, A. Abundes, M. Rodríguez, A. Cervantes, V. Alatriste (Mexico City, Mexico)

1:45pm-3:15pm: Prevalence of Restless Leg Syndrome in the general population of Montevideo, Uruguay in 2018

I. Amorin, H. Hackembruch, A. Lescano, M. Aguerre, O. Echevarria, S. Faliveni, J. García, E. Monllor (Montevideo, Uruguay)

1:45pm-3:15pm: Profiling of lipoproteins and associated lipids in serum samples from Idiopathic REM Sleep Behavior Disorder patients to identify biomarkers for Parkinson’s disease

A. Laguna, A. Iranzo, M. Serradell, N. Amigó, O. Yanes, M. Vila (Barcelona, Spain)

1:45pm-3:15pm: Progression of neuropsychiatric symptoms in Parkinson’s disease

J. Dlay, G. Duncan, T. Khoo, C. Williams-Gray, D. Breen, R. Barker, D. Burn, R. Lawson, A. Yarnall (Newcastle Upon Tyne, United Kingdom)

1:45pm-3:15pm: Progressive Myoclonus Ataxia: An International Database

S. Vd Veen, T. de Koning, D. Sival, M. Tijssen (Groningen, Netherlands)

1:45pm-3:15pm: Prolonged-release Melatonin for Sleep Disorders in Parkinson’s Disease: A Randomized trial

JH. Ahn, M. Kim, JK. Mun, J. Youn, S. Park, W. Jang, J. Park, E. Oh, JW. Cho, JS. Kim (Seoul, Republic of Korea)

1:45pm-3:15pm: Prospective observational study to follow up a cohort of Parkinson’s outpatients during a 4-week rehabilitation

E. Leblong, AL. Roy, B. Fraudet, A. Riou, E. Ceze, A. Rouxel, B. Nicolas, P. Gallien (Rennes, France)

1:45pm-3:15pm: Prospective study of cognition in SCA2

T. Monte, E. Reckziegel, M. Augustin, O. Barsottini, JL. Pedroso, F. Vargas, ML. Saraiva-Pereira, V. Leotti, L. Jardim (Porto Alegre, Brazil)

1:45pm-3:15pm: Prospective study on impulsive-compulsive behaviours in early Parkinson’s disease

V. Markovic, I. Stankovic, I. Petrovic, T. Stojkovic, V. Kostic (Belgrade, Serbia)

1:45pm-3:15pm: Psychosis in Prodromal Parkinson’s disease

I. Pachi, M. Maraki, M. Kosmidis, M. Yannakoulia, E. Dardiotis, G. Hadjigeorgiou, P. Sakka, G. Xiromerisiou, M. Stamelou, N. Scarmeas, L. Stefanis (Athens, Greece)

1:45pm-3:15pm: Pulmonary function in patients with Parkinson’s disease

V. Israel, B. Yamaguchi, M. Ferreira, S. Valderramas (Curitiba, Brazil)

1:45pm-3:15pm: Quality of Life Indicators and Psycho-Social Adaptation of Patients with Essential Tremor

A. Taskinbayeva (Almaty, Kazakhstan)

1:45pm-3:15pm: Quantification of regional iron content with Susceptibility Weighted Imaging in Huntington Disease Expansion Gene Carriers

ER. de Natale, H. Wilson, G. Dervenoulas, F. Niccolini, SJ. Tabrizi, M. Politis (London, United Kingdom)

1:45pm-3:15pm: Quantitative evaluation of gait ataxia of Multiple System Atrophy patients

C. Sato, S. Shirai, M. Matsushima, I. Yabe, H. Sasaki (Sapporo, Japan)

1:45pm-3:15pm: Quantitative Motor (Q-Motor) Assessments Suggest a Beneficial Central Effect of Laquinimod in a Phase II Study in Huntington Disease (LEGATO-HD)

R. Reilmann, M. Gordon, R. Schubert, K. Anderson, A. Feigin, S. Tabrizi, B. Leavitt, J. Stout, P. Piccini, B. Borowsky, G. Rynkowski, R. Volkinshtein, J. Savola, M. Hayden (Muenster, Germany)

1:45pm-3:15pm: Quantitative study of subthalamic ERG potassium channels in parkinsonian discharges

C. Mahapatra, R. Manchanda (Mumbai, India)

1:45pm-3:15pm: Quercetin Regulates Cadmium Induced Motor Dysfunction in Depletion of Dopamine and its Metabolites at Synapse

R. Gupta, RK. Shukla, AB. Pant, VK. Khanna (Lucknow, India)

1:45pm-3:15pm: Randomized, placebo-controlled, double-blind, two-period cross-over study to evaluate the safety, tolerability, and efficacy of a novel treatment combination for levodopa induced dyskinesia in Parkinson’s Disease (BUS-PD)

K. Chung, B. Lobb, S. O'Connor (Portland, OR, USA)

1:45pm-3:15pm: Rapidly onset progressive generalised dystonia parkinsonism in a young Indian male with rare FBXO 7 genetic mutation

S. Desai, N. Pampaniya, K. Mori, K. Shah (Vadodara, India)

1:45pm-3:15pm: Rare causes of Opsoclonus Myoclonus Ataxia Syndrome

A. Venkitachalam, N. Chaudhary (Mumbai, India)

1:45pm-3:15pm: Relationship Between Handgrip and Functional Mobility in a Brazilian Parkinsonian Elderly Population

L. Leandro, S. Kusma, H. Teive, C. Moreira (Curitiba, Brazil)

1:45pm-3:15pm: Relationship between parkinsonism and upper extremity function in patients with Parkinson’s disease

H. Sawada, M. Takahashi, A. Inaba, S. Orimo (Tokyo, Japan)

1:45pm-3:15pm: Relationship between Progressive Supranuclear Palsy and Caregiver Burden

Y. Inuzuka, J. de Courcy, J. Pike, J. Mellor, E. Viscidi, A. Paradis, A. Harrington, Y. Zabar (Zug, Switzerland)

1:45pm-3:15pm: Relationship between restless legs syndrome and various factors in pregnancy

L. čondić, S. Telarović (Zagreb, Croatia)

1:45pm-3:15pm: Reliability and Validity of Modified Four Square Step Test (mFSST) Performance in Individuals with Parkinson’s Disease.

A. Boddy, K. Mitchell, W. Brewer, J. Ellison, L. Perry, C. Andrea (St. Augustine, FL, USA)

1:45pm-3:15pm: Reliability, feasibility and validity of a novel digital monitoring platform assessing cognitive and motor symptoms in people with Stage I and II Huntington’s disease (HD)

F. Lipsmeier, C. Simillion, A. Atieh Bamdadian, A. Smith, S. Schobel, C. Gossens, P. Weydt, E. Wild, M. Lindemann (Basel, Switzerland)

1:45pm-3:15pm: REM density in isolated REM sleep without atonia

F. Dijkstra, M. Viaene, I. de Volder, P. Cras, D. Crosiers (Geel, Belgium)

1:45pm-3:15pm: Repetitive transcranial magnetic stimulation does not improve the sequence effect in freezing of gait

L. Gao, T. Mi, T. Wu, P. Chan (Beijing, China)

1:45pm-3:15pm: Research on the modifier gene of Hereditary spinocerebellar ataxia type 2

JLW. Wang, ZL. Liu (Changsha, China)

1:45pm-3:15pm: Respiratory Function and Functional Decline in Spinocerebellar Ataxia Type 2

N. Mello, M. Zonta, H. Teive, A. Meira, B. Zeigelboim (Curitiba, Brazil)

1:45pm-3:15pm: Restless Genital Syndrome in a patient with Dementia with Lewy Body

M. Abu Al-Melh, M. Farghal, B. Al-Failakawii (Kuwait, Kuwait)

1:45pm-3:15pm: Restless Leg Syndrome In Men: Examination Of Early Non-Motor Clinical Signs Of Parkinson’s Disease

M. şenol, M. Karaoğlan, H. Tekeli (Istanbul, Turkey)

1:45pm-3:15pm: Restless leg syndrome in Neuro-Behcet’s and Behcet’s disease

M. Kuzu Kumcu, S. Erdoğan, M. Sorgun, C. Yücesan (Ankara, Turkey)

1:45pm-3:15pm: Restoring AADC enzyme synthesis in AADC deficiency: MRI-Guided Delivery of AAV2-hAADC Gene Therapy to the Midbrain

K. Bankiewicz, T. Pearson, A. Grijalvo-Perez, A. Viehoever, W. San Sebastian, J. Imamura-Ching, Y. Seo, P. Larson, N. Gupta (San Francisco, CA, USA)

1:45pm-3:15pm: Results of community pharmacist-led structured medication reviews in Parkinson’s Disease

N. Oonk, P. Oude Avenhuis, K. Movig, K. Koehorst-Ter Huurne, WH. Nijmeijer, M. van Kesteren-Biegstraaten, J. Vd Palen, L. Dorresteijn (Enschede, Netherlands)

1:45pm-3:15pm: Reverse phenotyping of a 3.3Mb loss of 8p11.21p11.1, including SLC20A2, lead to a diagnosis of primary familial brain calcification

A. Kievit, L. Zutven, A. Boon (Rotterdam, Netherlands)

1:45pm-3:15pm: Reviewing the clinical and mutational spectrum of SLC20A2, PDGFB, PDGFRB, XPR1 and MYORG mutations in Primary Familial Brain Calcification (PFBC) for MDSGene

A. Balck, S. Schaake, J. Margolesky, A. Domingo, C. Klein, A. Westenberger (Lubeck, Germany)

1:45pm-3:15pm: Rhythmic disorders in idiopathic RBD: a potential new marker for future PD?

V. Cochen Decock, D. Verbizier, C. Geny, S. Dalla Bella (Montpellier, France)

1:45pm-3:15pm: RimbotulinumtoxinB in the treatment of adult sialorrhea

S. Isaacson, W. Ondo, M. Lew, K. Dashtipour, D. Chary, T. Clinch, F. Pagan (Boca Raton, FL, USA)

1:45pm-3:15pm: Risk Thresholds of Levodopa Dose for Dyskinesia in Chinese Patients with Parkinson’s Disease: A Pilot Study

GL. Liu, T. Feng (Beijing, China)

1:45pm-3:15pm: Rivastigmine for visual hallucinations in Parkinson’s disease

T. Mierlo, E. Foncke, R. Bie (Amsterdam, Netherlands)

1:45pm-3:15pm: rTMS-induced effects on Functional Tremor: a randomized, double-blind, controlled study

S. Taib, F. Ory-Magne, C. Brefel-Courbon, Y. Moreau, C. Thalamas, C. Arbus, M. Simonetta-Moreau (Toulouse, France)

1:45pm-3:15pm: Safety and Tolerability in Parkinson’s Disease Patients Treated with a Continuous Subcutaneous Infusion of ABBV-951: Design of a 52-Week Phase 3 Study

M. Facheris, J. Benesh, J. Streit, W. Robieson, C. Zadikoff, D. Standaert (North Chicago, IL, USA)

1:45pm-3:15pm: Safety of Bone marrow-derived Allogeneic Mesenchymal Stem Cells in Parkinson’s disease Patients

M. Schiess, J. Suescun, T. Ellmore, MF. Doursout, E. Furr -Stimming, Z. Mei, A. Gee (Houston, TX, USA)

1:45pm-3:15pm: Safety of Gocovri in Clinical Practice: One-year Post-launch Pharmacovigilance Data

C. Tanner, R. Pahwa, V. Vandevoorde, K. Wehrman, R. Elfont (San Francisco, CA, USA)

1:45pm-3:15pm: Safety of Iron Chelation in Patients with Brain Iron Overload

C. Fradette, T. Klopstock, L. Neumayr, I. Karin, G. Zorzi, T. Kmieć, B. Büchner, H. Steele, R. Horvath, P. Chinnery, A. Basu, C. Küpper, C. Neuhofer, F. Zibordi, N. Nardocci, A. Stilman, M. Spino, E. Vichinsky, F. Tricta (Toronto, ON, Canada)

1:45pm-3:15pm: Safinamide ameliorates motor deficits and plastic alterations before the onset of L-DOPA-induced dyskinesia in a rat model of Parkinson’s disease

M. Sciaccaluga, P. Mazzocchetti, G. Bastioli, V. Ghiglieri, B. Picconi, A. Tozzi, C. Caccia, C. Keywood, G. Padoani, P. Calabresi (Perugia, Italy)

1:45pm-3:15pm: Safinamide improves motor symptoms severity and daily living in Parkinson’s Disease (PD) patients

C. Cattaneo, E. Bonizzoni, C. Keywood (Milan, Italy)

1:45pm-3:15pm: SAFINAMIDE IN DAILY CLINICAL PRACTICE: ASSESSMENT OF EFFICACY AND TOLERABILITY IN PARKINSON´S DISEASE

A. Vinagre-Aragón, E. Mondragón-Rezola, I. Croitoru, A. Bergareche-Yarza, JJ. Poza-Aldea, A. Olaskoaga-Caballer, M. Iridoy-Zulet, M. Ruibal-Salgado, JC. Gómez-Esteban, K. Berganzo-Corrales, B. Tijero-Merino, J. Ruiz-Martínez (San Sebastián, Spain)

1:45pm-3:15pm: Safinamide in the treatment of URINARY symptoms in PARKinson’s disease (SURINPARK)

A. Gómez López, I. Pareés Moreno, S. Fanjul Arbós, JL. López Sendon, JC. Martínez Castrillo, A. Alonso Cánovas (Madrid, Spain)

1:45pm-3:15pm: Safinamide reduces membrane excitability and synaptic transmission of striatal spiny projection neurons in a rat model of Parkinson’s disease

A. Tozzi, M. Sciaccaluga, P. Mazzocchetti, G. Bastioli, V. Ghiglieri, B. Picconi, C. Caccia, C. Keywood, G. Padoani, P. Calabresi (Perugia, Italy)

1:45pm-3:15pm: Safinamide: real world evidence in Toledo´s Movement Disorders Unit

N. López-Ariztegui, MI. Morales-Casado, JC. Segundo-Rodríguez, A. Avila-Fernández, N. García-Alvarado, J. Pérez-Matos (Toledo, Spain)

1:45pm-3:15pm: Screening of mutations in PARK2 gene and Dopamine levels in Parkinson’s disease (PD) patients in Coimbatore population, India

B. Vellingiri, D. Venkatesan (Coimbatore, India)

1:45pm-3:15pm: Seeking regulatory feedback on novel clinical outcome assessments: a case example from the Huntington’s Disease – Regulatory Science Consortium (HD-RSC)

A. Mullin, R. Fuller, G. Stebbins, J. Stout, A. Robbins, P. Feigenbaum, M. Roche, E. Gantman, C. Sampaio, M. Brumfield (Tucson, AZ, USA)

1:45pm-3:15pm: Sequencing of single human nigral dopaminergic neurons for somatic copy number variants

D. Perez-Rodriguez, M. Kalyva, S. Santucci, K. Mokretar, M. Leija-Salazar, A. Schapira, T. Lashley, J. Holton, C. Proukakis (London, United Kingdom)

1:45pm-3:15pm: Serum MIR-96-5P and MIR-339-5P as a Potential Biomarker for Multiple System Atrophy and Parkinson’s Disease

A. Vallelunga, T. Iannitti, S. Capece, G. Somma, G. Dati, P. Barone, W. Meissner, M. Pellecchia (Salerno, Italy)

1:45pm-3:15pm: Severity of REM sleep without atonia (RSWA) correlates with cognitive functions in patients with REM sleep behaviour disorder (RBD)

M. Figorilli, P. Pisanu, M. Mascia, M. Meloni, R. Lecca, G. Gioi, P. Congiu, L. Tamburrino, G. Defazio, ML. Fantini, M. Puligheddu (Monserrato, Italy)

1:45pm-3:15pm: Sex-specific effect of ATXN2 rs7969300 polymorphism on age at onset in Spinocerebellar Ataxia type 2

L. Almaguer-Mederos, S. Gispert, D. Almaguer-Gotay, R. Aguilera-Rodríguez, Y. González-Zaldívar, Y. Vázquez-Mojena, D. Cuello-Almarales, D. Palenzuela, G. Auburger (Havana, Cuba)

1:45pm-3:15pm: Share the Care: Supporting Parkinson’s Disease Caregivers Through Peer Mentoring

J. Lee, E. Wallace, C. Niemet, S. Hess, B. Ouyang, J. Wilkinson, D. Hall, J. Chodosh, J. Fleisher (Philadelphia, PA, USA)

1:45pm-3:15pm: Shedding light on the relationship between dyskinesia assessed by a wearable device and impulsive compulsive behaviour in Parkinson’s disease

F. Morgante, A. de Angelis, C. Siri, M. Horne, A. Leake, D. Paviour, M. Edwards, L. Ricciardi (London, United Kingdom)

1:45pm-3:15pm: Short term use of bromocriptine for treatment of Parkinson’s disease during pregnancy

D. Taylor, P. Lewitt (West Bloomfield, MI, USA)

1:45pm-3:15pm: SLC6A4 repeat and single-nucleotide polymorphisms are associated with depression and rest tremor in Parkinson’s disease

X. Zhang, M. Zou, R. Liu, J. Wang, Q. Fan (Wenzhou, China)

1:45pm-3:15pm: Sleep Aspects on Video-Polysomnography in P.A53T SNCA Mutation Carriers

AM. Simitsi, C. Koros, M. Stamelou, D. Papadimitrioy, A. Bougea, I. Pachi, N. Papagiannakis, R. Antonelou, E. Angelopoulou, K. Lourentzos, L. Stefanis, A. Bonakis (Athens, Greece)

1:45pm-3:15pm: Sleep disordered breathing and REM sleep behavior disorder in military Veterans with Parkinson’s disease

A. Sarwar, S. Moore (Houston, TX, USA)

1:45pm-3:15pm: Sleep quality in Turkish patients with Parkinson’s disease

E. Tur, M. Demir, G. Kenangil, F. Domaç (Istanbul, Turkey)

1:45pm-3:15pm: Sleep-related quality of life predictors in Parkinson’s disease

D. Martínez-Roque, S. Castillo-Torres, C. Cerda-Contreras, I. Estrada-Bellmann, B. Chávez-Luévanos (Monterrey, Mexico)

1:45pm-3:15pm: Smartphone software for home monitoring of motor symptoms in Parkinson’s disease – The CloudUPDRS Smartphone Software in Parkinson’s (CUSSP) study

E. Menozzi, A. Jha, R. Oyekan, S. Schreglmann, A. Latorre, E. Mulroy, G. Roussos, C. Stamate, I. Daskalopoulos, J. Rothwell, K. Bhatia (London, United Kingdom)

1:45pm-3:15pm: SNCA G51D missense mutation causing juvenile onset Parkinson’s disease

C. Cooper, J. Goldman, C. Zabetian, I. Mata, J. Leverenz (Chicago, IL, USA)

1:45pm-3:15pm: SNP assessment and gene expression analysis of alpha-synuclein (SNCA), LRRK2 gene and parkin (PRKN) gene in chewing tobacco exposures and find out the risk of Parkinson’s disease

R. Ramachandran, E. E, V. Uthayakumar (Erode, India)

1:45pm-3:15pm: Social Network for the diagnosis of RLS

C. Guerra-Galicia, J. Blanco-Galina (San Luis Potosí, Mexico)

1:45pm-3:15pm: Social work support is associated with better health-related quality of life in late stage Parkinson’s disease

P. Gonzalez-Latapi, M. Rafferty, S. Wu, H. Chen, T. Simuni (Chicago, IL, USA)

1:45pm-3:15pm: Somatization disorder (SD) and Parkinson’s Disease (PD) in Mexican population

M. Rodriguez-Violante, A. Cervantes-Arriaga, A. Polo-Morales, A. Alcocer-Salas (Ciudad de México, Mexico)

1:45pm-3:15pm: Spastic ataxia and pseudo eye-of-the-tiger sign in a familiy with a novel compound heterozygous AFG3L2 mutations

G. Buda, S. Vishnopolska, J. Oliveri, F. Olivieri, G. Biagioli, L. Miquelini, A. Pellene, M. Marti, C. Calandra (Buenos Aires, Argentina)

1:45pm-3:15pm: Spastic Paraplegia Type 64: a Case Series

KCD. Donis, LAP. Paskulin, RBT. Tenório, JWR. Rocha, TOS. Silva, JMS. Saute (Porto Alegre, Brazil)

1:45pm-3:15pm: Spectrum of motor complications in advanced Parkinson’s disease: data from a large Romanian case series evaluated for suitability for device aided therapy

J. Szász, V. Constantin, K. Orbán, L. Bancu, D. Georgescu, J. Szederjesi, A. Rácz, I. Mihály, S. Szatmári (Tirgu Mures, Romania)

1:45pm-3:15pm: Speech impairment as a marker of clinical changes in premanifest Huntington’s disease

J. Chan, Y. Lie, J. Stout, A. Vogel (Melbourne, Australia)

1:45pm-3:15pm: Spinal Cord Stimulation for Severe Restless Leg Syndrome

C. Aquino, M. Zorn, S. Chamberlain, C. Bokat, P. Moretti, D. O'Dell (Salt Lake City, UT, USA)

1:45pm-3:15pm: Spinocerebellar ataxias in Southern Brazil: genotypic and phenotypic evaluation of 213 families

V. Rodrigues, F. Castilho Pelloso, A. Moro, S. Raskin, T. Ashizawa, F. Nascimento, C. Camargo, F. Germiniani, H. Teive (Curitiba, Brazil)

1:45pm-3:15pm: Spinocerebellar degeneration in Minami-Boso area of Japan – A hospital-based retrospective analysis

H. Shibayama, S. Akaike, K. Tajima, R. Takeuchi, F. Katada, S. Sato, T. Fukutaake, T. Matsukawa, H. Ishiura, S. Tsuji (Kamogawa, Japan)

1:45pm-3:15pm: Sporadic progressive ataxia and palatal tremor: A case report

Y. Liu, Y. Chen, Y. Chang (Kaohsiung City, Taiwan)

1:45pm-3:15pm: Startle Reflex as a possible biomarker associated with REM sleep behavior disorders in the prodromal stage of Parkinson’s disease

F. Traccis, M. Puligheddu, M. Figorilli, M. Carta, P. Devoto, G. Giua, ML. Fantini, D. Pani, M. Bortolato, R. Frau (Monserrato, Italy)

1:45pm-3:15pm: STAT-ON: a Wearable Inertial System to Objectively Evaluate Motor Symptoms in Parkinson’s Disease

D. Rodriguez-Martin, C. Pérez-López, A. Samà, M. Pié, A. Català, J. Cabestany, A. Rodríguez-Molinero (Vilanova I Geltrú, Spain)

1:45pm-3:15pm: Steroid responsive chorea in Moyamoya disease: illustrative cases

S. Medarametla, N. Boraiah, S. Swamy, S. Raju (Bangalore, India)

1:45pm-3:15pm: Stiff Limb Syndrome Progressing to Stiff Man Syndrome in a non-diabetic man

T. Ali, D. Ginjupally, Z. Guduru (Lexington, KY, USA)

1:45pm-3:15pm: Stigma and Quality of life in Parkinson’s disease patients on different treatment regimens

O. Vanta, L. Perju-Dumbrava, L. Perju-Dumbrava (Cluj-Napoca, Romania)

1:45pm-3:15pm: Stigma in Egyptian patients with Parkinson’s disease

M. Salim, A. Helmy, A. Shalash, E. Abdel Dayem (Cairo, Egypt)

1:45pm-3:15pm: Stimulation challenge test after STN DBS improves postoperative satisfaction in patients with Parkinson’s Disease

V. Geraedts, J. van Hilten, J. Marinus, A. Mosch, K. Naarding, C. Hoffmann, N. Vd Gaag, MF. Contarino (Leiden, Netherlands)

1:45pm-3:15pm: Study of eye movements as a tool in the diagnosis hereditary ataxias

D. Gasca Saldaña, Y. Sánchez Jimenez, MC. Boll (Mexico City, Mexico)

1:45pm-3:15pm: Study of prevalence of Axis-1 DSM-4 psychiatric disorders in patients with parkinsonism in a rural movement disorder clinic in Western India

D. Desai, S. Singh, S. Desai (Anand, India)

1:45pm-3:15pm: Study on the effect of levodopa administration on serum zinc levels in Parkinson’s disease patients

H. Matsuyama, K. Matsuura, H. Ishikawa, Y. Hirata, N. Kato, A. Niwa, Y. Narita, H. Tomimoto (Tsu, Japan)

1:45pm-3:15pm: Subcortical atrophy is an early event in Huntington’s disease

N. Rocha, L. Latham, O. Charron, G. Papadimitropoulos, G. Colpo, L. Freeman, E. Furr Stimming, A. Teixeira (Houston, TX, USA)

1:45pm-3:15pm: Successful altruistic living kidney donation in a patient with Huntington’s disease

C. Cooper, S. Chen, B. Bernard, J. Goldman (Chicago, IL, USA)

1:45pm-3:15pm: Successful Treatment of Orthostatic Tremor using Perampanel

A. Wadhwa, S. Schaefer (New Haven, CT, USA)

1:45pm-3:15pm: Sudden alopecia secondary to levodopa treatment

N. Garcia Alvarado, N. López Ariztegui, MI. Morales Casado, JC. Segundo Rodríguez, C. Schoendorff Ortega, R. Almansa Castillo, JA. Perez Matos, A. ávila Fernández, C. Marsal Alonso (Toledo, Spain)

1:45pm-3:15pm: Super-urgent liver transplantation for a 62 year old with Wilson’s disease presenting with acute liver failure

S. Shribman, A. Shenoy, W. Griffiths, A. Gimson, T. Warner (London, United Kingdom)

1:45pm-3:15pm: Supportive treatments for Ataxia, a Randomized Control Trial

MIA. Arain (Jamshoro, Pakistan)

1:45pm-3:15pm: Survival estimates for Spinocerebellar Ataxia type 2 based on age at onset and CAG repeats length

L. Almaguer-Mederos, R. Aguilera-Rodríguez, Y. González-Zaldívar, D. Almaguer-Gotay, D. Cuello-Almarales, Y. Vázquez-Mojena, L. Velásquez-Pérez (Holguín, Cuba)

1:45pm-3:15pm: Sustained mutant huntingtin lowering in the brain and cerebrospinal fluid of Huntington disease minipigs mediated by AAV5-miHTT gene therapy

A. Vallès-Sanchez, A. Stam, C. Brouwers, J. Klíma, B. Bohuslavová, R. Pintauro, M. Sogorb-Gonzalez, L. Paerels, V. Fodale, A. Bresciani, Z. Ellederová, B. Blits, J. Motlik, S. van Deventer, M. Evers, P. Konstantinova (Amsterdam, Netherlands)

1:45pm-3:15pm: SWALLOWING VIDEOENDOSCOPY IN PATIENTS WITH PARKINSON’S DISEASE WITH DEEP BRAIN STIMULATION

T. Alves, N. Oliveira, G. Diaféria, M. Palumbo, MG. Ghilardi, E. Fonoff, M. Padovani (São Paulo, Brazil)

1:45pm-3:15pm: Switching entacapone ‘non-responders’ to open-label opicapone: change in absolute OFF-time following the 1-year extension BIPARK-I study

J. Ferreira, A. Lees, W. Poewe, O. Rascol, A. Santos, D. Magalhães, J. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

1:45pm-3:15pm: Sydenham’s chorea: Clinical features and treatment outcome

S. Pandey, P. Rani (New Delhi, India)

1:45pm-3:15pm: Symptomatic treatment of hereditary spastic paraplegias with fampridine: a pilot study

M. Rosário, J. Ferreira, J. Ferro, L. Guedes (Lisbon, Portugal)

1:45pm-3:15pm: Systematic Assessment of 10 diagnostic marker candidates in biological fluids for Parkinson’s disease

B. Mollenhauer, R. Gera, N. Kruse, R. Barbour, W. Zago, S. Schade, B. Otte, C. Trenkwalder (South San Francisco, CA, USA)

1:45pm-3:15pm: Systematic review of Mucuna Pruriens as a treatment for Parkinson’s disease

TH. Boonmongkol, O. Phokaewvarangkul, S. Vimolmangkang, R. Bhidayasiri (Bangkok, Thailand)

1:45pm-3:15pm: Targeted deep sequencing of brain DNA for detection of somatic point mutations in synucleinopathies

M. Leija-Salazar, A. Pittman, K. Mokretar, A. Schapira, C. Proukakis (London, United Kingdom)

1:45pm-3:15pm: Targeted NGS of genes related to hereditary and sporadic NDDs and movement disorders in Italian cohort

G. Dati, M. Picillo, M. Ginevrino, A. Vallelunga, MT. Pellecchia, EM. Valente, P. Barone (Baronissi, Italy)

1:45pm-3:15pm: TELE PARK: Evaluation of the appropriation of a digitally guided self-rehabilitation device for patients with Parkinson’s disease and their professional entourage on a health territory in Brittany, France.

E. Leblong, AL. Roy, B. Fraudet, A. Riou, A. Durufle, JF. Aubry, B. Nicolas, P. Gallien (Rennes, France)

1:45pm-3:15pm: Temporal Emergence of Symptoms and Functional Impairments in Patients With Pantothenate Kinase-Associated Neurodegeneration (PKAN)

F. Greblikas, HA. Jinnah, T. Klopstock, A. Videnovic, C. Burns (San Diego, CA, USA)

1:45pm-3:15pm: Texas Biorepository of Human Induced Pluripotent Stem Cells for Studying Parkinson’s Disease

S. Wijemanne, H. Hong, G. Choudhury, J. Kim, J. Ramirez-Castaneda, A. Papanastassiou, M. Daadi (San Antonio, TX, USA)

1:45pm-3:15pm: TFEB-driven expression prevents neurodegeneration in a multiple system atrophy mouse model

ML. Arotcarena, M. Bourdenx, N. Dutheil, ML. Thiolat, E. Doudnikoff, S. Dovero, A. Ballabio, PO. Fernagut, W. Meissner, E. Bezard, B. Dehay (Bordeaux, France)

1:45pm-3:15pm: The applicability of the Scale for Assessment and Rating of Ataxia (SARA) in toddlers

S. Polet, A. Tadema, S. Hbrahimgel, M. Vanden Berg, M. Kuiper, R. Brandsma, D. Sival (Groningen, Netherlands)

1:45pm-3:15pm: The association parkinsonism and psychotic symptom in neurosyphilis

S. Nafia, N. Louhab, M. Chraa, N. Kissani (Marrakech, Morocco)

1:45pm-3:15pm: The cognitive profiles differ among freezing of gait subtypes in Parkinson’s disease

J. Longhurst, J. Caldwell, A. Ritter, V. Mishra, B. Bluett, M. Landers (Las Vegas, NV, USA)

1:45pm-3:15pm: The comparison of the clinical characteristics and treatment outcomes between non-troublesome and troublesome hemifacial spasm in 270 Thai patients

T. Sangpeamsook, Y. Pitakpatapee, A. Suengtaworn, J. Srikajon, P. Srivanitchapoom (Bangkok, Thailand)

1:45pm-3:15pm: The costs of caregiving in Parkinson’s disease

S. Horn, S. Wu, Y. Dai, F. Cubillos, N. Dahodwala (Miami, FL, USA)

1:45pm-3:15pm: The distinct pattern of movement disorders in Caspr2 and LGI1 antibody associated autoimmune encephalitis

F. Gövert, J. Becktepe, B. Balint, J. Varley, S. Irani, M. Titulaer, J. de Vries, B. Joubert, J. Honnorat, H. Ariño Rodríguez, J. Dalmau, G. Deuschl, F. Leypoldt (Kiel, Germany)

1:45pm-3:15pm: The effect of ADORA2A gene polymorphism on the dyskinesia of Parkinson’s Disease

BC. Ari, F. Mayda Domac, G. Ozgen Kenangil, N. Imamova, A. Cinar Kuskucu (Istanbul, Turkey)

1:45pm-3:15pm: The effect of ATP13A2/PARK9 levels on a-syn spreading in mice brains

T. Tsunemi, Y. Ishiguro, A. Okuzumi, A. Yoroisaka, N. Nukina, N. Hattori (Tokyo, Japan)

1:45pm-3:15pm: The Effect of Gocovri on Motor Aspects of Experiences of Daily Living: Analyses of MDS-UPDRS Part II Data from a Phase 3 Program

R. Hauser, D. Kremens, D. Chernick, R. Patni, J. Hubble (Tampa, FL, USA)

1:45pm-3:15pm: The effect of intranasal oxytocin in patients with functional motor symptoms: an open label case series

B. Demartini, D. Goeta, D. Di Benedetto, A. Casiraghi, D. Mazza, A. Priori, O. Gambini (Milano, Italy)

1:45pm-3:15pm: The effect of levodopa on speech in advanced Parkinson’s Disease: acoustic analysis and correlation with motor features and dyskinesia

F. Cavallieri, C. Budriesi, A. Gessani, V. Fioravanti, E. Menozzi, S. Contardi, F. Valzania, F. Antonelli (Reggio Emilia, Italy)

1:45pm-3:15pm: The effect of levodopa-carbidopa intestinal gel relative to optimized medical treatment on dyskinesia: Design and baseline characteristics for an open-label, randomized multicenter 12-week study in advanced Parkinson’s disease patients (DYSCOVER Study)

E. Alvarez, C. Spanaki, E. Pekkonen, L. Manzanares, Y. Liu, O. Sánchez-Soliño, L. Barbato (Elche, Spain)

1:45pm-3:15pm: The Effectiveness of Rehabilitation Using Honda Walking Assist in Parkinson’s Disease Patients; The Gait Analysis by a Markerless Motion Capture System

N. Kawashima, M. Iijima, T. Hamano, K. Nagami, M. Isogai, M. Komachi, T. Furukado, A. Kumon, K. Miyashita, A. Sato, K. Hasegawa (Fujisawa, Japan)

1:45pm-3:15pm: The effectiveness of two-weeks self-stretch based on post-isometric relaxation in Parkinson’s disease patients

A. Zimin, D. Yusupova (Moscow, Russian Federation)

1:45pm-3:15pm: The Effects of Apomorphine infusion on Head ptosis, a case report

O. Skogar (Stockholm, Sweden)

1:45pm-3:15pm: The effects of exercise focused on ankle joint movement for postural instability in patients with Parkinson’s disease: A pilot study

R. Taniuchi, T. Harada, T. Makino, S. Togashi, K. Matsukawa, T. Hoshii (Otake, Japan)

1:45pm-3:15pm: The Efficacy and Safety of Gocovri Based on Age: Special Population Analyses of a Phase 3 Study Program

R. Pahwa, C. Tanner, L. Zhang, R. Johnson, C. Leroue, R. Patni (Kansas City, KS, USA)

1:45pm-3:15pm: The evaluation of exosomes as a biomarker of Parkinson’s disease

Y. Ishiguro, T. Tsunemi, A. Yoroisaka, N. Hattori (Tokyo, Japan)

1:45pm-3:15pm: The First Chinese Case of Fragile X-associated Tremor/ Ataxia Syndrome :an underestimated disease in China

C. Zhao (Jinan, China)

1:45pm-3:15pm: The French NS-PARK/FCRIN network: a 5-year balance sheet

O. Rascol, JC. Corvol, F. Durif, E. Delappina, V. Chaigneau, JP. Azulay, P. Couratier, L. Defebvre, D. Devos, P. Damier, A. Doe, S. Drapier, S. Frismand, C. Geny, C. Giordana, JL. Houeto, P. Krystkowiak, E. Magnin, D. Maltete, W. Meissner, T. Moreau, E. Moro, P. Remy, C. Thiriez, S. Thobois, C. Tranchant, F. Viallet, M. Vidailhet (Paris, France)

1:45pm-3:15pm: The Frequency, Causes and Risk Factors of Discontinuation of Dopamine Agonists in Parkinson’s Disease Patients

N. Durmaz çelik, M. Kuzu Kumcu, S. Bostan, E. Yiğit Tekkanat, S. özkan (Eskisehir, Turkey)

1:45pm-3:15pm: The Genetic Basis of paediatric movement disorders: experience from the SYNaPS Study

R. Maroofian, V. Salpietro, H. Houlden (London, United Kingdom)

1:45pm-3:15pm: The Huntington’s Disease-Behavioral Questionnaire (HD-BQ): A New Screening Tool for Behavioral Disturbances in HD

J. Corey-Bloom, S. Aboufadel, I. Beltran-Najera, C. Snell, M. Williams, P. Gilbert (La Jolla, CA, USA)

1:45pm-3:15pm: The impact of clinical care coordination on patient quality of life in the Atypical Parkinsonism clinic

M. Harris, J. Donnelly, L. Massey, B. Ghosh (Southampton, United Kingdom)

1:45pm-3:15pm: The Impact of Parkinson’s Disease to Quality of Life

R. Pinzon, RDL. Sanyasi (Yogyakarta, Indonesia)

1:45pm-3:15pm: The Impact of Progressive Supranuclear Palsy (PSP) Disease Severity on Caregivers

T. Xie, X. Ye, J. de Courcy, K. Golden, Y. Bao, J. Zamudio, L. Chiodo, J. Morgan (Mettawa, IL, USA)

1:45pm-3:15pm: The influence of gender, associated neurological disorder and motive for polysomnography (PSG) in the manifestations of REM sleep behaviour disorder (RBD)

P. Bugalho, M. Salavisa (Lisbon, Portugal)

1:45pm-3:15pm: The influence of relationship quality on health-related quality of life when coping with Parkinson’s disease: a mediation analysis

M. Karlstedt, SM. Fereshtehnejad, D. Aarsland, J. Lökk (Huddinge, Sweden)

1:45pm-3:15pm: The longevity gene Klotho and its CSF protein profiles as modifier for Parkinson´s disease in a longitudinal study

M. Zimmermann, S. Lerche, C. Schulte, I. Wurster, G. Machetanz, C. Deuschle, A. Hauser, T. Gasser, D. Berg, E. Schleicher, W. Maetzler, K. Brockmann (Tuebingen, Germany)

1:45pm-3:15pm: The mGlu2/3 orthosteric antagonist LY-341,495 abolishes the anti-dyskinetic and anti-psychotic effects of the mGlu2 positive allosteric modulator LY-487,379 in the MPTP-lesioned marmoset

A. Hamadjida, S. Nuara, J. Gourdon, P. Huot (Montreal, QC, Canada)

1:45pm-3:15pm: The PLA2G6 Gene Mutation Causes Parkinson’s Disease: A Case Report

L. Kou, T. Wang, L. Liu, GX. Zhang (Wuhan, China)

1:45pm-3:15pm: The potential modifier effect of C9orf72 DNA methylation in C9ORF72 carriers

JM. Laffita-Mesa, CH. Kreidy, M. Paucar, P. Svenningsson (Stockholm, Sweden)

1:45pm-3:15pm: The Preferences of Patients with Parkinson’s Disease and their Family Members for Place of End-of-Life Care

R. Kozáková, R. Bužgová, M. Bar, M. škutová, P. Ressner, P. Bártová (Ostrava, Czech Republic)

1:45pm-3:15pm: The progression rate of sporadic adult-onset cerebellar ataxia : 1-year follow up study

PW. Ko, HW. Lee, K. Kang (Daegu, Republic of Korea)

1:45pm-3:15pm: The relationship between sound pressure level (SPL) and speech intelligibility in Parkinson’s disease following intensive speech treatment: LSVT LOUD and LSVT ARTIC

L. Ramig, E. Levy, M. Chang, K. Forrest, G. Moya-Gale (Boulder, CO, USA)

1:45pm-3:15pm: The relationship between the motor onset and the asymmetry of motor symptoms in patients with Parkinson’s Disease

Y. Trufanov, N. Svyrydova, V. Svistun, I. Harkava, H. Bondarenko, N. Zhhilova (Kyiv, Ukraine)

1:45pm-3:15pm: The Representativity of PSP patients included in clinical trials

LL. Mariani, R. Guimarães-Costa, D. Grabli, B. Letoullec, F. Cormier, B. Degos, B. Dubois, M. Vidailhet, L. Lacomblez, JC. Corvol (Paris, France)

1:45pm-3:15pm: The Roche HD Natural History Study – an external comparator by design

G. Hooper, G. Palermo, F. Hlavac, C. Finnegan, E. Frick, L. Boak, R. Doody, S. Schobel (Welwyn Garden City, United Kingdom)

1:45pm-3:15pm: The role of attention in functional movement disorders

A. Huys, P. Haggard, K. Bhatia, M. Edwards (London, United Kingdom)

1:45pm-3:15pm: The role of dysfunctional attentional processing in isolated minor hallucinations in Parkinson’s disease

H. Bejr-Kasem, J. Pagonabarraga, S. Martínez-Horta, F. Ruiz-Martínez, F. Bernasconi, F. Sampedro, J. Marín-Lahoz, A. Horta-Barba, I. Aracil-Bolaños, B. Pascual-Sedano, O. Blanke, J. Kulisevsky (Barcelona, Spain)

1:45pm-3:15pm: The Role of Dysfunctional BDNF in Remodeling the Parkinsonian Striatum Following Dopamine Neuron Grafting in CRISPR rs6265 Rats

N. Mercado, J. Stancati, T. Collier, C. Sortwell, I. Sandoval, C. Kemp, B. Daley, M. Duffy, K. Steece-Collier (Grand Rapids, MI, USA)

1:45pm-3:15pm: The role of genetic modifiers in Parkinson’s disease-associated LRRK2-G2019S mutation

T. Courtin, G. Ianello, H. Bertrand, S. Benromdhan, C. Tesson, C. Mhiri, JC. Corvol, S. Lesage, A. Brice (Paris, France)

1:45pm-3:15pm: The role of LRP10 mutations in Parkinson’s Disease and Dementia with Lewy Bodies

A. Manini, E. Monfrini, L. Straniero, M. Vizziello, G. Franco, S. Duga, A. Di Fonzo (Milan, Italy)

1:45pm-3:15pm: The role of stress-related genes and childhood trauma in the clinical phenotype of Functional Movement Disorders

P. Spagnolo, C. Maurer, G. Norato, C. Hodgkinson, M. Hallett (Bethesda, MD, USA)

1:45pm-3:15pm: The role of the cerebellum in the pathophysiology of cortical myoclonus: a neurophysiological study.

A. Latorre, L. Rocchi, G. Paparella, N. Manzo, A. Berardelli, J. Rothwell, K. Bhatia (London, United Kingdom)

1:45pm-3:15pm: The role of X-chromosome inactivation in the penetrance of X-linked dystonia-parkinsonism in women

CJ. Reyes, R. Ardicoglu, R. Rosales, RD. Jamora, CC. Diesta, K. Grütz, H. Pawlack, A. Domingo, C. Klein, A. Westenberger, N. Brüggemann (Lübeck, Germany)

1:45pm-3:15pm: The Sequelae of Kernicterus

Z. Aldaajani, E. Ali (Dhahran, Saudi Arabia)

1:45pm-3:15pm: The severity of motor dysfunctions and autonomic dysfunctions are not correlated in multiple system atrophy

T. Yamamoto, Y. Yamanaka, A. Sugiyama, S. Hirano, T. Uchiyama, M. Asahina, R. Sakakibara, S. Kuwabara (Chiba, Japan)

1:45pm-3:15pm: The short-term effect of combined facial exercise with botulinum toxin A injection in clinical practice in Thai patients with hemifacial spasm: A randomized controlled pilot crossover study

P. Soontrapa, Y. Pitakpatapee, A. Suengtaworn, J. Srikajon, T. Sangpeamsook, P. Srivanitchapoom (Bangkok, Thailand)

1:45pm-3:15pm: The statement about the effectiveness of non-medication methods in the complex treatment of spasticity of different genesis

O.. Tondiy (Kharkiv, Ukraine)

1:45pm-3:15pm: Think of Gluten Ataxia:A rare but potentially reversible cause of progressive neurological disorder

R. Mathur, K. Lal, A. Kyi (Grantham, United Kingdom)

1:45pm-3:15pm: Tongue Myokymia and Earache as a unique presentation Associated with Local Tongue Pathology: A Case Report and Review of Literature

N. Merghany, W. Ibrahim, S. Nasr (Cairo, Egypt)

1:45pm-3:15pm: TPK1 mutation induced childhood onset dystonia and dyskinesia

L. Au, A. Chan, C. Lau, V. Mok (Hong Kong, Hong Kong)

1:45pm-3:15pm: Transcranial Direct Current Stimolation (tDCS) on PD Patients with Freezing of Gait: Preliminary Findings

S. Scalise, G. Di Lazzaro, M. Alwardat, NB. Mercuri, M. Patera, G. Saggio, T. Schirinzi, A. Pisani (Rome, Italy)

1:45pm-3:15pm: Transcranial sonography in carriers of Gaucher disease

F. Omrani, N. Mohammadzade, M. Rohani, Z. Omrani, B. Zamani (Tehran, Islamic Republic of Iran)

1:45pm-3:15pm: Translating Preclinical Data to a Human Equivalent Dose for AMT-130 AAV Gene Therapy for Early Manifest Huntington’s Disease

M. Evers, M. de Haan, A. Valles-Sanchez, E. Sawyer, S. Gill, R. Roos, S. van Deventer, P. Konstantinova, J. Higgins (Amsterdam, Netherlands)

1:45pm-3:15pm: Treating Depression in Parkinson’s Disease: a Systematic Literature Review

C. Farrell, T. Yousaf, M. Politis (London, United Kingdom)

1:45pm-3:15pm: Treatment monitoring using objective and frequent digital testing in the D1PAM (LY3154207) phase 1B Parkinson’s disease clinical trial

J. Wang, C. Battioui, Y. Li, A. Calvin, L. Wu, A. Romano, B. Miller (Indianapolis, IN, USA)

1:45pm-3:15pm: Treatment of dopaminergic augmented RLS with Ecopipam, A D1 specific antagonist: an exploratory placebo controlled cross-over trial

O. Titlayo, W. Ondo (Houston, TX, USA)

1:45pm-3:15pm: Treatment of subcutaneous nodules after subcutaneous infusion of apomorphine

RWK. Borgemeester, GFH. Diercks, T. van Laar (Groningen, Netherlands)

1:45pm-3:15pm: Tremor and parkinsonism in Chromosomopathies – a systematic review

V. Carvalho, L. Guedes (Matosinhos, Portugal)

1:45pm-3:15pm: Trends in first line therapy for PD in Wales: A 16 year observational study

K. Orayj, A. Lacey, A. Akbari, O. Pickrell, E. Lane (Cardiff, United Kingdom)

1:45pm-3:15pm: Trihexyphenidyl-induced chorea in a patient with spastic torticollis: A case report

H. Kawasaki, O. Oota, S. Seo, K. Kei, T. Mistufuji, K. Takahashi, N. Tamura, T. Yamamoto (Moroyama, Japan)

1:45pm-3:15pm: Tumor Pathology in Patients with Huntington’s Disease in a Specialized Center of Buenos Aires, Argentina (Preliminary Data)

D. Dias, E. Gatto, J. Etcheverry, M. Cesarini, G. da Prat, F. Peralta Calderon (Capital Federal, Argentina)

1:45pm-3:15pm: Turkish Version of the Johns Hopkins Restless Leg Syndrome Quality of Life Questionnaire (RLS-QOL): Validity and Reliability Study

S. Güler, N. Turan (Edirne, Turkey)

1:45pm-3:15pm: Two heterozygous SNYE1 mutations presenting as spasmodic adductor dysphonia, task-specific jaw dystonia, generalized dystonia, and ataxia in a Jamaican man

E. Feinstein, P. Surathi (Newark, NJ, USA)

1:45pm-3:15pm: Two novel ANO10 mutations causing adult-onset autosomal recessive spinocerebellar ataxia

B. Bergmans, S. Donatello, M. Pandolfo, C. Depondt (Brugge, Belgium)

1:45pm-3:15pm: Two-year outcome of autologous peripheral nerve grafting to the substantia nigra at the time of DBS surgery in patients with Parkinson’s disease

C. van Horne, J. Quintero, J. Slevin, J. Gurwell, Z. Guduru, A. Welleford, N. El Seblani, G. Gerhardt (Lexington, KY, USA)

1:45pm-3:15pm: Understanding the Needs and Concerns of Newly Diagnosed People with Parkinson’s Disease

V. Todaro, M. Feeney, A. Diaz, S. Rosenfeld, J. Gannon (New York, NY, USA)

1:45pm-3:15pm: Unilateral delivery of cell-based therapy to the putamen and substantia nigra in patients with Parkinson’s disease who have an existing DBS system

J. Quintero, J. Slevin, Z. Guduru, J. Gurwell, G. Gerhardt, C. van Horne (Lexington, KY, USA)

1:45pm-3:15pm: Update from the international MDSGene initiative: International team science to perform genotype-phenotype correlations for hereditary movement disorders

S. Petkovic, S. Schaake, J. Huang, H. Madoev, A. Rasheed, K. Lohmann, C. Klein, C. Marras (Luebeck, Germany)

1:45pm-3:15pm: Use digital sensor and deep learning to evaluate motor performance in the D1PAM (LY3154207) phase 1B Parkinson’s disease clinical trial

Y. Li, Y. Guan, J. Wang, A. Calvin, J. Kyle, B. Miller (Indianapolis, IN, USA)

1:45pm-3:15pm: Use of Inappropriate Antipsychotics Among US Long-Term Care Residents with Parkinson’s Disease Psychosis

D. Kremens, V. Abler, S. Andes, N. Rashid, A. Shim (Philadelphia, PA, USA)

1:45pm-3:15pm: Use of syringe driver in End of Life Care in Parkinson’s Disease (PD)

N. Butt, M. Khwaja, A. Chatterjee (Reading, United Kingdom)

1:45pm-3:15pm: Usefulness of Heart Rate Variability to Identify the Risk of Falling in Huntington’s Disease

C. Terroba-Chambi, D. Vigo, M. Merello (Buenos Aires, Argentina)

1:45pm-3:15pm: Using cognitive computing to identify existing drugs with potential to stabilize mitophagy pathways associated with Parkinson’s Disease

N. Visanji, N. Moskal, G. Shi, A. Lacoste, S. Spangler, P. Lewis, A. Mcquibban (Toronto, ON, Canada)

1:45pm-3:15pm: Using functional status to aid interpretation of cUHDRS scores in patients with Huntington’s disease

D. Trundell, G. Palermo, J. Long, B. Leavitt, S. Schobel, S. Tabrizi (Welwyn Garden City, United Kingdom)

1:45pm-3:15pm: Using whole genome sequencing and intronic sequence analysis to identify pathogenic variants in Parkin-related Parkinson’s Disease

R. Davis, K. Kumar, F. Edema-Hildebrand, J-S. Park, B. Koentjoro, V. Gayevskiy, M. Cowley, N. Blair, C. Sue (St Leonards, Australia)

1:45pm-3:15pm: Utility of a smartphone app in discretely assessing and monitoring symptoms of Parkinson’s disease

N. Shaafi Kabiri, A. Best, S. Johnson, B. Ho, G. Eden, B. Dupee, M. Fedorovsky, J. Severson, D. Amato, B. Severson, J. Bhangu, J. Cosman, M. Erb, K. Thomas (Boston, MA, USA)

1:45pm-3:15pm: Utilization of Monotherapy and Combination Therapies in Advanced Parkinson Disease Patients During Levodopa-Carbidopa Intestinal Gel Treatment from the COSMOS Study

A. Fasano, JC. Parra, T. Gurevich, R. Jech, N. Kovács, P. Svenningsson, J. Szász, L. Bergmann, A. Johnson, O. Sanchez-Soliño, Z. Tang, L. Vela-Desojo (Toronto, ON, Canada)

1:45pm-3:15pm: Utilization patterns of Amantadine in Parkinson’s Disease patients enrolled in the French COPARK study

S. Perez-Lloret, L. Negre-Pages, P. Damier, A. Delval, P. Derkinderen, A. Destée, W. Meissner, F. Tison, O. Rascol (Bordeaux, France)

1:45pm-3:15pm: Validation of Acoustic Analysis of Swallowing as a Method of Screening for Orofaringeal Dysfunction at Parkinson

RSS. Santos, BSZ. Zeigelboim, GSS. Silva, MCN. Nunes, HGT. Teive (Curitiba, Brazil)

1:45pm-3:15pm: Variants in the beta-Glucocerebrosidase A (GBA) gene in German patients with Parkinson´s disease

A. Deutschlander, A. Wernick, R. Walton, A. Soto, O. Ross, Z. Wszolek (Jacksonville, FL, USA)

1:45pm-3:15pm: Vortioxetine treatment of depression in Parkinson’s disease

M. Russo, C. Carrarini, F. Dono, L. Ferri, M. Di Pietro, M. Onofrj (Chieti, Italy)

1:45pm-3:15pm: Wearable sensor use and monitoring effect of dopamine replacement therapy on motor parameters in a real life clinical setting

A. Podlewska, D. van Wamelen, A. Sauerbier, V. Leta, D. Trivedi, M. Parry, K. Ray Chaudhuri (Lodnon, United Kingdom)

1:45pm-3:15pm: Wearable versus marker-free technologies: does it matter for clinical gait analysis?

K. Otte, D. Drebinger, H. Röhling, T. Vater, D. Kroneberg, M. Voigt, B. Kayser, S. Mansow-Model, AU. Brandt, F. Paul, A. Lipp, T. Schmitz-Hübsch (Berlin, Germany)

1:45pm-3:15pm: WES analysis of Parkinson’s disease patients with Cancer

Y. Gao, G. Wang, X. Xie (Shanghai, China)

1:45pm-3:15pm: What connectivity tells us about neurodegeneration in Huntington disease? A fMRI study

P. de Azevedo, M. Nogueira, L. Ribeiro, B. de Campos, R. Guimarães, L. Piovesana, F. Cendes, I. Lopes-Cendes, C. Yasuda (Campinas, Brazil)

1:45pm-3:15pm: What do medical students think about functional movement disorders?

JB. Paredes, E. Villalba, A. Canovas, JL. Sendon, P. Torre, S. Argos, S. Madrona, J. Poles, V. Hristova, L. García, JC. Castrillo, I. Moreno (Madrid, Spain)

1:45pm-3:15pm: What patients need – a qualitative analysis of consultations prior to deep brain stimulation in patients with Parkinson’s disease

R. Dano, JN. Petry-Schmelzer, J. Steffen, G. Fink, M. Barbe (Cologne, Germany)

1:45pm-3:15pm: Whole Exome Sequencing Identifies a Homozygous POLG2 Missense Variant in an adult patient presenting with movement disorders and Mitochondrial DNA Depletion

P. Dosekova, V. Habalova, M. Skirkova, V. Han, A. Mosejova, Z. Gdovinova, M. Skorvanek, R. Ploski (Kosice, Slovakia)

1:45pm-3:15pm: Wide distribution of alpha-synuclein oligomers in Creutzfeldt-Jakob disease detected by a novel proximity ligation assay

R. Valenti-Azcarate, I. Martinez-Valbuena, C. Caballero, I. Marcilla Garcia, G. Marti, M. Carmona-Abellan, M. Tuñon-Alvarez, MR. Luquin-Piudo (Pamplona, Spain)

1:45pm-3:15pm: Wilson disease: a systematic review and meta-analysis in phenotype – genotype correlations

M. Ruiz-Lopez, A. Abrahao, ME. Freitas, J. Trinh, S. Fox (Madrid, Spain)

1:45pm-3:15pm: Wislon disease: clinical specificities of the disease course under normal ceruloplasmin in the blood, a clinical case from Kyrgyzstan

N. Chekeeva (Bishkek, Kyrgyzstan)

1:45pm-3:15pm: X-chromosomal Dystonia-Parkinsonism: a systematic review of published and unpublished clinical data

M. Pauly, M. Ruiz López, H. Madoev, R. Rosales, C. Diesta, R. Jamora, S. Petkovic, N. Brüggemann, A. Westenberger, C. Klein, A. Domingo (Lübeck, Germany)

1:45pm-3:15pm: Yerba mate tea (Ilex paraguariensis) exerts a neuroprotective effect on intrastriatal 6-OHDA-lesioned mice model of Parkinson’s disease

I. Taravini, G. Gomez, L. Tribbia, A. Cura, R. Rivero, M. Bernardi, J. Ferrario, B. Baldi-Coronel, O. Gershanik, E. Gatto (Gualeguaychú, Argentina)

1:45pm-3:15pm: “Best practice” guidelines for the collection and analysis of speech data in patients with Parkinson’s Disease (PD).

E. Tripoliti, L. Ramig (Boulder Colorado, CO, USA)

1:45pm-3:15pm: “Familial imprint” of Parkinson disease: the siblings’ cohort of PROPAG-AGEING

L. Baldelli, F. Provini, S. Schade, S. Jesús, P. Gómez-Garre, L. Sambati, S. Schreglmann, G. Calandra Buonaura, C. Halsband, M. Carrion, K. Bhatia, P. Mir, P. Cortelli, B. Mollenhauer, C. Trenkwalder, PPG. Propag-Ageing Consortium (Bologna, Italy)

1:45pm-3:15pm: “UPDRS-meter” – a digital and automatic UPDRS scoring application

Z. Yekutieli, S. Baer-Hassin, V. Livneh, T. Fay-Karmon, S. Israeli-Korn, G. Yahalom (Zichron Yaakov, Israel)

1:45pm-3:15pm: [18F] FDG-PET findings associated with cognitive impairment if multiple system atrophy

KW. Park, NR. Choi, SY. Jo, SJ. Kim, YJ. Park, SJ. Chung, CS. Lee (Seoul, Republic of Korea)

1:45pm-3:15pm: [18F]THK-5351 PET Imaging in Progressive Supranuclear Palsy Concomitant with Cerebellar Ataxia in Early-stage: Clinicopathological Observations

Y. Saitoh, K. Komatsu, E. Imabayashi, A. Moriya, H. Matsuda, Y. Saito, Y. Takahashi (Tokyo, Japan)

1:45pm-3:15pm: 123I-FP-CIT SPECT imaging in early PD patients versus mid and late onset PD: Longitudinal data from the PPMI study

C. Koros, A. Simitsi, M. Stamelou, A. Prentakis, A. Bougea, I. Pachi, D. Papadimitriou, I. Beratis, N. Papagiannakis, E. Angelopoulou, S. Papageorgiou, X. Geronicola Trapali, L. Stefanis (Athens, Greece)

1:45pm-3:15pm: 131-MIBG is less promising in differentiating Parkinson’s disease from other parkinsonism for early onset patients

D. Xu, WJ. Zhu, H. Wang, L. Huo (Beijing, China)

1:45pm-3:15pm: A case of osmotic demyelination syndrome presenting parkinsonism affected by blood alcohol concentration change

M. Kondo, A. Unaki, T. Kimura (Tokyo, Japan)

1:45pm-3:15pm: A case of severe blepharospasm after psoralen and ultraviolet A treatment

P. Ferreira, S. Moreira (Senhora da Hora, Portugal)

1:45pm-3:15pm: A characterization of the ADL-level in daily life with Parkinson`s Disease based on objective measurements and subjective experiences.

T. Thomsen, T. Kjær, L. Jørgensen, A. Haahr, K. Winge (Roskilde, Denmark)

1:45pm-3:15pm: A cortical signature of motor response to dopaminergic therapy in Parkinson’s disease

J. Baarbé, K. Lizarraga, J. Saravanamuttu, U. Saha, R. Chen (Toronto, ON, Canada)

1:45pm-3:15pm: A First in Human Study of PBT434, a Novel Small Molecule Inhibitor of Alpha-Synuclein Aggregation

D. Stamler, M. Bradbury, C. Wong, E. Offman (Newark, CA, USA)

1:45pm-3:15pm: A flowchart algorithm for the neurologist to discuss and attend sexual issues in Parkinson’s disease

G. Bronner, S. Hassin-Baer, AD. Korczyn, T. Gurevich (Ramat-Gan, Israel)

1:45pm-3:15pm: A general impaired-rhythm system underpins oro-motor, manual, and gait rhythmic disturbances in Parkinson’s disease

F. Puyjarinet, V. Bégel, C. Gény, V. de Cock, V. Driss, M. Cuartero, S. Pinto, S. Dalla Bella (Montpellier, France)

1:45pm-3:15pm: A genome wide pleiotropic approach to identify the genetic architecture of multiple system atrophy and its interaction with Parkinson’s disease

A. Ashokkumar Sreelatha, A. Shadrin, C. Blauwendraat, O. Frei, T. Gasser, G. Wenning, A. Singleton, H. Houlden, S. Scholz, O. Andreassen, M. Sharma (Tübingen, Germany)

1:45pm-3:15pm: A hexanucleotide repeat within a SINE-VNTR-Alu retrotransposon inserted in TAF1 modifies expressivity of X-linked dystonia-parkinsonism

A. Westenberger, C. Reyes, G. Saranza, V. Dobricic, H. Hanssen, A. Domingo, B-H. Laabs, A. Rakovic, P. Bauer, A. Rolfs, A. Münchau, L. Ozelius, R.. Jamora, R. Rosales, C. Diesta, K. Lohmann, I. König, N. Brüggemann, C. Klein (Kalakhang Maynila, Philippines)

1:45pm-3:15pm: A Lewy body disease of widely confirmed Lewy bodies in the cerebral cortexes including the occipital lobe without pathological changes in the hippocampal CA2/3 region

M. Ryo, K. Hasegawa, I. Saitoh, S. Yagishita (Tokyo, Japan)

1:45pm-3:15pm: A Neuroscientific approach for MCI Characterization using a Motor and Cognitive Dual-Task

G. Mancioppi, F. Fiorini, M. Timpano Sportiello, E. Rovini, F. Cavallo (Pontedera, Italy)

1:45pm-3:15pm: A novel heterozygous ANO3 mutation responsible for myoclonus-dystonia

C. Laurencin, E. Broussolle, T. Danaila, M. Anheim, J. Chelly, S. Thobois (Lyon, France)

1:45pm-3:15pm: A novel intermittent control paradigm to investigate oscillatory neuronal activity in the STN

M. Boca, N. Ray, C. Kobylecki, J. Evans, I. Loram, M. Silverdale (Manchester, United Kingdom)

1:45pm-3:15pm: A possible case of prodromal DLB with prominent hallucinations, autonomic dysfunction, and REM behavior disorder but absence of cognitive impairment

K. Amodeo (Rochester, NY, USA)

1:45pm-3:15pm: A protocol to probe the mechanisms underlying disordered sub-cortical processing in cervical dystonia using emotional faces.

S. Purcell, J. Monahan, I. Ndukwe, O. Killian, S. Narasimham, M. Perez Denia, O. Duggan, S. O Riordan, M. Hutchinson, R. Reilly (Dublin, Ireland)

1:45pm-3:15pm: A software framework for objective and quantitative audio-analysis of Embouchure Dystonia (ED)

M. Perez Denia, O. Killian, I. Ndukwe, S. Narasimham, S. O’Riordan, M. Hutchinson, R. B. Reilly (Dublin, Ireland)

1:45pm-3:15pm: A study of factors causing psychiatric abnomalities in patients with Parkinson’s disease

T. Syed, R. Borgohain (Hyderabad, India)

1:45pm-3:15pm: A Thorough QT Study of Apomorphine Sublingual Film in Patients With Parkinson’s Disease Complicated By “OFF” Episodes

F. Stocchi, K. Wilks, E. Peckham, M. de Pandis, K. Sciarappa, F. Agbo, R. Kleiman, D. Blum, B. Navia (Rome, Italy)

1:45pm-3:15pm: Aberrant structural connectivity of the executive network in Progressive Supranuclear Palsy

S. Prasad, A. Rajan, S. Mangalore, J. Saini, M. Ingalhalikar, P. Pal (Bangalore, India)

1:45pm-3:15pm: Abnormal frontal theta and beta oscillations during gait observation in Parkinson’s disease

AS. Singh, AIE. Espinoza, NN. Narayanan (Iowa City, IA, USA)

1:45pm-3:15pm: Abnormal Intracortical Facilitation in patients of Parkinson’s disease with REM Sleep Behavior Disorder

A. Bhattacharya, N. Kamble, R. Yadav, PK Pal

1:45pm-3:15pm: Abnormal metabolic brain network in multiple system atrophy and progressive supranuclear palsy: a replication on a new European cohort

T. Rus, E. Rebec, P. Tomše, A. Studen, M. Grmek, C. Tang, D. Eidelberg, M. Trošt (Ljubljana, Slovenia)

1:45pm-3:15pm: Abnormal respiratory rate and patterns in MSA

E. Driver-Dunckley, B. Goodman (Scottsdale, AZ, USA)

1:45pm-3:15pm: Abnormal Sensorimotor Processing in Cervical Dystonia in Functional Magnetic Resonance Imaging

L. Hvizdosova, P. Hok, D. Lachmanova, M. Nevrly, P. Otruba, P. Hlustik, P. Kanovsky (Olomouc, Czech Republic)

1:45pm-3:15pm: Abnormal thalamo-cortical functional connectivity patterns in Gilles de la Tourette Syndrome: a seed-based resting state fMRI study

L. Zapparoli, M. Porta, F. Devoto, N. Tedone, D. Servello, E. Paulesu (Milan, Italy)

1:45pm-3:15pm: AbobotulinumtoxinA Using 2 mL Dilution Maintains Durable Functional Improvements Across Multiple Treatment Cycles

K. Dashtipour, J. Otto, P. Maisonobe, L. Bahroo, D. Truong, R. Trosch (Loma Linda, CA, USA)

1:45pm-3:15pm: AbobotulinumtoxinA: evidence for long duration of response

K. Foster, A. Lysandropoulos, P. Picaut (Abingdon, United Kingdom)

1:45pm-3:15pm: Accuracy of clinical diagnosis of atypical parkinsonism: comparison of consensus clinical criteria with MRI criteria

D. Gwendoline, G. David, D. Bertrand, L. Stephane, C. Florence (Paris, France)

1:45pm-3:15pm: Accuracy of preoperative microelectrode trajectory planning in patients treated with DBS – an ongoing study

S. Ibrulj, S. Delalić, MB. Benedičič, D. Georgijev, DF. Flisar, M. Trošt (Ljubljana, Slovenia)

1:45pm-3:15pm: Activity of Neurosteroid GABAA Positive Allosteric Modulators in Preclinical Harmaline Model for Essential Tremor

R. Hammond, A. Robichaud, J. Doherty, F. Salituro, M. Quirk, M. Ackley, B. Farley, S. Mctighe, T. Kazboda, A. Althaus, C. Maciag, M. Blanco, S. Gee (Cambridge, MA, USA)

1:45pm-3:15pm: Acupuncture as Adjuvant Therapy for the Management of Cervical Dystonia

D. Bega, K. Park, A. Grimone, F. Lin, M. Ring (Chicago, IL, USA)

1:45pm-3:15pm: Acute hemichorea caused by infarction over globus pallidus interna

YP. Chang (Kaohsiung, Taiwan)

1:45pm-3:15pm: Acute Onset Parkinsonism Secondary to West Nile Virus Encephalitis

M. Purbaugh, F. Ali, T. Diesing, A. Hellman (Omaha, NE, USA)

1:45pm-3:15pm: Acute parkinsonism following an obstructive hydrocephalus and a ventriculoperitoneal shunt revision: a case report

J. Majuri, HR. Maanpää, A. Kotkansalo, J. Korpela, J. Joutsa (Lahti, Finland)

1:45pm-3:15pm: ADL impairment and quality of life in patients with essential tremor

P. Reker, S. Schnitzler, T. Thies, A. Josten, J. Becker, J. Steffen, J. Wirths, H. Dafsari, V. Visser-Vandewalle, M. Barbe (Cologne, Germany)

1:45pm-3:15pm: Adult-onset neuronal intranuclear inclusion disease presenting with intractable resting and intention tremor

YY. Chang, MY. Lan, YF. Chen, JS. Liu (Kaohsiung, Taiwan)

1:45pm-3:15pm: African American patients with Parkinson’s disease: A hospital-based study compared to Caucasian patients

T. Xie, D. Lee, M. Padmanaban, H. Yu, W. Kang, J. Johnson, J. Alshaikh, C. Yuen, M. Burns, F. Qian, B. Chiu (Chicago, IL, USA)

1:45pm-3:15pm: After-effects Of Transcranial direct current stimulation (tDCS) On Hand Biomechanics In A Patient With Secondary Dystonia

F. Yadolahi, M. Abedi (Tehran, Islamic Republic of Iran)

1:45pm-3:15pm: Age of onset and diagnosis of Essential Tremor

F. Jamal, S. Moore, G. Jackson, A. Sarwar (Houston, TX, USA)

1:45pm-3:15pm: Algorithm of a differentiated approach to the management of patients with tic hyperkinesis

S. Munasipova, Z. Zalyalova (Kazan, Russian Federation)

1:45pm-3:15pm: Alpha-synuclein expression and cytokine profile in blood of patients with Lewy body dementias

T. Usenko, M. Nikolaev, A. Bezroukova, A. Emelyanov, E. Gracheva, I. Milukhina, Y. Belceva, N. Zalutskaya, A. Timofeeva, S. Pchelina (Gatchina, Russian Federation)

1:45pm-3:15pm: Alpha-synuclein seeding activity in blood samples from synucleinopathy patients

T. Yamasaki, E. Song (Lexington, KY, USA)

1:45pm-3:15pm: Altered sensory processing in somatosensory and auditory domains in laryngeal dystonia

T. Mantel, C. Dresel, M. Welte, C. Zimmer, B. Haslinger (Munich, Germany)

1:45pm-3:15pm: Alternating bilateral deep brain stimulation in the internal pallidum and subthalamic nucleus in isolated segmental dystonia: a case report

A. Handberg, S. Jensen, AN. Høck, L. Hjermind, J. Brennum, B. Jespersen, M. Karlsborg, A. Løkkegaard (Copenhagen, Denmark)

1:45pm-3:15pm: Ambroxol treatment of primary macrophages derived from patients with GBA-associated Parkinson’s disease

A. Kopytova, M. Nikolaev, K. Senkevich, G. Baydakova, I. Miliukhina, E. Zakharova, S. Pchelina (Gatchina, Russian Federation)

1:45pm-3:15pm: Ambulatory monitoring of electrodermal activity (EDA) and Heart Rate Variability (HRV) for prediction of motor fluctuations in Parkinson’s Disease (PD)

D. Nene, P. Surathi, M. Mirian, W. Doo, M. Mckeown (Vancouver, BC, Canada)

1:45pm-3:15pm: Amimia in Parkinson’s Disease and its Relationship with Motor and Non-Motor Symptoms

T. Maycas-Cepeda, C. Feliz-Feliz, L. Gomez-Vicente, R. García-Cobos, P. Lopez-Ruiz, R. Arroyo, PJ. García- Ruiz (Pozuelo de Alarcon, Spain)

1:45pm-3:15pm: Amylin and insulin in Parkinson’s disease patients: a clinical and metabolic study

A. Sánchez-Gómez, M. Fernández, G. Alcarraz, R. Fernández, M. Ezquerra, A. Cámara, A. Novials, E. Muñoz, F. Valldeoriola, Y. Compta, MJ. Martí (Barcelona, Spain)

1:45pm-3:15pm: Amylin deposition in the brain of Parkinson’s disease patients

I. Martinez-Valbuena, R. Valenti-Azcarate, J. Sanchez, I. Marcilla Garcia, G. Marti Andres, MT. Tuñon-Alvarez, MR. Luquin Piudo (Pamplona, Spain)

1:45pm-3:15pm: Amylin single-nucleotide polymorphism and Parkinson’s disease

R. Valenti-Azcarate, I. Martinez-Valbuena, I. Marcilla Garcia, G. Marti, M. Carmona-Abellan, MT. Tuñon-Alvarez, MT. Luquin-Piudo (Pamplona, Spain)

1:45pm-3:15pm: An atypical and interesting feature of Parkinson´s disease

B. Santos, M. Spitz (Rio de Janeiro, Brazil)

1:45pm-3:15pm: An examination of real-world onabotulinumtoxinA utilisation for the treatment of lower limb spasticity: The Adult Spasticity International Registry (ASPIRE) study

A. Esquenazi, W. Jost, G. Bavikatte, D. Bandari, M. Munin, A. Zuzek, A. Patel, J. Largent, G. Francisco (Elkins Park, PA, USA)

1:45pm-3:15pm: An examination of real-world onabotulinumtoxinA utilization for the treatment of upper limb spasticity: The Adult Spasticity International Registry (ASPIRE) study

G. Francisco, G. Bavikatte, W. Jost, D. Bandari, S. Tan Tang, A. Zuzek, A. Patel, J. Largent, A. Esquenazi (Taoyuan, Taiwan)

1:45pm-3:15pm: An Informant-based Simple Questionnaire for Executive Function Assessment in Dementia with Lewy Bodies and Alzheimer’s Disease

YS. Liang, GU. Hung, CY. Wei, PY. Chiu (Changhua, Taiwan)

1:45pm-3:15pm: An Internet of Things system for patient empowerment: a case study on measuring patients’ understanding of causal relationships between symptoms and behaviour

L. Karni, M. Memedi, E. Kolkowska, I. Scandurra, P. de Roos, DA. Nyholm, G. Klein (Örebro, Sweden)

1:45pm-3:15pm: An outlook: Palliative care for patients with Parkinsonism syndrome

MI. Arain (Jamshoro, Pakistan)

1:45pm-3:15pm: Analysis of brain network changes due to focused ultrasound VIM thalamotomy

N. Tani, S. Oshino, K. Hosomi, H. Khoo, S. Yamamoto, T. Yanagisawa, N. Hattori, M. Kanemoto, H. Mochizuki, H. Kishima (Suita, Japan)

1:45pm-3:15pm: Analysis of brain-derived blood exosomes for diagnostics of synucleinopathies

S. Dutta, I. Rosario, K. Paul, J-A. Palma, S. Perlman, W. Poon, H. Kaufmann, B. Fogel, J. Bronstein, B. Ritz, G. Bitan (Los Angeles, CA, USA)

1:45pm-3:15pm: Analysis of cortical oscillatory activities may identify a subgroup of Parkinson’s disease patients with suboptimal responses to deep brain stimulation of the subthalamic nucleus

M. Bočková, M. Lamoš, P. Klimeš, P. Jurák, J. Halámek, S. Goldemundová, M. Baláž, I. Rektor (Brno, Czech Republic)

1:45pm-3:15pm: Anterior EEG slowing in Dementia with Lewy Bodies: a multicenter European cohort study

L. Bonanni, R. Franciotti, F. Nobili, M. Kramberger, JP. Taylor, S. Garcia-Ptacek, M. Onofrj, NW. Falasca, D. Arnaldi, D. Aarsland (Chieti, Italy)

1:45pm-3:15pm: Apigenin loaded Phospholipid based nanoemulsion in Therapeutics of Parkinson’s Disease Via Attenuation of Oxidative Stress and Upregulation of Dopamine.

M-R. Rahman, V-K. Kumar (Allahabad, India)

1:45pm-3:15pm: APOmorphine infusion and aMYLoid deposition in Parkinson’s disease (APOMYL): preliminary clinical and amyloid imaging data

D. van Wamelen, M. Politis, D. Aarsland, P. Odin, T. van Laar, T. Henriksen, B. Corcoran, G. Vivian, H. Wilson, M. Parry, A. Sauerbier, N. Mulholland, K. Chaudhuri (London, United Kingdom)

1:45pm-3:15pm: Applicability of modified definition of Vascular Parkinsonism in patients with Parkinsonism attending outpatient department: A tertiary care hospital-based study in south India

S. Jaiswal (Hyderabad, India)

1:45pm-3:15pm: Application of the Movement Disorders Society Criteria for diagnosis of Progressive Supranuclear Palsy

F. Ali, H. Botha, E. Ahlskog, J. Bower, A. Hassan, D. Dickson, J. Whitwell, K. Josephs (Rochester, MN, USA)

1:45pm-3:15pm: Approaches to assessing of disorders of voluntary posture control in patients with Parkinson’s disease

A. Buniak, I. Maryenko, S. Likhachev, O. Alenikova (Minsk, Belarus)

1:45pm-3:15pm: Assessing Tele-Health Outcomes in Multiyear Extensions of Parkinson’s Disease Trials (AT-HOME PD): An Update on Recruitment

R. Schneider, L. Omberg, T. Myers, S. Anthwal, E. Kayson, C. Tarolli, M. Daeschler, E. Macklin, E. Dorsey, L. Mangravite, M. Schwarzschild, T. Simuni (Chicago, IL, USA)

1:45pm-3:15pm: Assessment of neuronal morphology to determine the differential susceptibility to Parkinson’s disease using MPTP in two genetically distinct mice strains

B. Bhaduri, I. Datta, R. Yadav, P. Alladi (Bangalore, India)

1:45pm-3:15pm: Assessment of occupationally exposed organic solvents and welding fumes induced DNA damage and SNPs (PARK13, LRRK2 and CAST gene) and risk of Parkinson’s disease

K. Kalimuthu, R. Ramachndran, A. Arulsamy, S. Savariar (Annamalainagar, India)

1:45pm-3:15pm: Associated movements disorders to Hereditary Spastic Paraplegia (HSP) in a case series from South Spain

A. Adarmes Gómez, S. Jesús Maestre, D. Macías García, C. Méndez Del-Barrio, R. Martin, F. Carrillo García, P. Gómez Garré, P. Mir Rivera (Seville, Spain)

1:45pm-3:15pm: Association between hand functions, hand reaction time and balance in patients with idiopathic Parkinson’s disease

AC. Kalkan, T. Kahraman, BO. Ugut, B. Donmez Colakoglu, A. Genc (Izmir, Turkey)

1:45pm-3:15pm: Association between quality of life and physical functions in patients with idiopathic Parkinson’s disease

BO. Ugut, T. Kahraman, AC. Kalkan, B. Donmez Colakoglu, A. Genc (Izmir, Turkey)

1:45pm-3:15pm: Association between the side of onset and the motor and non-motor symptoms in Parkinson’s Disease

J. Silva, R. Guimarães, A. D'Abreu (Campinas, Brazil)

1:45pm-3:15pm: Association between transfer activities and health-related quality of life in patients with Parkinson’s disease

AC. Kalkan, T. Kahraman, BO. Ugut, B. Donmez Colakoglu, A. Genc (Izmir, Turkey)

1:45pm-3:15pm: Association of Charcot-Marie-Tooth disease, Parkinson’s disease and FIG4 mutations

I. Posada-Rodríguez, C. Domínguez-González (Madrid, Spain)

1:45pm-3:15pm: Asymmetrical striatal dopamine transporter binding correlates with excess contralateral rest tremor

A. Fois, F. Chang, R. Barnett, K. London, N. Mahant, A. Ha, Z. Aldaajani, B. Cruse, H. Morales-Briceno, K. Ma, V. Fung (Dhahran, Saudi Arabia)

1:45pm-3:15pm: Attentional Intervention to Improve Cognition and Gait in Parkinson’s Disease: Side of Onset Effects

A. Cronin-Golomb, O. Barthelemy, A. Marin, B. Davis, S. Alshuaib, T. Ellis, J. Degutis (Boston, MA, USA)

1:45pm-3:15pm: Attitude of Parkinson Patients towards Participation in Clinical Trials and Brain or Tissue Donation for Research

S. Khan, J. Foo, N. Chia, S. Agustin, S. Neo, T. Yaw, A. Lok, A. Ng, L. Tan (Singapore, Singapore)

1:45pm-3:15pm: Atypical presentation of Dopa-responsive dystonia- late onset with severe swallowing difficulty

C. Zhao, L. Li, H. Li, J. Zhang (Jinan, China)

1:45pm-3:15pm: Automated analysis for quantification of tremor from pen-on-paper Archimedes spirals

A. R, R. Rajan, A. Saini, A. Srivastava (New Delhi, India)

1:45pm-3:15pm: Automated analysis of neck muscle ultrasound can distinguish cervical dystonia from healthy controls

C. Kobylecki, R. Cunningham, A. Siddique, M. Sánchez, M. Edwards, M. Silverdale, I. Loram (Manchester, United Kingdom)

1:45pm-3:15pm: Automated Metabolic Pattern Analysis in the Differential Diagnosis of Parkinsonism in a Swedish Cohort

I. Markaki, C. Tang, M. Lilja Lindström, D. Eidelberg, P. Svenningsson, I. Savitcheva (Stockholm, Sweden)

1:45pm-3:15pm: Automated Quantitative MRI Biomarkers in Differentiation of Progressive Supranuclear Palsy and Multiple System Atrophy from Parkinson Disease

H. You, Y. Luo, Y. Zhang, H. Wang, B. Hou, L. Shi, F. Feng (Beijing, China)

1:45pm-3:15pm: Availability of levodopa and clinicopathological features of patients with multiple system atrophy

C. Ishida, K. Komai, K. Takahashi, Y. Motozaki, A. Tagami, S. Shibata, M. Asakawa (Kanazawa, Japan)

1:45pm-3:15pm: Awareness of Levodopa/Carbidopa spacing with meals in patients of Idiopathic Parkinson’s disease – Insights from an Indian Parkinson’s Registry

N. Sawal, K. Shukla (Chandigarh, India)

1:45pm-3:15pm: Baicalein incorporated nanoliposome disaggregates alpha-synuclein fibrils

F. Aliakbari, D. Morshedi, H. Mohammad-Beigi, D. Otzen (Tehran, Islamic Republic of Iran)

1:45pm-3:15pm: Baseline analysis of PROSPECT-M-UK: a longitudinal study of PSP, CBS and MSA

E. Jabbari, J. Woodside, V. Chelban, A. Costantini, N. Holland, N. Leigh, D. Burn, N. Pavese, A. Gerhard, C. Kobylecki, M. Hu, A. Church, J. Rohrer, H. Houlden, J. Rowe, H. Morris (London, United Kingdom)

1:45pm-3:15pm: Baseline hyposmia and RBD symptoms are associated with faster, but differential, cognitive decline at 2 years in the PPMI study

G. Nomikos, J. Xiao, M. Yang, V. Irzhevsky (Cambridge, MA, USA)

1:45pm-3:15pm: Beneficial and protective effects of Terminalia chebula in a murine model of Parkinson’s disease

A. Kumar, S. Farhat (New Delhi, India)

1:45pm-3:15pm: Beneficial effect of estrogen on nigrostriatal dopaminergic neurons in drug-naïve postmenopausal Parkinson’s disease

YH. Lee, JH. Cha, SJ. Chung, HS. Yoo, YH. Sohn, BS. Ye, PH. Lee (Seoul, Republic of Korea)

1:45pm-3:15pm: Beyond the Periphery: Central Auditory Processing in Parkinsonian Disorders

E. de Groote, K. de Keyser, A. Bockstael, D. Botteldooren, P. Santens, M. de Letter (Ghent, Belgium)

1:45pm-3:15pm: Biallelic ZNF142-null mutations in patients with early-onset generalized dystonia

M. Zech, M. Skorvanek, V. Han, P. Dosekova, Z. Gdovinova, M. Wagner, R. Berutti, T. Strom, P. Havránková, A. Fečíková, F. Laccone, R. Jech, J. Winkelmann (Munich, Germany)

1:45pm-3:15pm: Bilateral Globus Pallidum interna stimulation for Blepharospasm

DR. Ginjupally, T. Ali, C. van Horne, Z. Guduru (Lexington, KY, USA)

1:45pm-3:15pm: Bilateral Globus pallidus interna Deep Brain Stimulation in Cranio-Cervical Dystonia (Meige syndrome) patient in Hong Kong

C. Lau, C. Zhu, D. Chan, K. Ma, L. Au, A. Chan, R. Wong, J. Yeung, W. Poon, V. Mok (Hong Kong, Hong Kong)

1:45pm-3:15pm: Bilateral INO in PSP

H. Gupta (Overland Park, KS, USA)

1:45pm-3:15pm: Bilateral vestibulopathy due to neurosarcoidosis mimicking Parkinsonian syndrome

M. Hamaguchi, H. Fujita, K. Suzuki (Utsunomiya, Japan)

1:45pm-3:15pm: Biomarkers of the Level of Cognitive Impairment (CI) in patients with Parkinson’s Disease (PD): MRS study

I. Karaban', N. Karasevich, Z. Rozhkova (Kyiv, Ukraine)

1:45pm-3:15pm: Blood brain barrier dysfunction cause idiopathic adult onset ventriculomegaly?

E. Oh, H. Chang, S. Kim, S. Kim, J. Heo (Daejeon, Republic of Korea)

1:45pm-3:15pm: Blood–brain barrier breakdown in an adult mouse model of Parkinson’s disease

E. Del-Bel, F. Grano (Ribeirão Preto, Brazil)

1:45pm-3:15pm: Body Mass Gain in Parkinson’s Disease Following Deep Brain Stimulation: A Systematic Review

J. Steinhardt, T. Münte, S. Schmid, B. Wilms, N. Brüggemann (Lübeck, Germany)

1:45pm-3:15pm: Botulinum toxin content and activity: Potential implications for duration of efficacy in patients with cervical dystonia

M. Field, A. Splevins, M. Schans, J. Langenberg, D. Noort, P. Picaut, K. Foster (Rijswijk, Netherlands)

1:45pm-3:15pm: Botulinum toxin for the management of dystonic scoliosis in children

D. Ferman, T. Sanger (Los Angeles, CA, USA)

1:45pm-3:15pm: Botulinum toxin injections reduce the symptoms of dystonic tremor and improve sensorimotor function for hand dexterity

L. Rocchi, A. Latorre, G. Paparella, E. Menozzi, L. Peppoloni, F. Valero-Cuevas, C. Cordivari, K. Bhatia, J. Rothwell (London, United Kingdom)

1:45pm-3:15pm: Braak model in Parkinson disease using MRI biomarkers

N. Pyatigorskaya, L. Yahia-Cherif, R. Valabregue, R. Gaurav, M. Mongin, C. Ewenczyk, C. Gallea, F. Gargouri, E. Bardinet, I. Arnulf, M. Vidailhet, S. Lehericy (Paris, France)

1:45pm-3:15pm: BST1 rs4698412 allelic variant increases the risk of gait or balance deficits in patients with Parkinson’s disease

Y. Shen, J. Wang, K. Zhang (Nanjing, China)

1:45pm-3:15pm: Bumetanide to treat Parkinson’s disease patients suffering from freezing of gait resistant to both dopamine replacement treatment and subthalamic deep brain stimulation: an open-label pilot study (BumFOG)

P. Damier, W. Kamel, J. Al Hashel (Kuwait, Kuwait)

1:45pm-3:15pm: Camptocormia in Parkinson’s disease – impaired kinesthesia of the trunk extensors

R. Wolke, J. Kuhtz-Buschbeck, G. Deuschl, N. Margraf (Kiel, Germany)

1:45pm-3:15pm: Can the Quantified Timed Up and Go (QTUG) device support decision making for patients undergoing Deep Brain Stimulation?

J. Somerset, B. Hammersley, M. Bonello (Liverpool, United Kingdom)

1:45pm-3:15pm: Carotid Intima-Media Thickness and its correlates in people with Parkinson’s disease: a pilot study

S. Castillo-Torres, C. Soto-Rincón, D. Cantú-García, A. Mendoza-Garcia, D. Díaz-Pérez, D. Martínez-Roque, B. Chávez-Luévanos, I. Estrada-Bellmann, F. Góngora-Rivera (Monterrey, Mexico)

1:45pm-3:15pm: Carpal Tunnel Syndrome in Patients with Tremor

L. Jackson, F. Ali (Rochester, MN, USA)

1:45pm-3:15pm: Carrier Mediated Delivery System Bearing Dopamine for Effective Management of Parkinsonism

M. Bhargava, S. Bhargava (Kanpur, India)

1:45pm-3:15pm: Case of task-specific tremor and task-specific dystonia with contralateral spread

L. Jackson, F. Ali (Rochester, MN, USA)

1:45pm-3:15pm: Case Report: Co-occurrence of Motor Neuron Disease and Parkinsonism

B. Barton (Chicago, IL, USA)

1:45pm-3:15pm: Case-control study of risk developing parkinsonism in Alzheimer’s disease in relation to hypertension, dyslipidemia, and diabetes in Taiwan

W. Lin, PY. Chiu (Changhua, Taiwan)

1:45pm-3:15pm: Central cholinergic activity and risk of falls in patients with Parkinson’s disease and freezing of gait

E. Pelosin, G. Lagravinese, G. Bonassi, M. Putzolu, A. Mirelman, R. Marchese, L. Avanzino (Genova, Italy)

1:45pm-3:15pm: Central effects of botulinum neurotoxin injections in cervical dystonia – a longitudinal structural MRI-study

D. Weise, C. Awissus, P. Baum, J. Classen, A. Villringer, P. Ragert, C. Weise (Leipzig, Germany)

1:45pm-3:15pm: Cerebellar brain inhibition and cervical dystonia: exploring clinico-electrophysiological associations

R. Sondergaard, LS. Gan, Y. Jasaui, J. Sarna, S. Furtado, T. Pringsheim, D. Martino (Calgary, AB, Canada)

1:45pm-3:15pm: Cerebellar involvement in progressive supranuclear palsy and corticobasal degeneration

S. Jo, KW. Park, N. Choi, CS. Lee, MS. Kim (Seoul, Republic of Korea)

1:45pm-3:15pm: Cerebellar rTMS theta burst for postural instability in progressive supranuclear palsy: a double blind cross-over sham controlled study using wearing sensors technology

A. Pilotto, MC. Rizzetti, A. Lombardi, M. Biggi, G. Verzeroli, W. Maetzler, C. Hansen, B. Borroni, A. Padovani (Brescia, Italy)

1:45pm-3:15pm: Cerebellar transcranial magnetic stimulation with neuronavigation for postural instability in PSP

M. George, W. Devries, M. Dale (Charleston, SC, USA)

1:45pm-3:15pm: Cerebral differences between dopamine-resistant and dopamine-responsive Parkinson’s tremor

MF. Dirkx, H. Zach, A. van Nuland, BR. Bloem, I. Toni, RC. Helmich (Nijmegen, Netherlands)

1:45pm-3:15pm: Cervical and Lumbosacral Spondylosis is common in patients with Parkinsonism in rural Western India

S. Desai (Anand, India)

1:45pm-3:15pm: Changes of cutaneous and cortical silent responses in a random sample of Lithuania patients with Parkinson disease

L. Sinkunaite, J. Svilpauske-Lauryniene, D. Garsviene, D. Surkiene (Kaunas, Lithuania)

1:45pm-3:15pm: Characterising the role of alpha-synuclein in ferroptotic programmed cell death in the context of Parkinson’s Disease

L. Mahoney-Sánchez, H. Bouchaoui, K. Timmerman, A. Jonneaux, S. Ayton, J. Duce, JC. Devedjian, D. Devos (Lille, France)

1:45pm-3:15pm: Characteristic Parkinsonism Questionnaire for the Discrimination of Parkinson’s Disease Dementia from Vascular Dementia

PY. Chiu (Changhua, Taiwan)

1:45pm-3:15pm: Characteristics and correlative factors of autonomic dysfunction in Chinese Parkinson’s disease

Z. Zhou, LP. Zhu, XT. Zhou, XX. Zhou, YW. Zhao, LX. Qin, Y. Yang, LJ. Fang, Y. Tian, ZQ. Wang, QY. Sun, Q. Xu, JC. Li, JF. Guo, XX. Yan, BS. Tang (Changsha, China)

1:45pm-3:15pm: Characteristics and outcome of patients with Parkinson’s disease admitted to intensive care unit

O. Benhadj Salem, S. Demeret, A. Demoule, F. Bolgert, H. Outin, T. Sharshar, D. Grabli (Paris, France)

1:45pm-3:15pm: Characteristics of African American Parkinson’s Disease patients seen in a Large Clinic Practice

M. Dean, M. Patel, K. Barnes, D. Standaert (Birmingham, AL, USA)

1:45pm-3:15pm: Characteristics of arm tremors in primary orthostatic tremor

J. Tashiro, H. Ohtsuka, M. Hirotani, Y. Iida, S. Hamada, H. Soma, M. Nonaka, S. Honma, A. Takei, F. Moriwaka, K. Tashiro (Sapporo, Japan)

1:45pm-3:15pm: Characteristics of gait and quality of life in Parkinson’s disease

JW. Kim, SM. Cheon (Busan, Republic of Korea)

1:45pm-3:15pm: Characteristics of patients with essential tremor evaluated for deep brain stimulation surgery at a tertiary center

L. Deuel, J. Feuerstein, B. Berman, B. Hoyt, D. Kern (Aurora, CO, USA)

1:45pm-3:15pm: Characterization of the motor phenotype and striatal muscle analysis in a mouse model of hereditary spasticity

A. Vignaud, C. Rivares, W. Noort, B. Koopmans, M. Loos, RT. Jaspers, M. Kalinichev (Les Ulis, France)

1:45pm-3:15pm: CHCHD2 maintains the MICOS and inhibits PINK1/Parkin mediated mitophagy in an experimental model of Parkinson’s disease

X. Chen, M. Zhou, XQ. Zhu, SX. Huang, WY. Guo, Z. Pei, PY. Xu (Guangzhou, China)

1:45pm-3:15pm: Cholecalciferol (VD3) attenuated motor deficits and dyskinesia in Hemi-Parkinsonian mice: behavioural, biochemical & electrophysiological implications

A. Bayo-Olugbami, A. Oyewole, A. Nafiu, A. Amin, B. Ogundele, B. Owoyele, C. Lee (Ilorin, Nigeria)

1:45pm-3:15pm: Circumstances of Falls in Single and Recurrent Fallers with Parkinson’s Disease

I. Castro, H. Cavalcanti, G. Valença, J. Filho, L. Almeida (Salvador, Brazil)

1:45pm-3:15pm: Classification of idiopathic cervical dystonia: an observational study

P. Tater, N. Sarma, S. Pandey (New Delhi, India)

1:45pm-3:15pm: Clear versus conversational speech in Parkinson’s disease, progressive supranuclear palsy, and multiple system atrophy

T. Tykalova, D. Skrabal, J. Klempir, E. Ruzicka, J. Rusz (Prague, Czech Republic)

1:45pm-3:15pm: Clinical and genetic characteristics of a new mutation causing Segawa´s disease in a Spanish kindred

J. Hernández-Vara, S. Lucas (Barcelona, Spain)

1:45pm-3:15pm: Clinical and imaging characteristics of manifest LRRK2 and GBA carriers: The PPMI cohort

A. Siderowf, T. Simuni, M. Brumm, L. Uribe, C. Caspell-Garcia, H. Cho, C. Coffey, T. Foroud, B. Mollenhauer, C. Tanner, K. Kieburtz, L. Chahine, D. Weintraub, K. Marek (Chicago, IL, USA)

1:45pm-3:15pm: Clinical and imaging characteristics of non-manifest LRRK2 and GBA carriers: The PPMI cohort

A. Siderowf, T. Simuni, L. Uribe, C. Caspell-Garcia, H. Cho, C. Coffey, T. Foroud, B. Mollehauer, C. Tanner, K. Kieburtz, L. Chahine, D. Weintraub, K. Marek (Philadelphia, PA, USA)

1:45pm-3:15pm: Clinical Applications of Non-Invasive Neuromodulation associated with kinesiotherapy in focal dystonia patients: report of three cases

C. Souza, J. Goulardins, D. Boari, S. Casagrande, J. Papaterra, C. Boffino, C. Tanaka, K. Monte-Silva (Sao Paulo, Brazil)

1:45pm-3:15pm: Clinical Associations of Hand Deformities in Parkinson´s Disease

JF. Baizabal-Carvallo, M. Alonso-Juarez, R. Fekete (Valhala, NY, USA)

1:45pm-3:15pm: Clinical Characteristics that Impact OnabotulinumtoxinA Treatment Adherence in Patients with Spasticity from ASPIRE

A. Esquenazi, W. Feng, G. Wittenberg, P. Gallien, A. Baricich, K. Fanning, A. Zuzek, G. Francisco, D. Bandari (Elkins Park, PA, USA)

1:45pm-3:15pm: Clinical comparison of right onset PD vs left onset PD

B. Tserensodnom (Ulaanbaatar, Mongolia)

1:45pm-3:15pm: Clinical features of constipation in patients with Parkinson’s disease: a cross-sectional study in China

LP. Zhu, XT. Zhou, Z. Zhou, LJ. Fang, XX. Zhou, YW. Zhao, LX. Qin, Y. Tian, ZQ. Wang, QY. Sun, Q. Xu, JC. Li, JF. Guo, XX. Yan, BS. Tang (Changsha, China)

1:45pm-3:15pm: Clinical heterogeneity and neuropathological correlation in progressive supranuclear palsy – description of 4 cases

A. André, M. Malaquias, C. Pinto, M. Calejo, A. Correia, M. Pires, P. Pinto, A. Mendes, M. Magalhães, R. Taipa (Faro, Portugal)

1:45pm-3:15pm: Clinical patterns of gait freezing in Parkinson’s disease and their response to interventions: an observer-blinded study

O. Gavriliuc, S. Paschen, A. Andrusca, C. Schlenstedt, G. Deuschl (Chisinau, Republic of Moldova)

1:45pm-3:15pm: Clinical Profile and Response to EMG-Guided Botulinum toxin (BTX) Injection in Writers’ Cramp (WC)- A Study of 25 Indian Patients

P. Agarwal, P. Palekar (Mumbai, India)

1:45pm-3:15pm: Clinical profile and treatment response patterns in patients of Truncal Dystonia: A retrospective case series from a tertiary care hospital in India

S. Mehta, S. Ray, V. Lal (Chandigarh, India)

1:45pm-3:15pm: Clinical Response to 72-h Lumbar CSF Drainage in Idiopathic Normal Pressure Hydrocephalus associated with Parkinsonism: Timing and Correlates

G. Mostile, G. Raudino, G. Portaro, F. Certo, A. Nicoletti, G. Barbagallo, M. Zappia (Catania, Italy)

1:45pm-3:15pm: Cognition and Gait in Parkinson’s Disease

A. Fatima (Lahore, Pakistan)

1:45pm-3:15pm: Cognitive dysfunction can predict the body weight loss in patients with Parkinson’s disease

RW. Ou, QQ. Wei, YB. Hou, XQ. Yuan, HF. Shang (Chengdu, China)

1:45pm-3:15pm: Cognitive dysfunction in patients with Parkinson’s disease and psychosis

A. Lenka, S. Hegde, S. Arumugham, R. Yadav, P. Pal (Washington, DC, USA)

1:45pm-3:15pm: Cognitive event related potentials as biomarker of non-motor phenotypes in Parkinson’s Disease

N. Koshel, S. Kryzhanovskyi, N. Karasevych, A. Pisaruk, I. Karaban (Kyiv, Ukraine)

1:45pm-3:15pm: Cognitive impairment in patients with Parkinson’s syndrome

SH. Rakhimova, I. Usmonaliev, Y. Musaeva (Tashkent, Uzbekistan)

1:45pm-3:15pm: Combined Botulinum Toxin and Gpi DBS therapy in intractable cervical dystonia

AM. Macerollo, BH. Hammersley, ME. Esposito, JS. Somerset, RE. Ellis, MB. Bonello, JP. Panicker, DD. Damodoran, JOF. Farah, PE. Eldridge, SA. Alusi (Naples, Italy)

1:45pm-3:15pm: Communication Calendar for Interdisciplinary Therapy of Parkinson’s Disease

F. Adib Saberi, D. Dressler (Hamburg, Germany)

1:45pm-3:15pm: Community Home Care Nurses Training for Parkinson Disease

ST. Chua, LW. Li, HL. Ng, LT. Tan (Novena, Singapore)

1:45pm-3:15pm: Comorbid Parkinson’s disease and Myasthenia Gravis: A Case-Control Study

K. Lafaver, D. Mohanty, C. Bodkin, M. Brown, A. Druker, J. Farmer, J. Fleisher, I. Gambhir, T. Harlow, F. Leon-Sarmiento, C. Perry, Z. Wang, A. Espay (Louisville, KY, USA)

1:45pm-3:15pm: Comorbid Parkinson’s disease in a Korean patient with Alexander’s disease

KY. Kwon, JW. Cho, JK. Park (Seoul, Republic of Korea)

1:45pm-3:15pm: Comparative Grey and White Matter Tau Pathology in LBD and PSP using Digital Histologic Measurements

D. Coughlin, C. Petersen, R. Lobrovich, D. Wolk, A. Siderowf, D. Weintraub, E. Lee, J. Trojanowski, M. Grossman, D. Irwin (Philadelphia, PA, USA)

1:45pm-3:15pm: Comparative Study of Dry Needling under Ultrasound Guidance and Extracorporeal Shock Wave Therapy for Myofascial Pain and Spasticity Management

R. Bubnov, L. Kalika (Kyiv, Ukraine)

1:45pm-3:15pm: Comparison of LFP-physiomarkers for DBS programming

G. Wenzel, S. Ewert, A. Horn, B. van Wijk, A. Kühn (Berlin, Germany)

1:45pm-3:15pm: Comparison of motor and non-motor symptoms in operated and medically treated dystonia patients

A. Maurer, U. Hidding, W. Hamel, C. Moll, C. Gerloff, M. Gelderblom, S. Zittel-Dirks (Hamburg, Germany)

1:45pm-3:15pm: Comparison of motor, non motor symptoms, impulse control disorders and quality of life in patients with young versus late onset Parkinson’s disease

S. Meka, R. Kandadai, T. Syed, R. Borgohain (Hyderabad, India)

1:45pm-3:15pm: Compensatory Amygdala Activity during motor timing and selection in PD

SPD. Allahdadian, H. Rafipoor, E. Yargholi, M. Mirian, MJM. Mckeown (Vancouver, BC, Canada)

1:45pm-3:15pm: Comprehensive clinico-pathophysiological assessment of constipation in Parkinson’s disease

E. de Pablo-Fernandez, V. Passananti, N. Zárate-López, A. Emmanuel, T. Warner (London, United Kingdom)

1:45pm-3:15pm: Computing algorithms can detect bradykinesia from smartphone videos

S. Williams, H. Fang, D. Wong, S. Relton, C. Graham, J. Alty (Leeds, United Kingdom)

1:45pm-3:15pm: Concentration of short chain fatty acids in the peripheral blood of patients with Parkinson disease

C. Shin, Y. Lim, TB. Ahn (Seoul, Republic of Korea)

1:45pm-3:15pm: Concomitant brain pathologies have no major impact on clinical milestones in progressive supranuclear palsy

M. Jecmenica-Lukic, C. Kurz, G. Respondek, O. Grau-Rivera, Y. Compta, E. Gelpi, C. Troakes, J. van Swieten, A. Giese, S. Roeber, T. Arzberger, G. Höglinger (Munich, Germany)

1:45pm-3:15pm: Constipation with selected prodromal features increases risk of subsequent Parkinson’s Disease

E. Brown, S. Goldman, K. Albers, S. Vanden Eeden, C. Tanner (San Francisco, CA, USA)

1:45pm-3:15pm: Continuous dopaminergic treatment with levodopa/carbidopa intestinal gel in multiple system atrophy: report of three patients

S. Delalic, S. Ibrulj, N. Zupancic, D. Flisar, M. Trost, Z. Pirtosek, M. Kojovic (Ljubljana, Slovenia)

1:45pm-3:15pm: Continuous levodopa- carbidopa gel recovers motor cortex plasticity in advanced Parkinson’s disease

K. Kolmancic, N. Prezelj, N. Kriznar Zupancic, M. Trost, D. Flisar, M. Gregoric Kramberger, R. Rajnar, Z. Pirtosek, M. Kojovic (Ljubljana, Slovenia)

1:45pm-3:15pm: Contribution of pedunculopontine nucleus cholinergic neurons to L-DOPA-induced dyskinesia and PD motor deficits in hemi-parkinsonian rats

N. Chambers, J. Sergio, C. Saito, K. Lanza, C. Bishop (Binghamton, NY, USA)

1:45pm-3:15pm: Corneal confocal microscopy: An imaging biomarker of neurodegeneration in Parkinson’s disease

M. Silverdale, I. Petropoulos, A. Kalteniece, R. Malik, C. Kobylecki, M. Ferdousi, S. Lim (Salford, United Kingdom)

1:45pm-3:15pm: Correlation between Pareidolia and cerebral perfusion by SPECT in Parkinson’s disease without dementia: A retrospective study

H. Akamine, T. Tokashiki (Ginowan, Japan)

1:45pm-3:15pm: Correlation Between PDQ-39 and MDS-UPDRS Scores in a Phase 3 Randomized Controlled Trial of Patients with Parkinson’s Disease

T. Lokhandwala, A. Lee, B. Yue, A. Thach, B. Navia (Palm Harbor, FL, USA)

1:45pm-3:15pm: Correlation of P300 parameters with cognition and impulse control disorders in patients with idiopathic Parkinson’s disease

R. Kandadai, R. Annakula, S. Sarva, S. Meka, T. Syed, S. Tandra, S. Turaga, R. Borgohain (Hyderabad, India)

1:45pm-3:15pm: Correlation of Retinal Nerve Fiber Layer Thickness and X-Linked Dystonia Parkinsonism Measured by Spectral-Domain Optical Coherence Tomography

MA. de Guzman, F. Levina, C. Go, E. Palisoc (Manila, Philippines)

1:45pm-3:15pm: Cortical excitability in focal dystonia patients using threshold tracking technique

FCF. Chang, S. Kim, P. Menon, N. Geevasinga, N. Mahant, S. Babu, S. Vucic, V. Fung (Westmead, Australia)

1:45pm-3:15pm: Cortical FDG-PET patterns predict long-term motor progression and disability milestones in Parkinson’s disease

A. Pilotto, A. Imarisio, E. Premi, SP. Caminiti, L. Presotto, A. Sala, R. Turrone, R. Grasso, A. Alberici, B. Paghera, MC. Rizzetti, B. Borroni, D. Perani, A. Padovani (Brescia, Italy)

1:45pm-3:15pm: Cortical gamma oscillations as biomarkers for levodopa-induced dyskinesia

C. Güttler, J. Altschüler, K. Tanev, S. Böckmann, JK. Haumesser, A. Kühn, C. van Riesen (Berlin, Germany)

1:45pm-3:15pm: Cortical Homeostatic Plasticity Alteration in Cervical Dystonia

S. Caverzasio, N. Amato, G. Bramati, G. Koch, A. Kaelin-Lang, S. Galati (Lugano, Switzerland)

1:45pm-3:15pm: Cortical thickness analysis in Parkinson’s disease with urinary symptoms

R. Roh, K. Kim, K. Koh (Seoul, Republic of Korea)

1:45pm-3:15pm: Cough sensitivity and aspiration pneumonia in Parkinson’s disease

S. Tomita, T. Oeda, S. Takaya, M. Kohsaka, K. Park, A. Umemura, Y. Mori, T. Ishihara, S. Nomoto, M. Tahara, K. Yamamoto, H. Sawada (Kyoto, Japan)

1:45pm-3:15pm: CXCL12 is involved in α-synuclein-triggered neuroinﬂammation of Parkinson’s disease

Y. Li, M. Niu, J. Liu (Shanghai, China)

1:45pm-3:15pm: Daytime Sleepiness Effects on Motor Symptoms in De Novo Parkinson’s Disease

E. Bayram, R. Yilmaz, K. Longardner, M. Akbostanci, I. Litvan (La Jolla, CA, USA)

1:45pm-3:15pm: DBS Programming In Tremor And Akinetic-Rigid Predominant Parkinson’s Disease

Z. Guduru, D. Ginjupally, T. Ali, N. El Seblani, J. Quintero, C. van Horne (Lexington, KY, USA)

1:45pm-3:15pm: DCM extract of Scutellaria Pinnatifida modulate alpha-synuclein fibrillation and protects dopaminergic SH-SY5Y cells against rotenone

S. Parsafar, D. Morshedi, M. Mohammadi (Tehran, Islamic Republic of Iran)

1:45pm-3:15pm: Deciphering Corticobasal Syndrome: are clinical features and FDG-PET imaging capable of predicting amiloyd status?

J. Parmera, A. Coutinho, A. Neto, M. Aranha, C. Ono, C. Buchpiguel, R. Nitrini, E. Barbosa, S. Brucki (São Paulo, Brazil)

1:45pm-3:15pm: Deciphering the role of posttranslational modifications on α-synuclein aggregation and toxicity

T. Outeiro (Goettingen, Germany)

1:45pm-3:15pm: Deep Brain Stimulation (DBS) clinical impedance measurements of the Medtronic Clinician 8840 versus the Samsung Galaxy Tab S2 tablet interface

D. Caputo, S. Danish, E. Hargreaves (New Brunswick, NJ, USA)

1:45pm-3:15pm: Deep Brain Stimulation as second line advanced treatment for PD after LCIG

A. Faust-Socher, F. Abu Ahmad, N. Giladi, A. Hilel, Y. Shapira, D. Klepikov, A. Ezra, L. Raif, T. Gurevich (Tel Aviv, Israel)

1:45pm-3:15pm: Deep Brain Stimulation for atypical tremors secondary to Neuroferritinopathy: Single center experience

S. Chandra, J. Randhawa, M. Schiess (Houston, TX, USA)

1:45pm-3:15pm: Deep Brain Stimulation of VIM Thalamic Nucleus for Tremor Control

J. Santos (Rio de Janeiro, Brazil)

1:45pm-3:15pm: Deep Brain Stimulation Wash-in/out Periods Quantified using a Palm-Worn Device to Monitor Rigidity

T. Perera, WL. Lee, M. Jones, J. Tan, E. Proud, A. Begg, N. Sinclair, R. Peppard, H. Mcdermott (East Melbourne, Australia)

1:45pm-3:15pm: Deep mitochondrial sequencing in Parkinson’s disease reveals possible genetic modifiers of reduced penetrance in Parkin/PINK1 mutation carriers

J. Trinh, A. Hicks, K. Wasner, M. Farrer, F. Hentati, P. Bauer, S. Imhoff, K. Kandaswamy, N. Ouzren, M. Werber, A. Rolfs, V. Kostic, A. Lang, P. Pramstaller, P. Seibler, K. Lohmann, A. Gruenewald, C. Klein (Luebeck, Germany)

1:45pm-3:15pm: Deep phenotyping adult onset isolated cervical dystonia; the importance of symptomatic anxiety and depression.

I. Ndukwe, J. Dover, P. Lynch, F. O'Keeffe, S. O'Riordan, M. Hutchinson (Dublin, Ireland)

1:45pm-3:15pm: Defective human motion perception in cervical dystonia correlates with coexisting tremor

D. Martino, E. Pelosin, G. Abbruzzese, L. Avanzino (Genova, Italy)

1:45pm-3:15pm: Defining biomarkers to discriminate between organic and functional dystonia

A. Stephan, D. Benninger (Lausanne, Switzerland)

1:45pm-3:15pm: Demographic Influences on Wearing Off Symptoms in Parkinson’s Disease

L. Chahine, G. Cummin, S. Chen, J. Buchanich, B. Edison, M. Daeschler, S. Kahl, C. Kopil, C. Marras (Toronto, ON, Canada)

1:45pm-3:15pm: Dentate nucleus functional connectivity changes and their relationship with motor and non motor symptoms in patients with essential tremor

S. Pietracupa, S. Tikoo, S. Tommasin, M. Bologna, N. Petsas, K. Bharti, G. Grillea, A. Berardelli, P. Pantano (Rome, Italy)

1:45pm-3:15pm: Depression and anxiety in cervical dystonia

M. Munteanu (Bucharest, Romania)

1:45pm-3:15pm: Depression and cognitive impairment in isolated focal-onset dystonia: prevalence and risk factors in a group of Romanian patients

OL. Bajenaru, I. Popescu-Olaru, E. Serban, L. Cozma, F. Raicu, R. Cocos, L. Dumitrescu, BO. Popescu (Bucharest, Romania)

1:45pm-3:15pm: Depression, Anxiety and Sleep Disturbances in Patients with Craniocervical Dystonias

Z. Khayatova, Z. Zalyalova (Kazan, Russian Federation)

1:45pm-3:15pm: Describing Dystonia Phenomenology and Preliminary Treatment Response in Migraine Patients

A. Yoo, S. Bobker, S. Broner, A. Lee, G. Auerbach, L. Klebanoff, M. Vo, H. Sarva (New York, NY, USA)

1:45pm-3:15pm: Descriptive Presentation of MRI Findings in Multiple Sclerosis Patients with Tonic Spasm

M. Salari, M. Etemadifar, SH. Ghourchian (Tehran, Islamic Republic of Iran)

1:45pm-3:15pm: Detection of impaired finger dexterity by objective keyboard typing test in Parkinson’s Disease: A feasibility study

P. Panyakaew, K. Duangjino, R. Bhidayasiri (Bangkok, Thailand)

1:45pm-3:15pm: Development and Validation of the Parkinson’s Disease Medication Adherence Scale (PD- MAS)

M. Tosin, B. Oliveira (Niterói, Brazil)

1:45pm-3:15pm: Development of a patient-reported Botulinum Toxin Response Scale (BTRS) for neurological disorders: a feasibility study.

D. Gupta, C. Gao, S. Pullman (Burlington, VT, USA)

1:45pm-3:15pm: Development of a questionnaire to assess sensory trick in patients with dystonia

L. Avanzino, G. Bonassi, N. Cothros, E. Pelosin, R. Marchese, G. Abbruzzese, F. Morgante, D. Martino (Genova, Italy)

1:45pm-3:15pm: Diagnosis and Treatment Experiences in a Real-World Sample of Tourette Syndrome and Tic Disorder Sufferers

I. Malaty, D. Shineman, W. Deeb (Gainesville, FL, USA)

1:45pm-3:15pm: Diagnostic accuracy of Progressive Supranuclear Palsy: Experience of a movement disorders center

M. Gultekin (Kayseri, Turkey)

1:45pm-3:15pm: Differences in botulinum toxin long-term treated and non-treated cervical dystonia patients in somatosensory task-related functional imaging response.

M. Nevrly, P. Hlustik, P. Hok, M. Kaiserova, P. Otruba, Z. Tudos, P. Kanovsky (Olomouc, Czech Republic)

1:45pm-3:15pm: Differences in resting state fMRI distinguish multiple system atrophy and Parkinson disease

A. Peterson, E. Dayan, N. Browner, D. Drazheva, M. Sklerov (Chapel Hill, NC, USA)

1:45pm-3:15pm: Different patterns of cortical and subcortical perfusion changes in essential tremor and tremor-dominant Parkinson’s disease using voxel-based analysis of 3D arterial spin-labeling imaging

L. Jin, J. Wang, C. Wang (Shanghai, China)

1:45pm-3:15pm: Differential Item Functioning in the Unified Dyskinesia Rating Scale (UDysRS) based on Duration of Parkinson’s Disease and Dyskinesia

X. Ren, J. Lin, S. Luo, C. Goetz, G. Stebbins, E. Cubo (Burgos, Spain)

1:45pm-3:15pm: Differential Value of Brain Magnetic Resonance Imaging in MSA-C and SCAs

M. Kim, JK. Mun, JH. Ahn, JS. Kim, J. Youn, JW. Cho (Seoul, Republic of Korea)

1:45pm-3:15pm: Differentiation of Progressive Supranuclear Paralysis from Multisystem Atrophy and Parkinson’s Disease by Cranial MRI

E. Natera-Villalba, V. Ros-Castelló, A. Sánchez-Sánchez, A. Gómez-López, P. Pérez-Torre, JL. López Sendón, I. Parées-Moreno, JC. Martínez-Castrillo, A. Alonso-Cánovas (Madrid, Spain)

1:45pm-3:15pm: Diplopia and visual complaints in non-demented patients with Parkinson disease: a Japanese single center cross-sectional survey

K. Ota, K. Takahashi, K. Seo, H. Kawasaki, K. Ikeda, T. Mitsufuji, T. Fukuoka, Y. Ito, Y. Nakazato, N. Tamura, N. Araki, T. Yamamoto (Saitama-Ken, Japan)

1:45pm-3:15pm: Directional lead local field potentials show distinct spatial resolution

J. Jimenez-Shahed, M. Ozturk, A. Viswanathan, S. Sheth, N. Ince (Houston, TX, USA)

1:45pm-3:15pm: Discriminative power of different olfactory domains in Parkinson’s disease

YW. Zhao, RC. He, JX. Yang, Y. Zhang, XT. Zhou, XX. Zhou, LX. Qin, Y. Tian, ZQ. Wang, QY. Sun, Q. Xu, JC. Li, JF. Guo, XX. Yan, BS. Tang (Changsha, China)

1:45pm-3:15pm: Do non-motor fluctuations temporarily match ON/OFF motor condition?

E. Del Prete, E. Schmitt, S. Meoni, V. Fraix, A. Castrioto, P. Pelissier, R. Ceravolo, E. Moro (Grenoble, France)

1:45pm-3:15pm: Does Anticholinergic Burden Affect the Outcomes in Patients Diagnosed with Parkinson’s Disease?

S. Taylor, E. Jones (York, United Kingdom)

1:45pm-3:15pm: Does automated analysis of repeat DaTscan imaging aid diagnosis in suspected Lewy body disorders?

F. Richardson, N. Vennart, P. Bartholomew, C. Mcdonald (Gateshead, United Kingdom)

1:45pm-3:15pm: Does lesion localisation predict tremor characteristics in patients with focal cerebellar lesion?

A. Kovács, M. Kiss, A. Kamondi (Budapest, Hungary)

1:45pm-3:15pm: Does the truth lie within the gut? Investigating the gut microbiome in an Australian cohort of Parkinson’s disease patients

J. Kenna, S. Mcgregor, M. Horne, A. Tay, S. Ghosh, F. Mastaglia, A. Jefferson, A. Gorecki, M. Bakeberg, S. Walters, R. Anderton (Perth, Australia)

1:45pm-3:15pm: Does Transcranial Direct Current Simulation Improve Motor Functions in Patients with Parkinson’s disease?

E. Bahbah, M. Morsi, M. Aziz, A. Hassanen, A. Ali, M. Abdelmongy, M. Sinokrot, A. Negida, A. Shalash (Damietta, Egypt)

1:45pm-3:15pm: Domain-specific impact of mood/anxiety disorders on quality of life in idiopathic dystonia

D. Martino, Y. Jasaui, J. Sarna, S. Furtado, S. Patten, T. Pringsheim (Calgary, AB, Canada)

1:45pm-3:15pm: Drooling in Parkinson’s Disease: A [123I]FP-CIT SPECT study

V. Suarez Contreras, Y. Tayyabah, S. Caminiti, M. Politis (London, United Kingdom)

1:45pm-3:15pm: Drug Utilization in a Real World Cohort with Progressive Supranuclear Palsy

G. Hoeglinger, D. Oleske, J. Zamudio, R. Diegidio, J. Holman (Munich, Germany)

1:45pm-3:15pm: Drug-induced dystonia

JB. Paredes, V. Hristova, J. Poles, S. Madrona, P. Torre, I. Moreno, S. Argos, A. Canovas, JC. Castrillo, JL. Moreno (Madrid, Spain)

1:45pm-3:15pm: Dry eye in Parkinson’s disease: symptoms, consequences and treatment options

I. Csoti, N. Koleva-Alazeh (Leun, Germany)

1:45pm-3:15pm: Dynamic causal modelling of cortical activity in task-specific dystonia

JC. Chen, CC. Chen (Taichung, Taiwan)

1:45pm-3:15pm: Dyskinesia Rates in Patients with Parkinson’s Disease on CVT-301 (levodopa inhalation powder)

E. Pourcher, A. Corbin, J. Qian, C. Kenney (Quebec City, QC, Canada)

1:45pm-3:15pm: Dysregulated long non-coding RNA in Parkinson’s disease contributes to the apoptosis of dopaminergic neuron

Y. Fan, Z. Xue (Wuhan, China)

1:45pm-3:15pm: Dystonic opisthotonus: A clinical clue to neurodegeneration with brain iron accumulation in young adults

S. Mehta, V. Lal (Chandigarh, India)

1:45pm-3:15pm: Dystonic storm with a change of stimulation from constant voltage to constant current

Z. Guduru, T. Yamasaki, J. Guwell, J. Lamm, D. Ginjupally, S. Grupke, C. van Horne (Lexington, KY, USA)

1:45pm-3:15pm: Dystonic tics in patients with Gilles de la Tourette syndrome

N. Szejko, A. Jakubczyk, A. Dunalska, P. Janik (Warsaw, Poland)

1:45pm-3:15pm: Dystonic versus parkinsonian tremor

J. Svantnerova, Z. Kosutzka, M. Minar (Bratislava, Slovakia)

1:45pm-3:15pm: Early diagnosis of progressive supranuclear palsy using quantitative MRI analysis of brain structure

K. Seo, T. Yamamoto, H. Kawasaki, T. Hukuoka, Y. Nakazato, K. Takahashi, I. Matunari, H. Matuda, N. Tamura, N. Araki (Saitama, Japan)

1:45pm-3:15pm: Early Impairment of Chopsticks Skill Predict Atypical Parkinsonism

YE. Kim, H. Ma, YJ. Kim (Anyang-Si, Republic of Korea)

1:45pm-3:15pm: Early postural instability is an effective predictor of future freezing of gait in Parkinson’s disease

J. Lee (Goyang-Si, Republic of Korea)

1:45pm-3:15pm: Early stage Parkinson’s disease patients with GBA mutation have more severe motor symptoms and difficult to differentiate in routine clinical practice

S. Abe, K. Komatsu, H. Satoi, H. Saiki, Y. Oka (Osaka, Japan)

1:45pm-3:15pm: Ecopipam, a selective D1 antagonist in development for the treatment of Tourette syndrome in children and adolescents: The Phase 2b D1AMOND Study

J. Dubow, D. Kim, R. Bittman, S. Wanaski, J. Swalec, T. Cunniff (Northbrook, IL, USA)

1:45pm-3:15pm: Effect of a Combined Treatment with Botulinum Toxin and Biofeedback Exercises in Pisa Syndrome

A. Castagna, A. Crippa, D. Anastasi, M. Meloni, A. Montesano, A. Marzegan (Milano, Italy)

1:45pm-3:15pm: Effect of Botulinum Toxin Treatment on Cervical Dystonia

S. Tomic, M. Tomasevic, D. Hardi, T. Gilman Kuric, Z. Popovic (Osijek, Croatia)

1:45pm-3:15pm: Effect of Levodopa on gut microbiome in Parkinson’s Disease (PD)

A. Hannoun, D. Ward, J. Flahive, J. Friedman, A. Deb, K. Smith (Worcester, MA, USA)

1:45pm-3:15pm: Effect of rTMS over supplementary motor area on motor cortical excitability: a study using realistic sham stimulation as placebo

S. Kodama, M. Hamada, Y. Shirota, T. Sasaki, K. Sato, J. Otsuka, C. Hosoda, Y. Ugawa, T. Toda (Tokyo, Japan)

1:45pm-3:15pm: Effectiveness of exome sequencing in Parkinson’s disease of Chinese population

YW. Zhao, HX. Pan, L. Jiang, Y. He, Q. Zeng, XT. Zhou, XX. Zhou, LX. Qin, Y. Tian, ZQ. Wang, QY. Sun, Q. Xu, JC. Li, JF. Guo, XX. Yan, BS. Tang (Changsha, China)

1:45pm-3:15pm: Effects of an intensive rehabilitation program (SIROCCO) on prefrontal activity during walking in patients with Parkinson Disease

I. Hoang, M. Ranchet, M. Cheminon, R. Derollepot, H. Devos, S. Perrey, J. Luauté, L. Paire-Ficout, T. Danaila (Bron, France)

1:45pm-3:15pm: Effects of levodopa on LTP-like plasticity induced by quadripulse magnetic stimulation in Parkinson’s disease

S. Moriyasu, T. Shimizu, T. Honda, Y. Ugawa, R. Hanajima (Yonago, Japan)

1:45pm-3:15pm: Effects of levodopa on prosaccade performance and visual target eccentricity

A. Yugeta, Y. Terao, Y. Ugawa (Tokyo, Japan)

1:45pm-3:15pm: Effects of the Neuromodulation of Sensorimotor Rhythms on the Event-Related Desynchronization Phenomenon in Parkinson’s Disease

MD. Del Castillo, JI. Serrano, E. Rodríguez, E. Rocon, JP. Romero, J. Andreo, A. Arroyo, N. Malpica, H. Melero, M. Gil, E. Sanz (Madrid, Spain)

1:45pm-3:15pm: Efficacy and Safety of AbobotulinumtoxinA in Adults with Cervical Dystonia: Similar Results Between 1mL and 2mL Dilution Methods

K. Dashtipour, R. Hauser, S. Isaacson, D. Truong, L. Bahroo, A. Patel, P. Maisonobe, J. Otto (Loma Linda, CA, USA)

1:45pm-3:15pm: Efficacy of Stereotactic lesioning in Multi-etiological tremor

D. Srinivas, R. Yadav, P. Pal (Bangalore, India)

1:45pm-3:15pm: Efficacy, Safety, and Tolerability of Supratherapeutic Doses of Apomorphine Sublingual Film for the Treatment of “OFF” Episodes in Patients With Parkinson’s Disease

C. Olanow, F. Stocchi, K. Wilks, E. Peckham, M. de Pandis, K. Sciarappa, R. Kleiman, D. Blum, B. Navia (New York, NY, USA)

1:45pm-3:15pm: Embouchure dystonia evoked with tactile stimulation recorded by MEG

B. Bulica, C. Sidiropoulos, A. Mahajan, A. Zillgitt, S. Bowyer (Royal Oak, MI, USA)

1:45pm-3:15pm: Enhancing the Proteasomal Degradation of Alpha Synuclein: “The Hallmark” to attenuating the Progression of Parkinson’s Disease

B. Adebisi, M. Adeleke (Osogbo, Nigeria)

1:45pm-3:15pm: Estimating the long-term effect of early levodopa treatment initiation in Parkinson’s disease

L. Vd Heuvel, J. Krijthe, L. Evers, M. Meinders, B. Post, T. Heskes, B. Bloem (Nijmegen, Netherlands)

1:45pm-3:15pm: Evaluating Multimodal Integration of Abnormalities in Adult Onset Idiopathic Focal Dystonia (AOIFD) via Multivariate Pattern Analysis (MVPA) and Ensemble Learning (EL)

S. Narasimham, D. Valeriani, S. O'Riordan, M. Hutchinson, K. Simonyan, R. Reilly (Dublin, Ireland)

1:45pm-3:15pm: Evaluation of bedside screening tests to detect dysphagia in Parkinson’s disease

F. Brugger, J. Walch, M. Galovic, S. Hägele-Link, S. Stöckli, M. Müller-Baumberger, G. Kägi (St. Gallen, Switzerland)

1:45pm-3:15pm: Evaluation of Childhood Tremor Electrophysiogically Influences Diagnosis and Treatment and Outcome

B. Lavenstein, E. Akano, M. Hallett (Bethesda, MD, USA)

1:45pm-3:15pm: Evaluation of Clinical Peculiarities of Violations of Vertical Vision in Patients with Parkinson’s Disease

M. Salokhiddinov, D. Akramova (Tashkent, Uzbekistan)

1:45pm-3:15pm: Evaluation of Constipation in Patients with Parkinson’s Disease and its Correction

M. Salokhiddinov, D. Akramova (Tashkent, Uzbekistan)

1:45pm-3:15pm: Evaluation of dose rate of photobiomodulation (light) therapy in patients with Parkinson’s Disease: Double blind placebo-controlled pilot trial. Is there a dose frequency per week that influences quality of life, mobility and cognition?

J. Bullock-Saxton, L. Laakso, A. Lehn, F. Read, K. Harm, A. Gosling, S. Hardy, P. Newcombe, A. Nolan, E. Tune (Brisbane, Australia)

1:45pm-3:15pm: Examining level of hemoglobin in patients with parkinson’s disease and the role of hemoglobin level in the disease course

SH. Shohimardonov, K. Daminova (Tashkent, Uzbekistan)

1:45pm-3:15pm: Examining supplementary motor area-primary motor cortex connectivity in tremor-dominant Parkinson’s disease using a novel transcranial magnetic stimulation protocol to inform clinical practice

BK. Rurak, J. Rodrigues, B. Power, P. Drummond, AM. Vallence (Murdoch, Australia)

1:45pm-3:15pm: Exercise and physical activity for people with Progressive Supranuclear Palsy

S. Slade, D. Finkelstein, J. Mcginley, M. Morris (Ivanhoe, Australia)

1:45pm-3:15pm: Exosomes from patients with Parkinson’s disease are pathological in mice

C. Han, N. Xiong, X. Guo, J. Huang, K. Ma, L. Liu, Y. Xia, S. Yin, L. Kou, F. Wan, J. Hu, G. Zhang, T. Wang (Wuhan, China)

1:45pm-3:15pm: Exploratory Analysis of Electrocortical Signal Complexity in Patients with Progressive Supranuclear Palsy and Corticobasal Degeneration

G. Mostile, L. Giuliano, R. Terranova, A. Luca, G. Donzuso, G. Portaro, C. Rascunà, V. Sofia, A. Nicoletti, M. Zappia (Catania, Italy)

1:45pm-3:15pm: Exploring the cognitive workload during a visual search task in Parkinson’s disease

M. Ranchet, J. Morgan, A. Akinwuntan, H. Devos (Kansas City, KS, USA)

1:45pm-3:15pm: Expression analysis of candidate genes in a cell model of affected and unaffected THAP1 mutation carriers and controls

H. Baumann, M. Trilck-Winkler, M. Grosse, A. Münchau, V. Kostic, C. Klein, F. Kaiser, P. Seibler, K. Lohmann (Belgrade, Serbia)

1:45pm-3:15pm: Factors Affecting Mortality in Late Stage Parkinson’s Disease

S. Dempsey, L. Mcdonald, I. Sayers, WK. Gray, A. Hand, R. Walker (Newcastle Upon Tyne, United Kingdom)

1:45pm-3:15pm: Factors associated with dyskinesia in Parkinson’s disease in Mainland China

X. Zhou, LF. Fang, XT. Zhou, XX. Zhou, YW. Zhao, LX. Qin, Y. Tian, ZQ. Wang, QY. Sun, Q. Xu, JC. Li, JF. Guo, XX. Yan, BS. Tang (Changsha, China)

1:45pm-3:15pm: Fall History and Gait Variability can Predict Falls in Individuals With Parkinson’s Disease

L. Ma, P. Chan (Beijing, China)

1:45pm-3:15pm: Features of neural activity of globus pallidus in a patient with cervical dystonia and putaminal stroke: case study

A. Gamaleya, A. Tomskiy, S. Usova, V. Popov, AG. Shaikh, A. Sedov (Moscow, Russian Federation)

1:45pm-3:15pm: Firing pattern of single neurons in the subthalamic nucleus of Tourette Syndrome patients identifies optimal deep brain stimulation target site

M. Vissani, R. Cordella, S. Micera, L. Romito, A. Mazzoni (Pontedera, Italy)

1:45pm-3:15pm: First Experience with MR-guided Focused Ultrasound in the Treatment of X-linked Dystonia-Parkinsonism (XDP)

WC. Chang, T. Taira, RDG. Jamora, PY. Chiu, W. Lin (Changhwa, Taiwan)

1:45pm-3:15pm: Frailty in Parkinson’s disease: A systematic review

N. Smith, L. Brennan, D. Gaunt, Y. Ben-Shlomo, E. Henderson (Bath, United Kingdom)

1:45pm-3:15pm: Freezing of gait as a reflection of disturbed general time processing in Parkinson’s disease? A new look on a complex phenomenon

J. Wagner, A. Gulberti, J. Verrel, S. Tunc, T. Bäumer, W. Hamel, AK. Engel, C. Gerloff, CKE. Moll, A. Münchau, M. Pötter-Nerger (Hamburg, Germany)

1:45pm-3:15pm: Frequency of impulse control disorder in Parkinson’s disease: insights from the Luxembourg cohort

S. Binck, C. Pauly, P. Kolber, L. Pavelka, L. Stute, D. Reiter, M. Vaillant, M. Gantenbein, E. Glaab, J. Ferrand, L. Geffers, G. Hipp, R. Krueger, NJ. Diederich (Strassen, Luxembourg)

1:45pm-3:15pm: Functional Limits of Stability and Standing Balance in people with and without Freezing of Gait

N. Hasegawa, K. Maas, V. Shah, P. Carlson-Kuhta, J. Nutt, F. Horak, T. Asaka, M. Mancini (Portland, OR, USA)

1:45pm-3:15pm: Functional mobility tests and their relationship with disease stage in patients with Parkinson’s Disease

B. üğüt, T. Kahraman, A. Kalkan, A. Genç, B. çolakoğlu (Izmir, Turkey)

1:45pm-3:15pm: Gait impairment in Parkinson’s Disease: An [123I]FP-CIT SPECT study

V. Suarez Contreras, Y. Tayyabah, S. Caminiti, M. Politis (London, United Kingdom)

1:45pm-3:15pm: Gaze – evoked nystagmus in PSP patients: Is it really atiypical? A case series of eight patients

MK. Klarendic, MA. Hribar, SB. Battelino, MGK. Kramberger, MK. Kojovic (Ljubljana, Slovenia)

1:45pm-3:15pm: GBA-LRRK2 Parkinson’s Disease: a clinical case

L. Azevedo Kauppila, D. Pimenta Silva, A. Castro Caldas, M. Coelho, J. Ferreira, L. Correia Guedes (Lisboa, Portugal)

1:45pm-3:15pm: Gender differences in Motor symptoms, Non-Motor symptoms and Quality of Life in Parkinson’s disease: COPPADIS-2015 study cohort

M. Aguilar, P. Pastor, B. Solano, I. Cabo, MJ. Catalan, V. Nogueira, V. Puente, JM. Garcia, R. Perez, C. Borrué, M. Mata, M. Alvarez, AB. Rodriguez, L. Vela, Y. Macías, MJ. Marti, P. Martinez, D. Santos (Sabadell, Spain)

1:45pm-3:15pm: Gender differences of fatigue characteristics in people with Parkinson’s disease

G. Cilga, T. Kahraman, AC. Kalkan, B. Donmez Colakoglu, A. Genc (Manisa, Turkey)

1:45pm-3:15pm: Gender-specific effects of uric acid on the development of freezing of gait in Parkinson’s disease

JH. Jung, SJ. Chung, YH. Sohn, PH. Lee (Seoul, Republic of Korea)

1:45pm-3:15pm: Genetic and clinical investigation of young onset dystonia in Korea: What can we learn?

JW. Cho, M. Kim, JK. Park, J. Ahn, J. Youn (Seoul, Republic of Korea)

1:45pm-3:15pm: Genetics and phenotypes of recessive parkinsonism in French and North African populations

S. Lesage, A. Lunati, M. Houot, S. Benromdhan, C. Tesson, F. Clot, C. Mhiri, E. Lohmann, JC. Corvol, A. Brice (Paris, France)

1:45pm-3:15pm: Genomic variants associated with cognitive impairment in Parkinson’s disease: Ethnicity-specific GWAS

SJ. Chung, N. Choi, J. Kim, K. Kim, MJ. Kim, YJ. Kim, HS. Ryu, KW. Park (Anyang, Republic of Korea)

1:45pm-3:15pm: Genotype-phenotype relations for the isolated Dystonia Genes TOR1A, THAP1, GNAL, ANO3, KMT2B, PRKRA and HPCA: MDSGene Systematic Review

LM. Lange, J. Junker, S. Loens, L. Olschewski, S. Schaake, S. Petkovic, M. Kasten, A. Westenberger, A. Domingo, A. Madoev, I. König, C. Marras, KP. Bhatia, S. Camargos, C. Klein, K. Lohmann (Lübeck, Germany)

1:45pm-3:15pm: Ginsenoside Rb1 Prevents MPTP-Induced Changes in Hippocampal Memory via Regulation of the α-Synuclein/PSD-95 Pathway

S. Qu, Y. Zhang, X. Meng, Y. Liu, X. Zhang (Foshan, China)

1:45pm-3:15pm: Glabellar tap predicts dopamine transporter deficiency in parkinsonism

S. Nuuttila, J. Joutsa, M. Eklund, E. Jaakkola, E. Mäkinen, T. Noponen, T. Ihalainen, F. Scheperjans, V. Kaasinen (Turku, Finland)

1:45pm-3:15pm: GluRδ2 protein reduction in cerebellar Purkinje cells contributes to the pathogenesis of essential tremor

MK. Pan, YS. Li, CL. Ni, WC. Liu, E. Cortes, JP. Vonsattel, E. Louis, P. Faust, SH. Kuo (Taipei, Taiwan)

1:45pm-3:15pm: GNAO1 gene mutation: generalized dystonia without epilepsy.

Z. Guduru, T. Ali, J. Gurwell, D. Ginjupally (Lexington, KY, USA)

1:45pm-3:15pm: Goal setting for botulinum toxin injections: Impact of the Upper Limb International Spasticity (ULIS) programme

K. Fheodoroff, S. Ashford, J. Jacinto, A. Brashear, P. Maisonobe, A. Lysandropoulos, L. Turner-Stokes (Hermagor, Austria)

1:45pm-3:15pm: GPi DBS does not affect sensory thresholds in hereditary/idiopathic dystonia

C. Listik, R. Gisbert Cury, V. da Silva, S. Carvalho Barbosa Casagrande, E. Listik, L. Link, R. Galhardoni, E. Reis Barbosa, M. Jacobsen Teixeira, D. de Andrade (Sao Paulo, Brazil)

1:45pm-3:15pm: Gray matter atrophy in Parkinson’s disease and freezing of gait assessed using surface-based algorithm – results of an open, longitudinal, single-centre study

P.. Kanovsky, M.. Vastik, K.. Mensikova, P.. Hok, J.. Valosek, P.. Hlustik (Olomouc, Czech Republic)

1:45pm-3:15pm: Guided Self-rehabilitation Contracts combined with simultaneous injections of abobotulinumtoxinA into upper and lower limbs in spastic hemiparesis: baseline data from the ENGAGE study

J-M. Gracies, G. Francisco, R. Jech, S. Khatkova, C. Rios, P. Maisonobe (Créteil, France)

1:45pm-3:15pm: Harmonics: A reliable marker in tremor analysis for the differential diagnosis of Parkinson’s disease and multiple system atrophy

D. Su, S. Yang, J. Zhou, H. Pan, T. Feng (Beijing, China)

1:45pm-3:15pm: Health-related quality of life in cervical dystonia; the hidden and unaddressed effect of anxiety

I. Ndukwe, P. Lynch, J. Dover, C. O’Neill, F. O’Keeffe, S. O'Riordan, M. Hutchinson (Dublin, Ireland)

1:45pm-3:15pm: Healthcare disparities in patients with Parkinson’s disease: A comprehensive literature review and call to action

S. Naik, V. Holiday, L. Dixon, M. Kolikonda, K. Lafaver (Louisville, KY, USA)

1:45pm-3:15pm: Hemifacial Involvement in a Patient with Oculopalatal Tremor Due to Inferior Olivary Hypertrophy

C. Gill, M. Bailey (Chicago, IL, USA)

1:45pm-3:15pm: Hemifacial Spasm and Related Comorbidities

A. Akyol Gurses, N. Kiylioglu, A. Akyol (Aydin, Turkey)

1:45pm-3:15pm: Hereditary spastic paraplegia 11 is easy to be misdiagnosed as adult metachromatic leukodystrophy

S. Park, AR. Kim, N. Kim, WY. Park, JS. Kim, ES. Oh (Seoul, Republic of Korea)

1:45pm-3:15pm: Heterogeneous patterns of striatal dopamine loss in patients with young- versus old-onset Parkinson’s disease

NE. Woo, SJ. Chung, HS. Yoo, YH. Lee, PH. Lee, YH. Sohn (Seoul, Republic of Korea)

1:45pm-3:15pm: High cost of medications for Parkinson’s Disease patients in a rural population of Gujarat, India

A. Pandya, E. Albert-Stone, A. Deb, S. Desai (Worcester, MA, USA)

1:45pm-3:15pm: High intensity interval training elevates circulating BDNF and miRNAs level in patients with idiopathic Parkinson’s disease

P. Malczynska, B. Kaminski, M. Siemiatycka, A. Pawłowska, I. Przybylska, J. Langfort, J. Marusiak, M. Chalimoniuk (Warsaw, Poland)

1:45pm-3:15pm: High repressive activity of olive extracts on the cell line model of Parkinson disease against ROS induction

D. Morshedi (Tehran, Islamic Republic of Iran)

1:45pm-3:15pm: High-Beta and High-Gamma Power Oscillations from Subthalamic Nucleus distinguishes Parkinson’s Disease Subtypes

F. Godinho, J. Luccas, B. Bianqueti, A. Fim Neto, T. Almeida, MS. Rocha, T. Yoneyama, D. Soriano (São Bernardo, Brazil)

1:45pm-3:15pm: High-throughput screening using a Drosophila model of Parkinson’s disease

FJ. Lopez, C. Solana, E. Masia, MJ. Vicent, N. Paricio (Valencia, Spain)

1:45pm-3:15pm: Hip fracture in patients with a new diagnosis of Parkinson’s Disease – estimating the 5-year risk

L. Evans, A. Johansen, B. Mohamed, EC. Thomas (Cardiff, United Kingdom)

1:45pm-3:15pm: Holmes Tremor : contribution of Botulinum toxin injection strategy guided by electromyographic (EMG) polygraphic recording

F. Jomier, Y. Beaugendre Ahmar, E. Apartis, D. Grabli (Paris, France)

1:45pm-3:15pm: Hoover’s Sign in Parkinson’s Disease

A. Vasilenko, M. Karpova (Chelyabinsk, Russian Federation)

1:45pm-3:15pm: How cognitive effort increases Parkinson’s tremor – an effictive connectivity fMRI study

MF. Dirkx, H. Zach, A. van Nuland, BR. Bloem, I. Toni, R. Helmich (Nijmegen, Netherlands)

1:45pm-3:15pm: Hydrocephalic presentation of PSP and follow-up after ventricular-peritoneal shunting: Case report

A. Taskinbayeva, CH. Shashkin, R. Kaiyrzhanov (Almaty, Kazakhstan)

1:45pm-3:15pm: Hypothalamic functional connectivity correlates with autonomic symptom burden in patients with Multiple System Atrophy

M. Sklerov, N. Browner, D. Drazheva, E. Dayan (Chapel Hill, NC, USA)

1:45pm-3:15pm: Identification of potential new genes involved in autosomal recessive forms of Parkinson’s disease

C. Tesson, A. Honoré, V. Drouet, H. Bertrand, S. Lesage, A. Brice (Paris, France)

1:45pm-3:15pm: Identification of protein biomarker/s in CSF of Parkinson’s disease (PD) with cognitive impairment

A. Naskar, A. Stezin, D. Gadara, S. Ahuja, V. Menon, N. Kamble, J. Saini, S. Hegde, U. Tatu, P. Pal, P. Alladi (Bangalore, India)

1:45pm-3:15pm: Identifying genetic Parkinson’s disease patients worldwide: Exploiting novel ways of team science

E-J. Vollstedt, M. Kasten, C. Klein (Lübeck, Germany)

1:45pm-3:15pm: Identifying healthy Parkin mutation carriers based on sensor-based posturography and gait analysis

J. Prasuhn, M. Borsche, A. Hicks, M. Gögele, C. Egger, C. Kritzinger, L. Langlott, M. Kasten, C. Klein, P. Pramstaller, N. Brüggemann (Lübeck, Germany)

1:45pm-3:15pm: Identifying Incident Cases of Neurodegenerative Parkinsonism in a Large Observational At-Risk Cohort: the PPMI study

L. Chahine, K. Kieburtz, M. Brumm, C. Caspell-Garcia, C. Coffey, A. Siderowf, D. Weintraub, C. Tanner, T. Foroud, D. Galasko, B. Mollenhauer, T. Simuni, K. Marek (Pittsburgh, PA, USA)

1:45pm-3:15pm: Identifying perceptual, motor and cognitive components contributing to the slowness of information processing in Parkinson’s disease and the implication in the quality of life

A. Arroyo, J. Andreo, J. Periañez, G. Lubrini, M. Rios, JP. Romero (Pozuelo de Alarcon, Spain)

1:45pm-3:15pm: Impact of a high-fat diet on the behavior of A53T alpha-Synuclein Parkinson’s disease mice

M. Temmel, V. Niederkofler, R. Rabl, H. Roemer, B. Hutter-Paier (Grambach, Austria)

1:45pm-3:15pm: Impact of fixed or flexible abobotulinumtoxinA injection intervals on patient outcomes: Analyses from a 3-year observational study following patients with cervical dystonia

C. Colosimo, T. Chung, D. Charles, V. Misra, S. Om, P. Maisonobe (Terni, Italy)

1:45pm-3:15pm: Impact of OFF periods on aspects of employment for people with Parkinson’s disease

I. Iresha Abeynayake, L. Marinucci, M. Klingler, C. Kenney (Aardsley, NY, USA)

1:45pm-3:15pm: Impact of overweight and obesity on functional and clinical outcomes of early Parkinson’s disease

R. Kim, JS. Jun (Seoul, Republic of Korea)

1:45pm-3:15pm: Impact of quantitative assessment of parkinsonian symptoms using wearable technology on treatment decisions

C. Thomas, B. Mohamed, M. Silverdale, C. Kobylecki, L. Osborne, R. Saha, P. Bain, D. Heisters, C. Carroll (Cardiff, United Kingdom)

1:45pm-3:15pm: Impaired intracortical inhibition predicts response to medication in Parkinson’s disease patients

SR. Filipović, A. Kačar, S. Milanović, M. Ljubisavljević, VS. Kostić (Beograd, Serbia)

1:45pm-3:15pm: Impaired LTP-like plasticity in Parkinson’s Disease can be restored by γ-transcranial alternating current stimulation

A. Guerra, A. Suppa, F. Asci, V. D'Onofrio, V. Sveva, M. Bologna, A. Berardelli (Rome, Italy)

1:45pm-3:15pm: Impaired lysosomal catabolism of alpha-synuclein in parkinsonian LRRK2(R1441G) mutant mouse embryonic fibroblasts

WL. Ho, CT. Leung, HF. Liu, LF. Li, DB. Ramsden, SL. Ho (Hong Kong, Hong Kong)

1:45pm-3:15pm: Improvement of Essential Tremor after Cortical Cerebral Infarction

D. Riley (Warrensville Heights, OH, USA)

1:45pm-3:15pm: Improvement of lower extremity Holmes tremor with intrathecal baclofen: First Report

S. Saad, C. Kilbane, H. Abboud (Cleveland, OH, USA)

1:45pm-3:15pm: Improving neuroprotective effects of resveratrol by brain targeting through chitosan glutamate nanoparticles in MPTP induced parkinsonism

M-R. Rahman, V-K. Kumar (Allahabad, India)

1:45pm-3:15pm: Improving outcomes in hospitalized Parkinson’s patients

S. Aslam, E. Simpson, M. Baugh, H. Shill (Phoenix, AZ, USA)

1:45pm-3:15pm: Impulse control disorders and (romantic) jealousy in Parkinson’s disease: a patients’ vs. partners’ perspective

E. Pipan, S. Delalić, A. Herzog, M. Trošt, Z. Pirtošek, D. Flisar, N. Kovacs, D. Georgiev (Ljubljana, Slovenia)

1:45pm-3:15pm: Incidence of drooling in Parkinson’s Disease and Impact on Quality of Life

B. Gibbons, B. Mohamed, C. Thomas (Cardiff, United Kingdom)

1:45pm-3:15pm: Increased Brain-Chin/Leg EEG Synchronicity in Sleep in Parkinson’s Disease

O. Vaou, A. Depold Hohler, J. Wang, X. Zhang, F. Lombardi, A. Quaicoe, R. Endalapur, J. Holsapple, P. Ivanov (Boston, MA, USA)

1:45pm-3:15pm: Increased lysosphingolipids levels in blood of patients with multiple system atrophy

K. Senkevich, G. Baydakova, A. Emelyanov, M. Nikolaev, A. Kopytova, I. Miliukhina, E. Gracheva, A. Kudrevatykh, I. Krasakov, L. Khublarova, I. Fursova, Y. Irishina, N. Zalutskaya, Y. Beltseva, E. Zakharova, S. Pchelina (Saint-Petersburg, Russian Federation)

1:45pm-3:15pm: Increased vesicular monoamine transporter alleviate MPTP-induced impairment of neurogenesis

K. Ma, G. Zhang, C. Han, X. Guo, Y. Xia, F. Wan, L. Kou, S. Yin, L. Liu, N. Xiong, J. Huang, T. Wang (Wuhan, China)

1:45pm-3:15pm: Inertial Sensor-Based Tremor and Bradykinesia Quantification and Potential for Early Disease Identification in Fragile X-associated Tremor/Ataxia Syndrome (FXTAS)

D. Bang, D. Hall, J. Joyce, E. Robertson, G. Pal, J. O'Keefe (Chicago, IL, USA)

1:45pm-3:15pm: Influence of peripheral immune system on cognitive profile in Parkinson’s disease

L. Magistrelli, E. Storelli, V. Milner, E. Rasini, F. Marino, M. Cosentino, C. Comi (Varese, Italy)

1:45pm-3:15pm: Influence of spatial filtering on EEG signal stochasticity measurements in Parkinson’s Disease

D. Herraez-Aguilar, A. Maitín, R.. Perezzan, D. Del Castillo, I. Serrano, E. Rodríguez, E. Rocon, A. Arroyo, J. Andreo, J. Romero (Pozuelo de Alarcon, Spain)

1:45pm-3:15pm: Inﬂuence of the spinal manipulation on muscle spasticity: a randomized controlled trial

L. Shestopalova, T. Voloshyn (Truskavets, Ukraine)

1:45pm-3:15pm: Inhibitory Repetitive Transcranial Magnetic Stimulation of Pre-Supplementary Motor Area Improves Levodopa-Induced Dyskinesia in Parkinson’s Disease

A. Lohse, D. Meder, D. Herz, A. Løkkegaard, H. Siebner (Copenhagen, Denmark)

1:45pm-3:15pm: Initial Validation of the Cortical Basal ganglia Functional Scale (CBFS) in two international, multicenter cohorts: 4RTNI and PROSPECT

A. Boxer, P. Wang, H. Morris, G. Stebbins, A. Lang (Toronto, ON, Canada)

1:45pm-3:15pm: Insight into the heterogeneity of essential tremor

G. Paparella, M. Bologna, I. Berardelli, G. Ferrazzano, L. Angelini, P. Giustini, D. Alunni-Fegatelli, A. Berardelli (Rome, Italy)

1:45pm-3:15pm: Intact visuomotor forward models in adults with Tourette Syndrome

A. Djodari-Irani, L. Kurvits, T. Mainka, A. Kühn, C. Ganos, F. Ostendorf (Berlin, Germany)

1:45pm-3:15pm: Interactions within Fine Motor Control Network in Task-specific Dystonia

S. Merchant, E. Frangos, S. Horovitz, T. Popa, J. Parker, M. Hallett (Charleston, SC, USA)

1:45pm-3:15pm: Interleaving stimulation in Parkinson’s disease: interesting to whom?

C. França, E. Barbosa, R. Iglesio, M. Teixeira, R. Cury (São Paulo, Brazil)

1:45pm-3:15pm: Interleaving stimulation mode can improve better the health-related quality of life in primary generalized or segmental dystonia than standard bilateral pallidal deep brain stimulation

N. Kovács, A. Juhasz, D. Pintér, M. Harmat, I. Balás, J. Janszky (Pécs, Hungary)

1:45pm-3:15pm: Investigating Physical and Cognitive Changes over Two Years in Patients with Moderate to Late Stage Parkinson’s Disease in Northumbria

L. Macdonald, I. Sayers, S. Dempsey, W. Gray, A. Hand, R. Walker (North Shields, United Kingdom)

1:45pm-3:15pm: Investigating the cellular role of LRRK2 in the immune system

I. Nazish, R. Bandopadhyay (London, United Kingdom)

1:45pm-3:15pm: Investigation of the Effects of Propranolol on DRD3, SLC1A2 and HTRA2 Gene Expression in Patients with Essential Tremor

M. Gultekin, N. Kandemir, M. Mirza, M. Kara, N. Tascıoglu, M. Dundar (Kayseri, Turkey)

1:45pm-3:15pm: Ipsilateral worsening of essential tremor by thalamic deep brain stimulation

U. Hidding, C. Choe, B. Müller, C. Buhmann, W. Hamel, C. Moll, C. Gerloff, M. Pötter-Nerger, S. Zittel (Hamburg, Germany)

1:45pm-3:15pm: Is directional stimulation of the VIM superior to omnidirectional stimulation in patients with essential tremor?

S. Fliegen, P. Nikolov, C. Hartmann, P. Slotty, J. Vesper, A. Schnitzler, S. Groiß (Düsseldorf, Germany)

1:45pm-3:15pm: Is primary writing tremor a form fruste of dystonia?

A. Latorre, L. Rocchi, A. Berardelli, J. Rothwell, K. Bhatia (Rome, Italy)

1:45pm-3:15pm: Is safinamide helpful in multiple system atrophy?

R. Simões, A. Gonçalves, JJ. Ferreira (Lisboa, Portugal)

1:45pm-3:15pm: Is teleneurology effective in screening for spasticity?

K. Harper, B. Eoff, F. Phibbs, D. Isaacs, S. Gallion, E. Thomas, J. Scott, M. Hacker, D. Charles (Nashville, TN, USA)

1:45pm-3:15pm: Is the personal Kinetigraph useful in the management of Parkinson´s disease patients? A retrospective study from a tertiary movement disorder center

E. Krause, J. Randhawa, R. Mehanna (Houston, TX, USA)

1:45pm-3:15pm: Is there evidence of bradykinesia in patients with Essential Tremor?

D. Colella, M. Bologna, G. Paparella, A. Cannavacciuolo, S. Pietracupa, A. Guerra, A. Berardelli (Rome, Italy)

1:45pm-3:15pm: Is VIM-DBS in ET-plus patients as effective as in ET patients?

J. Steffen, J. Petry-Schmelzer, T. Dembek, J. Becker, G. Fink, V. Visser-Vandewalle, M. Barbe (Cologne, Germany)

1:45pm-3:15pm: K0706, A Potent Orally Bioavailable Brain-Penetrating Selective Inhibitor of cABL Protein Tyrosine Kinase, Exhibits Neuroprotective Activity in Preclinical Models of Parkinson’s Disease

S. Mandhane, D. Soni, K. Jani, P. Sengupta, A. Patel, R. Bambal, V. Ramanathan, Y. Zala, N. Dharmadhikari, C. Rao, A. Raghavan, N. Damle (Vadodara, India)

1:45pm-3:15pm: Kinematic Analysis of Facial, Upper and Lower Limb Bradkinesia in Parkinson’s Disease

A. Cannavacciuolo, M. Bologna, A. Formica, D. Colella, G. Paparella, A. Guerra, A. Berardelli (Rome, Italy)

1:45pm-3:15pm: Language disorders in Progressive Supranuclear Palsy: an underestimated condition?

E. Del Prete, L. Tommasini, D. Frosini, S. Mazzucchi, C. Pagni, U. Bonuccelli, R. Ceravolo (Pisa, Italy)

1:45pm-3:15pm: Left STN DBS And Right CZI DBS In A Patient With Tremor-Predominant Parkinson’s Disease

T. Ali, D. Ginjupally, G. Quintero, C. van Horne, Z. Guduru (Lexington, KY, USA)

1:45pm-3:15pm: Levodopa Induced dyskinesia in patients with Parkinson’s disease and polymorphisms gene DRD3 dopamine receptor

I. Zhukova, N. Zhukova, E. Kolupaeva, S. Ivanova, M. Nikitina, O. Izhboldina, I. Mironova (Tomsk, Russian Federation)

1:45pm-3:15pm: Levodopa response in later stages of Parkinson’s disease: a case-control study

M. Fabbri, M. Coelho, D. Abreu, L. Guedes, M. Rosa, A. Antonini, J. Ferreira (Lisbon, Portugal)

1:45pm-3:15pm: Levodopa-carbidopa intestinal gel infusion: a video analysis of long-term effect on gait and posture

C. Pongmala, M. Fabbri, CA. Artusi, M. Zibetti, L. Lopiano (Turin, Italy)

1:45pm-3:15pm: Limitations of Curcumin as a Therapeutic Agent in Rotenone Induced Dopaminergic Neurodegeneration: Insights from Drosophila Model of Parkinson’s Disease

M. Ayajuddin, SC. Yenisetti (Zunheboto, India)

1:45pm-3:15pm: Lip movement contribution in speech production of persons with Parkinson’s Disease

P. Upadhyay, S. Gudwani, K. Sharma, R. Sagar, R. Dhamija, S. Kumaran (New Delhi, India)

1:45pm-3:15pm: Liquid Levodopa/Carbidopa – An underutilized, cost effective treatment of advanced Parkinson’s disease in the developing world

A. Panwar, N. Sawal (Chandigarh, India)

1:45pm-3:15pm: Local beta band synchronization predicts clinically-selected deep brain stimulation contact in Parkinson’s disease patients

W. Lipski, HJ. Park, A. Jorge, A. Kent, Y. Pathak, RM. Richardson (Pittsburgh, PA, USA)

1:45pm-3:15pm: Long-term adherence with wearing a multi-sensor watch in the Personalized Parkinson Project

L. Evers, R. Kapur, T. V.D. Zande, M. Meinders, B. Bloem, W. Marks, JR. (Nijmegen, Netherlands)

1:45pm-3:15pm: Long-term effect of levodopa-carbidopa intestinal gel on axial signs in Parkinson’s disease

M. Fabbri, P. Chatkaew, C. Artusi, A. Romagnolo, M. Rizzone, M. Zibetti, L. Lopiano (Turin, Italy)

1:45pm-3:15pm: Long-Term Effects of LPS and Alcohol in Rats: A Model of Neuro-Degenerative Disease

M. Schiess, M. Doursout, J. Campo, Z. Peng, A. Sundaresan, S. Umar (Lawrence, KS, USA)

1:45pm-3:15pm: Long-term treatment of cervical dystonia with abobotulinumtoxinA

A. Jochim, T. Meindl, T. Mantel, S. Zwirner, F. Castrop, B. Haslinger (Munich, Germany)

1:45pm-3:15pm: Longitudinal assessment of genetic determinants of cognitive decline in Parkinson’s disease

M. Bakeberg, A. Jefferson, M. Byrnes, S. Ghosh, F. Mastaglia, R. Stell, J. Kenna, S. Walters, M. Hoes, A. Ford, R. Anderton (Nedlands, Australia)

1:45pm-3:15pm: Longitudinal progression of spatiotemporal parameters of turning in idiopathic Parkinson’s disease patients with Freezing of Gait

L. Pillai, A. Glover, T. Virmani (Little Rock, AR, USA)

1:45pm-3:15pm: Longstanding cervical dystonia followed by parkinsonism – coincidence, risk factor or syndromic association?

B. Balint, F. Gövert, A. Latorre, E. Mulroy, R. Erro, A. Batla, T. Warner, K. Bhatia (London, United Kingdom)

1:45pm-3:15pm: Machine learning classifiers and subjective vocal perception of Parkinson’s disease patients and healthy control

Y. Manor, S. Naor, D. Shpunt, N. Diamant, A. Hillel, A. Ezra, I. Opher, Y. Hauptman, R. Aloni-Lavi, A. Faust-Socher, H. Shabtai, R. Peled, A. Migirov, T. Gurevich (Tel Aviv, Israel)

1:45pm-3:15pm: Management of poor response to Botulinum toxin in cervical dystonia: a multicentre audit

H. Tucker, F. Osei-Poku, D. Ashton, R. Lally, J. Alty, C. Kobylecki (Salford, United Kingdom)

1:45pm-3:15pm: MDS Translation Program for MDS-UPDRS and UDysRS

S. Luo, N. Lapelle, P. Martin, C. Goetz, G. Stebbins (Durham, NC, USA)

1:45pm-3:15pm: MDS-UPDRS Part III predictors of Part II Item Scores in PPMI

J. Cedarbaum, Z. Xiao, M. Yang (Cambridge, MA, USA)

1:45pm-3:15pm: Measuring perceived-health status in Parkinson’s Disease – the role of London Handicap Scale

D. Silva, M. Coelho, T. Soares, T. Vale, L. Guedes, R. Maciel, A. Antunes, S. Camargos, A. Valadas, C. Godinho, D. Maia, P. Lobo, R. Maia, T. Teodoro, C. Rieder, A. Velon, M. Rosas, A. Calado, V. Caniça, F. Cardoso, J. Ferreira (Lisbon, Portugal)

1:45pm-3:15pm: Measuring progression of nigrostriatal degeneration in Parkinson’s disease using 18F-AV-133 vesicular monoamine transporter type-2 (VMAT2) PET

S. Xu, V. Dore, P. Alexander, Y. Lie, S. Bozinovski, R. Mulligan, K. Young, V. Villemagne, C. Rowe (Melbourne, Australia)

1:45pm-3:15pm: Medical and Device-Guided Therapies and Deep Brain Stimulation in Parkinson’s disease: Experience of a Tertiary Centre from Turkey

Y. Sucullu Karadag, D. Divanlıoglu, E. Kocabicak, N. Subutay Oztekin, D. Belen (Ankara, Turkey)

1:45pm-3:15pm: Medical management after subthalamic nucleus deep brain stimulation in patients with Parkinson’s Disease

A. Bertholo, R. Cury (São Paulo, Brazil)

1:45pm-3:15pm: Memantine and 3D gait analysis in patient with Parkinson’s disease: an observer-blind randomized clinical trial

I. Miliukhina, E. Gracheva (Saint-Petersburg, Russian Federation)

1:45pm-3:15pm: Memory enhancing effect of Combined Alcoholic Extract of Cedrus deodara Loud. and Vitex Nirgundi in scopolamine-induced cognitive impairment in mice

A. Jain, S. Jain (Sagar, India)

1:45pm-3:15pm: MEMs-based Measurement and Classification System of Tremors in Parkinson Disease using MDS-UPDRS Scale as a Parameter

A. Delatorre, J. Marques (Florianópolis, Brazil)

1:45pm-3:15pm: Metabolic syndrome and insulin resistance in Parkinson’s disease: could they affect motor or cognitive symptoms?

M. Hussein, A. Khamis, R. Soliman, S. Ali (Beni Suef, Egypt)

1:45pm-3:15pm: Microstructural Changes in Basal Ganglia and Cerebellar Networks in Patients with Idiopathic Blepharospasm

M. Esposito, T. Yousaf, H. Wilson, S. Peluso, L. Santoro, F. Manganelli, G. Pagano, M. Politis (Naples, Italy)

1:45pm-3:15pm: Modeling the Effect of Patient’s Perception of Non-Motor and Motor Function on Parkinson’s Disease Severity

C. Goetz, S. Luo, G. Stebbins (Chicago, IL, USA)

1:45pm-3:15pm: Modifiable factors and progression of motor symptoms and cognitive decline in Parkinson’s disease

E. Forbes, T. Tropea, S. Mantri, J. Morley (Philadelphia, PA, USA)

1:45pm-3:15pm: Modulation of cerebellar and basal ganglia loops affects vestibular processing in Parkinson’s disease

J. Liao, C. Mcintyre, A. Shaikh (Cleveland, OH, USA)

1:45pm-3:15pm: Monitoring Parkinson’s disease symptoms during daily life: A feasibility study

M. Heijmans, J. Habets, C. Herff, M. Kuijf, P. Kubben (Maastricht, Netherlands)

1:45pm-3:15pm: Motor and Non-Motor Symptom Burden in Parkinsonian and Cerebellar Phenotypes of Probable MSA

M R. Rukmani, R. Yadav, P K. Pal, B. Bhaskarapillai, T N. Sathyaprabha (Bangalore, India)

1:45pm-3:15pm: Motor and non-motor symptoms in the prediagnostic phase of progressive supranuclear palsy: the Step-Back PSP study.

C. Painous, C. Simonet, A. Garrido, N. Caballol, M. Guasp, A. Cámara, F. Valldeoriola, JE. Muñoz, MJ. Martí, Y. Compta (Barcelona, Catalonia)

1:45pm-3:15pm: Motor intracortical excitability before speech onset in adults who stutter

A. Elfers, S. Hommel, N. Neef, AW. von Gudenberg, W. Paulus, M. Sommer (Bad Emstal, Germany)

1:45pm-3:15pm: Motor learning and long duration response to levodopa in Parkinson’s disease.

G. Sciacca, G. Mostile, I. Disilvestro, G. Donzuso, R. Manna, G. Portaro, C. Rascunà, S. Salomone, F. Drago, A. Nicoletti, M. Zappia (Catania, Italy)

1:45pm-3:15pm: Motor Response Inhibition – A potential tool to determine optimum STN-DBS setting

H. Kumar, A. Roy, S. Choudhury, P. Basu, M. Baker, S. Baker (Kolkata, India)

1:45pm-3:15pm: Motor Responses to Apomorphine Sublingual Film Compared With Levodopa in Patients With Parkinson’s Disease and “OFF” Episodes: Post Hoc Analysis From a Phase 3 Study

J. Hui, S. Fox, W. Neeson, P. Bhargava, E. Pappert, D. Blum, B. Navia (Los Angeles, CA, USA)

1:45pm-3:15pm: Motor-based assessment of prodromal Parkinson’s disease combining wearable sensors and machine learning

E. Rovini, A. Moschetti, L. Fiorini, D. Esposito, C. Maremmani, F. Cavallo (Pontedera, Italy)

1:45pm-3:15pm: Movement disorders associated with intracranial and extracranial artery diseases

N. Choi, KW. Park, S. Jo, SJ. Chung (Seoul, Republic of Korea)

1:45pm-3:15pm: MRI cortical layer study in patients with Parkinson’s disease in Uzbekistan

A. Umarov, D. Tolibov (Tashkent, Uzbekistan)

1:45pm-3:15pm: Multiple System Atrophy – perspectives in diagnosis?

P. Alster, D. Koziorowski, L. Królicki, A. Friedman (Warsaw, Poland)

1:45pm-3:15pm: Multiple system atrophy with predominant striato-nigral degeneration (MSA-P) and TDP-43 pathology: an unusual pathologic variant of MSA

L. Nwabuobi, D. Tomishon, N. Shneider, S. Fahn, J. Vonsattel, E. Cortes (New York, NY, USA)

1:45pm-3:15pm: Multiple System Atrophy: phenotypic spectrum approach coupled with brain FDG PET

A. Eusebio, E. Guedj, JP. Azulay, M. Renaud, M. Boucekine, S. Grimaldi (Marseille, France)

1:45pm-3:15pm: Musician’s dystonia: results from a large US case series

C. Stephen, M. Charness (Boston, MA, USA)

1:45pm-3:15pm: Myoclonus-Dystonia Syndrome Due to a Novel Mutation in the Epsilon-Sarcoglycan (SGCE) Gene

C. Gonzalez Robles, A. Rojo Sebastian, J. Garcia Diaz (Alcala de Henares, Spain)

1:45pm-3:15pm: Myokymia and Tremor-like Involuntary Movement in A Patient with Chronic Inflammatory Demyelinating Polyradiculoneuropathy

CH. Tsai, Y. Aoh, YC. Guo, MK. Lu (Taichung, Taiwan)

1:45pm-3:15pm: Natural History of Movement Abnormalities on Hereditary Spastic Paraplegia: validation of timed functional instruments

J. Saute, G. Machado, AP. Zanardi, V. Martins, D. Burguêz, L. Jacinto-Scudeiro, E. Monteiro, L. Peyré-Tartaruga (Porto Alegre, Brazil)

1:45pm-3:15pm: Network localization of cervical dystonia based on causal brain lesions

J. Joutsa, D. Corp, R. Darby, C. Delnooz, B. Vande Warrenburg, D. Cooke, C. Prudente, J. Ren, M. Reich, A. Batla, K. Bhatia, H. Jinnah, H. Liu, M. Fox (Boston, MA, USA)

1:45pm-3:15pm: Neuroanatomical and clinical predictors of pain in patients with early de novo Parkinson’s disease

. Cousins, H. Wilson, T. Yousaf, S. Caminiti, M. Politis (London, United Kingdom)

1:45pm-3:15pm: Neuroinflammation and activation of Zif-268 in dyskinetic 6-OHDA-lesioned rats is counteracted by association of a 5-HT1A/1B receptor agonist and an A2A receptor antagonist

A. Pinna, G. Costa, M. Serra, M. Morelli (Monserrato, Italy)

1:45pm-3:15pm: Neuromelamin-MRI in patients with Pure Autonomic Failure

O. Roman, P. Trujillo-Diaz, K. Hay, I. Biaggioni, C. Shibao, D. Claassen (Nashville, TN, USA)

1:45pm-3:15pm: Neuromodulatory potentials of revasterol and Carpogon capitatus Roxb on the rat brain: Novel approach for Parkinson’s diseases

DS. Singh, MS. Singh, PK. Kumar, YK. Gupta (Allahabad, India)

1:45pm-3:15pm: Neuromuscular electrical stimulation for the treatment of jaw-closing dystonia

C. Miller-Patterson, E. Burton (Pittsburgh, PA, USA)

1:45pm-3:15pm: Neuropathy in patients treated with LCIG in the Czech and the Slovak Republic

P. Havránková, J. Klempíř, J. Roth, E. Růžička, M. Baláž, M. Bareš, I. Rektorová, M. Kaiserová, P. Kaňovský, M. Minár, K. Gmitterová, P. Valkovič, M. škorvánek, V. Haň, L. Skička, J. Necpál, M. Grófik, E. Kurča, R. Jech (Praha, Czech Republic)

1:45pm-3:15pm: Neurophysiologic characterization of Re-emergent tremor (RET) in Parkinson’s disease

G. Leodori, D. Belvisi, A. Fabbrini, M. de Bartolo, M. Costanzo, F. Undurraga, A. Conte, A. Berardelli (Bethesda, MD, USA)

1:45pm-3:15pm: Neuroprotective actions of red propolis extract and formononetin in a rat model of Parkinson’s disease

M. Gomes, S. Barroso, J. de Oliveira, D. Marques, A. Santos, J. Cardoso (Aracaju, Brazil)

1:45pm-3:15pm: Neuroprotective effect of crocus sativus in lead-induced dopaminergic neurotoxicity in Meriones shawi: A possible link with Parkinson’s disease

L. Tamegart, A. Abbaoui, R. Makbal, M. Zroudi, M. Bouyatas, B. Bouizgarne, H. Gamrani (Marrakesh, Morocco)

1:45pm-3:15pm: Neuroprotective effect of Lemon oil on 6-OHDA-Induced Apoptosis in PC12 Cells through the ROS-NO Pathway

V. Kumar (Allahabad, India)

1:45pm-3:15pm: Neuroprotective effect of Yerba mate (Ilex paraguariensis) in a Drosophila model of Parkinson ’s disease

P. Ballestero, A. Bernardi, H. Hauche Pedernera, O. Gershanik, N. Muraro, J. Ferrario (Capital Federal, Argentina)

1:45pm-3:15pm: NEUROPSYCHIATRIC SYMPTOMS IN EARLY TO ADVANCED PATIENTS WITH THE RICHARDSON’S SYNDROME VARIANT OF PROGRESIVE SUPRANUCLEAR PALSY

A. Horta-Barba, J. Pagonabarraga, S. Martinez-Horta, B. Pascual-Sedano, J. Marin-Lahoz, J. Perez-Perez, I. Aracil-Bolanos, H. Bejr-Kasem, A. Campolongo, C. Izquierdo, F. Sampedro, J. Kulisevsky (Barcelona, Spain)

1:45pm-3:15pm: New Neuropathological Staging System for Lewy Body Disease

J. Toledo, L. Walker, J. Trojanowski, I. Mckeith, J. Attems (Houston, TX, USA)

1:45pm-3:15pm: Nigral Iron Load as Diagnostic Parameter in Parkinson’s Disease

S. Franthal, L. Pirpamer, N. Homayoon, M. Koegl, P. Katschnig-Winter, K. Wenzel, C. Langkammer, S. Ropele, F. Fazekas, R. Schmidt, P. Schwingenschuh (Graz, Austria)

1:45pm-3:15pm: Nigrostriatal degeneration in DYT-PRKRA: new insights on a rare disorder

MJ. Pinto, J. Massano, MJ. Rosas, A. Oliveira (Porto, Portugal)

1:45pm-3:15pm: No difference in balance and gait parameters of the patients with akinetic-rigid and tremor-dominant Parkinson’s disease

AC. Kalkan, T. Kahraman, BO. Ugut, B. Donmez Colakoglu, A. Genc (Izmir, Turkey)

1:45pm-3:15pm: No evidence for early emotional processing in the subthalamic nucleus – a single neuron study

T. Sieger, T. Serranová, F. Růžička, D. Urgošík, R. Jech (Prague, Czech Republic)

1:45pm-3:15pm: Nocturnal stridor in multiple system atrophy: video-polysomnography and clinical features

H. Ryu, J. Paek, S. You, M. Kim, Y. Kim, J. Kim, K. Kim, S. Lee, S. Chung (Daegu, Republic of Korea)

1:45pm-3:15pm: Non-motor symptoms and risk of functional dependency in early Parkinson’s disease

R. Kim, D. Yoo, JH. Im, HJ. Kim, B. Jeon (Seoul, Republic of Korea)

1:45pm-3:15pm: Non-motor symptoms contribute to the caregiver burden in Progressive Supranuclear Palsy

ZC. Chen, YM. Liu (Jinan, China)

1:45pm-3:15pm: Non-motor symptoms in Myoclonus-Dystonia: a comparison to other dystonia subtypes

E. Timmers, M. Smit, A. Kuiper, A. Bartels, S. Vander Veen, A. Vander Stouwe, P. Santens, B. Bergmans, M. Tijssen (Groningen, Netherlands)

1:45pm-3:15pm: Novel familial HPCA mutation associated with autosomal recessive dystonia: Strengthening the role of HPCA in hereditary movement disorders.

S. Siegert, W. Schmidt, R. Bittner, S. Gobara, M. Freilinger (Vienna, Austria)

1:45pm-3:15pm: Nrf2 pathway in patients with Parkinson’s disease

T. Schirinzi, S. Petrillo, G. Di Lazzaro, N. Mercuri, E. Bertini, F. Piemonte, A. Pisani (Rome, Italy)

1:45pm-3:15pm: Nutritional status in patients with Parkinson’s disease and its relationship with the motor phenotype.

R. Cruz, J. Balderas, C. Navarro, L. Zuazua, M. Rodriguez, A. Cervantes (Mexico City, Mexico)

1:45pm-3:15pm: Objective assessment of motor states in Parkinson’s disease using partial least squares and smartphone data

M. Memedi, S. Aghanavesi (Borlänge, Sweden)

1:45pm-3:15pm: Objective evaluation criteria for diagnosis of spasmodic dysphonia

K. Kleim, K. Simonyan, T. Ball (Freiburg, Germany)

1:45pm-3:15pm: Ocular Motor Dysfunction as the Predictable Milestone of Life Prognosis in Progressive Supranuclear Palsy

T. Ishihara, T. Oeda, S. Tomita, A. Umemura, M. Kohsaka, K. Park, M. Tahara, K. Yamamoto, H. Sawada (Kyoto, Japan)

1:45pm-3:15pm: Oculopalatal tremor (OPT) in a patient with anti-GAD brainstem encephalitis: A case report

MF. Ip, SH. Li, TY. Wai, LY. Wong (Sheung Shui, Hong Kong)

1:45pm-3:15pm: OnabotulinumtoxinA Reduces Disability in Treatment-Naive Adult Patients with Spasticity: Results from the ASPIRE Study

W. Jost, A. Ellenbogen, G. Wittenberg, K. Ngo, J. Largent, A. Zuzek, G. Francisco, A. Esquenazi (Irvine, CA, USA)

1:45pm-3:15pm: OnabotulinumtoxinA treatment in adults with spasticity reduces caregiver burden: Results from the ASPIRE study

A. Esquenazi, A. Ellenbogen, G. Wittenberg, K. Ngo, J. Largent, A. Zuzek, G. Francisco, W. Jost (Elkins Park, PA, USA)

1:45pm-3:15pm: Optimal Parameters of Deep Brain Stimulation in Essential Tremor: A Meta-Analysis and Novel Programming Strategy

D. Bogdan, T. van Laar, M. Oterdoom, G. Drost, M. van Dijk, M. Beudel (Groningen, Netherlands)

1:45pm-3:15pm: Oromandibular Dystonia: Clinical Data from 68 Patients

M. Balal, M. Demirkiran (Adana, Turkey)

1:45pm-3:15pm: Orthostatic jaw tremor, a diagnostic challenge

R. Moraes, F. Sousa, P. Pereira, J. Freitas, L. Santos, J. Junior, M. Rocha (Sao Paulo, Brazil)

1:45pm-3:15pm: Orthostatic tremor – a case series

L. Colmenares, L. Jones, Y. Tai, P. Bain (London, United Kingdom)

1:45pm-3:15pm: Orthostatic Tremor Mimics: A Case Series

M. Minar, I. Straka, Z. Kosutzka (Bratislava, Slovakia)

1:45pm-3:15pm: Oscillaotory activity in the globus pallidus internus in patients with Parkinson’s disease

P. Zhuang, M. Hallett, D. Meng, Y. Zhang, J. Li, J. Li (Beijing, China)

1:45pm-3:15pm: Osteopathic Manipulative Medicine to Improve Balance and Quality of Life in Parkinson Disease

S. Yao, J. Docherty, J. Mancini, A. Leder, J. Difrancisco-Donoghue (Old Westbury, NY, USA)

1:45pm-3:15pm: Overnight unilateral withdrawal of VIM-DBS to identify reversibility of gait disturbances

D. Kroneberg, D. Kübler, B. Al-Fatly, AC. Meyer, GH. Schneider, A. Kühn (Berlin, Germany)

1:45pm-3:15pm: Pain assessment and pain management study in patients with Parkinson’s disease in Uzbekistan

A. Umarov, D. Tolibov (Tashkent, Uzbekistan)

1:45pm-3:15pm: Pain in patients with multiple system atrophy: a pain-related evoked potential study

M. Takeda, F. Okada, H. Tachibana, S. Kasama, H. Yoshikawa (Nishinomiya, Japan)

1:45pm-3:15pm: Parkinson Disease Clinical Subtypes Predict Dementia and Mortality Risk

P. Myers, M. Campbell, A. Weigand, N. Cairns, J. Jackson, C. Lessov-Schlaggar, J. Perlmutter (St. Louis, MO, USA)

1:45pm-3:15pm: PARKINSON DISEASE HAMPERS PARTICIPATION IN THE CIVIC RESPONSIBILITY OF VOTING: a study of barriers to expression of a fundamental human right

O. Oguntunde, O. Ojo, O. Agabi, M. Rizig, N. Okubadejo (Lagos, Nigeria)

1:45pm-3:15pm: Parkinson’s Disease Presentation in Calabar, Nigeria

S. Oparah, U. Williams, J. Mwankon (Calabar, Nigeria)

1:45pm-3:15pm: Parkinson’s disease-associated mutations of PLA2G6 alters the membrane dynamics and α-synuclein stability

ａ. Mori, T. Hatano, T. Inoshita, K. Shiba-Fukushima, T. Koinuma, C. Yamashita, A. Okuzumi, Y. Imai, ｎ. Hattori (Tokyo, Japan)

1:45pm-3:15pm: Parkinson’s disease and melanoma: a serie of 33 patients

J. Doridam, M. Nader, A. Melin, MF. Avril, E. Maubec, B. Degos (Paris, France)

1:45pm-3:15pm: Parkinson’s disease polygenic risk score is not associated with impulse control disorders: a longitudinal study

J. Ihle, F. Artaud, S. Bekadar, G. Magnone, H. Bertrand, S. Sambin, LL. Mariani, C. Scherzer, A. Elbaz, JC. Cornol (Paris, France)

1:45pm-3:15pm: Parkinsonian syndrome associated to C9orf72 expansion

S. Novo Ponte, E. Gamo González, P. Sánchez Alonso (Majadahonda, Spain)

1:45pm-3:15pm: Parkinsonism and rapidly progressive dementia secondary to free-living ameba

M. Rubio Hernandez, I. Rodriguez Leyva, M. Tello Zavala, A. Ortiz Alvarez, C. Gallegos Rios (San Luis Potosi, Mexico)

1:45pm-3:15pm: Parkinsonism in HIV positive persons in South Africa

FH. Amod (Durban, South Africa)

1:45pm-3:15pm: Patient-Centered Outcomes of Deep Brain Stimulation in Parkinson’s Disease

R. Moraes, J. Freitas, R. Ferreira, P. Pereira, P. Terzian, F. Godinho, M. Rocha (Sao Paulo, Brazil)

1:45pm-3:15pm: Patients Experiencing Motor Fluctuations With Parkinson’s Disease (PD): Participant Characteristics in the Accordance Phase 3 Efficacy and Safety Trial of Accordion Pill™ Carbidopa/Levodopa

P. Lewitt, R. Gendreau, J. Meckler, A. Hotovely-Salomon, N. Navon (West Bloomfield, MI, USA)

1:45pm-3:15pm: Pattern and Presentation of Parkinson Disease in two Teaching Hospitals in Enugu, South East Nigeria

B. Ezeala-Adikaibe (Enugu, Nigeria)

1:45pm-3:15pm: Pediatric Deep Brain Stimulation in Secondary Dystonia using Stereotactic Depth Electrode Targeting

M. Liker, T. Sanger (Los Angeles, CA, USA)

1:45pm-3:15pm: Per-oral image guided gastrojejunostomy insertion for levodopa-carbidopa intestinal gel in Parkinson’s disease is safe and may be advantageous

F. Baig, L. Mooney, M. Selikhova, M. Rolinski, K. Szewczyk-Krolikowski, N. Collin, A. Whone (Bristol, United Kingdom)

1:45pm-3:15pm: Peripheral Blood Mononuclear Cells (PBMCs) are Useful Biomarkers of Mitochondrial Dysfunction in Parkinson Disease Patients with Pathogenic Parkin and LRRK2 Mutations

P. Campbell, J. Harvey, A. Costantini, H. Morris, A. Schapira (London, United Kingdom)

1:45pm-3:15pm: Pharmacokinetics of ABBV-951 Following 24-Hour Continuous Subcutaneous Infusion to Arm, Abdomen and Thigh

M. Rosebraugh, P. Kym, W. Liu, M. Facheris, J. Benesh (North Chicago, IL, USA)

1:45pm-3:15pm: Pharmacokinetics of Accordion Pill™ Carbidopa/Levodopa Following Multiple Doses in Patients With Parkinson’s Disease

C. Olanow, F. Stocchi, M. Leinonen, N. Navon, J. Meckler, R. Gendreau (Sarasota, FL, USA)

1:45pm-3:15pm: Phenotypic segregation in kindred with a novel ANO3 variant

V. Carvalho, F. Correia, J. Martins, J. Massano, T. Temudo (Matosinhos, Portugal)

1:45pm-3:15pm: Phenotypic spectrum of Progressive Supranuclear Palsy in a Tunisian cohort

A. Nasri, A. Neji, I. Kacem, T. Lansari, S. Mrabet, A. Gargouri, M. Ben Djebara, R. Gouider (Tunis, Tunisia)

1:45pm-3:15pm: Phenotypic variability and extreme age of presentation of GCH1 gene mutation in dopa-responsive dystonia

F. Abu Ahmad, P. Ponger, M. Rotstein, A. Migirov Sandrovitz, N. Giladi, A. Orr-Urtreger, T. Gurevich, S. Ben-Shachar (Tel Aviv, Israel)

1:45pm-3:15pm: Physiotherapy in cervical dystonia with focus on clinical assessments on ICF

M. Steinboeck, H. Unger (Bad Aibling, Germany)

1:45pm-3:15pm: Plasma-based circulating long non-coding RNA AS-Uch1 as a novel diagnostic biomarker for Parkinson’s disease

Y. Fan, Z. Xue (Wuhan, China)

1:45pm-3:15pm: Population Exposure-Response Modeling of the Effects of Apomorphine Sublingual Film on QTc in Patients With Parkinson’s Disease and “OFF” Episodes

F. Agbo, Y. Chiu, S. Chapel, G. Galluppi, D. Blum, B. Navia (Fort Lee, NJ, USA)

1:45pm-3:15pm: Population Exposure-Response Models of Apomorphine Sublingual Film in Healthy Subjects and Patients With Parkinson’s Disease and “OFF” Episodes

F. Agbo, Y. Chiu, S. Chapel, G. Galluppi, D. Blum, B. Navia (Fort Lee, NJ, USA)

1:45pm-3:15pm: Positive response to Botulinum Toxin injections in a patient with Painless Hand with Moving Fingers: A Case Report and Literature Review

Z. Rosensweet, A. Persaud, E. Gaitour, N. Shneyder (Jacksonville, FL, USA)

1:45pm-3:15pm: Post stroke dystonia and dystonic tremor: Clinical features and neuroimaging findings

S. Pandey, P. Tater (New Delhi, India)

1:45pm-3:15pm: Posterior cortical atrophy (PCA) attributable to corticobasal degeneration

H. Sienkiewicz-Jarosz, E. Bucior (Warsaw, Poland)

1:45pm-3:15pm: Postural Abnormalities in Parkinson’s Disease: an Epidemiological and Clinical Multicenter Study

C. Geroin, M. Gandolfi, R. Ceravolo, M. Capecci, E. Andrenelli, M. Ceravolo, L. Bonanni, M. Onofrj, M. Vitale, M. Catalan, P. Polverino, C. Bertolotti, S. Mazzucchi, S. Giannoni, N. Smania, S. Tamburin, L. Vacca, F. Stocchi, F. Radicati, C. Artusi, M. Zibetti, L. Lopiano, A. Fasano, M. Tinazzi (Verona, Italy)

1:45pm-3:15pm: Postural alterations in patients with Progressive Supranuclear Palsy

C. Palmisano, M. Todisco, V. Maltese, R. Cilia, N. Pozzi, A. Canessa, M. Canesi, J. Volkmann, C. Frigo, G. Pezzoli, I. Isaias (Würzburg, Germany)

1:45pm-3:15pm: Postural instability secondary to hypoxic injury to the bilateral globus pallidi

D. Shpiner, J. Margolesky, H. Moore (Miami, FL, USA)

1:45pm-3:15pm: Pramipexole regulates the depressive-like symptom through dopamine D3 not dopamine D2 receptor in a mouse model of Parkinson’s disease

SZ. Wei, F. Wang, CF. Liu (Suzhou, China)

1:45pm-3:15pm: Predicting domain specific cognitive impairment in Parkinson’s disease

P. Zarifkar, J. Kim, C. La, P. Borghammer, K. Poston (Palo Alto, CA, USA)

1:45pm-3:15pm: Predicting the impact of Parkinson’s disease on a patient’s gait: the potential of innovative approaches based on instrumented clinical tests

K. Lebel, C. Duval, E. Goubault, S. Bogard (Montréal, QC, Canada)

1:45pm-3:15pm: Predictors of quality of life in dystonia – a longitudinal study

J. Junker, J. Hall, B. Berman, M. Vidailhet, E. Roze, I. Malaty, J. Jankovic, S. Reich, A. Espay, N. Patel, J. Perlmutter, H. Jinnah, V. Brandt, N. Brueggemann (Luebeck, Germany)

1:45pm-3:15pm: Predictors of Retention for Carbidopa/Levodopa Intestinal Gel in Parkinson Disease

A. Nagy, T. Davis, T. Hassell, P. Hedera, D. Isaacs, H. Koons, F. Phibbs, S. Afrow, J. Fang (Nashville, TN, USA)

1:45pm-3:15pm: Preferred place of death (PPOD) in PD, PSP and MSA

C. Morris, R. Walker, M. Lee, J. Adamson (Newcastle, United Kingdom)

1:45pm-3:15pm: Prefrontal cortex high beta power correlates with the severity of anxiety and depression in Parkinson’s disease patients

C. de Hemptinne, W. Chen, C. Racine, A. Seritan, J. Mergenthaler, S. Rajagopalan, J. Ostrem, P. Starr (San Francisco, CA, USA)

1:45pm-3:15pm: Pregnancy and Delivery Complications in Women with Inherited Isolated Dystonia

M. San Luciano, V. Shanker, S. Bressman, D. Raymond, R. Saunders-Pullman (San Francisco, CA, USA)

1:45pm-3:15pm: Premature State of Oligodendrocytes Potentially Provides Critical Period for Extracellular Pathological α-Synuclein to Invade Oligodendrocyte Lineage Cells

S. Kaji, T. Maki, T. Ayaki, R. Takahashi (Kyoto, Japan)

1:45pm-3:15pm: Preparing enhanced arm swing facilitates gait initiation in Parkinson’s disease: a combined EEG-EMG-IMU study

J. Weersink, N. Maurits, B. de Jong (Groningen, Netherlands)

1:45pm-3:15pm: Prevalence and Patterns of Rest and Action Tremor in Drug-naïve Parkinson’s Disease

D. Gupta, J. Boyd, S. Kuo (Burlington, VT, USA)

1:45pm-3:15pm: Prevalence and predisposing factors of Parkinson disease: A barangay community-based study in Quezon, Philippines

MC. Rosales, DJ. Robles, RCN. Rodriguez, NB. Romana, JM. Rosales, G. Salazar, R. Rosales (Manila, Philippines)

1:45pm-3:15pm: Prevalence of advanced Parkinson’s disease in Thai patients with Parkinson’s disease using the Consensus on the Definition of Advance Parkinson’s disease (CEPA Study): A single-center study

J. Srikajon, P. Srivanitchapoom, Y. Pitakpatapee, A. Pisarnpong, T. Sangpeamsook, A. Suengtaworn (Bangkok, Thailand)

1:45pm-3:15pm: Prevalence of Neurodegenerative movement disorders in different clinical Practices of Hyderabad, Pakistan

M. Arain (Jamshoro, Pakistan)

1:45pm-3:15pm: Prevalence of Parkinson’s disease and parkinsonism in Kyrgyzstan

C. Shambetova (Bishkek, Kyrgyzstan)

1:45pm-3:15pm: PRKN Positive Parkinson’s Disease Masked as Dopa-Responsive Dystonia

S. Chiu, A. Elkouzi, L. Almeida (Gainesville, FL, USA)

1:45pm-3:15pm: Progressive Parkinsonism and Cognitive Changes: A Rare Presentation of Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids (CLIPPERS)

M. Khyat-Khoei, J. Randhawa, E. Furr-Stimming, R. Samudralwar, S. Chandra (Houston, TX, USA)

1:45pm-3:15pm: Prospective Characterization of Genetically Confirmed X-linked Dystonia Parkinsonism Patients and their Families: A 1 year longitudinal feasibility study

P. Acuna, J. de Guzman, N. Ganza-Bautista, J. Lagarde, C. Go, N. Sharma (Boston, MA, USA)

1:45pm-3:15pm: Protective effects of β-Nicotinamide Adenine Dinucleotide against motor deficits and dopaminergic neuronal damage in a Parkinson’s disease mouse model

C. Shan, YL. Gong, QQ. Zhuang, YF. Hou, SM. Wang, ST. Li, JM. Liu (Shanghai, China)

1:45pm-3:15pm: PRRT2 mutations are associated with a wide intrafamilial ad interfamilial phenotypic variability

M. Vizziello, R. Dilena, A. Giacobbe, E. Monfrini, G. Franco, A. Di Fonzo (Milano, Italy)

1:45pm-3:15pm: PSP-like syndrome after aortic in adults (Mokri syndrome)

S. Tisel, J. Ahlskog, J. Matsumoto, J. Duffy, K. Josephs (Minneapolis, MN, USA)

1:45pm-3:15pm: Pupillary response to light and tasks in early and late onset essential tremor patients

J. Becktepe, F. Gövert, L. Kasiske, M. Yalaz, K. Witt, G. Deuschl (Kiel, Germany)

1:45pm-3:15pm: Puzzle resolution as cognitive test in Parkinson´s disease patients

C. Borrue-Fernandez, D. Santos-García, J. Pagonabarraga, B. Pascual-Sedano, M. Mata, C. Study Group (Madrid, Spain)

1:45pm-3:15pm: QPS over the supplementary motor area induced cortical excitability changes in human primary motor cortex: Comparison with Placebo effect

K. Sato, M. Hamada, Y. Shirota, S. Kodama, Y. Sugiyama, Y. Ugawa, C. Hosoda, T. Toda (Tokyo, Japan)

1:45pm-3:15pm: Quality of life in isolated dystonia – a cross-sectional study

J. Junker, B. Berman, D. Wahba, J. Hall, J. Perlmutter, J. Jankovic, I. Malaty, V. Brandt, S. Reich, A. Espay, N. Patel, E. Roze, M. Vidailhet, H. Jinnah, N. Brueggemann (Luebeck, Germany)

1:45pm-3:15pm: Quantifying eye and gait abnormalities in Parkinson’s patients after Deep brain stimulation

Z. Su, M. Brzezick, J. Fitzgerald, C. Antoniades (Oxford, United Kingdom)

1:45pm-3:15pm: Quantitative Assessment of Saccadic Eye Movements in Progressive Supranuclear Palsy and Idiopathic Parkinson’s Disease

C. Fearon, Y. Llamas-Osorio, L. Williams, A. Laffan, P. Moloney, R. Field, R. Reilly, T. Lynch (Dublin, Ireland)

1:45pm-3:15pm: Quantitative assessments better delineate rare disease: reconsidering the diagnostic criteria in ATP1A3+ Rapid-Onset Dystonia-Parkinsonism (RDP)

I. Haq, B. Snively, K. Sweadner, C. Suerken, J. Cook, L. Ozelius, C. Whitlow, A. Brashear (Winston Salem, NC, USA)

1:45pm-3:15pm: Quantitative Gait Assessment of Patients with Essential Tremor Using Wireless Sensors

V. Sharma, S. Moon, H. Devos, K. Lyons, R. Pahwa (Kansas City, KS, USA)

1:45pm-3:15pm: Quantitative straight and circular walking parameters for detecting ON and OFF medication states in early PD

MF. Corrà, N. Vila-Chã, J. Damasio, S. Duarte, A. Sardoreira-Bràs, P. Salgado, M. Calejo, C. Hansen, H. Minh Pham, R. Magalhães, M. Correia, W. Maetzler, L. Maia (Porto, Portugal)

1:45pm-3:15pm: Rapid Picture Naming in Parkinson’s Disease Using the Mobile Universal Lexicon Evaluation System (MULES) Test

J. Conway, C. Gonzalez, S. Fallon, J. Martone, L. Hasanaj, A. Lepor, L. Serrano, J. Rucker, S. Galetta, S. Frucht, L. Balcer (New York, NY, USA)

1:45pm-3:15pm: Rapidly progressive cognitive decline and hemi-dystonia due to anti-neuronal surface antibodies

F. Rolim, L. Mendes, P. Braga Neto, R. Sampaio, G. Ferreira, P. Nóbrega, V. Mesquita, F. Maia (Fortaleza, Brazil)

1:45pm-3:15pm: Rare manifestation of CNS Lupus: Parkinsonism

C. Wantaneeyawong, K. Kumchana (Chiang Mai, Thailand)

1:45pm-3:15pm: RDP is associated with bulbar and limb weakness: broadening the phenotype of ATP1A3+ Rapid-Onset Dystonia-Parkinsonism (RDP)

I. Haq, B. Snively, J. Cook, C. Suerken, K. Sweadner, L. Ozelius, C. Whitlow, A. Brashear (Winston Salem, NC, USA)

1:45pm-3:15pm: Real-life gait performance as a marker for motor fluctuations: the Parkinson@home Validation study

L. Evers, J. Raykov, R. Badawy, K. Claes, M. Meinders, J. Krijthe, T. Heskes, M. Little, B. Bloem (Nijmegen, Netherlands)

1:45pm-3:15pm: Reduced interhemispheric and premotor-motor connectivity during handwriting in patients with writer’s cramp

N. Thirugnanasambandam, T. Zimmermann, A. Pillai, J. Shields, S. Horovitz, M. Hallett (Bethesda, MD, USA)

1:45pm-3:15pm: Reducing Ataxic Side Effects from VIM DBS Implantation in Essential Tremor: Advantages of Directional Stimulation

D. Roque (Chapel Hill, NC, USA)

1:45pm-3:15pm: Relationship between functional exercise capacity and balance in patients with idiopathic Parkinson’s disease

BO. Ugut, T. Kahraman, AC. Kalkan, B. Donmez Colakoglu, A. Genc (Izmir, Turkey)

1:45pm-3:15pm: Relationship between intestinal bacteria, bacterial metabolites and residual pesticides in Parkinson’s disease

M. Hirayama, T. Hamaguchi, M. Ito, T. Ishida, M. Kuki, T. Maeda, K. Kashihara, Y. Tsuboi, K. Ohno (Hukuoka, Japan)

1:45pm-3:15pm: Relationship of cognitive processing speed with postural stability in non-demented Parkinson’s disease patients

J. Andreo Jover, A. Arroyo Ferrer, P. López Serrano, J. Periañez, M. Rios-Lago, G. Lubrini, JP. Romero Muñoz (Madrid, Spain)

1:45pm-3:15pm: REM sleep behavior disorder and REM sleep without atonia is a progression marker in Parkinson’s disease: a report from the DeNoPa cohort

F. Sixel-Döring, L. Zimansky, ML. Muntean, B. Mollenhauer, C. Trenkwalder (Kassel, Germany)

1:45pm-3:15pm: Repetitive transcranial magnetic stimulation can improve anxiety in Parkinson’s disease: a randomized, double-blind and controlled trial

A. Makkos-Weisz, N. Kovács, P. Endre, M. Kovács, D. Pintér (Pécs, Hungary)

1:45pm-3:15pm: Resting state functional connectivity changes in dystonia

A. Vo, N. Nguyen, K. Schindlbeck, D. Eidelberg (Manhasset, NY, USA)

1:45pm-3:15pm: Resting-state EEG functional connectivity in Parkinson’s disease

R. Shoorangiz, E. Peterson, R. Jones, L. Livingston, I. Kirk, L. Tippett, M. Livingstone, T. Anderson, J. Dalrymple-Alford (Christchurch, New Zealand)

1:45pm-3:15pm: Resting-State fMRI in Essential Tremor after MRgFUS treatment

C. Kindler, V. Purrer, N. Upadhyay, V. Keil, V. Borger, C. Pieper, L. Scheef, H. Boecker, U. Wuellner (Bonn, Germany)

1:45pm-3:15pm: Retinal thickness and microvascular pattern in early Parkinson’s disease.

C. Rascunà, C. Terravecchia, A. Russo, G. Mostile, CE. Cicero, A. Luca, N. Castellino, A. Longo, T. Avitabile, M. Reibaldi, M. Zappia, A. Nicoletti (Catania, Italy)

1:45pm-3:15pm: Risk of Parkinson’s in idiopathic anosmia

R. Rees, S. Gane, C. Philpott, A. Noyce, A. Schrag (Norwich, United Kingdom)

1:45pm-3:15pm: Role of APOE ε4 status and Sex on Somatosensory Integration and Dual-Task Cost in Parkinson’s disease

D. Martini, R. Morris, G. Mcbarron, T. Madhyastha, T. Grabowski, SC. Hu, C. Zabetian, A. Hiller, K. Chung, J. Quinn, F. Horak (Portland, OR, USA)

1:45pm-3:15pm: Role of microRNA-153 and -223 in Parkinson disease

M. Cressatti, W. Song, L. Jawura, J. Galindez, O. Canie, A. Velly, M. Gornitsky, H. Schipper (Montreal, QC, Canada)

1:45pm-3:15pm: Role of pallidotomy in secondary dystonia in pediatric patients

K. Garg, M. Singh, V. Goyal (New Delhi, India)

1:45pm-3:15pm: Saccade profiles in Tourette syndrome

Y. Sugiyama, H. Fukuda, Y. Terao, S. Tokushige, K. Hoshino, M. Hamada, Y. Ugawa, T. Toda (Tokyo, Japan)

1:45pm-3:15pm: Safety and effectiveness of levodopa-carbidopa intestinal gel for advanced Parkinson’s disease : a large single-center study

A-S. Blaise, G. Baille, N. Carrière, D. Devos, K. Dujardin, G. Grolez, A. Kreisler, M. Kyheng, C. Moreau, E. Mutez, D. Seguy, L. Defebvre (Lille, France)

1:45pm-3:15pm: Safety and Tolerability of Apomorphine Sublingual Film During Maintenance Treatment in Patients With Parkinson’s Disease and “OFF” Episodes: A Pooled Analysis

W. Ondo, A. Ellenbogen, S. Isaacson, A. Espay, C. Singer, P. Bhargava, M. Worden, D. Blum, B. Navia (Houston, TX, USA)

1:45pm-3:15pm: Safety and Tolerability of opicapone in Parkinson’s disease

M. Campins Romeu, M. Losada López, I. Sastre Bataller, MJ. Pérez García, I. Martínez Torres (Valencia, Spain)

1:45pm-3:15pm: Scene Induced emotion processing in Parkinson’s disease: BOLD-fMRI study

S. Boujraf, M. Benzagmout, B. Alami, H. Amadou, H. El Hamdaoui, A. Bennani, M. Jaafari, I. Rammouz, M. Maaroufi, D. Boussaoud (Fez, Morocco)

1:45pm-3:15pm: Searching for the optimal functional target for deep brain stimulation in Essential Tremor

D. Kübler, B. Al-Fatly, D. Kroneberg, S. Ewert, C. van Riesen, G-H. Schneider, A. Horn, A. Kühn (Berlin, Germany)

1:45pm-3:15pm: Selective Disinhibition of Thalamus by Globus Pallidus Internus: Failure of a Normal Control Mechanism in Childhood Dystonia

T. Sanger, E. Arguelles, M. Liker (Los Angeles, CA, USA)

1:45pm-3:15pm: Self-reported substance abuse in a real-world sample of Tourette Syndrome and other tic disorder subjects

W. Deeb, A. Elkouzi, I. Malaty (Gainesville, FL, USA)

1:45pm-3:15pm: Sensitivity of magnetic resonance imaging findings in the diagnosis of progressive supranuclear palsy

L. Marques, V. Silva, J. Araújo, S. Varanda, G. Carneiro, M. Rodrigues (Braga, Portugal)

1:45pm-3:15pm: Serological analysis of circulating Alpha Synuclein protein levels by Surface Plasmon Resonance (SPR) In Parkinson’s disease

A. Singh, T. Bajaj, A. Dey, S. Dey (New Delhi, India)

1:45pm-3:15pm: Serotonergic function in De Novo Parkinson’s Disease

HK. Park, JJ. Lee, YM. Park (Goyang, Republic of Korea)

1:45pm-3:15pm: Serum Inflammatory Profile for the Discrimination of tremor severity in essential tremor

Z. Muruzheva, D. Traktirov, I. Ivleva, V. Maystrenko, M. Karpenko (Saint-Petersburg, Russian Federation)

1:45pm-3:15pm: Serum mucosal chemokine levels in patients with Parkinson disease.

S. Haji, W. Sako, N. Murakami, Y. Osaki, Y. Izumi (Tokushima, Japan)

1:45pm-3:15pm: Serum non-mercaptalbumin as a potential biomarker in Parkinson’s disease and related disorders

S. Ueno, T. Hatano, A. Okuzumi, S. Saiki, Y. Oji, A. Mori, T. Koinuma, M. Fujimaki, H. Takeshige-Amano, K. Yasukawa, Y. Yatomi, H. Ikeda, N. Hattori (Tokyo, Japan)

1:45pm-3:15pm: Serum uric acid level as a biomarker in sporadic and familial (p.A53T alpha synuclein carriers) Parkinson’s disease: Longitudinal data from the PPMI study

C. Koros, AM. Simitsi, M. Stamelou, D. Papadimitriou, A. Bougea, I. Pachi, N. Papagiannakis, A. Prentakis, E. Angelopoulou, R. Antonellou, M. Bozi, X. Geronicola Trapali, L. Stefanis (Athens, Greece)

1:45pm-3:15pm: Serum uric acid levels and cognitive function in Parkinson’s disease

J. Difrancisco-Donoghue, W. Werner, B. Krishnamachari, K. Arabian, E. Thomas, D. Granger, R. Gallagher (Irvine, CA, USA)

1:45pm-3:15pm: Sexual Needs & function assessment of patients with Parkinson’s disease in the tertiary movement disorder’s center

S. Peleg Nesher, Y. Manor, A. Rosenberg, S. Naor, T. Taichman, A. Ezra, D. Roque, J. Shurer, D. Drazheva, N. Browner, K. Robertson, T. Gurevich (Tel Aviv, Israel)

1:45pm-3:15pm: Shuffling gait may be pitfall in neurological examination in Parkinson’s disease

J. Park, HT. Kim (Seoul, Republic of Korea)

1:45pm-3:15pm: Skin in the game: Small fiber neuropathy in Parkinson’s disease and atypical parkinsonisms.

R. Infante, G. Rizzo, A. Incensi, C. Scaglione, S. Capellari, V. Donadio, R. Liguori (Bologna, Italy)

1:45pm-3:15pm: Smell and taste in cervical dystonia: a contribution to understand dystonia pathophysiology.

T. Herr, T. Hummel, M. Vollmer, C. Willert, B. Lehnert, M. Kronenbürger (Greifswald, Germany)

1:45pm-3:15pm: Social Cognition and Habituation in Cervical Dystonia

B. Ellement, Y. Jasui, J. Sarna, S. Furtado, T. Pringsheim, B. Callahan, D. Martino (Calgary, AB, Canada)

1:45pm-3:15pm: Social Cognition, Neuropsychological functioning & Mood Disorder in Cervical Dystonia (CD)

R. Monaghan, D. Mccormack, I. Ndukwe, T. Burke, N. Pender, S. O’Riordan, M. Hutchinson, F. O'Keeffe (Dublin, Ireland)

1:45pm-3:15pm: Spatial distribution of functional clusters coding for reward and movement information in the striatal direct and indirect pathways

MW. Jung, JH. Shin (Daejeon, Republic of Korea)

1:45pm-3:15pm: Special features of parkinsonism with congenital anomalies of cerebral vessels

AS. Norboboev, FAY. Odinaev, GUL. Rakhmatullaeva (Tashkent, Uzbekistan)

1:45pm-3:15pm: Spectrum of parkinsonian phenotypes associated with GCH1 mutation.

D. Al-Shorafat, A. Shetty, D. Munoz, A. Fasano, A. Lang (Toronto, ON, Canada)

1:45pm-3:15pm: Speculation on the timing of iron deposition in the putamen of patients with multiple system atrophy: multimodal MRI study

MJ. Lee, JH. Lee (Yangsan-Si, Republic of Korea)

1:45pm-3:15pm: Speech and language changes in cognitive impairment subtypes in patients with Parkinson´s disease

A. Kušnírová, Z. Košutzká, M. Hajdúk, M. Králová, M. Pápayová, M. Egryová, P. Valkovič, Z. Cséfalvay (Bratislava, Slovakia)

1:45pm-3:15pm: Spin turns and step turns in advanced Parkinson’s disease: a new clinical gait sign?

O. Gavriliuc, S. Paschen, A. Andrusca, C. Schlenstedt, G. Deuschl (Chisinau, Republic of Moldova)

1:45pm-3:15pm: Spiral loop width differentiates essential tremor and dystonic tremor

R. Rajan, R. Anandapadmanabhan, A. Saini, A. Srivastava (New Delhi, India)

1:45pm-3:15pm: Steering the Volume of Tissue Activated with Directional Deep Brain Stimulation Lead in the Globus Pallidus internus

S. Zhang, E. Pereira, N. Pouratian, A. Kent, B. Cheeran, L. Venkatesan, A. Schnitzler (Plano, TX, USA)

1:45pm-3:15pm: Stereopsis as a Visual Biomarker for Parkinson’s Disease

T. Sang, J. Fatehi, E. Mostofi, B. Zheng, F. Ba (Edmonton, AB, Canada)

1:45pm-3:15pm: Stiff Limb Syndrome Masquerading As a Focal Limb Dystonia

P. Morrison, R. Barbano (Rochester, NY, USA)

1:45pm-3:15pm: Stimulation Frequency and Active Contact Location Influence Speech Problems in Parkinson’s Disease Patients with Bilateral Subthalamic Deep Brain Stimulation

O. Phokaewvarangkul, K. Boonpang, R. Bhidayasiri (Bangkok, Thailand)

1:45pm-3:15pm: Stimulus-induced paroxysmal cranial dyskinesia and Nail Patella Syndrome in a multigenerational family with a novel mutation in the LMX1B gene

S. Bech, A. Loekkegaard, T. Nielsen, A. Nørremølle, L. Hasholt, Y. Mang, J. Nielsen, H. Eiberg, L. Hjermind (Copenhagen, Denmark)

1:45pm-3:15pm: STN-DBS programing for dyskinesia: a case report

L. Li, Y. Zhang (Beijing, China)

1:45pm-3:15pm: Striatal dopaminergic dysregulation and dystonia-like movements induced by peripheral nerve crush in a transgene DYT1 mouse model

L. Rauschenberger, A. Stengl, S. Knorr, K. Grundmann-Hauser, J. Volkmann, CW. Ip (Würzburg, Germany)

1:45pm-3:15pm: Striatal dopaminergic regulation of micrographia in parkinsonism

M. Eklund, J. Joutsa, S. Nuuttila, E. Mäkinen, E. Jaakkola, T. Noponen, T. Ihalainen, M. Koivisto, S. Teperi, F. Scheperjans, V. Kaasinen (Turku, Finland)

1:45pm-3:15pm: Structural connectivity changes in prodromal Parkinson’s disease patients: a multimodal MRI study

V. Suarez Contreras, G. Pagano, J. Fernandez Bonfante, H. Wilson, M. Politis (London, United Kingdom)

1:45pm-3:15pm: Structural Connectivity Predicts Clinical Outcomes of Deep Brain Stimulation for Tourette Syndrome

K. Johnson, G. Duffley, D. Servello, A. Bona, M. Porta, J. Ostrem, E. Bardinet, M-L. Welter, A. Lozano, J. Baldermann, J. Kuhn, D. Huys, T. Foltynie, M. Hariz, E. Joyce, L. Zrinzo, Z. Kefalopoulou, J-G. Zhang, F-G. Meng, CC. Zhang, Z. Ling, X. Xu, X. Yu, A. Smeets, L. Ackermans, V. Visser-Vandewalle, A. Mogilner, M. Pourfar, L. Almeida, A. Gunduz, W. Hu, K. Foote, M. Okun, C. Butson (Salt Lake City, UT, USA)

1:45pm-3:15pm: Structural network fingerprints for GPI-DBS in dystonia

G. Gonzalez-Escamilla, M. Muthuraman, M. Reich, N. Koirala, C. Riedel, M. Glaser, F. Lange, G. Deuschl, J. Volkmann, S. Groppa (Mainz, Germany)

1:45pm-3:15pm: Study of cardiac sympathetic denervation by 18F-FDOPA PET-CT Imaging in early Parkinson disease (EPD) and Atypical parkinsonian syndromes (APS)

K C. Chudasama, VG. Goyal, C P. Patel, MV. Srivastava, MBS. Singh, MT. Tripathi, VY. Y, AR. Roy (Delhi, India)

1:45pm-3:15pm: Substantia Nigra Hyperechogenicity in Parkinson’s Disease and Essential Tremor and its Association with Premotor Symptoms of Parkinson’s Disease

M. Uribe Roca, A. Chertcoff, L. Bandeo, M. Saucedo, F. Pantiu, L. de Francesco, L. Leon Cejas, M. Pacha, G. Napoli, P. Bonardo, O. Martinez, M. Fernandez Pardal, R. Reisin (Buenos Aires, Argentina)

1:45pm-3:15pm: Subthalamic Neurons Fire Differently In Planned Versus Reactive Movements

A. Fazl, K. Katlowitz, M. Pourfar, A. Mogilner, D. London (Livingston, NJ, USA)

1:45pm-3:15pm: Successful late rehabilitation based on botulinum therapy

T. Kuznetsova, A. Svetkina (Samara, Russian Federation)

1:45pm-3:15pm: Successful treatment of Parkinson’s disease-related impulse control disorder with bilateral STN DBS

T. Stiep, D. Spengler Shpiner, C. Luca (Miami, FL, USA)

1:45pm-3:15pm: Sustained Functional Benefits After a Single Injection with AbobotulinumtoxinA Using a 2mL Injection Volume in Adults with Cervical Dystonia

A. Patel, M. Lew, A. Brashear, K. Dashtipour, S. Isaacson, R. Hauser, W. Ondo, P. Maisonobe, J. Otto (Overland Park, KS, USA)

1:45pm-3:15pm: Sustained release triple drug loaded Microbaloons for management of Parkinson’s Disease

S. Bhargava (Prayagraj, India)

1:45pm-3:15pm: Swallowing assessment in Parkinson’s Disease using Dynamic Magnetic Resonance Imaging (dMRI)

SG. Gudwani, PU. Upadhyay, KS. Sharma, RS. Sagar, SSK. Kumaran, RKD. Dhamija (New Delhi, India)

1:45pm-3:15pm: Symptomatic palatal tremor combined with unilateral limb tremor and parkinsonism

SK. Song, JH. Kang (Jeju-Si, Republic of Korea)

1:45pm-3:15pm: Synaptic dysfuncion in a Drosophila model of PARK14

T. Hatano, A. Mori, T. Inoshita, K. Fukushima-Shiba, T. Koinuma, C. Yamashita, Y. Imai, N. Hattori (Tokyo, Japan)

1:45pm-3:15pm: Synaptic function in Parkinson’s disease associated with GBA mutations

T. Eid, R. Bandopadhyay, T. Lashley, J. Hardy, J. Holton, T. Warner, P. Francis (London, United Kingdom)

1:45pm-3:15pm: Tactile and proprioceptive dysfunction differentiates between cervical dystonia with and without tremor

L. Avanzino, A. Cherif, O. Crisafulli, F. Carbone, A. Ravaschio, P. Morasso, J. Zenzeri, R. Marchese, G. Abbruzzese, E. Pelosin, J. Konczak (Genova, Italy)

1:45pm-3:15pm: Tardive Cervical Dystonia: Treatment with Botulinum: Treatment with Botulinum Toxin Guided by Electromyography

LFV. Vasconcellos, MS. Spitz, DN. Nassif, BRA. Andrade (Rio de Janeiro, Brazil)

1:45pm-3:15pm: Task Specific Dystonia and Its Response to Botulinum Neurotoxin Treatment

R. Ortiz, T. Mertsalmi, F. Scheperjans, E. Pekkonen (Helsinki, Finland)

1:45pm-3:15pm: Task-specific lower limb dystonia only during walking stairs

JS. Baik, HI. Ma (Seoul, Republic of Korea)

1:45pm-3:15pm: Tau and amyloid-beta inclusions are present in pancreatic beta-cells of patients with synucleinopathies

I. Martinez-Valbuena, R. Valenti-Azcarate, J. Sanchez, I. Marcilla Garcia, I. Amat-Villegas, MT. Tuñon-Alvarez, MR. Luquin Piudo (Pamplona, Spain)

1:45pm-3:15pm: Technology-based assessment of motor impairment in de novo Parkinson’s disease patients: implications for diagnostic accuracy and early identification of distinct phenotypes

G. Di Lazzaro, M. Ricci, T. Schirinzi, G. Saggio, NB. Mercuri, A. Pisani (Rome, Italy)

1:45pm-3:15pm: The association between frailty and Parkinson’s in the ReSPOnD trial

N. Smith, D. Gaunt, A. Whone, Y. Ben-Shlomo, E. Henderson (Bath, United Kingdom)

1:45pm-3:15pm: The carotid ultrasonography revealed vagus nerve atrophy of the patients with parkinsonism

S. Abe, T. Hirato, H. Saiki (Osaka, Japan)

1:45pm-3:15pm: The Chinese Parkinson’s disease Registry scheme

XT. Zhou, XX. Zhou, YW. Zhao, LX. Qin, Q. Xu, Y. Tian, LJ. Fang, ZQ. Wang, QY. Sun, JC. Li, JF. Guo, XX. Yan, BS. Tang (Changsha, China)

1:45pm-3:15pm: The congruence of asymmetry between motor symptoms and retinal thickness in Parkinson’s disease

W. Suh, JY. Hong, SY. Kang (Wonju, Republic of Korea)

1:45pm-3:15pm: The contribution of cerebrovascular risk factors, metabolic and inflammatory changes to cognitive decline in Parkinson’s disease

I. Rektor, B. Vesely, N. Bohnen, E. Koritakova, E. Kurca, P. Valkovic (Brno, Czech Republic)

1:45pm-3:15pm: The differential role of subthalamic and nigral neurons in gait control in Parkinson´s disease patients

A. Gulberti, M. Horn, J. Wagner, M. Schaper, J A. Koeppen, C. Buhmann, A. Sharott, M. Westphal, A K. Engel, C. Gerloff, W. Hamel, CKE. Moll, M. Pötter-Nerger (Hamburg, Germany)

1:45pm-3:15pm: The Dutch Parkinson and Microbiome Study (DUPARM): Gut Microbiome Composition of Treatment-Naïve De Novo Parkinson’s Disease Patients

J. Boertien, S. Vander Zee, T. van Laar (Groningen, Netherlands)

1:45pm-3:15pm: The Dutch Yips Study

E. van Wensen, HJ. Vd Zaag, BP. Vd Warrenburg (Apeldoorn, Netherlands)

1:45pm-3:15pm: The effect of active contact localization on motor symptoms in deep brain stimulation of the subthalamic nucleus for Parkinson’s disease

T. Ten Brinke, V. Odekerken, P. Schuurman, R. de Bie (Amsterdam, Netherlands)

1:45pm-3:15pm: The effect of baseline cognitive status of Parkinson’s disease on the outcome after deep brain stimulation surgery

KW. Park, NR. Choi, SY. Jo, MS. Kim, NE. Han, SR. Jeon, SJ. Chung (Seoul, Republic of Korea)

1:45pm-3:15pm: The effect of coexistent neurodegenerative disorders on the clinical features of idiopathic normal pressure hydrocephalus

A. Hattori, T. Tsunemi, N. Hattori (Bunkyo-Ku, Japan)

1:45pm-3:15pm: The effect of Guided Self-rehabilitation Contracts combined with simultaneous injections of abobotulinumtoxinA into upper and lower limbs on voluntary movements in adults with spastic hemiparesis

J-M. Gracies, G. Francisco, R. Jech, S. Khatkova, C. Rios, P. Maisonobe (Créteil, France)

1:45pm-3:15pm: The effect of Kinesio Taping therapy on Cervical Dystonia

J. Magalhães, A. Rosso, F. Rezende (Rio de Janeiro, Brazil)

1:45pm-3:15pm: The Effects of Computer Based Cognitive Rehabilitation on working memory in patients with Parkinson’s disease: A Systematic Review

A. Loekkegaard, M. Niemeijer, K. Svaerke (Copenhagen, Denmark)

1:45pm-3:15pm: The effects of obstacle size and timing on prefrontal cortex activation in patients with Parkinson’s disease

I. Maidan, T. Sharon, I. Kurz, H. Bernad-Elazari, S. Shustak, I. Galperin, N. Giladi, A. Mirelman, J. Hausdorff (Tel Aviv, Israel)

1:45pm-3:15pm: The effects of onabotulinum toxin on neurophysiological tests in patients with hemifacial spasm

O. Kocak, A. Tokcaer (Ankara, Turkey)

1:45pm-3:15pm: The effects of timed exposure to bright light in improving the gait patterns of patients with Parkinson’s disease – A pilot study

L. Alibiglou, T. Ruopp (Tehran, Islamic Republic of Iran)

1:45pm-3:15pm: The effects of zonisamide on motor and non-motor symptoms in patients with Parkinson’s disease: a 3-month open-label study

K. Suzuki, H. Fujita, T. Matsubara, T. Kadowaki, K. Funakoshi, Y. Watanabe, T. Shiina, H. Sakuramoto, M. Hamaguchi, K. Hirata (Tochigi, Japan)

1:45pm-3:15pm: The Efficacy and Safety of Subcutaneous Apomorphine in Patients with Parkinson’s Disease: A Meta-Analysis Randomized Controlled Trials

M. Azharuddin, M. Adil, P. Ghosh, M. Sharma (New Delhi, India)

1:45pm-3:15pm: THE EXPRESSION OF INOS IN MOUSE EXPERIMENTAL MODEL POINTS TO INFLAMMATORY CONDITIONS ASSOCIATED WITH PARKINSON’S DISEASE

N. Djebli (Mostaganem, Algeria)

1:45pm-3:15pm: The first tremor dominant Parkinson’s Disease treatment in Taiwan using MR-guided focused ultrasound

HC. Lai, WK. Tsai, WC. Chang (Changhua County, Taiwan)

1:45pm-3:15pm: The frequency and impact of mutations in the GBA gene and APOε4 polymorphisms on the clinical features of Dementia with Lewy Bodies among Ashkenazi Jews

T. Shiner, A. Mirelman, Y. Rozenblum, G. Kave', M. Gana Weisz, A. Bar-Shira, A. Thaler, R. Shahar, T. Gurevich, A. Orr-Urtreger, N. Giladi, N. Bregman (Tel Aviv, Israel)

1:45pm-3:15pm: The Genetic Landscape of Complex Childhood-Onset Hyperkinetic Movement Disorders

M. Kurian, V. Leuzzi, K. Peall, R. Pons, R. Dale, E. de Grandis, S. Yilmaz, J. Cobben, R. Guerrini, E. Sheridan, P. Vieira, J. Uusimaa, P. Munot, F. Muntoni, M. Smith, S. Mohammed, E. Meyer, J. Ng, A. Papandreou, H. Baide, F. Danti, A. Macaya, J. Ortigoza, K. Gorman, B. Perez Duenas (Barcelona, Spain)

1:45pm-3:15pm: The impact of HIV on the severity and course of Parkinson’s disease: a clinical case

A. Kudrevatykh, E. Gracheva, I. Miliukhina (St. Petersburg, Russian Federation)

1:45pm-3:15pm: The impact of medication and deep brain stimulation on visuo-motor coordination in Parkinson’s disease

J. Daneault, A. Sadikot, B. Carignan, M. Panisset, C. Duval (Newark, NJ, USA)

1:45pm-3:15pm: The impact of physical activity and exercise on people living with dystonia

L. Bradnam, R. Meiring, A. Mccambridge (Auckland, New Zealand)

1:45pm-3:15pm: The Impact of Progressive Supranuclear Palsy (PSP) Disease Severity on Healthcare Resource Utilization (HCRU)

T. Xie, X. Ye, J. de Courcy, J. Mellor, J. Zamudio, L. Chiodo, Y. Bao (Mettawa, IL, USA)

1:45pm-3:15pm: The Impact of the New Classification Criteria on the Incidence of Tremor Syndromes

A. Avila, N. Caballol, A. Planas-Ballvé, MI. Gómez-Ruiz, M. Balagué-Marmaña, X. Cardona (Barcelona, Spain)

1:45pm-3:15pm: The Impact of Tourette Syndrome and Tic Disorders on Education, Occupational and Personal Life

I. Malaty, D. Shineman, W. Deeb (Gainesville, FL, USA)

1:45pm-3:15pm: The long-term effect of continuous apomorphine treatment on camptocormia in Parkinson´s disease: a 24-months longitudinal open, prospective follow-up study

K. Mensikova, M. Kaiserova, M. Vastik, M. Nevrly, S. Kurcova, P. Kanovsky (Olomouc, Czech Republic)

1:45pm-3:15pm: The management of Parkinson’s Disease during pregnancy: literature review, case series and multi-disciplinary input

C. Young, R. Phillips, L. Ebenezer, R. Zutt, C. Mitchell, K. Peall (Cardiff, United Kingdom)

1:45pm-3:15pm: The mechanism of tremor-modulating properties of propranolol and primidone in essential tremor: A study with transcranial magnetic stimulation and eye blink classical conditioning paradigm

K. Vogelnik, N. Prezelj, R. Perellon Alfonso, P. Klavžar, M. Gregorič Kramberger, D. Flisar, D. Georgiev, Z. Pirtošek, M. Kojović (Ljubljana, Slovenia)

1:45pm-3:15pm: The optimal connectivity profile of thalamic deep brain stimulation electrodes to effectively treat Essential Tremor

B. Al-Fatly, S. Ewert, D. Kuebler, D. Kroneberg, A. Horn, A. Kuehn (Berlin, Germany)

1:45pm-3:15pm: The Oral Metagenome and Metatranscriptome of Early Stage Parkinson’s Disease and their Relationship with Clinical and Functional Outcome Measures of Motor and Nonmotor Function

D. Mihaila, J. Donegan, M. Vidal, D. Larocca, R. Ericson, S. Barns, C. Neville, R. Uhlig, F. Middleton (Syracuse, NY, USA)

1:45pm-3:15pm: The physiologic complexity of hand tremor identifies Parkinsonian tremor and essential tremor

D. Su, Z. Liu, H. Pan, T. Feng, J. Zhou (Beijing, China)

1:45pm-3:15pm: The Power of Normal Saline in Reducing Skin Nodules in Apomorphine

F. Leen, A. Evans, T. Canento, M. Ghaly, C. Wools, B. Cruse, M. Beckley (Melbourne, Australia)

1:45pm-3:15pm: The Prevalence of Essential Tremor in Edirne and Its Districts Concomitant Comorbid Conditions

S. Güler, A. Caylan, N. Turan (Edirne, Turkey)

1:45pm-3:15pm: The prevalence of ICBs in patients treated with apomorphine infusion: a retrospective analysis

P. Barbosa, A. Lees, A. Djamshidian, T. Warner (Innsbruck, Austria)

1:45pm-3:15pm: The Progressive Supranuclear Palsy Functional Disability Scale: Sensitivity to change

I. Piot, K. Schweyer, G. Respondek, M. Grimm, M. Stamelou, P. Sckopke, T. Schenk, C. Goetz, G. Stebbins, G. Höglinger (Munich, Germany)

1:45pm-3:15pm: The relationship between constipation and alteration of gut microbiota in patients with Parkinson’s disease

BI. Zao An, M. Ye (Nanjing, China)

1:45pm-3:15pm: The role of Dopamine in Preparatory Inhibition: What can we learn from Parkinson’s disease?

E. Wilhelm, C. Quoilin, G. Derosiere, A. Jeanjean, J. Duqué (Brussels, Belgium)

1:45pm-3:15pm: The role of mitochondria in modifying penetrance of Parkin gene variants

M. Castelo, J. Trinh, A. Zanon, J. Rainer, P. Bauer, K. Kandaswamy, M. Werber, A. Rolfs, A. Grunewald, M. Borsche, K. Lohmann, C. Klein, P. Pramstaller, I. Pichler, A. Hicks (Bolzano, Italy)

1:45pm-3:15pm: The role of Parkinson’s disease-associated RHOT1/Miro1 variants in mitochondrial dysfunction and impaired cellular quality control

A. Chemla, C. Berenguer-Escuder, F. Massart, P. Seibler, C. Klein, D. Grossmann, A. Grünewald, R. Krüger (Belvaux, Luxembourg)

1:45pm-3:15pm: The role of the gut microbial dysbiosis and serum inflammatory profile for the discrimination of clinical subtypes in Parkinson’s disease

I. Miliukhina, E. Ermolenko, E. Gracheva, A. Istomina, M. Kotyleva, E. Agapova, A. Suvorov (Saint-Petersburg, Russian Federation)

1:45pm-3:15pm: The STN Sweet Spot for Tremor Control in Parkinson’s Disease

T. Stiep, A. Diaz, I. Cajigas, J. Jagid, C. Luca (Miami, FL, USA)

1:45pm-3:15pm: The study on brain function network of Parkinson’s disease with depression

Y. Qiu, L. Wang (Guangzhou, China)

1:45pm-3:15pm: The SUNRISE-PD Study, a clinical trial of AXO-LENTI-PD: a CNS-directed gene therapy for the treatment of Parkinson’s Disease

G. Corcoran, P. Korner, J. Wright, Y. Mo, J. Benoit, K. Binley, J. Miskin, N. Tuckwell, D. Zamoryakhin, T. Foltynie, R. Barker, K. Mitrophanous, S. Palfi (New York, NY, USA)

1:45pm-3:15pm: The trace of substantia nigra hyperechogenicity: a clinical observation

A. Alonso-Canovas, JL. Sendon-Moreno, G. Garcia-Ribas, N. Monterde-Gonzalez, C. Jara-Laguna, JC. Martinez-Castrillo, J. Masjuan (Madrid, Spain)

1:45pm-3:15pm: The ultrasonographic assessment of vagus nerve atrophy comparison with autonomic dysfunction in Parkinson’s disease

T. Hirato, S. Abe, H. Saiki (Kita-Ku, Osaka, Japan)

1:45pm-3:15pm: The ultrasound image of the nuclei raphes changes in the group of depressed patients with cervical dystonia and blepharospasm

AK. Krzak-Kubica, JG. Gawryluk, MD. Doręgowska, KP. Plinta, MR. Rudzińska-Bar (Katowice, Poland)

1:45pm-3:15pm: The Use of Exergames in Neurorehabilitation in People with Parkinson’s Disease: Its Impact on Daily Life

B. Zeigelboim, H. Teive, M. Severiano, G. Dos Santos, M. da Rosa, M. José, R. Sampaio, J. Malisky (Curitiba, Brazil)

1:45pm-3:15pm: Therapeutic management of complicated Parkinson’s disease: clinical application of the Motor Fluctuation Indices

R. Bonomo, G. Mostile, A. Nicoletti, M. Zappia (Catania, Italy)

1:45pm-3:15pm: THOR 201: A Proof-of-Concept Study Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of L-dopa delivered by Impel’s Precision Olfactory Delivery (PODTM) to Parkinson’s Disease Patients in an OFF Episode (in the presence of Dopa Decarboxylase Inhibitor)

S. Shrewsbury, J. Campbell, M. Swardstrom, A. Lehn, K. Satterly, J. Hoekman (Seattle, WA, USA)

1:45pm-3:15pm: Three cases of early tremor in the course of Guillain-Barré Syndrome

S. Ten Holter, M. Louter, F. Eftimov, J. Dijk (The Hague, Netherlands)

1:45pm-3:15pm: Three-year follow-up of a patient with a rare combination of taupathy (PSP) and synucleopathy (MSA)

D. Aygun (Samsun, Turkey)

1:45pm-3:15pm: Tic Detector – Role of Electromyography

W. Deeb, S. Cernera, A. Gunduz, M. Okun (Gainesville, FL, USA)

1:45pm-3:15pm: Time-Frequency analysis of Gait-EEG signals for freezing of gait in a PD patient

J. Li, Y. Zhang (Beijing, China)

1:45pm-3:15pm: To compare early / late onset MSA from the PAN American MSA (PANMSA) database

M. Cesarini, E. Gatto, J. Etcheverry, G. da Prat, F. Peralta (Caba, Argentina)

1:45pm-3:15pm: To respond or not to respond to paired associative stimulation: proof of intervention by cerebello-cortical circuit

A. Kishore, P. James, P. Rajeswari, A. Thejaus, G. Sarma, S. Meunier (Trivandrum, India)

1:45pm-3:15pm: Touching Nose: Alleviating Maneuvers (Sensory Tricks) in Orofacial Dystonia

NG. Bülbül, MG. şenol (Istanbul, Turkey)

1:45pm-3:15pm: Towards unobtrusive Parkinson’s disease detection via motor symptoms severity inference from multimodal smartphone-sensor data

D. Iakovakis, S. Hadjidimitriou, V. Charisis, K. Kyritsis, A. Papadopoulos, M. Stadtschnitzer, H. Jaeger, I. Dagklis, S. Bostantjopoulou, Z. Katsarou, L. Klingelhoefer, S. Mayer, R. Reichmann, D. Trivedi, A. Podlewska, A. Rizos, K. Chaudhuri, A. Delopoulos, L. Hadjileontiadis (Thessaloniki, Greece)

1:45pm-3:15pm: Transcranial neuromodulation of the Frontal Eye Fields: targeting Temporal Discrimination Thresholds (TDT) in Adult Onset Primary Torsion Dystonia (AOPTD)

O. Killian, I. Ndukwe, S. Narasimham, S. O'Riordan, M. Hutchinson, R. Reilly (Dublin, Ireland)

1:45pm-3:15pm: Transcranial ultrasound in atypical parkinsonism: how reliable is it in real clinical practice? A multi-centre comprehensive study

A. Alonso-Canovas, JI. Tembl-Ferrairo, I. Martinez Torres, JL. Lopez Sendon-Moreno, I. Parees-Moreno, E. Monreal-Laguillo, P. Perez-Torre, R. Toledano, G. Garcia-Ribas, J. Masjuan, JC. Martinez-Castrillo, U. Walter (Rostock, Germany)

1:45pm-3:15pm: Tremoroton, a new open source tool for tremor analysis

F. Vial, P. Kassavetis, M. Hallett (Bethesda, MD, USA)

1:45pm-3:15pm: Trust the Patient’s Report, not the Doctor’s: Non-Motor Symptoms and Quality of Life in Cervical Dystonia

I. Ndukwe, J. Dover, P. Lynch, C. O'Neill, S. O'Riordan, M. Hutchinson (Dublin, Ireland)

1:45pm-3:15pm: Tsallis entropy of EEG correlates with future cognitive decline in patients with Parkinson’s disease

SM. Keller, A. Meyer, JG. Bogaarts, U. Gschwandtner, P. Fuhr, V. Roth (Basel, Switzerland)

1:45pm-3:15pm: Two Patients with Dopamine Transporter Deficiency Treated with Deep Brain Stimulation

J. Maclean, D. Ferman, T. Sanger, A. Tongol (Los Angeles, CA, USA)

1:45pm-3:15pm: Unilateral increase of blink reflex recovery cycle in drug-naive hemiparkinson syndrome.

G. Sciacca, G. Mostile, I. Disilvestro, G. Donzuso, R. Manna, G. Portaro, C. Rascunà, S. Salomone, F. Drago, A. Nicoletti, M. Zappia (Catania, Italy)

1:45pm-3:15pm: Unraveling biological processes implicated in MSA and PD by transcriptomic analysis

A. Perez-Soriano, M. Arnal, D. Giraldo, M. Fernandez, T. Botta-Orfila, Y. Compta, R. Fernández-Santiago, M. Ezquerra, D. Tartaglia, MJ. Martí (Barcelona, Spain)

1:45pm-3:15pm: Unusual expression of fragile X premutation in a female patient: clinical and tractographic description

V. Ros-Castelló, E. Natera-Villalba, A. Sánchez-Sánchez, A. Gómez-López, P. Pérez-Torre, S. Fanjul, J. López-Sendón, A. Alonso-Cánovas, JC. Martínez-Castrillo, J. álvarez-Linera, I. Pareés (Madrid, Spain)

1:45pm-3:15pm: Use of Chemodenervation for Secondary Limb Dystonia in Parkinson’s Disease: A Single Center Experience

V. Veerappan, M. Brodsky (Portland, OR, USA)

1:45pm-3:15pm: Using Quantitative Susceptibility Mapping to Predict Dementia in Parkinson’s Disease

G. Thomas, L. Leyland, J. Acosta-Cabronero, R. Weil (London, United Kingdom)

1:45pm-3:15pm: Utilising Magnetic Resonance Spectroscopy to investigate synucleinopathies

N. Khalil, E. Matar, S. Duffy, S. Lewis (Camperdown, Australia)

1:45pm-3:15pm: Utility of Eye Movement Abnormalities in Differentiating Neurodegenerative versus non-Neurodegenerative Parkinsonism

A. Margolius, D. Hengartner, O. Hogue, X. Garcia, S. Patel, A. Ahmed, H. Fernandez, XX. Yu (Bogota, Colombia)

1:45pm-3:15pm: Validation of the Clinical Dementia Rating Scale Sum of Boxes in Parkinson’s Disease

J. Rick, S. Xie, E. Mamikonyan, B. Deck, S. Rudovsky, A. Chen-Plotkin, N. Dahodwala, J. Morley, J. Duda, J. Trojanowski, D. Weintraub (Philadelphia, PA, USA)

1:45pm-3:15pm: Validation of the diagnostic criteria for progressive supranuclear palsy in pathologically confirmed patients

I. Aiba, Y. Saito, Y. Yokokawa, T. Katayama, M. Kenjo, R. Hashimoto, S. Sakakibara, M. Sato, H. Nakatsuji, A. Inukai, Y. Iwasaki, M. Mimuro, A. Akagi, M. Yoshida (Nagoya, Japan)

1:45pm-3:15pm: Validation of the Hebrew version of the Unified Dyskinesia Rating Scale (UDysRS)

A. Socher, A. Thaler, H. Shabtai, J. Zitser, T. Shainer, M. Kestenbaum, A. Rosenberg, A. Bar David, A. Ezra, T. Taichman, M. Brozgol, T. Herman, G. Stebbins, C. Goetz, S. Luo, P. Martinez-Martin, N. Giladi, T. Gurevich (Mdrid, Spain)

1:45pm-3:15pm: Validation of the Movement Disorder Society criteria for the diagnosis of 4R-tauopathies

G. Respondek, MJ. Grimm, I. Piot, T. Arzberger, Y. Compta, E. Englund, LW. Ferguson, E. Gelpi, A. Giese, S. Roeber, DJ. Irwin, WG. Meissner, C. Nilsson, A. Pantelyat, A. Rajput, JB. Rowe, JC. van Swieten, C. Troakes, GU. Höglinger (London, United Kingdom)

1:45pm-3:15pm: Validation of the PREDIGT Score for the Incidence Rate of Parkinson disease

J. Li, T. Mestre, J. Tomlinson, M. Frasier, E. Lang, B. Mollenhauer, T. Ramsay, D. Manuel, M. Schlossmacher (Goettingen, Germany)

1:45pm-3:15pm: Vascular Parkinsonism and Parkinson’s Disease: clinical differences concerning balance impairment

R. Jesus, R. Raimundo, C. Azoia, M. Mendes, V. Espirito-Santo, A. Almeida, I. Rego, AG. Velon (Vila Real, Portugal)

1:45pm-3:15pm: Vascular risk factors and depression in multiple system atrophy

LY. Zhang, B. Cao, QQ. Wei, RW. Ou, HF. Shang (Chengdu, China)

1:45pm-3:15pm: Vertebral pain and bone mineral density in women with Parkinson’s disease

I. Karaban, V. Povoroznyuk, M. Bystrytska, N. Karasevich, N. Grygorieva (Kyiv, Ukraine)

1:45pm-3:15pm: Visual evoked potentials alterations in DLB

C. Carrarini, M. Russo, F. Anzellotti, F. Dono, S. Nanni, M. Onofrj, L. Bonanni (Chieti, Italy)

1:45pm-3:15pm: Visual sensory processing is altered in myoclonus dystonia

C. Clement, N. Nicolas, C. Cécile, E. Eavan, R. Romain, M. Marie, P. Pierre, E. Emmanuel, Y. Yulia (Paris, France)

1:45pm-3:15pm: Vocal cords electromyography abnormalities in multiple system atrophy phenotypes: relevance for the pathophysiology of stridor

M. Todisco, E. Alfonsi, I. Isaias, R. Zangaglia, B. Minafra, M. Terzaghi, N. Pozzi, C. Pacchetti (Pavia, Italy)

1:45pm-3:15pm: Zonisamide ameliorates levodopa-induced dyskinesia via striatal cholinergic system in a rat model of Parkinson’s disease

S. Kaneko, S. Morise, R. Tohge, M. Oki, M. Nakamura, N. Takenouchi, H. Kusaka (Hirakata, Japan)

1:45pm-3:15pm: Сhange In The Body Composition Of Patients With Parkinsonism For 2 Years

D,A. Akramova, G. Rakhimbaeva, D. Bobomuratova (Tashkent, Uzbekistan)

1:15pm-2:45pm: “Poised for Parkinson’s”: Group classes in Alexander technique for managing symptoms of Parkinson’s disease

M. Gross, R. Ravichandra, M. Norcia, R. Cohen (Moscow, ID, USA)

1:15pm-2:45pm: “Brain-first” vs. “body-first” Parkinson’s disease is determined by RBD-status – a multi-modality imaging study

J. Horsager, K. Knudsen, K. Andersen, C. Skjærbæk, T. Fedorova, J. Geday, J. Kraft, E. Bech, E. Danielsen, M. Møller, N. Pavese, D. Brooks, P. Borghammer (Aarhus N, Denmark)

1:15pm-2:45pm: “Dual Frequency” Deep Brain Stimulation Paradigm for Axial Symptoms in Parkinson’s Disease

J. Karl, B. Ouyang, L. Verhagen Metman (Chicago, IL, USA)

1:15pm-2:45pm: (Not) sleeping with the enemy: Cognitive correlates of nocturnal sleep disturbances in Parkinson’s disease

S. Castillo-Torres, C. Cerda-Contreras, D. Roque-Martínez, D. Díaz-Pérez, X. Ortiz-Jiménez, B. Chávez-Luévanos, I. Estrada-Bellmann (Monterrey, Mexico)

1:15pm-2:45pm: 11C-PBB3 PET in PD: does alpha-synuclein pathology start in axonal terminals?

M. Matarazzo, A. Pérez-Soriano, V. Sossi, N. Vafai, E. Shahinfard, K. Ju-Chieh Cheng, J. Mckenzie, N. Neilson, Q. Miao, H. Shinotoh, M. Higuchi, A. Stoessl (Vancouver, BC, Canada)

1:15pm-2:45pm: 18F-DPA714 PET reveals neuroinflammatory activity in the Substantia nigra of patients with Parkinson disease

S. Lavisse, C. Wimberley, S. Goutal, M. Bottlaender, B. Kuhnast, MA. Peyronneau, M. Sarazin, P. Hantraye, C. Thiriez, P. Remy (Fontenay Aux Roses, France)

1:15pm-2:45pm: A case of dystonia with dystonic tremor treated with DBS targeting the VOA and VIM thalamus

L. Jackson, B. Klassen, J. Bower, F. Ali (Rochester, MN, USA)

1:15pm-2:45pm: A Comparative Study of Measured and Predicted Metrics of Respiratory Function in People with Parkinson’s Disease (PD)

L. Mcmahon, O. Lennon, C. Blake, D. Mcgrath (Dublin, Ireland)

1:15pm-2:45pm: A comparison of serial position effects between patients with MCI due to Parkinson’s disease and patients with MCI due to Alzheimer’s disease

A. Meyer, I. Handabaka, MM. Ehrensperger, U. Gschwandtner, F. Hatz, AU. Monsch, RD. Stieglitz, P. Fuhr (Basel, Switzerland)

1:15pm-2:45pm: A Dual-Center Study of Pain and Other Non-motor Symptoms in Parkinson disease

P. Ghosh, P. Imbriani, N. Caputi, L. Covington, A. Sparks, T. Schirinzi, Y. Salnikova, S. Natoli, A. Pisani (Washington Dc, DC, USA)

1:15pm-2:45pm: A Large-Scale Survey of Rock Steady Boxing (RSB) Utilization in Parkinson’s Disease

D. Bega, D. Larson, M. Rafferty (Chicago, IL, USA)

1:15pm-2:45pm: A machine learning approach to predict non-responders to subthalamic nucleus deep brain stimulation in Parkinson disease patients based on preoperative characteristics

J. Habets, M. Janssen, A. Duits, B. de Greef, A. Mulders, L. Sijben, Y. Temel, M. Kuijf, P. Kubben, C. Herff (Maastricht, Netherlands)

1:15pm-2:45pm: A new screening tool to detect psychoaffective states in patients with Parkinson´s disease

C. Schedlich-Teufer, M. Sommerauer, S. Jost, S. Schnitzler, H. Dafsari, E. Kalbe, J. Kessler, M. Barbe (Cologne, Germany)

1:15pm-2:45pm: A Pilot Study of Gamma Knife Radiosurgery Targeting the Subthalamic Nucleus in Elderly and Infirmed Parkinson’s Disease Patients Not Amenable to Deep Brain Stimulation

P. Drummond, M. Pourfar, D. Kondziolka (New York, NY, USA)

1:15pm-2:45pm: A Prospective Study of the Effects of Deep Brain Stimulation on Constipation and Olfaction in Parkinson Disease

S. Kola, A. Bharucha, D. Prichard, K. Feuerhak, A. Hassan (Rochester, MN, USA)

1:15pm-2:45pm: A randomised rater-blinded study of motor consequences of inactivity in Parkinson’s disease revealing a new phenomenon: Stasis Induced Akinesia

M. Schumacher, S. Tisch (Sydney, Australia)

1:15pm-2:45pm: A Registry for Parkinson’s Disease in Utah

P. Moretti, A. Nakashima, M. Zorn, S. Woltz, L. Farese, L. Cannon-Albright, S. Pulst (Salt Lake City, UT, USA)

1:15pm-2:45pm: A Study of Social Cognition in Parkinson’s Disease

S. Meenakshisundaram, LN. Ranganathan (Chennai, India)

1:15pm-2:45pm: A videographic tool for quantitative assessment of the Glabellar Reflex

A. Braczynski, J. Schulz, S. Leonhardt, C. Hoog Antink (Aachen, Germany)

1:15pm-2:45pm: Accelerometer-Based Gait Analysis for Patients with Parkinson’s Disease

S-T. Tang, C-H. Tai, Y-H. Lai, T-C. Lee (Taoyuan, Taiwan)

1:15pm-2:45pm: Accuracy of the MoCA in Detecting PD-MCI in the Ontario Neurodegenerative Disease Research Initiative study

KB. Zaidi, C. Marras, A. Troyer, A. Lang, M. Masellis, D. Grimes, D. Kwan, JB. Orange, A. Roberts, B. Levine, M. Jog, T. Steeves, B. Tan, P. Mclaughlin (Toronto, ON, Canada)

1:15pm-2:45pm: Actigraphically Characterized Infradian Rest-Activity Rhythms in Parkinson’s Disease

C. Brooks, R. Koehler, MK. Erb, F. Mortazavi, J. Bhangu, K. Thomas (Boston, MA, USA)

1:15pm-2:45pm: Activity of Cerebral Networks, Amyloid and Microglia in Corticobasal Syndrome: the ActiGliA study

C. Palleis, J. Levin, M. Brendel, L. Beyer, BS. Rauchmann, S. Loosli, E. Wlasich, K. Boetzel, A. Danek, R. Perneczky, C. Haass, G. Hoeglinger (Munich, Germany)

1:15pm-2:45pm: Acute unilateral involuntary movement in a patient with posterior reversible encephalopathy syndrome

P-Y. Chen (Taipei, Taiwan)

1:15pm-2:45pm: Adrenergic Receptor Modulation of Non-Motor Symptoms in Parkinson’s Disease

M. Rangwala, E. Hogg, E. Tan, H. Lu, A. Garland Becerra, M. Tagliati (Los Angeles, CA, USA)

1:15pm-2:45pm: Adult-Onset Parainfectious Opsoclonus-Myoclonus: Report of Two Cases

MI. Gaston, I. Rubio, J. Muruzabal, R. Larumbe, M. Martin, L. Martinez (Pamplona, Spain)

1:15pm-2:45pm: Adult-onset stereotypy — An atypical presentation of frontotemporal dementia

C. Walsh, L. Brennan, J. Ratliff (Philadelphia, PA, USA)

1:15pm-2:45pm: Advanced autonomous motor state detection from wrist-worn sensor in persons with PD

J. Goschenhofer, F. Pfister, K. Yuksel, J. Thomas, B. Fischl, A. Ceballos-Baumann, U. Fietzek (München, Germany)

1:15pm-2:45pm: Advanced Stage of Parkinson’s Disease: From Identification to Characterization and Disease Burden Assessment Using a Nationwide Database

Y. Barer, T. Gurevich, G. Chodick, N. Giladi, R. Gross, R. Cohen, L. Bergmann, Y. Jalundhwala, V. Shalev, A. Thaler (Tel Aviv-Yafo, Israel)

1:15pm-2:45pm: Aerobic exercise alters brain structure and function in Parkinson’s disease – a randomized controlled trial

M. Johansson, I. Cameron, N. Vander Kolk, N. de Vries, I. Toni, B. Bloem, R. Helmich (Nijmegen, Netherlands)

1:15pm-2:45pm: Age-related failure in compensatory mechanisms and its relation to the Parkinson phenotype: evidence from a SPECT study in early and late-onset PD

G. Palermo, D. Frosini, S. Giannoni, M. Giuntini, D. Volterrani, U. Bonuccelli, R. Ceravolo (Pisa, Italy)

1:15pm-2:45pm: Alpha-synuclein interacts with BAF complex in nucleus

N. Sugeno, T. Hasegawa, J. Kobayashi, S. Yoshida, M. Ezura, A. Kikuchi, A. Takeda, M. Aoki (Sendai, Japan)

1:15pm-2:45pm: Alterations of Blood Pressure Circadian Rhythm in Alpha-Synucleinopathies

A. Romagnolo, F. Vallelonga, A. Merola, C. Di Stefano, G. Sobrero, V. Milazzo, M. Zibetti, CA. Artusi, M. Fabbri, MG. Rizzone, S. Maule, L. Lopiano (Turin, Italy)

1:15pm-2:45pm: Amyloid load and cognitive decline in Parkinson’s disease: preliminary longitudinal findings

M. Stark, T. Melzer, D. Myall, R. Keenan, T. Pitcher, KL. Horne, L. Livingston, M. Macaskill, J. Dalrymple-Alford, T. Anderson (Christchurch, New Zealand)

1:15pm-2:45pm: An explorative study on the value of clinical features for diagnosing Parkinson’s disease

S. Suwijn, R. de Bie (Amsterdam, Netherlands)

1:15pm-2:45pm: An external relative to an internal focus of attention enhances motor learning in children with poor motor imagery ability

R. Abdollahipour, M. Bahmani, M. Babak, W. Land (Olomouc, Czech Republic)

1:15pm-2:45pm: Analysis from genotype to phenotype: Improvement in freezing of gait after subthalamic deep brain stimulation (STN-DBS) in a Parkinson’s disease patient with copy number variations of Parkin gene.

LW. Liu, WF. Yu, JL. Hu, S. Chen, ZX. Zhao, YM. Liu (Jinan, China)

1:15pm-2:45pm: Analysis of the role of known susceptibility genes of Parkinson’s disease in cancer

P-E. Sugier, M. Law, M. Iles, M. Meta-Analysis Consortium, M. Kvaskoff, T. Truong, A. Elbaz (Saint-Aubin, France)

1:15pm-2:45pm: Anatomical correlates of VTAs in directional STN DBS

M. Pilleri, M. Piacentino, S. Rinaldo, T. Mesiano, G. Ielo, M. Mondani, S. D'Auria, R. Eleopra (Milano, Italy)

1:15pm-2:45pm: Annual Incidence of Parkinson’s Disease in Mexico: A Report of National Public Health Institutions

E. Velazquez-Avila, D. Martinez-Ramirez, A. Banegas-Lagos, A. Cervantes-Arriaga, K. Salinas-Barbosa, S. Isais-Millan, M. Rodriguez-Violante (Monterrey, Mexico)

1:15pm-2:45pm: Antibiotic exposure and Risk for Parkinson’s Disease

T. Mertsalmi, E. Pekkonen, F. Scheperjans (Helsinki, Finland)

1:15pm-2:45pm: Antipsychotics Use in Parkinson’s Disease and Mortality Risks

WM. Liu, JH. Wang, HY. Chen, R. Lo (Hualien, Taiwan)

1:15pm-2:45pm: Anxiety and dopaminergic stimulation in patients with Parkinson´s disease.

A. Camacho Nieto, AR. Franco Salinas, L. Ruiz-Escribano Menchen, MJ. Gallardo Alcañiz, JP. Cabello Rosa, J. Vaamonde Gamo (Ciudad Real, Spain)

1:15pm-2:45pm: Apathy and cognitive profile in Parkinson´s disease: A cross-sectional study in Cali-Colombia

B. Muñoz, J. Valderrama, L. Botero, J. Orozco (Cali, Colombia)

1:15pm-2:45pm: Appendectomy and risk of Parkinson’s disease: A meta-analysis using real-world evidence

S. Hussain, A. Najmi (New Delhi, India)

1:15pm-2:45pm: Applicability of questionnaires and study of the prevalence of REM Sleep Behavior Disorder (RBD) in Parkinson’s disease

M. Cordellini, A. Machado, C. Costa (Curitiba, Brazil)

1:15pm-2:45pm: Applicability of short form of Montreal Cognitive Assessment to Brazilian Portuguese

M. Olchik, C. Rieder, L. Scudeiro, R. Millette, R. Rech, A. Ayres (Porto Alegre, Brazil)

1:15pm-2:45pm: Appropriateness of DAT Scan Ordering in a University Hospital Practice

Z. Togher, S. Fullam, J. Britton, J. Duignan, R. Killeen, S. O'Riordan, M. Hutchinson (Dublin 4, Ireland)

1:15pm-2:45pm: Apraxia of Eye Lid Opening in patients with advanced Parkinson’s disease undergoing subthalamic stimulation – a single-centre experience.

K. Shetty, S. Krishan, K. Kesavapisharady, D. Puthenveedu, A. Kishore (Thiruvananthapuram, India)

1:15pm-2:45pm: Are there associations between altered brain connectivity and dopaminergic medication in Parkinson’s disease patients with freezing of gait?

A. Potvin-Desrochers, A. Atri, C. Paquette (Montreal, QC, Canada)

1:15pm-2:45pm: Are transventricular approaches associated with increased haemorrhage in functional stereotactic neurosurgery? A comparative study on 550 patients

J. Runge, A. Saryyeva, C. Blahak, C. Schrader, H. Bäzner, HH. Capelle, M. Abdallat, M. Wolf, TM. Kinfe, JK. Krauss (Hannover, Germany)

1:15pm-2:45pm: Are we underestimating the dysautonomic burden in GBA related a-synucleinopathies?

G. Lazzeri, E. Monfrini, I. Trezzi, M. Vizziello, M. Percetti, G. Franco, L. Borellini, A. Arighi, A. Di Fonzo (Milan, Italy)

1:15pm-2:45pm: Arm levitation as an early manifestation in MELAS syndrome: A case report

D. Gunal, I. Midi, E. Erdil (Istanbul, Turkey)

1:15pm-2:45pm: Art du Deplacement (ADD)/Parkour therapy for people with Parkinson’s disease (PDP)

M. Schwed, T. Getrost, K. Torchia, G. Yao (Pfungstadt, Germany)

1:15pm-2:45pm: Arterial spin labelling detects subcortical hypoperfusion in early drug-naïve patients with Parkinson’s disease

SP. Caminiti, G. Pagano, G. Dervenoulas, T. Yousaf, H. Wilson, M. Politis (London, United Kingdom)

1:15pm-2:45pm: Assessing the validity and reliability of MANAGE-PD tool to identify patients with Parkinson’s disease inadequately controlled on oral medications – Results from an international survey of general neurologists and movement disorder specialists

A. Antonini, P. Odin, Y. Jalundhwala, P. Schmidt, A. Skalicky, L. Kleinman, J. Zamudio, K. Onuk, P. Kukreja, Y. Bao, F. Cubillos, H. Fernandez (Padua, Italy)

1:15pm-2:45pm: Association between alteration in social cognition and impulse control disorder in Parkinson’s disease

L. Zuazua-Vidal, M. Rodríguez-Violante, R. Solís-Vivanco, A. Pérez-González, A. Alcocer-Salas, A. Cervantes-Arriaga (Mexico City, Mexico)

1:15pm-2:45pm: Association between Parkinson disease and the risk of cardiovascular disease and all-cause mortality: A nationwide, register-based cohort study

DH. Kim, DY. Kwon, MH. Park, KW. Park (Ansan City, Republic of Korea)

1:15pm-2:45pm: Association between sleep disturbances in Parkinson’s disease and bioimaging

M. Nagai, T. Tsujii, R. Ando, Y. Yamanishi, S. Tada, Y. Hosokawa (Ehime, Japan)

1:15pm-2:45pm: Association of active and passive smoking with Parkinson’s disease in women: the E3N cohort study

M. Canonico, F. Artaud, D. Cerasuolo, I. Degaey, P. Gerbouin-Rerolle, A. Kowal, E. Roze, G. Severi, MC. Boutron-Ruault, A. Elbaz (Villejuif, France)

1:15pm-2:45pm: Association of alexithymia and Parkinson’s Disease (PD) in Mexican population

L. Zuazua, M. Rodriguez, A. Cervantes, A. Balderas, R. Cruz, A. Alcocer, A. Perez, O. Esquivel, L. Navarro (Mexico City, Mexico)

1:15pm-2:45pm: Association of metallic air pollution with Parkinson’s disease: a French nationwide incidence study

T. Vlaar, E. Lequy-Flahault, E. Moutengou, C. Meyer, S. Leblond, A. Elbaz, F. Moisan (Villejuif, France)

1:15pm-2:45pm: Association of MRI-derived estimated brain age and cognitive ability in Parkinson’s disease

K-L. Horne, R. Shoorangiz, L. Livingston, S. Grenfell, M. Almuqbel, B. Young, M. Pascoe, M. Livingstone, M. Macaskill, D. Myall, T. Pitcher, T. Anderson, J. Dalrymple-Alford, T. Melzer (Chrsitchurch, New Zealand)

1:15pm-2:45pm: Associations of gait disorders and future falls in the elderly: a prospective population-based study

K. Marini, P. Mahlknecht, O. Schorr, M. Baumgartner, A. Djamshidian, A. Gasperi, S. Kiechl, G. Rungger, H. Stockner, J. Willeit, W. Poewe, K. Seppi (Innsbruck, Austria)

1:15pm-2:45pm: ATP1A3 Gene Mutations Associated With Rapid-Onset Dystonia-Parkinsonism (RDP) Presenting As Functional Neurologic Disorder: A Report of Two Cases

T. Biller, R. Chuang, S. Ro (Seattle, WA, USA)

1:15pm-2:45pm: Auditory processing in young patients of Essential Tremor

P. Shetty, Y. Belur, R. Yadav, P. Yuvaraj, A. Rajasekaran, N. Shivashankar, S. Hegde, P. Pal (Bangalore, Karnataka, India)

1:15pm-2:45pm: Automated Diagnosis of Idiopathic Parkinson’s Disease Using Deep Convolutional Neural Networks

YH. Sung, DH. Shin, EY. Kim (Incheon, Republic of Korea)

1:15pm-2:45pm: Automated Interpretation of FP-CIT-SPECT images based on Artificial Intelligence

M. Meier, J. Hammes, A. Drzezga, T. Dratsch, C. Kobe, D. Dos Santos, T. van Eimeren (Cologne, Germany)

1:15pm-2:45pm: Autonomic dysfunction in early Parkinson’s disease: a prospective study

I. Stankovic, I. Petrovic, T. Pekmezovic, V. Markovic, T. Stojkovic, N. Dragasevic Miskovic, M. Svetel, V. Kostic (Belgrade, Serbia)

1:15pm-2:45pm: Autonomic features in E46K-SNCA carriers

M. Carmona-Abellán, I. Gabilondo, A. Murueta, V. Khurana, R. Luquin, B. Tijero, R. Del Pino, M. Acera, R. Sanchez-Pernaute, JC. Gomez-Esteban (Bilbao, Spain)

1:15pm-2:45pm: BeatPark: a new wearable device for gait auto-rehabilitation in Parkinson’s disease delivering adapted musical stimulation.

V. Cochen Decock, D. Dotov, L. Damm, MC. Picot, P. Ihalainen, V. Driss, C. Geny, B. Bardy, S. Dalla Bella (Montpellier, France)

1:15pm-2:45pm: Beneficial effect of 36-month bilateral subthalamic stimulation on quality of sleep compared to standard-of-care medication in Parkinson’s disease

H. Dafsari, S. Jost, A. Sauerbier, V. Visser-Vandewalle, K. Ashkan, M. Silverdale, J. Evans, P. Löhrer, A. Rizos, JN. Petry-Schmelzer, G. Fink, M. Barbe, A. Antonini, P. Martinez-Martin, K. Ray-Chaudhuri, L. Timmermann (Cologne, Germany)

1:15pm-2:45pm: Bilateral Globus pallidus internus deep brain stimulation as rescue therapy for ineffective subthalamic stimulation

A. Sanchez-Rodriguez, M. Sierra, J. Martino, M. Martinez, R. Roberto, I. Gonzalez Aramburu, J. Infante (Santander, Spain)

1:15pm-2:45pm: Bilateral STN-DBS after bilateral pallidotomy for Parkinson’s disease: A Case Report

CC. Zhang, LB. Wang, DY. Li, BM. Sun (Shanghai, China)

1:15pm-2:45pm: Bladder Training for Urinary Tract Symptoms in PD – A Randomised Controlled Trial

C. Mcdonald, J. Rees, K. Winge, J. Newton, D. Burn (Gateshead, United Kingdom)

1:15pm-2:45pm: Blood Metagenomics Analyses of Brazilian Parkinson’s Disease Patients: A Clinical Substype Study

G. Poralla, V. Rayol, N. Woldmar, B. Fadel, L. Giacomin, A. Rosso, L. Pizzatti (Rio de Janeiro, Brazil)

1:15pm-2:45pm: Blue light therapy glasses in Parkinson’s disease: patients’ experience and effectiveness

K. Smilowska, D. van Wamelen, A. Schoutens, M. Meinders, B. Bloem (Nijmegen, Netherlands)

1:15pm-2:45pm: BODILY AND FACIAL EMOTION RECOGNITION IN PARKINSON´S DISEASE

Z. Kosutzka, P. Brandoburova, I. Straka, V. Veronika, P. Valkovic, M. Hajduk (Bratislava, Slovakia)

1:15pm-2:45pm: Body Representation Impairments in Parkinson’s disease: A Preliminary Report

J. Cardona, C. Martinez, W. Correa, J. Grisales, C. Trujillo, F. Marmolejo-Ramos (Santiago de Cali, Colombia)

1:15pm-2:45pm: Brain amyloid contribution to cognitive dysfunction in Lewy bodies disorders: a pilot study

R. Biundo, E. Fiorenzato, D. Cecchin, C. Salvotti, L. Weis, A. Antonini (Venice, Italy)

1:15pm-2:45pm: Can Google Glass improve freezing of gait in parkinsonism? A pilot study

A. Lee, N. Hellmers, M. Vo, P. Popa, C. Henchcliffe, H. Sarva, C. Campbell (New York, NY, USA)

1:15pm-2:45pm: Can Safinamide Help to Stabilize Dopaminergic Treatment in Parkinson’s Disease?

B. Solano Vila, A. Cots Foraster, M. Montserrat Roses (Girona, Spain)

1:15pm-2:45pm: Cardiovascular autonomic function and MCI in Parkinson’s disease

CE. Cicero, L. Raciti, R. Monastero, G. Mostile, G. Donzuso, G. Sciacca, A. Luca, C. Terravecchia, L. Giuliano, R. Baschi, M. Davì, M. Zappia, A. Nicoletti (Catania, Italy)

1:15pm-2:45pm: Caudal posterior substantia nigra iron increases longitudinally in Parkinson’s disease

N. Bergsland, R. Zivadinov, F. Schweser, J. Hagemeier, D. Lichter, T. Guttuso, JR. (Buffalo, NY, USA)

1:15pm-2:45pm: Central Insulin Resistance Index is Independent of Peripheral Insulin Resistance in Parkinson’s disease

M. Tagliati, E. Hogg, T. Wu, K. Makwana, H. Maghzi, A. Garland, E. Tan, C. Riera (Los Angeles, CA, USA)

1:15pm-2:45pm: Cerebellar Structural changes in Patients with Parkinson’s disease and Essential Tremor

A. Lopez, P. Trujillo, B. Landman, P. Hedera, D. Claassen (Nashville, TN, USA)

1:15pm-2:45pm: Challenges in Parkinson’s Disease Diagnosis in a Patient with Ipsilateral Hemimelia

G. Fabiani, FMB. Germiniani, HA. Teive (Curitiba, Brazil)

1:15pm-2:45pm: Change of extracellular glutamate and GABA level in striatum during deep brain stimulation of the entopeduncular nucleus in rats

CB. Cho, JH. Sung (Suwon, Republic of Korea)

1:15pm-2:45pm: Changes in Neuromelanin MRI Signal in Parkinson’s Disease: A Longitudinal Study

R. Gaurav, L. Yahia-Cherif, G. Mangone, N. Pyatigorskaya, R. Valabregue, C. Ewenczyk, M. Hutchison, J. Corvol, M. Vidailhet, S. Lehéricy (Paris, France)

1:15pm-2:45pm: Changing for a rechargeable neurostimulator in Parkinson’s disease patients: safety and feasibility

T. Wirth, C. Laurencin, J. Berthiller, A. Brindzeu, E. Simon, G. Polo, P. Mertens, E. Broussolle, T. Danaila, S. Thobois (Strasbourg, France)

1:15pm-2:45pm: Characteristics of lower gastrointestinal tract dysfunction in patients with Parkinson disease

T. Uchiyama, T. Yamamoto, K. Suzuki, T. Kadowaki, H. Nakajima, R. Sakakibara, S. Kuwabara, K. Hirata, M. Murai (Chiba, Japan)

1:15pm-2:45pm: Characteristics of spontaneous brain activity in left- and right-onset Parkinson’s disease patients

K. Li, W. Su, H. Zhao, C. Li, X. Ma, B. Lou, M. Chen, H. Chen (Beijing, China)

1:15pm-2:45pm: Characteristics of the clinical and cerebral metabolism in Parkinson’s disease with atrophy in nucleus basalis of Meynert

MY. Gang, T. Baba, Y. Hosokai, Y. Nishio, A. Kikuchi, K. Hirayama, T. Hasegawa, M. Aoki, A. Takeda, E. Mori, K. Suzuki (Sendai, Japan)

1:15pm-2:45pm: Characterization of the gastrointestinal dysfunction in the 6-hydroxydopamine rat model of Parkinson’s disease

X. Chai, S. Diwakarla, R. Pustovit, R. Mcquade, M. Di Natale, C. Ermine, C. Parish, D. Finkelstein, J. Furness (Melbourne, Australia)

1:15pm-2:45pm: Characterizing olfactory impairment in patients with Parkinson’s disease and related disorders

Y. Watanabe, K. Suzuki (Mibu, Shimotsuga, Tochigi, Japan)

1:15pm-2:45pm: Circadian and Homeostatic Modulation of Multi-unit Activity in Dopaminergic and Striatal Structures

K. Fifel, T. Deboer (Leiden, Netherlands)

1:15pm-2:45pm: Classify Parkinson’s Disease with Mild Cognitive Impairment: Machine Learning Approach

SS. Cho, C. Li, Y. Koshimori, J. Kim, L. Christopher, M. Dı´ez-Cirarda, M. Valli, A. Mihaescu, S. Houle, A. Strafella (Toronto, ON, Canada)

1:15pm-2:45pm: Clinical and DAT Imaging Characteristics of Participants with Scans without Evidence of Dopaminergic Deficit (SWEDDs): PPMI Cohort 2 year follow-up

K. Marek, T. Simuni, A. Siderowf, D. Lafontant, C. Caspell-Garcia, C. Coffey, B. Mollenhauer, C. Tanner, K. Kieburtz, L. Chahine, J. Seibyl (New Haven, CT, USA)

1:15pm-2:45pm: Clinical and epidemiological data on Parkinson’s disease in older adults: experience of a single Italian centre.

T. Schirinzi, G. Di Lazzaro, M. Pierantozzi, A. Stefani, N. Mercuri, A. Pisani (Rome, Italy)

1:15pm-2:45pm: Clinical and neuroimaging heterogeneity of dementia with Lewy bodies

A. Chimagomedova, E. Vasenina, O. Levin (Moscow, Russian Federation)

1:15pm-2:45pm: Clinical correlation between 99mTc-TRODAT-1 SPECT and parkinsonism

AC. Chen (Taichung, Taiwan)

1:15pm-2:45pm: Clinical Management of Incipient Wearing-off with the 19-Items Wearing off Questionnaire (WOQ-19)

V. Puente Périz, I. Navalpotro Gómez, A. Crespo Cuevas, A. Puig Pijuan, A. Fernandez Lebrero, D. Lahoz (Barcelona, Spain)

1:15pm-2:45pm: Clinical profile of idiopathic Parkinson’s disease in patients admitted to Mohamed VI University Hospital center of Marrakech

A. Boudanga, N. Jalami, M. Chraa, N. Kissani (Marrakech, Morocco)

1:15pm-2:45pm: Clinical Results in Argentines Patients with STN DBS in Parkinson’s Disease

C. Ramirez Gomez, N. Portinari, J. Travi, V. Montilla Uzcategui, F. Micheli, F. Piedimonte (Buenos Aires, Argentina)

1:15pm-2:45pm: Clinical-instrumental algorithm for assessment visuospatial dysfunction in patients with Parkinson’s disease

K. Stepanchenko (Kharkiv, Ukraine)

1:15pm-2:45pm: Clinical, genetic and radiological characterization of patients with movement disorders and basal ganglia calcification

F. Arienti, G. Franco, E. Monfrini, A. Seresini, A. Di Fonzo (Milan, Italy)

1:15pm-2:45pm: Clinical, motor and global cognition in patients with in early stages of Parkinson disease

J. Orozco, J. Valderrama, Y. Castaño, J. Arango, A. Navarro, B. Muñoz (Cali, Colombia)

1:15pm-2:45pm: Clinimetric properties of direct contemporaneous FOG score rating

K. Ziegler, AO. Ceballos-Baumann, UM. Fietzek (Munich, Germany)

1:15pm-2:45pm: Clostridium Difficile Infection and Risk of Parkinson’s Disease: A Swedish Population-Based Cohort Study

X. Kang, A. Ploner, J. Ludvigsson, D. Williams, N. Pedersen, K. Wirdefeldt (Solna, Sweden)

1:15pm-2:45pm: Co-administration of levodopa and zonisamide reduces the serotonin transporter expression in a rat model of Parkinson’s disease

R. Tohge, S. Kaneko, S. Morise, M. Oki, M. Nakamura, N. Takenouchi, H. Kusaka (Hirakata, Japan)

1:15pm-2:45pm: Cognitive ability characterization of rat model with mutated alpha-synuclein overexpression

C. Laloux, C. Lachaud, K. Timmerman, E. Bezard, R. Bordet, D. Devos (Lille, France)

1:15pm-2:45pm: Cognitive and psychiatric course in the initial lustrum of Parkinson disease: the glass is half full

D. Weintraub, C. Caspell-Garcia, H. Cho, T. Simuni, A. Siderowf, C. Coffey, D. Aarsland, R. Alcalay, L. Chahine, J. Eberling, A. Espay, J. Hamilton, J. Leverenz, I. Litvan, I. Richard, L. Rosenthal, M. York (Philadelphia, PA, USA)

1:15pm-2:45pm: Cognitive changes after deep brain stimulation of the subthalamic nucleus in Parkinson’s disease: A longitudinal study.

J. Mana, F. Růžička, A. Fečíková, E. Růžička, D. Urgošík, R. Jech, O. Bezdicek (Prague, Czech Republic)

1:15pm-2:45pm: Cognitive complaint in Parkinson’s disease patients with normal cognition: Canary in the coal mine?

R. Purri, L. Brennan, J. Rick, S. Xie, B. Deck, L. Chahine, N. Dahodwala, A. Chen-Plotkin, J. Duda, J. Morley, R. Akhtar, J. Trojanowski, D. Weintraub (Philadelphia, PA, USA)

1:15pm-2:45pm: Cognitive impairment in Parkinson’s Disease: A cross-sectional association study

A. Simon, C. Rodriguez-Blazquez, MJ. Forjaz, P. Martinez-Martin (Madrid, Spain)

1:15pm-2:45pm: Cognitive impairment in patients with Parkinson’s Disease

E. Kolupaeva, I. Zhukova, N. Zhukova, M. Nikitina, O. Izhboldina, I. Mironova, Z. Kislukhina (Tomsk, Russian Federation)

1:15pm-2:45pm: Cognitive impairment profile of patients with Essential Tremor and Parkinson’s Disease

A. Abundes-Corona, A. Cervantes-Arriaga, R. Zerón-Martínez, R. Solís-Vivanco, O. Cárdenas-Saenz, M. Rodríguez-Violante (Mexico City, Mexico)

1:15pm-2:45pm: Cognitive Inhibitory Control and Response to Dopaminergic Medication in Parkinson’s Disease

M. El Haddouchi, A. Handberg, K. Svaerke, A. Loekkegaard (Copenhagen, Denmark)

1:15pm-2:45pm: Cognitive multi-domain assessment in Parkinson’s disease: A more sensitive approach

C. Trujillo, S. Baez, E. Herrera, A. Garcia, A. Ibañez, J. Cardona (Santiago de Cali, Colombia)

1:15pm-2:45pm: Cognitive outcomes of STN-DBS in GBA mutation carriers with PD

G. Pal, E. Hill, T. Foltynie, V. Lythe, R. Alcalay, P. Garcia, K. Marder, R. Saunders-Pullman, S. Bressman, J. Aasly, B. Ouyang, Y. Liu, S. Anderson, B. Bernard, L. Verhagen (Chicago, IL, USA)

1:15pm-2:45pm: Cognitive Processes That Indirectly Effect Olfactory Dysfunction in Parkinson’s Disease

B. Chase, A. Mertens, J. Santo, K. Markopoulou (Omaha, NE, USA)

1:15pm-2:45pm: Cognitive profile of degenerative parkinsonian syndromes in the French West Indies and relationship with eye movements recordings

A. Petit, A. Lackmy, R. Edragas, S. Belson, A. Mongis-Marlin, C. Stattner, F. Triboulet, G. Lepage, B. Tressieres, B. Gaymard, A. Lannuzel (Fort de France, Martinique)

1:15pm-2:45pm: Cognitive Profile of Patients with Parkinson´s Disease and Subthalamic Nucleus Deep Brain Stimulation

E. Barbosa, J. Santos, H. Fichman (Rio de Janeiro, Brazil)

1:15pm-2:45pm: Cognitive Training in Parkinson’s Disease: Experience in a Rehabilitation Hospital from Brazil

N. Sousa, A. Neri, I. Brandi, S. Brucki (Salvador, Brazil)

1:15pm-2:45pm: Combined STN and NBM DBS in PD and mild to moderate Parkinson’s dementia

R. Nickl, P. Fricke, P. Capetian, M. Reich, J. Krapp, V. Sturm, J. Volkmann, C. Matthies (Wuerzburg, Germany)

1:15pm-2:45pm: Comparing motor and neuropathological features of Parkinson’s disease dementia and dementia with Lewy bodies

D. Hansen, T. Lashley, J. Holton, T. Warner (London, United Kingdom)

1:15pm-2:45pm: Comparison between [11C]PE2I PET and [123I]FP-CIT SPECT as markers of DAT expression in early Parkinson’s disease

T. Yousaf, G. Pagano, H. Wilson, B. Corcoran, G. Vivian, M. Politis (London, United Kingdom)

1:15pm-2:45pm: Comparison between the Movement Disorders Society – Non-Motor Rating Scale (MDS-NMS) and the Non-Motor Symptoms Scale (NMSS)

A. Schrag, A. Rizos, C. Rodriguez-Blazquez, D. Weintraub, KR. Chaudhuri, P. Martinez-Martin (Madrid, Spain)

1:15pm-2:45pm: Comparison of autonomic symptoms on Parkinson’s disease and essential tremor with SCOPA-AUT

J. Gonzalez (Lima, Peru)

1:15pm-2:45pm: Comparison of Current DBS Platforms in the United States

L. Surillo, U. Yazdani, S. Chitnis (Dallas, TX, USA)

1:15pm-2:45pm: Comparison of Dementia Patients With and Without Parkinson’s Disease Before Dementia-related Psychosis Occurs: An Administrative Claims Data Analysis

A. Shim, B. Skoog, V. Abler, N. Rashid, R. Halpern, E. Koep, M. Frazer (San Diego, CA, USA)

1:15pm-2:45pm: Comparison of high versus low frequency subthalamic stimulation on eye movement

MG. Ghilardi, L. Stock, C. Kruger-Zechlin, Z. Deeb, E. Fonoff, L. Timmermann, J. Waldthaler (Sao Paulo, Brazil)

1:15pm-2:45pm: Comparison of PDE10A and DAT expression as markers of disease burden in early Parkinson’s disease

G. Pagano, H. Wilson, T. Yousaf, F. Niccolini, N. Khan, D. Martino, R. Gunn, E. Rabiner, P. Piccini, T. Foltynie, M. Politis (London, United Kingdom)

1:15pm-2:45pm: Comparison of Zonisamide with Non-Levodopa, Anti-Parkinson’s disease Drugs in the Incidence of Parkinson’s Disease-Relevant Symptoms

H. Iwaki, M. Tagawa, K. Iwasaki, K. Kawakami, M. Nomoto (Toon, Japan)

1:15pm-2:45pm: Complement C3a receptor antagonist attenuates tau hyperphosphorylation via glycogen synthase kinase 3β signaling pathways

JJ. Hu, T. Wang (Wuhan, China)

1:15pm-2:45pm: Composite UHDRS shows extensive spatial correlation with grey matter and white matter volume in Huntington’s disease gene carriers

C. Estevez-Fraga, E. Johnson, F. Rodrigues, P. Zeun, A. Durr, D. Langbehn, B. Leavitt, R. Roos, S. Gregory, R. Scahill, G. Rees, S. Tabrizi (London, United Kingdom)

1:15pm-2:45pm: Compression Therapy: A Treatment of Rubral Tremor

D. Nacopoulos (Erie, PA, USA)

1:15pm-2:45pm: Computerized cognitive test profile of 100 patients with and without Amyloid beta 1-42 burden

F. Waga, I. Liepelt-Scarfone, M. Bentele, W. Maetzler, S. Becker, M. Timmers, L. van Nueten, G. Salvadore, K. Brockmann, M. Hobert, J. Streffer, D. Berg (Titusville, NJ, USA)

1:15pm-2:45pm: Connectivity alterations in dopaminergic and cholinergic networks mediate cognitive performance in patients with Parkinson’s disease: a resting-state fMRI study

ER. de Natale, SP. Caminiti, Z. Chappell, T. Yousaf, H. Wilson, M. Politis (London, United Kingdom)

1:15pm-2:45pm: Construct validity of the Movement Disorders Society – Non Motor Rating Scale (MDS-NMS)

KR. Chaudhuri, A. Rizos, C. Rodriguez-Blazquez, D. Weintraub, A. Schrag, P. Martinez-Martin (London, United Kingdom)

1:15pm-2:45pm: Controlling levodopa and deep brain stimulation induced dystonia with interleaving and fractionalized current steering

A. Mammis, E. Feinstein (Newark, NJ, USA)

1:15pm-2:45pm: Correlating subcortical structure and function in idiopathic Parkinson’s disease: A cross-sectional morphometric and [18F]-DOPA PET study

M. Rolinski, V. Sossi, A. Stoessl, C. Marshall, S. Gill, P. Clatworthy, A. Whone (Bristol, United Kingdom)

1:15pm-2:45pm: Correlation between striatal CIT uptake and Mini-Mental State Examination in Parkinson’s disease

OD. Kwon, SG. Park, SB. Lee, JA. Park (Daegu, Republic of Korea)

1:15pm-2:45pm: Correlation between substantia nigra measurement and UPDRS

N. Mohammadzade, F. Omrani, A. Habibi (Tehran, Islamic Republic of Iran)

1:15pm-2:45pm: Correlation of local field potentials (LFPs) to electromyography (EMG) of the rostral zona incerta (rZI) and subthalamic nucleus (STN) in Parkinson’s Disease (PD)

D. Kern, L. Kahn, S. Ojemann, A. Abosch, J. Thompson (Aurora, CO, USA)

1:15pm-2:45pm: Cortical and subcortical atrophy in typical and variant Parkinson-plus syndromes: PROSPECT-M-UK study

N. Holland, S. Jones, J. Woodside, E. Jabbari, V. Chelban, A. Costantini, PN. Leigh, D. Burn, N. Pavese, A. Gerhard, C. Kobylecki, M. Hu, A. Church, J. Rohrer, H. Houlden, H. Morris, J. Rowe (Cambridge, United Kingdom)

1:15pm-2:45pm: Cortical cholinergic dysfunction correlates with microglial activation in the Substantia Innominata in patients with REM sleep behavior disorder

K. Stær, A. Iranzo, M. Stokholm, K. østergaard, M. Eroles, M. Otto, K. Svendsen, A. Pla, D. Vilas, J. Santamaria, A. Møller, C. Gaig, P. Borghammer, D. Brooks, E. Tolosa, N. Pavese (Aarhus N, Denmark)

1:15pm-2:45pm: Could we optimize the stimulation parameters setting of directional leads with a patient-specific imaging software in implanted parkinsonian patients?

AS. Rolland, N. Carriere, G. Touzet, L. Defebvre, N. Reyns, D. Devos, C. Moreau (Lille Cedex, France)

1:15pm-2:45pm: Daily variability of non-motor symptoms as a reflection of circadian dysregulation in Parkinson’s disease

O. Alenikova, S. Likhchev, A. Buniak, M. Liashkovich (Minsk, Belarus)

1:15pm-2:45pm: Data quality, acceptability and reliability of the Movement Disorders Society – Non Motor Rating Scale (MDS-NMS)

C. Rodriguez-Blazquez, A. Schrag, D. Weintraub, A. Rizos, KR. Chaudhuri, P. Martinez-Martin (Madrid, Spain)

1:15pm-2:45pm: Day Hospitals Reinvented : the future of Parkinson’s care

J. Adenwalla, S. Jones, M. Oliver, N. Noushad, B. Mohamed, C. Thomas, T. Williams, S. Mahon (Cardiff, United Kingdom)

1:15pm-2:45pm: DBS for Parkinson-Dementia syndrome: Stimulation of both Globus Pallidus internus & the Nucleus Basalis of Meynert using the same electrode lead

C. Nombela, A. Lozano, C. Villanueva-Iza, J. Barcia (Madrid, Spain)

1:15pm-2:45pm: DBS for PD in Albania

I. Zekja, R. Alimehmeti, F. Dashi, S. Grabova, M. Petrela, M. Rralacolli, J. Kruja (Tirana, Albania)

1:15pm-2:45pm: DBS in Parkinson’s disease: Experience from Egypt

A. Mansour, Z. Fayed (Cairo, Egypt)

1:15pm-2:45pm: Deceleration capacity of heart rate: is cardiac vagal modulation impaired in idiopathic Parkinson’s disease?

C. Carricarte Naranjo, C. Marras, N. Visanji, D. Cornforth, L. Sanchez-Rodriguez, B. Schüle, S. Goldman, M. Estevez, P. Stein, A. Lang, H. Jelinek, A. Machado (La Habana, Cuba)

1:15pm-2:45pm: Decline in Neural Connectivity in Olfactory Spatial Attention: A Comparative Study in the Progression of Parkinson’s Disease

H. Chatterjee, G. Elumalai, N. Osakwe, N. Sewram (Georgetown, Guyana)

1:15pm-2:45pm: Decreased baroreflex sensitivity in Parkinson’s disease is associated with orthostatic hypotension

P. Turcani, P. Valkovic, P. Siarnik, S. Sutovsky (Bratislava, Slovakia)

1:15pm-2:45pm: Decreased Cannabinoid Type 1 Receptor Density in Parkinson’s Disease: A [18F]FMPEP-d2 PET Study

A. Brück, H. Al-Abdulrasul, J. Tuisku, R. Ajalin, J. Hirvonen, J. Rinne (Turku, Finland)

1:15pm-2:45pm: Deep Brain Stimulation (DBS) in Pantothenate Kinase-Associated Neurodegeneration (PKAN): An Experience in a Thai Patient

P. Termsarasab, P. Boonkongchuen, T. Pulkes, O. Trachoo, A. Boongird (Bangkok, Thailand)

1:15pm-2:45pm: Deep Brain Stimulation as a Rescue When Duodenal Levodopa Infusion Fails: Report of 2 Cases

N. Nathoo, T. Sankar, O. Suchowersky, F. Ba (Edmonton, AB, Canada)

1:15pm-2:45pm: Deep Brain Stimulation for Parkinson’s disease: the Paradox of More Technological Approaches

D. Soh, T. Ten Brinke, A. Lozano, A. Fasano (Toronto, ON, Canada)

1:15pm-2:45pm: Deep Brain Stimulation in Parkinson’s Disease: Experience of the Neurology Department of Marrakesh

Z. Chourafa, M. Chraa, N. Louhab, N. Kissani (Marrakesh, Morocco)

1:15pm-2:45pm: Deep brain stimulation in patients with chronic anti-coagulation treatment: a series of 35 patients

J. Krauss, L. Cassini Ascencao, J. Runge, A. Saryyeva (Hannover, Germany)

1:15pm-2:45pm: Deep brain stimulation of Caudal Zona incerta: Case series

DR. Ginjupally, Z. Guduru, T. Hines Iii, T. Ali, G. Quintero, C. van Horne (Lexington, KY, USA)

1:15pm-2:45pm: Deep Brain Stimulation of Subthalamic Nucleus (DBS-STN) in Parkinson Disease (PD): Acute Clinical Effects in Hypothalamic control

D. Dos Santos, E. Barbosa, R. Cury (São Paulo, Brazil)

1:15pm-2:45pm: Deep Brain Stimulation of the Subthalamic Nucleus and Globus Pallidus for apathy in PD patients

X. Zhang, A. Xie (Qingdao, China)

1:15pm-2:45pm: Deep brain stimulation-guided optogenetic rescue of parkinsonian symptoms

B. Degos, M. Vandecasteele, S. Valverde, C. Piette, G. Gangarossa, W. Derousseaux, A. Aristieta Arbelaiz, J. Touboul, L. Venance (Paris, France)

1:15pm-2:45pm: Depression as a risk factor for impulse compulsive disorders in Parkinson’s disease: a prospective survival study

J. Marín-Lahoz, F. Sampedro, S. Martinez-Horta, J. Pagonabarraga, J. Kulisevsky (Barcelona, Spain)

1:15pm-2:45pm: Depressive Symptoms are Associated with Lower Locus Coeruleus Volumes in Parkinson’s disease

C. Farrell, G. Pagano, E. de Natale, M. Politis (London, United Kingdom)

1:15pm-2:45pm: Design of the PERSPECTIVE study: PERsonalized SPEeCh Therapy for actIVE conversation

J. Maas, N. de Vries, B. Bloem, J. Kalf (Nijmegen, Netherlands)

1:15pm-2:45pm: Developing an innovative telephone support line for people with Parkinson’s Disease

F. Mancini, T. Carta, S. Thomas, F. Bona, E. Buijs, P. Nee, B. Bloem (Milan, Italy)

1:15pm-2:45pm: Development of a Predictive Model for Progressive Supranuclear Palsy Using Real World Data

E. Viscidi, Y. Zabar, T. Dam, M. Juneja, J. Kupferman, V. Kupelian, S. Eaton, I. Litvan, G. Hoglinger (Cambridge, MA, USA)

1:15pm-2:45pm: Development of an unsupervised analysis pipeline for human microelectrode recordings

SF. Abalde, MD. Mendonça, G. Marques, R. Matias, R. Barbosa, C. Reizinho, A. Seromenho-Santos, P. Pires, P. Bugalho (Lisbon, Portugal)

1:15pm-2:45pm: Diagnosing Dementia with Lewy Bodies – Characterizing the prevalence and underlying relationships between core and supportive clinical features

E. Matar, K. Ehgoetz Martens, G. Halliday, S. Lewis (Sydney, Australia)

1:15pm-2:45pm: Diagnostic potential of automated diffusion imaging for the differential diagnosis of multiple system atrophy and Parkinson’s disease

F. Krismer, V. Beliveau, K. Seppi, G. Goebel, G. Wenning, E. Gizewski, W. Poewe, C. Scherfler (Innsbruck, Austria)

1:15pm-2:45pm: Dielectric Properties of a Blood Plasma Predict Motor Deficits in a 6-Hydroxydopamine-Induced Rat Model of Parkinson’s Disease

E. Dalle, W. Daniels, M. Mabandla (Durban, South Africa)

1:15pm-2:45pm: Different patterns of brain activity during lower limb movements in Parkinson’s disease patients with and without freezing of gait

N. Piramide, E. Sarasso, E. Canu, S. Galantucci, A. Tettamanti, MA. Volontè, M. Filippi, F. Agosta (Milan, Italy)

1:15pm-2:45pm: Differential diagnosis of Parkinsonian Syndromes – combining clinical and imaging data in a machine-learning approach

T. Meindl, Y. Li, A. Jochim, T. Mantel, A. Hapfelmeier, B. Haslinger (Munich, Germany)

1:15pm-2:45pm: Differential effects of stimulation amplitude and lead laterality of deep brain stimulation of the subthalamic nucleus on speech and Parkinsonian motor symptoms

E. Tripoliti, B. Veggia, M. Hariz, P. Limousin (Reggio Emili, Italy)

1:15pm-2:45pm: Differential temporal processing across Lewy body disorders and relation to cognitive fluctuations

E. Matar, J. Phillips, K. Ehgoetz Martens, G. Halliday, S. Lewis (Sydney, Australia)

1:15pm-2:45pm: Differentiating the substantia nigra pars compacta and ventral tegmental area in early-stage Parkinson’s disease using quantitative susceptibility mapping

P. Macdonald, E. Alushaj, N. Handfield-Jones, A. Khan, A. Owen (London, ON, Canada)

1:15pm-2:45pm: Directional Deep Brain Stimulation Lead Implantation: A Single Center Experience

R. Kochanski, A. Borghei, G. Pal, L. Verhagen Metman, F. Lynn, J. Karl, S. Sani (Chicago, IL, USA)

1:15pm-2:45pm: Directional deep brain stimulation: what’s for?

R. Zangaglia, B. Minafra, F. Bruschi, NG. Pozzi, F. Avantaggiato, C. Pacchetti (Pavia, Italy)

1:15pm-2:45pm: Directional leads in deep brain stimulation – surgical handling and evolving therapy options

C.. Matthies, P.. Fricke, R.. Nickl, P.. Capetian, F.. Steigerwald, J.. Volkmann (Wuerzburg, Germany)

1:15pm-2:45pm: Directional stimulation for Dystonic tremor

I. Aviles-Olmos, M. Alegre, J. Artieda, J. Guridi, M. Rodriguez-Oroz (Pamplona, Spain)

1:15pm-2:45pm: Disrupted Functional Brain Connectome in Parkinson’s Disease Patients with Freezing of Gait

N. Li, L. Wang, X. Suo, J. Li, J. Peng, J. Zhang, R. Peng (Chengdu, China)

1:15pm-2:45pm: Disrupted salience network dynamics in Parkinson´s disease patients with impulse control disorders

I. Navalpotro-Gomez, J. Kim, PM. Paz-Alonso, M. Delgado-Alvarado, A. Quiroga-Varela, H. Jimenez-Urbieta, M. Carreiras, AP. Strafella, MC. Rodriguez-Oroz (San Sebastian, Spain)

1:15pm-2:45pm: Distinct neuronal correlates underpin impulsive action and impulsive choice in Tourette disorder

C. Atkinson-Clement, A. de Liege, C. Porte, Y. Klein-Koerkamp, B. Beranger, A. Hartmann, Y. Worbe (Paris, France)

1:15pm-2:45pm: Distributed Global Functional Connectivity Networks Predict Responsiveness to L-DOPA and Subthalamic Deep Brain Stimulation

C. Wu, T. Foltynie, P. Limousin, L. Zrinzo, H. Akram (Philadelphia, PA, USA)

1:15pm-2:45pm: DNAJC13 in Parkinson’s disease; characterization of the p.N855S knock-in mouse model

J. Follett, J. Fox, E. Gustavsson, M. Farrrer (Vancouver, BC, Canada)

1:15pm-2:45pm: Does Deep Brain Stimulation in Parkinson’s Disease Change Disease Progression in the Long Run?

A. Løkkegaard, B. Jespersen, M. Karlsborg, A. Clausen, S. Jensen, B. Thomsen (Copenhagen, Denmark)

1:15pm-2:45pm: Does microelectrode recording increase haemorrhage? A comparative study in a large patient cohort over 20 years

J. Runge, A. Saryyeva, M. Wolf, C. Blahak, C. Schrade, HH. Capelle, TM. Kinfe, H. Bäzner, M. Abdallat, JK. Krauss (Hannover, Germany)

1:15pm-2:45pm: Does Physical Activity impact Resting State Functional Connectivity in Parkinson Disease Patients?

R. Guimarães, A. Vieira, B. Campos, L. Piovesana, P. Azevedo, J. Zuiani, A. D'Abreu, F. Cendes (Campinas, Brazil)

1:15pm-2:45pm: Does the magnitude of improvement of UPDRS III at the preoperative L-dopa test predict the degree of medication decrease one year after subthalamic nucleus Deep Brain Stimulation?

A. Fredricks, G-M. Hariz, J. Linder, L. Eriksson, L. Forsgren, M. Hariz, P. Blomstedt (Umea, Sweden)

1:15pm-2:45pm: Dopamine dysregulation syndrome and levodopa-induced dyskinesias in patients with Parkinson’s disease on the background of deep stimulation of the subthalamic nucleus

S. Omarova, N. Fedorova, A. Tomskiy, A. Gamaleya, E. Bril (Moscow, Russian Federation)

1:15pm-2:45pm: Dopamine substitution increases connectivity between premotor and motor areas in Parkinson’s disease – a DCM-Study

P. Loehrer, V. Seeger, I. Weber, C. Oehrn, H. Dafsari, M. Tittgemeyer, L. Timmermann (Marburg, Germany)

1:15pm-2:45pm: Dopaminergic imaging in patients with basal ganglia calcification presenting with parkinsonism

A. Planas-Ballvé, N. Caballol, M. Balagué, E. Peral, L. Cano, X. Cardona, L. Vila, A. ávila (Sant Joan Despí, Spain)

1:15pm-2:45pm: Dorsolateral striatal neuronal activity in a rat model of Parkinson`s disease with levodopa-induced dyskinesias

X. Jin, D. Milakara, K. Schwabe, J. Krauss, M. Alam (Nanjing, China)

1:15pm-2:45pm: Dual-task in Parkinson’s disease: a gait analysis and functional MRI study

E. Sarasso, A. Gardoni, S. Galantucci, A. Tettamanti, MA. Volontè, M. Filippi, F. Agosta (Milan, Italy)

1:15pm-2:45pm: Dynamic functional connectivity signature of cognitive decline in Parkinson’s disease

E. Fiorenzato, A. Strafella, J. Kim, R. Schifano, L. Weis, A. Antonini, R. Biundo (Venice, Italy)

1:15pm-2:45pm: Dysautonomia as a predictor of cognitive outcome after deep brain stimulation in Parkinson’s disease

V. Cabreira, P. Castro, J. Freitas, M. Rosas, E. Azevedo (Porto, Portugal)

1:15pm-2:45pm: Dysbiosis of Gut Microbiota in a selected population of Italian Parkinson’s Disease patients

R. Cerroni, D. Pietrucci, M. Conti, V. Unida, A. Farcomeni, M. Pierantozzi, NB. Mercuri, S. Biocca, A. Desideri, A. Stefani (Rome, Italy)

1:15pm-2:45pm: eCARE-PD, a digital health platform for patient empowerment and online health tracking: experiences with co-design

T. Mestre, S. Grosjean, L. Bonneville, D. Grimes, E. Bate, M. Lê (Ottawa, ON, Canada)

1:15pm-2:45pm: EEG guided neurofeedback boosts effects of motor cortex neuromodulation of rTMS in Parkinson´s Disease Patients

J. Romero, A. Arroyo, J. Andreo, M. Del Castillo, J. Serrano, E. Rocon, N. Malpica, E. Melero, E. Sanz, M. Gil, E. Rodriguez (Madrid, Spain)

1:15pm-2:45pm: Effect of Deep brain stimulation and Continuous infusion of levodopa-carbidopa intestinal therapy on non-motor symptoms in patients with advance Parkinson’s disease

V. Vuletic (Rijeka, Croatia)

1:15pm-2:45pm: Effect of deep brain stimulation on endothelial function and heart rate variability in Parkinson’s disease

JH. Yoon, DG. Park (Suwon, Republic of Korea)

1:15pm-2:45pm: Effect of global cognitive score on motor and quality of life outcomes after deep brain stimulation in patients with Parkinson’s disease or essential tremor

E. Staikova, D. Loring, M. Delong, S. Triche, C. Buetefisch, C. Esper, T. Wichmann, L. Scorr, L. Higginbotham, P. Aia, S. Factor, S. Miocinovic (Atlanta, GA, USA)

1:15pm-2:45pm: Effect of neurofeedback facilitation of the gait and balance imagery-related SMA activation on gait function in PD

M. Mihiara, H. Otomune, Y. Kajiyama, H. Fujimoto, N. Hattori, I. Miyai, K. Hanayama, Y. Sunada, H. Mochizuki (Kurashiki, Japan)

1:15pm-2:45pm: Effect of non-contact boxing on non-motor symptoms in Parkinson’s disease

A. Ghaffar, R. Gallagher, L. Rubin, S. Dharia, L. Ketigian, J. Whalen, Z. Scheid, K. Patel, J. Zhu, C. Michaelides, A. Leder (Old Westbury, NY, USA)

1:15pm-2:45pm: Effect of Subthalamic Deep Brain Stimulation (DBS) on Impulsive Control Disorders (ICD) and Dopamine Dysregulation Syndrome (DDS) – A Randomized Controlled Trial Evaluating Deep Brain Stimulation Using a New Multiple Source, Constant-Current Rechargeable System for Management of Symptoms of Parkinson’s Disease (INTREPID)

M. Okun, R. Jain, L. Chen, I. Study Group, A. Tröster (Gainesville, FL, USA)

1:15pm-2:45pm: Effective deep brain stimulation co-modulate cross-frequency coupling

S. Groppa, M. Glaser, N. Koirala, M. Bange, M. Muthuraman (Mainz, Germany)

1:15pm-2:45pm: Effects of dance and walking program on spatiotemporal gait parameters in Parkinson’s disease

A. Nogueira Haas, M. Santos Delabary, R. Gimenes Donida, M. Wolffenbuttel, E. Passos Monteiro, L. Peyré-Tartaruga (Porto Alegre, Brazil)

1:15pm-2:45pm: Effects of deep brain stimulation of the subthalamic nucleus on the postoperative levodopa response: one year follow up

E. Kocabicak, O. Yildiz, D. Aygun, Y. Temel (Maastricht, Netherlands)

1:15pm-2:45pm: Effects of Directional Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson’s disease

G. Tommasi, L. Bertolasi, A. Nicolato, F. Sala, B. Bonetti, M. Longhi (Verona, Italy)

1:15pm-2:45pm: Effects of exergaming on attentional deficits and dual-tasking in Parkinson’s disease

E. Schaeffer, J. Busch, B. Roeben, S. Otterbein, P. Saraykin, E. Leks, I. Liepelt-Scarfone, M. Synofzik, M. Elshehabi, W. Maetzler, C. Hansen, S. Andris, D. Berg (66041, Germany)

1:15pm-2:45pm: Effects of Handwriting Exercise on Functional Outcome in Parkinson’s Disease: A Randomized Controlled Trial

N. Vorasoot, P. Termsarasab, K. Thadanipon, T. Pulkes (Bangkok, Thailand)

1:15pm-2:45pm: Effects of multi-professional education program for management of Parkinson’s disease alterations on quality of life of people who are living with disease: a randomized clinical trial

C. Dias, A. Costa, E. Okamoto, A. Sartori, C. Silva, M. Piemonte (São Paulo, Brazil)

1:15pm-2:45pm: Effects of rechargeable battery of deep brain stimulation on the quality of life and satisfaction in patients with Parkinson’s disease

S. Jo, KW. Park, N. Choi, MS. Kim, HS. Ryu, SJ. Chung (Seoul, Republic of Korea)

1:15pm-2:45pm: Effects of three different physical therapies in body composition of Parkinson’s disease

AOF. Fagundes, EPM. Monteiro, MSD. Delabary, APZ. Zanardi, MZC. Casal, VFM. Martins, MW. Wolffenbuttel, ANH. Haas, FGM. Martinez, LPT. Tartaruga (Porto Alegre, Brazil)

1:15pm-2:45pm: Establishing the first apomorphine treatment registry in Thailand: prospective data collection to inform optimal care of Parkinson’s disease patients

R. Bhidayasiri, O. Phokaewvarangkul, K. Boonpang, T. Boonmongkol, Y. Thongchuam, N. Kantachadvanich, J. Sringean, P. Panyakaew, P. Jagota (Bangkok, Thailand)

1:15pm-2:45pm: Evaluating Perceptions of Deep Brain Stimulation in DBS-naïve Patients with Parkinson’s Disease – A Pilot Study

S. Das, S. Ramesh, M. Baldassari, M. Rasool, J. Ratliff, D. Kremens, T. Alexander, C. Matias, TW. Liang, C. Wu (Philadelphia, PA, USA)

1:15pm-2:45pm: Evaluating Volume Changes in the Substantia Nigra Pars Compacta (SNc) in Parkinson’s Disease (PD) in a Study-Specific Magnetic Resonance Imaging (MRI) Template

E. Biondetti, R. Gaurav, L. Yahia-Cherif, G. Mangone, N. Pyatigorskaya, R. Valabregue, C. Ewenczyk, M. Hutchison, JC. Corvol, MJ. Vidailhet, S. Lehéricy (Paris, France)

1:15pm-2:45pm: Evaluation of Device-Assisted Treatment using a wearable accelerometry wrist sensor

A. Johansson, M. Lundgren, M. öthman, D. Nyholm (Stockholm, Sweden)

1:15pm-2:45pm: Evaluation of gut microbiota in patients with Parkinson’s disease using a gas chromatography–mass spectrometry in Russia

I. Krasakov, I. Litvinenko (Saint-Petersburg, Russian Federation)

1:15pm-2:45pm: Evaluation of Imidazoline 2 binding sites reflecting astroglia pathology in Huntington’s Disease: An in vivo [11C]BU99008 PET study

H. Wilson, F. Niccolini, G. Dervenoulas, R. Tyacke, J. Myers, R. Gunn, D. Nutt, E. Rabiner, S. Tabrizi, M. Politis (London, United Kingdom)

1:15pm-2:45pm: Evaluation of Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson’s Disease: An in vivo [11C]BU99008 PET study

H. Wilson, G. Dervenoulas, G. Pagano, R. Tyacke, J. Myers, R. Gunn, E. Rabiner, D. Nutt, M. Politis (London, United Kingdom)

1:15pm-2:45pm: Evaluation of nigral neuronal apoptosis during postnatal development and adulthood of mice strains with differential sensitivity to MPTP

Y. H, V. Dj, C. Sagar, R. Tr, P. Alladi (Bangalore, India)

1:15pm-2:45pm: Evaluation of the Zeez Sleep Pebble for Sleep Disturbance in Parkinson’s Disease

S. Milne, S. Cummins, C. Carroll (Plymouth, United Kingdom)

1:15pm-2:45pm: Evidence of altered Serotonergic Network in Parkinson’s disease by using a multi-modal MRI and PET imaging approach

SP. Caminiti, Z. Chappell, A. Carotenuto, G. Dervenoulas, T. Yousaf, G. Pagano, H. Wilson, M. Politis (London, United Kingdom)

1:15pm-2:45pm: Executive functions correlate with DaT-SPECT laterality in Parkinson’s disease

T. Alvarez-Avellon, E. Suarez-San Martin, C. Garcia-Fernandez, J. Alvarez-Carriles, R. Ribacoba, F. Cuetos, M. Menendez-Gonzalez (Oviedo, Spain)

1:15pm-2:45pm: Expenditures on pesticides and incidence of Parkinson’s disease in French farmers: a nationwide study

L. Perrin, J. Spinosi, L. Chaperon, S. Kab, F. Moisan, A. Elbaz (Villejuif Cedex, France)

1:15pm-2:45pm: Experimental model of developing of Parkinson’s disease

M. Tukhtamishev, F. Akhmedova (Tashkent, Uzbekistan)

1:15pm-2:45pm: Exploratory analysis of the relationship between pain and mood disturbances in Parkinson’s disease

C. Vila, A. Sparks, P. Imbriani, N. Caputi, L. Covington, T. Schirinzi, S. Natoli, A. Pisani, P. Ghosh (Washington, DC, USA)

1:15pm-2:45pm: Exploring the Lexicon of Fatigue in Parkinson Disease: A Qualitative Approach

S. Mantri, S. Albert, S. Kahl, M. Daeschler, E. Mamikonyan, C. Kopil, C. Marras, L. Chahine (Durham, NC, USA)

1:15pm-2:45pm: Exploring the relationship between motor and non-motor fluctuations in Parkinson’s disease: patient’s perspective, clinician’ s assessment and objective measures from a wearable device

A. Leake, A. de Angelis, M. Horne, D. Paviour, J. Coebergh, M. Edwards, F. Morgante, L. Ricciardi (London, United Kingdom)

1:15pm-2:45pm: Extracellular α-synuclein enters dopaminergic neurons by modulating flotillin-1-assisted DAT endocytosis

T. Hasegawa, J. Kobayashi, N. Sugeno, S. Yoshida, T. Akiyama, Y. Miki, M. Fukuda, M. Ezura, A. Kikuchi, T. Baba, A. Takeda, K. Wakabayashi, H. Okano, M. Aoki (Sendai, Japan)

1:15pm-2:45pm: Extrastriatal dopaminergic and serotonergic pathways in Parkinson’s disease and in dementia with Lewy bodies: a 123I-FP-CIT study

A. Pilotto, F. Schianodicola, E. Premi, R. Grasso, R. Turrone, S. Gipponi, A. Scalvini, E. Cottini, B. Pagherà, V. Garibotto, MC. Rizzetti, L. Bonanni, B. Borroni, S. Morbelli, F. Nobili, UP. Guerra, D. Perani, A. Padovani (Brescia, Italy)

1:15pm-2:45pm: Fatigue in Parkinson’s Disease

D. Silva, TR. Alcântara-Silva, AL. Alcântara-Silva, S. Suzuki-Godoy (Goiânia, Brazil)

1:15pm-2:45pm: Fatigue in Parkinson’s disease and its relation with disease duration and treatment

D. Nassif, J. Pereira (Rio de Janeiro, Brazil)

1:15pm-2:45pm: FDG PET: a good predictive tool for CNS inflammation

M. Nader, F. Fluchere, T. Witjas, A. Eusebio, JP. Azulay (Marseille, France)

1:15pm-2:45pm: Fixation suppression the easy way – when nothing else matters

F. Gandor, M. Tesch, H. Neuhauser, D. Gruber, HJ. Heinze, G. Ebersbach, T. Lempert (Beelitz-Heilstaetten, Germany)

1:15pm-2:45pm: Focus on the Locus: Ultra-high field MRI evaluation of locus coeruleus structure and function in Parkinson’s Disease

C. Madelung, D. Meder, A. Løkkegaard, H. Siebner (Hvidovre, Denmark)

1:15pm-2:45pm: Four square step test in patients with early de novo Parkinson’s disease

JH. Kim, YM. Park, IS. Kim, SB. Koh (Seoul, Republic of Korea)

1:15pm-2:45pm: Fractional anisotropy patterns in non-demented Parkinson’s disease patients using hierarchical cluster analysis

H. Erostarbe, A. Inguanzo, R. Sala, A. Abos, A. Campabadal, C. Uribe, H. Baggio, Y. Compta, M. Marti, F. Valldeoriola, C. Junque, B. Segura (Barcelona, Spain)

1:15pm-2:45pm: Frailty status predicts falls in early Parkinson’s disease

S. Holland, R. Morris, B. Galna, L. Rochester, A. Yarnall (Newcastle Upon Tyne, United Kingdom)

1:15pm-2:45pm: Freezer or non-freezer: what is in between?

M. Mancini, K. Smulders, S. Stuart, R. Morris, F. Horak, J. Nutt (Portland, OR, USA)

1:15pm-2:45pm: Freezing of Gait in Parkinson’s Disease: Risk Factors and Associated Nonmotor Symptoms

D. Lichter, L. Hershey (Buffalo, NY, USA)

1:15pm-2:45pm: Freezing of gait in Parkinson’s disease: a review of current neuroimaging evidence for the development of effective therapies

A. Potvin-Desrochers, C. Paquette (Montreal, QC, Canada)

1:15pm-2:45pm: Frequency and pattern of movement disorders in a Neurologic clinic in North Central Nigeria: a 3- year review

E. Iwuozo, R. Obiako (Makurdi, Nigeria)

1:15pm-2:45pm: Frequency of Cardiovascular Abnormalities in Mexican Patients with Early Parkinson´s Disease

JA. Juárez, M. Violante, A. Arriaga, A. González, A. Salas, L. Vidal, R. Vicioso, C. Roa, I. López, M. Soto (Mexico, Mexico)

1:15pm-2:45pm: Frequency-dependent abnormalities of intrinsic brain activity in Parkinson´s disease

L. Krajcovicova, R. Marecek, I. Rektorova (Brno, Czech Republic)

1:15pm-2:45pm: Frequency, course and predictors of fatigue in Parkinson’s disease patients and population-based controls

E. Warrlich, EJ. Vollstedt, R. Modreanu, B. Hauptmann, V. Tadic, S. Tunc, C. Kritzinger, J. Prasuhn, A. Balck, M. Borsche, H. Hanssen, N. Brüggemann, C. Klein, M. Kasten (Luebeck, Germany)

1:15pm-2:45pm: Functional and dysfunctional impulsivities changes after deep brain stimulation of the subthalamic nucleus

R. Kardous, B. Giordana, L. Stefanini, H. Joly, A. Mulliez, C. Giordana, B. Bailet, M. Borg, J. Yelnik, JJ. Lemaire, M. Benoit, D. Fontaine (Nice, France)

1:15pm-2:45pm: Functional Biomarkers of Parkinson’s Disease: Changes in Brain-Wide Network Connectivity in Default Mode and Fronto-Parietal Control Networks

P. Macdonald, N. Hiebert, L. Naci, A. Owen (Dublin, Ireland)

1:15pm-2:45pm: Functional Bowel Symptoms in Parkinson´s Disease

K. Murtomäki, T. Mertsalmi, E. Jaakkola, E. Mäkinen, J. Joutsa, R. Levo, E. Pekkonen, V. Kaasinen, F. Scheperjans (Hus, Finland)

1:15pm-2:45pm: Functional brain connectome in drug-naïve Parkinson’s disease patients

R. de Micco, F. Agosta, S. Basaia, M. Siciliano, C. Cividini, G. Tedeschi, A. Tessitore, M. Filippi (Naples, Italy)

1:15pm-2:45pm: Functional Capacity in patients with Parkinson’s Disease are related to advanced glycation end-products

JEN. Almeida, NAT. Luna, ROD. Iborra, ANG. Alonso, ADR. -Lima (São Paulo, Brazil)

1:15pm-2:45pm: Functional connectivity and microstructural alterations in regions of synaptic density loss in DLB and PDD

T. Yousaf, G. Dervenoulas, G. Pagano, C. Loane, H. Wilson, A. Chandra, O. Cousins, R. Gunn, E. Rabiner, F. Niccolini, M. Esposito, L. Ricciardi, D. Aarsland, M. Politis (London, United Kingdom)

1:15pm-2:45pm: Functional connectivity within the cerebellum and brainstem in essential tremor patients– a tailored resting state fMRI approach

S. Sharifi, ES. Scheijbeler, WVP. Potters, AFR. Rootselaar (Amsterdam, Netherlands)

1:15pm-2:45pm: Functional connectome in Parkinson’s disease mild cognitive impairment

M. Delgado-Alvarado, V. Ferrer-Gallardo, I. Navalpotro-Gómez, S. Moia, M. Carreiras, C. Caballero-Gaudes, MC. Rodríguez-Oroz (Torrelavega, Spain)

1:15pm-2:45pm: Functional magnetic-resonant imaging in child cerebral palsy with epilepsy

D. Aminova, K. Aminov (Tashkent, Uzbekistan)

1:15pm-2:45pm: Functional MRI activation during the Symbol Digit Modalities Test in Parkinson’s disease

G. Grolez, R. Viard, R. Lopes, JP. Pruvo, K. Dujardin, L. Defebvre, C. Moreau (Lille, France)

1:15pm-2:45pm: Functional Proteomic Analysis of Leukocytes from Parkinson’s Disease Patients: A Clinical Perspective on Biomarkers Identification

N. Woldmar, B. Fadel, G. Poralla, L. Giacomin, J. Evaristo, F. Nogueira, A. Rosso, L. Pizzatti (Rio de Janeiro, Brazil)

1:15pm-2:45pm: Gait patterns may distinguish Parkinsonian patients with and without mild cognitive impairment: a data mining approach

M. Amboni, C. Ricciardi, C. de Santis, G. Ricciardelli, S. Cuoco, G. Improta, L. Iuppariello, G. Santangelo, M. Cesarelli, P. Barone (Baronissi (salerno), Italy)

1:15pm-2:45pm: Gamma-glutamyltransferase and the risk of Parkinson’s disease: A National Health Service big data analysis

D. Yoo, R. Kim, E. Jung, K. Han, C. Shin, J. Lee (Seoul, Republic of Korea)

1:15pm-2:45pm: Gastrointestinal disorders in various forms of parkinsonism

R. Matmurodov, KH. Khalimova, EL. Abduqodirov (Tashkent, Uzbekistan)

1:15pm-2:45pm: Gastrointestinal microbiome in Parkinson’s disease in a Bavarian cohort

F. Marxreiter, A. Cosma-Grigorov, H. Gassner, H. Meixner, Z. Kohl, M. Neurath, S. Wirtz, J. Winkler (Erlangen, Germany)

1:15pm-2:45pm: Gastrointestinal symptoms as a risk factor for the appearance of motor fluctuations in patients with advanced Parkinson disease

C. Borrue-Fernandez, M. Boimorto (San Sebastian Reyes, Spain)

1:15pm-2:45pm: Gastrointestinal symptoms predict cognitive decline in Parkinson’s Disease

A. Gonçalves, A. Mendes, N. Vila-Chã, I. Moreira, S. Cavaco (Porto, Portugal)

1:15pm-2:45pm: Gender differences for Motor and non motor symptoms in Parkinson’s Disease among Pakistani population

S. Naureen, A. Arshad, N. Ahmad (Islamabad, Pakistan)

1:15pm-2:45pm: Gender-dependent improvement in the survival of Parkinson’s disease patients in Finland

T. Kuusimäki, S. Kurki, J. Sipilä, H. Salminen-Mankonen, O. Carpén, V. Kaasinen (Turku, Finland)

1:15pm-2:45pm: Genotype influences circuit compensation in Parkinson’s disease

K. Schindlbeck, A. Vo, N. Nguyen, C. Tang, M. Niethammer, V. Dhawan, V. Brandt, R. Saunders-Pullman, S. Bressman, D. Eidelberg (Manhasset, NY, USA)

1:15pm-2:45pm: Global implementation of efficacious voice treatment for Parkinson’s disease: LSVT LOUD in Germany, France and Japan

L. Ramig, T. Brauer, C. Airiau, M. Fujiu-Kurachi (Boulder, CO, USA)

1:15pm-2:45pm: Glycopyrrolate as inhalation for treating sialorrhea in Parkinson’s Disease

L. Velzen, J. Masselink, L. Dorresteijn, K. Movig (Enschede, Netherlands)

1:15pm-2:45pm: Glymphatic system activity in Parkinson’s disease: diffusion tensor image analysis along the perivascular space (DTI‑ALPS)

JM. Kim, YJ. Bae (Seongnam, Republic of Korea)

1:15pm-2:45pm: Gray Matter Abnormalities in Parkinson’s disease: a Voxel-wise meta-analysis

XR. Xu, Q. Han, JY. Lin, L. Wang, HF. Shang (Chengdu, China)

1:15pm-2:45pm: Gray matter substrates of depression in blepharospasm

J. Yang, YB. Hou, QQ. Wei, RW. Ou, W. Song, B. Cao, HF. Shang (Chengdu, China)

1:15pm-2:45pm: Grey matter atrophy in Parkinson’s disease with long-duration response

G. Donzuso, G. Sciacca, G. Mostile, A. Nicoletti, M. Zappia (Catania, Italy)

1:15pm-2:45pm: Gustatory Connectivity in Parkinson’s Disease Progression

H. Chatterjee, G. Elumalai, N. Sewram, N. Osakwe (Georgetown, Guyana)

1:15pm-2:45pm: Gut microbiota in Parkinson disease with mild cognition impairment in a southern Chinese cohort.

TZ. Ren, K. Nie, LJ. Wang (Guangzhou, China)

1:15pm-2:45pm: Health associated quality of life (HAQL) and humor/cognitive complaints predict mortality in Parkinson’s disease (PD)

P. Bugalho, R. Barbosa, F. Ladeira, J. Marto, C. Borbinha, L. Conceição, M. Saraiva, M. Salavisa, B. Meira, M. Fernandes (Lisbon, Portugal)

1:15pm-2:45pm: Heart Rate Variability and Cognitive Impairment in Parkinson’s Disease

C. Terroba-Chambi, D. Vigo, M. Merello (Caba, Argentina)

1:15pm-2:45pm: Hemispheric Differences in Motor Circuitry of Parkinson’s disease: Metabolism and Micro-Structure

DAN. Stein, N. Goldberg, L. Domachevsky, H. Bernstine, M. Nidam, D. Groshar, M. Lorberboym, S. Israeli-Korn, M. Gomori, Y. Assaf, S. Hassin-Baer (Tel-Aviv, Israel)

1:15pm-2:45pm: Higher levels of physical activity is associated with fewer non-motor symptoms in early Parkinson’s disease: a 1-year follow-up study

S. Ng, N. Chia, M. Abbas, KY. Tay, WL. Au, EK. Tan, L. Tan (Singapore, Singapore)

1:15pm-2:45pm: Higher probability of prodromal Parkinson’s disease is related to lower performance in all cognitive domains

A. Bougea, M. Maraki, M. Yannakoulia, M. Stamelou, G. Xiromerisiou, M. Kosmidis, E. Dardiotis, G. Hadjigeorgiou, P. Sakka, C. Anastasiou, L. Stefanis, N. Scarmeas (Athens, Greece)

1:15pm-2:45pm: How Commonly Does Parkinson’s Disease Present with Dystonia?

P. Popa, C. Brown, C. Henchcliffe, H. Sarva (New York, NY, USA)

1:15pm-2:45pm: How Parkinson’s Disease Affects Value-Based Decisions

L. Montaser-Kouhsari, R. Gerraty, A. Bakkour, D. Shohamy (New York, NY, USA)

1:15pm-2:45pm: How reliable are non-blinded evaluations of motor UPDRS? a comparison of blinded vs. un-blinded UPDRS scores in 14 patients with advanced Parkinson´s disease

G-M. Hariz, A. Fredricks, R. Stenmark, J. Linder, M. Hariz, L. Forsgren, P. Blomstedt (Umea, Sweden)

1:15pm-2:45pm: Humming bird sign in craniovertebral junction anomaly leading to misdiagnosis of progressive supranuclear palsy

D. Desai, D. Pandya, S. Desai (Anand, India)

1:15pm-2:45pm: Hypermethylation of PGC-1α in peripheral blood leukocytes of patients with Parkinson’s disease

X. Yang, SQ. Xu, W. Qian, Q. Xiao (Shanghai, China)

1:15pm-2:45pm: Hyposmia as a marker of (non-)motor disease progression in Parkinson’s disease

D. Roos, J. Twisk, P. Raijmakers, R. Doty, H. Berendse (Amsterdam, Netherlands)

1:15pm-2:45pm: Identification and Characterization of Selective and High Affinity Small Molecules as Positron Emission Tomography (PET) Imaging Tracers for Pathological Alpha-Synuclein

E. Tsika, E. Vokali, J. Molette, M. Ravache, P. Rodriguez, V. Darmency, K. Piorkowska, S. Poli, H. Kroth, F. Capotosti, D. Lowe, J. Stoehr, M. Kosco-Vilbois, A. Pfeifer, A. Muhs (Lausanne, Switzerland)

1:15pm-2:45pm: Identifying altered resting state network connectivity in Parkinson’s disease with mild cognitive impairment

J. Yang, K. Mcmahon, D. Copland, G. Byrne, J. O'Sullivan, N. Dissanayaka (Herston, Australia)

1:15pm-2:45pm: Identifying delirium in people with Parkinson’s disease: the Determine-PD pilot study

R. Lawson, S. Richardson, A. Yarnall, D. Burn, L. Allan (Newcastle Upon Tyne, United Kingdom)

1:15pm-2:45pm: Identifying subtypes of Mild Cognitive Impairment in Parkinson’s disease using cluster analysis

D. Pourzinal, JH. Yang, G. Byrne, J. O'Sullivan, L. Mitchell, K. Mcmahon, D. Copland, N. Dissanayaka (St Lucia, Australia)

1:15pm-2:45pm: Imaging biomarker for progression of motor symptoms in advanced Parkinson’s disease

K. Furukawa, N. Sawamoto, A. Shima, D. Kambe, A. Nishida, I. Wada, H. Sakamaki, K. Yoshimura, Y. Fushimi, T. Okada, K. Togashi, R. Takahashi (Kyoto, Japan)

1:15pm-2:45pm: Imaging Brain Insulin Resistance in Parkinson’s Disease using [¹⁸F]FDG-PET

E. Hogg, P. Linesch, T. Wu, E. Tan, Z. Fan, W. Gao, A. Waxman, M. Tagliati (Los Angeles, CA, USA)

1:15pm-2:45pm: Imaging correlates of impaired self-awareness of cognitive deficits in Parkinson’s disease

F. Maier, A. Greuel, M. Hoock, M. Tahmasian, F. Jessen, I. Csoti, L. Timmermann, C. Eggers (Cologne, Germany)

1:15pm-2:45pm: Impact of Cognitive Profile on Impulse Control Disorders Presence and Severity in Parkinson’s Disease

A. Martini, L. Weis, E. Fiorenzato, R. Schifano, V. Cianci, A. Antonini, R. Biundo (Newcastle-under-Lyme, United Kingdom)

1:15pm-2:45pm: Impact of Nordik Walking training in patients with Progressive Supranuclear Palsy

R. Kandel, B. Bhattarai (Lalitpur, Nepal)

1:15pm-2:45pm: IMPACT OF PAIN ON STROKE AND HYPERTENSION AS COMORBIDITIES IN PARKINSON’S DISEASE

V. Wijaya, R. Pinzon, A. Al Jody (Yogyakarta, Indonesia)

1:15pm-2:45pm: Impact of pallidal deep brain stimulation on activities of daily living in patients with craniocervical dystonia – a multi-center survey

J. Huebl, T. Andermann, C. Blahak, J. Krauss, M. Südmeyer, J. Volkmann, K. Bötzel, A. Wolters, A. Kühn (Berlin, Germany)

1:15pm-2:45pm: Impact of Sub-Thalamic Nucleus Deep Brain Stimulation on Cognition and Behavior in Parkinson Patients

F. Mameli, F. Ruggiero, M. Reitano, E. Gianoli, D. Tedino, L. Borellini, F. Cogiamanian, S. Barbieri, A. Priori, R. Ferrucci (Milan, Italy)

1:15pm-2:45pm: Impaired cerebral vasoreactivity in patients with Parkinson’s disease: clinical and imaging correlates

I. Estrada-Bellmann, D. Cantú-García, S. Castillo-Torres, A. Mendoza-García, H. Sánchez-Terán, D. Díaz-Pérez, D. Roque-Martínez, S. Saldívar-Dávila, H. Martínez, T. Moreno-Andrade, B. Chávez-Luévanos, F. Góngora-Rivera (Monterrey, NL, Mexico)

1:15pm-2:45pm: Impaired colour discrimination is associated with hallucinations in Dementia with Lewy Bodies

E. Matar, K. Ehgoetz Martens, J. Phillips, G. Halliday, S. Lewis (Sydney, Australia)

1:15pm-2:45pm: Impaired fonction of mirror neurons and the role of levodopa in PD patients

T. Danaila, P. Jaulent, C. Laurencin, J. Xie, H. Klinger, P. Krolak-Salmon, S. Thobois (Lyon, France)

1:15pm-2:45pm: Impulse control and pain : a link in Parkinson’s disease.

G. Albani, L. Pradotto, G. Veneziano, P. Cipresso, E. Pedroli, F. Scarpina, A. Mauro, M. Semonella, A. Cistaro (Piancavallo-Verbania, Italy)

1:15pm-2:45pm: Impulse control and repetitive behavior disorders are more common in PD patients with levodopa-induced dyskinesias

F. Paolini Paoletti, N. Tambasco, G. Cappelletti, P. Eusebi, S. Simoni, P. Nigro, E. Brahimi, M. Filidei, P. Calabresi (Perugia, Italy)

1:15pm-2:45pm: Impulse Control Disorders in a Brazilian population with Parkinson´s disease -an observational study

B. Veiga, V. Borges, H. Ferraz, C. Aquino, C. Giacominelli, SM. Silva, S. Lestingi (São Paulo, Brazil)

1:15pm-2:45pm: In vivo increased striatal iron deposition in Parkinson’s Disease Dementia and Dementia with Lewy Body

S. Rota, T. Yousaf, H. Wilson, G. Dervenoulas, G. Pagano, D. Aarsland, M. Politis (London, United Kingdom)

1:15pm-2:45pm: Incidental iron deposition in basal ganglia: does the pattern matter? Fifteen years’ experience in a tertiary care center.

á. Beltrán Corbellini, P. Pérez Torre, A. Alonso Cánovas, F. Rodríguez Jorge, JL. Chico García, P. Parra Díaz, E. Natera Villalba, A. Gómez López, S. Fanjul Arbos, JL. López Sendón, JC. Martínez Castrillo, I. Parées Moreno (Madrid, Spain)

1:15pm-2:45pm: Increased fractional anisotropy in precuneus in Parkinson’s disease without mild cognitive impairment – a diffusion tensor imaging study

A. Nagano-Saito, J. Houde, C. Bedetti, M. Côté, O. Monchi (Montreal, QC, Canada)

1:15pm-2:45pm: Increased hub function in posterior medial cortex in Parkinson’s disease without mild cognitive impairement – A resting state fMRI study –

A. Nagano-Saito, P. Bellec, S. Jobert, B. Mejia-Constain, C. Degroot, A. Lafontaine, A. Hanganu, J. Lissemore, K. Smart, C. Benkelfat, O. Monchi (Montreal, QC, Canada)

1:15pm-2:45pm: Inflammatory Conditions in Parkinson’s Disease

B. Krishnamachari, S. Shermon, M. Goldfinger, A. Leder, B. Harper, J. Donoghue (Old Westbury, NY, USA)

1:15pm-2:45pm: Influence of cognitive abilities on prominence production in mild dysarthric patients with Parkinson’s disease

T. Thies, D. Mücke, A. Lowit, J. Steffen, E. Kalbe, M. Barbe (Cologne, Germany)

1:15pm-2:45pm: Influence of Cognitive Deficits and Tremor Severity of the Development of Depression in Nondemented Patients with Essential Tremor

M. Petrova, O. Grigorova, M. Raycheva, L. Traykov (Sofia, Bulgaria)

1:15pm-2:45pm: Influence of controlled-release levodopa on quality of sleep and nocturnal movements

E. Schaeffer, L. Zaunbrecher, I. Liepelt-Scarfone, C. Hansen, W. Maetzler, S. Nussbaum, B. Roeben, M. Elshehabi, P. Saraykin, S. Otterbein, J. Busch, D. Berg (Kiel, Germany)

1:15pm-2:45pm: Initial programming in STN-DBS for Parkinson’s disease: Standard vs. Steered Stimulation

R. Maciel, D. Soh, R. Munhoz, Y. Poon, S. Kalia, M. Hodaie, A. Lozano, A. Fasano (Toronto, ON, Canada)

1:15pm-2:45pm: Instrumental evaluation of sleep disturbance and autonomic nervous system dysfunction in idiopathic Parkinson’s disease

MD. Doręgowska, MT. Toś, JM. Malkiewicz, JS. Siuda, MR. Rudzińska-Bar (Katowice, Poland)

1:15pm-2:45pm: Integrity of Mirror Neuron System in cervical dystonia: an fMRI study

A. Castagna, S. Di Tella, V. Blasi, M. Cabinio, F. Baglio (Milano, Italy)

1:15pm-2:45pm: Intensity-based exercise groupings in Parkinson’s Disease: Analysis from the Parkinson’s Foundation Quality Improvement Initiative (PF-QII)

D. Larson, A. Margolius, G. Hanzhi, S. Wu, A. Angela, M. Miriam, T. Simuni (Gainseville, FL, USA)

1:15pm-2:45pm: Interactive dual task exercises delivered via smart speaker: a feasibility study

J. Dean, J. Domingos (Aurora, CO, USA)

1:15pm-2:45pm: Interleaved deep brain stimulation for dyskinesia management in Parkinson’s disease

C. Aquino, G. Duffley, D. Hedges, J. Vorwerk, P. House, H. Ferraz, J. Rolston, C. Butson, L. Schrock (Minneapolis, MN, USA)

1:15pm-2:45pm: Intestinal nerve damage and gut dysfunction in mouse models of Parkinson’s Disease

R. Mcquade, R. Constable, E. Lei, M. Di Natale, J. Berger, J. Kauhausen, C. Parish, D. Finkelstein, J. Furness, S. Diwakarla (Melbourne, Australia)

1:15pm-2:45pm: Intraoperative test stimulation of the subthalamic nucleus reduces the search space for chronic stimulation settings in Parkinson’s disease

V. Geraedts, R. van Ham, J. Marinus, J. van Hilten, A. Mosch, C. Hoffmann, N. Vd Gaag, MF. Contarino (Leiden, Netherlands)

1:15pm-2:45pm: Introduction of an Assessment Toolkit Increases the Rate of DLB Diagnosis

A. Surendranathan, J. Kane, A. Bentley, S. Barker, J. Taylor, A. Thomas, I. Mckeith, D. Burn, J. O'Brien (Cambridge, United Kingdom)

1:15pm-2:45pm: Investigation of 531 cases of neuromelanin sensitive imaging, about its characteristics by disease

K. Matsuura, Y. Ii, M. Maeda, K. Tabei, M. Umino, H. Tomimoto (Tsu, Japan)

1:15pm-2:45pm: Investigation of back pain in patients with Parkinson’s Disease

O. Yaremchuk, I. Yaremchuk (Chernivtsi, Ukraine)

1:15pm-2:45pm: Ipsilesional arm levitation after left hemispheric stroke: a case series

M. Klarendic, N. Prezelj, R. Berlot, V. Zgonc, M. Kojovic (Ljubljana, Slovenia)

1:15pm-2:45pm: Is 18F-FDG-PET/CT a helpful tool to diagnose PSP clinical variants?

G. Marti-Andres, M. Riverol-Fernandez, R. Valentí-Azcárate, M. Fernández-Matarrubia, E. Prieto-Azcárate, J. Arbizu-Azcarate, MR. Luquin-Piudo (Pamplona, Spain)

1:15pm-2:45pm: Is awake physiological confirmation necessary for DBS treatment of Parkinson’s disease today? A comparison of intraoperative imaging, physiology, and physiology imaging-guided DBS in the past decade

GH. Lu, ZX. Yin, YY. Luo, YW. Jin (Nanchang, China)

1:15pm-2:45pm: Is DAT imaging abnormality in Normal Pressure Hydrocephalus always suggestive of degeneration? Evidences from three cases

C. Del Gamba, A. Bruno, D. Frosini, D. Volterrani, N. Benedetto, C. Pacchetti, P. Perrini, M. Cosottini, U. Bonuccelli, R. Ceravolo (Pisa, Italy)

1:15pm-2:45pm: Is Dizziness a sign before DLB onset?

M. Matsumura (Tokyo, Japan)

1:15pm-2:45pm: Is Microelectrode Recording mandatory for Deep Brain Stimulation in Parkinson’s disease?

J. Bajaj, M. Singh, V. Goyal, S. Girishan, K. Garg (Delhi, India)

1:15pm-2:45pm: Is reduction in UPDRS-3 OFF score the best indicator of response to DBS?

P. Millar Vernetti, M. Rossi, C. Terroba Chambi, M. Merello (Buenos Aires, Argentina)

1:15pm-2:45pm: Karl Marx, Rosa Luxemburg, and Deep Brain Stimulation: is there a connection?

M. Hariz, P. Krack, A. Lees (Umea, Sweden)

1:15pm-2:45pm: Kick Out PD: Mobility, Quality of Life, and Feasibility Outcomes in a Pilot Study of a PD-Specific Karate Intervention

B. Sennott, C. Niemet, M. Lee, C. Whitelock, M. Sanghvi, Y. Liu, J. Chodosh, D. Hall, C. Comella, J. Fleisher (Chicago, IL, USA)

1:15pm-2:45pm: KICK OUT PD: Qualitative Analysis of Expectations and Outcomes in a Pilot Study of a Parkinson’s Disease Karate Intervention

J. Fleisher, C. Niemet, B. Sennott, M. Lee, C. Whitelock, M. Sanghvi, J. Chodosh, D. Hall, C. Comella (New York, NY, USA)

1:15pm-2:45pm: Kinetic Sensors for Ambulatory Gait and Balance Evaluation in Parkinson’s Disease

K. Sharma, A. Cucca, R. Sills, J. Jung, A. Feigin, M. Biagioni (New York, NY, USA)

1:15pm-2:45pm: Knowledge, Attitude and Practices about Movement Disorders in India

B. Shetty, S. Mittal, P. Kukkle (Bangalore, India)

1:15pm-2:45pm: Large Sample Study on Paroxysmal Kinesigenic Dyskinesia: Genotype-Phenotype Analysis and Diagnosis Recommendations

L. Cao, XJ. Huang, SG. Wang, WT. Tian, HD. Tang, JY. Shen, C. Zhang, ZY. Zhu, FX. Zhan, XQ. Che, SD. Chen, XL. Liu, T. Wang, YQ. Xu, HW. Gui, L. Zheng, L. Wu, TY. Rong, M. Zhang, Y. Wang, GH. Bi, WG. Tang, BS. Tang, XM. Yin, X. Mao, S. Zeng, JL. Wang, J. Li, Q. Liu, XN. Guo, CY. Wang, W. Lu, RX. Zhang, XR. Liu, Y. Zhang, ZG. Liu, GH. Zhao (Shanghai, China)

1:15pm-2:45pm: Late onset idiopathic cerebral edema associated with deep brain stimulation

M. Blázquez Estrada, P. Siso García, E. Suárez Sanmartín, J. Sol Alvarez, E. Santamarta Liébana, C. García Fernández, B. Lozano Aragoneses, J. Alvarez Carriles, A. Sáiz Ayala (Oviedo, Spain)

1:15pm-2:45pm: LATE ONSET OF PARKINSON’S DISEASE

I. Smolentseva, N. Amosova, A. Kuzmina (Moscow, Russian Federation)

1:15pm-2:45pm: Levocarb-induced diplopia in idiopathic Parkinson’s disease: a case report

S. Joza, F. Ba (Edmonton, AB, Canada)

1:15pm-2:45pm: Levodopa Effects on Visuospatial Working Memory in Parkinson’s Disease

E. Bayram, I. Litvan, B. Wright, C. Grembowski, D. Harrington (La Jolla, CA, USA)

1:15pm-2:45pm: Levodopa/carbidopa Intestinal Gel in Treatment of Non-Motor Symptoms in Advanced Parkinson’s Disease

W. Kamel, J. Al Hashel (Beni Suef, Egypt)

1:15pm-2:45pm: Life expectancy with and without Parkinson’s disease in the general population

L. Dommershuijsen, A.. Ikram, K. Ikram (Rotterdam, Netherlands)

1:15pm-2:45pm: Local anesthesia vs general anesthesia in STN-dDBS operation: a clinical comparison of the outcome of patients with advanced Parkinson’s disease

M. Koivu, J. Resendiz-Nieves, J. Eerola-Rautio, F. Scheperjans, R. Kivisaari, E. Pekkonen (Helsinki, Finland)

1:15pm-2:45pm: Local field potential recordings in the human pallidum using externalized directional DBS leads

L. Johnson, J. Aman, D. Escobar Sanabria, J. Wang, R. Patriat, M. Petrucci, M. Hill, G. Molnar, S. Cooper, L. Schrock, C. Mackinnon, N. Harel, M. Park, J. Vitek (Minneapolis, MN, USA)

1:15pm-2:45pm: Long term evolution of ventilatory function in Parkinson’s disease

G. Baille, C. Chenivesse, T. Perez, D. Devos, L. Defebvre, C. Moreau (Lille, France)

1:15pm-2:45pm: Long term outcome of STN-DBS for Parkinson Disease patients using Directional mode setting programs

K. Kimura, H. Kishida, T. Kawasaki, N. Ueda, F. Tanaka (Yokohama, Japan)

1:15pm-2:45pm: Long-term changes in myocardial sympathetic innervation and function in synucleinopathies

G. Lamotte, C. Holmes, T. Wu, D. Goldstein (Bethesda, MD, USA)

1:15pm-2:45pm: Long-term effects of bilateral subthalamic nucleus stimulation on sleep in patients with Parkinson’s disease

J. Choi, H. Kim, D. Yoo, J. Im, S. Paek, B. Jeon (Seoul, Republic of Korea)

1:15pm-2:45pm: Long-term follow up of unilateral focused ultrasound subthalamotomy for the treatment of motor features in asymmetric PD

J. Máñez-Miró, R. Martinez-Fernandez, M. Del álamo, F. Hernandez-Fernandez, R. Rodríguez-Rojas, J. Pineda-Pardo, F. Alonso-Frech, L. Vela-Desojo, J. Obeso (Móstoles-Madrid, Spain)

1:15pm-2:45pm: Long-term Motor and Non-motor Outcomes in Parkinson’s Disease Following Deep Brain Stimulation

D. Isaacs, T. Davis, F. Phibbs, J. Fang, A. Nagy, H. Koons, T. Hassell, P. Konrad, H. Yu, P. Hedera (Nashville, TN, USA)

1:15pm-2:45pm: Long-term Yearly Trends of Feeding Tube Placement in Neurodegenerative Disorders

D. Kim, R. Jones, A. D'Abreu, J. Friedman, U. Akbar (Providence, RI, USA)

1:15pm-2:45pm: Longitudinal Analysis of the Corticospinal tract microstructure in Parkinson’s Disease Patients

R. Guimarães, L. Piovesana, P. Azevedo, B. Campos, F. Cendes (Campinas, Brazil)

1:15pm-2:45pm: Longitudinal analysis of the relation between trajectories of dopaminergic agonists use and BMI in Parkinson’s disease

F. Artaud, PC. Lee, M. Vidailhet, JC. Corvol, A. Elbaz (Saint-Aubin, France)

1:15pm-2:45pm: Longitudinal Change of Substantia Nigra Hyperechogenicity in Parkinson’s Disease Cohort

T. Toomsoo, I. Rubanovits, R. Kerner, T. Asser, M. Vähi, P. Taba (Tallinn, Estonia)

1:15pm-2:45pm: Longitudinal Cortical Changes Associated with Apathy in Parkinson’s Disease

E. Canu, F. Agosta, F. Imperiale, T. Stojković, I. Stankovic, S. Basaia, A. Fontana, V. Markovic, I. Petrović, E. Stefanova, V. Kostic, M. Filippi (Milan, Italy)

1:15pm-2:45pm: Low and high beta band activity in the primary sensorimotor cortex is diminished by ipsilateral subthalamic stimulation in Parkinsonian patients

G. Tamas, A. Kelemen, B. Javor-Duray, M. Palotai, L. Halasz, L. Eross, G. Fekete, L. Bognar, G. Deuschl, M. Muthuraman (Budapest, Hungary)

1:15pm-2:45pm: Low doses of scopolamine exacerbates dementia among Drosophila with Parkinson’s disease pathophysiology

G. Chandran (Mysore, India)

1:15pm-2:45pm: Lymphocyte Senescence in Parkinson’s Disease

M. Jensen, K. Scott, M. Camacho, A. Kouli, R. Wijeyekoon, I. Solim, R. Barker, C. Williams-Gray (Cambridge, United Kingdom)

1:15pm-2:45pm: Maladaptive Nigrovagal Neuronal Plasticity Causes Ascending Alpha-Synucleinopathy in a Novel Environmental Toxin Based Rat Model of Parkinsonism

T. Subramanian, K. Le, S. Hojjatinia, K. Venkiteswaran, M. Subramanian, L. Anselmi, C. Bove, R. Travagli (Hershey, PA, USA)

1:15pm-2:45pm: Mandibular Advancement Device in Parkinson’s disease: an efficacious and usable device in a disabling disease

V. Cochen Decock, M. Castel, I. Bonafé (Montpellier, France)

1:15pm-2:45pm: MCI reverters have a favorable cognitive prognosis and cortical integrity in Parkinson’s disease

SJ. Chung, Y-H. Park, YH. Sohn, J-M. Lee, PH. Lee (Seoul, Republic of Korea)

1:15pm-2:45pm: Measurement properties of the MDS-NMS Non-motor Fluctuations Subscale

MJ. Forjaz, A. Ayala, C. Rodriguez-Blazquez, A. Schrag, D. Weintraub, A. Rizos, KR. Chaudhuri, P. Martinez-Martin (Philadelphia, PA, USA)

1:15pm-2:45pm: Measuring cognitive decline in PD-MCI patients with high level education: Do we have the appropriate tools?

L. Mentzer, A. Richardson, T. Nevo, S. Meyer, S. Rosenblum, N. Gemerman, S. Hassin-Baer, S. Israeli-Korn, T. Fay-Karmon, V. Livneh, G. Yahalom (Ramat-Gan, Israel)

1:15pm-2:45pm: Measuring disease progression with neuroimaging in MSA-a systematic review

B. Heim, F. Krismer, W. Poewe, K. Seppi (Innsbruck, Austria)

1:15pm-2:45pm: Medical evaluation as gold standard to control iPrognosis application derived data for early Parkinson’s disease detection

L. Klingelhoefer, S. Bostanjopoulou, D. Trivedi, S. Hadjidimitriou, S. Mayer, Z. Katsarou, V. Charisis, M. Stadtschnitzer, S. Dias, G. Ntakakis, N. Grammalidis, K. Kyritsis, H. Jaeger, D. Iakovakis, I. Ioakeimidis, F. Karayiannis, J. Diniz, A. Delopoulos, L. Hadjileontiadis, H. Reichmann, K. Chaudhuri (Dresden, Germany)

1:15pm-2:45pm: Metabolic network abnormalities in drug-naive Parkinson’s disease

O. Lucas-Jimenez, K. Schindlbeck, C. Tang, S. Morbelli, D. Arnaldi, M. Pardini, M. Pagani, F. Nobili, D. Eidelberg (Bilbao, Spain)

1:15pm-2:45pm: Metabolic Surgery in the adjuvant management of Parkinson’s Disease

C. Jauregui Pasache, W. Kunz Martínez, A. Pérez Pacheco (Querétaro, Mexico)

1:15pm-2:45pm: MIBG myocardial scintigraphy identifies premotor PD/DLB during a negative DAT scan period

R. Sakakibara, F. Tateno, Y. Aiba (Sakura, Japan)

1:15pm-2:45pm: Micro structural Changes in Substantia Nigra are associated with Severity of Parkinson’s Disease.

A. Safai, S. Rane, S. Prasad, J. Saini, P. Pal, M. Ingalhalikar (Pune, India)

1:15pm-2:45pm: Microglia as modulators of exosomal alpha-synuclein transmission

Y. Xia, T. Wang, GX. Zhang, JS. Huang, N. Xiong, L. Liu, F. Wan, L. Kou, SJ. Yin, JJ. Hu, YD. Sun, JW. Wu (Wuhan, China)

1:15pm-2:45pm: Midbrain Atrophy in Patients with Preclinical Progressive Supranuclear Palsy

JH. Ahn, M. Kim, J. Youn, JS. Kim, JK. Mun, PH. Lee, SB. Koh, TB. Ahn, JW. Cho (Seoul, Republic of Korea)

1:15pm-2:45pm: Mild Cognitive Impairment in Parkinson’s disease in South Indian population – Development of a test battery and assessment of prevalence and characteristics

S. Krishnan Nair, R. Ramesh, G. Sarma, D. Puthenveedu, R. Menon, A. Kishore (Thiruvananthapuram, India)

1:15pm-2:45pm: Mild Cognitive Impairment in Young Onset Parkinson Disease

A. Troster, C. Schweer (Phoenix, AZ, USA)

1:15pm-2:45pm: Mindfulness Based Stress Reduction in People with Parkinson’s Disease and their Carepartners

D. Shah, S. Mantri, J. Cooney, A. Allen, K. Durham, J. Brantley, R. Vereen, P. Hickey, B. Scott (Durham, NC, USA)

1:15pm-2:45pm: Mindfulness Training to Reduce Anxiety in Parkinson’s Disease: A Cautionary Tale about Wearable Technology

D. Mohanty, A. Lingaiah, J. Doak, A. Jacob, R. Castellanos, V. Holiday, A. Espay, K. Lafaver (Louisville, KY, USA)

1:15pm-2:45pm: Misdiagnosis in blepharospasm: the common imitators which should not be missed

S. Desai, S. Thati, D. Desai (Anand, India)

1:15pm-2:45pm: Mitigation Effects of a Novel Herbal Medicine Hepad, on neurophysiology.

BJ. Park, DH. Kim, JM. Park (Daejeon, Republic of Korea)

1:15pm-2:45pm: Mitochondrial Complex 1, Sigma 1 Receptor and Synaptic Vesicle protein 2A density in early de novo patients with Parkinson’s Disease: pilot PET data

G. Pagano, H. Wilson, A. Mansur, S. Caminiti, R. Comley, H. Tsukada, R. Gunn, E. Rabiner, M. Politis (London, United Kingdom)

1:15pm-2:45pm: Moaning: genetic analysis of a family with eight affected members

M. Rossi, M. Gisatulin, C. Perandones, C. Klein, M. Merello, K. Lohmann (Buenos Aires, Argentina)

1:15pm-2:45pm: Molecular correlates of survival and clinical severity in Progressive Supranuclear Palsy

M. Malpetti, L. Passamonti, T. Rittman, P. Vázquez Rodríguez, W R. Bevan-Jones, F I. Aigbirhio, J T. O'Brien, J B. Rowe (Cambridge, United Kingdom)

1:15pm-2:45pm: Motor and non-motor symptoms differences between Vascular Parkinsonism (VP) and Parkinson’s Disease (PD) patients in early stages

R. Raimundo, M. Mendes, R. Jesus, C. Azoia, A. Almeida, AG. Velon (Vila Real, Portugal)

1:15pm-2:45pm: Motor and non-motor symptoms related to sleep disturbances in Parkinson’s disease

D. van Wamelen, V. Leta, A. Podlewska, Y. Wan, A. Sauerbier, A. Rizos, P. Martinez-Martin, K. Chaudhuri (Madrid, Spain)

1:15pm-2:45pm: Motor compensation in Parkinson’s disease: a multimodal neuroimaging study

N. Villain, N. Pyatigorskaya, S. Lehericy, R. Vallabregue, S. Fernandez-Vidal, MO. Habert, G. Mangone, JC. Corvol, M. Vidailhet, D. Grabli (Paris, France)

1:15pm-2:45pm: Motor Networks in Tremor-Dominant Parkinson’s Disease. A resting-state functional MRI and diffusion tensor imaging analysis.

Z. Chappell, H. Wilson, M. Politis (London, United Kingdom)

1:15pm-2:45pm: Motor Symptoms in Typical Brain Aging

J. Zitser, K. Casaletto, A. Staffaroni, C. Sexton, A. Wolf, J. Brown, B. Miller, J. Kramer (San Francisco, CA, USA)

1:15pm-2:45pm: Movement and symptom-modulated local field potentials in globus pallidus internus of Parkinson’s disease

J. Aman, L. Johnson, D. Sanabria, J. Wang, M. Hill, S. Cooper, L. Schrock, M. Petrucci, G. Molnar, C. Mackinnon, R. Patriat, N. Harel, M. Park, J. Vitek (Minneapolis, MN, USA)

1:15pm-2:45pm: Movement disorders in chronic obstructive pulmonary disease (COPD); the effect of pulmonary disease to brain

K. Methawasin, R. Suppawat, P. Petborom, M. Wongwandee, S. Rungruanghiranya, T. Asawavichienjinda (Ongkharak, Thailand)

1:15pm-2:45pm: Movement disorders in neurologic consultation of Marrakesh University Hospital

L. Berrhoute, J. El Mesbahy, N. Kissani (Marrakesh, Morocco)

1:15pm-2:45pm: Movement Disorders Spectrum in a Private Practice setup in India : A 7 Year Study

P. Kukkle (Bangalore, India)

1:15pm-2:45pm: Movement disorders spectrum in patients with frontotemporal dementia

YU. Shpilyukova, E. Fedotova, D. Grishina, S. Illarioshkin (Moscow, Russian Federation)

1:15pm-2:45pm: MR-guided high intensity focused ultrasound in Parkinson’s disease: A case report with a 5 year follow up

S. Haegele-Link, N. Wegener, F. Brugger, J. Walch, R. Bauer, E. Martin, B. Werner, D. Brogle, G. Kaegi (St. Gallen, Switzerland)

1:15pm-2:45pm: Multi-modal MRI in patients with genetically confirmed familial cortical myoclonic tremor with epilepsy type 1

F. Xie, B. Wang, J. Wang, Z. Cen, W. Wei, Y. Chen, H. Sun, D. Yang, Y. Lou, X. Chen, S. Chen, H. Wang, L. Wang, S. Wang, X. Qiu, Y. Ding, H. Yin, S. Wu, B. Zhang, Y. Zang, W. Luo (Hangzhou, China)

1:15pm-2:45pm: Multimodal Graph Theory Analysis Identifies Reward Network in Prediction of Motor Response to Deep Brain Stimulation

J. Muller, L. Li, C. Matias, M. Alizadeh, J. Miao, S. Thalheimer, V. Romo, F. Mohamed, C. Wu (Philadelphia, PA, USA)

1:15pm-2:45pm: Multimodal PET and fcMRI reveals regional modulation by STN DBS correlating to motor outcomes

J. Younce, A. Tanenbaum, M. Campbell, J. Perlmutter, S. Norris (St Louis, MO, USA)